<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY b024-030-9780702070280 SYSTEM "b024-030-9780702070280" NDATA IMAGE><!ENTITY b024-035-9780702070280 SYSTEM "b024-035-9780702070280" NDATA IMAGE><!ENTITY f024-001-9780702070280 SYSTEM "f024-001-9780702070280" NDATA IMAGE><!ENTITY f024-002-9780702070280 SYSTEM "f024-002-9780702070280" NDATA IMAGE><!ENTITY f024-003-9780702070280 SYSTEM "f024-003-9780702070280" NDATA IMAGE><!ENTITY f024-004-9780702070280 SYSTEM "f024-004-9780702070280" NDATA IMAGE><!ENTITY f024-005-9780702070280 SYSTEM "f024-005-9780702070280" NDATA IMAGE><!ENTITY f024-006a-9780702070280 SYSTEM "f024-006a-9780702070280" NDATA IMAGE><!ENTITY f024-006b-9780702070280 SYSTEM "f024-006b-9780702070280" NDATA IMAGE><!ENTITY f024-007-9780702070280 SYSTEM "f024-007-9780702070280" NDATA IMAGE><!ENTITY f024-008-9780702070280 SYSTEM "f024-008-9780702070280" NDATA IMAGE><!ENTITY f024-009-9780702070280 SYSTEM "f024-009-9780702070280" NDATA IMAGE><!ENTITY f024-010ad-9780702070280 SYSTEM "f024-010ad-9780702070280" NDATA IMAGE><!ENTITY f024-011-9780702070280 SYSTEM "f024-011-9780702070280" NDATA IMAGE><!ENTITY f024-012-9780702070280 SYSTEM "f024-012-9780702070280" NDATA IMAGE><!ENTITY f024-013-9780702070280 SYSTEM "f024-013-9780702070280" NDATA IMAGE><!ENTITY f024-014-9780702070280 SYSTEM "f024-014-9780702070280" NDATA IMAGE><!ENTITY f024-015-9780702070280 SYSTEM "f024-015-9780702070280" NDATA IMAGE><!ENTITY f024-016ac-9780702070280 SYSTEM "f024-016ac-9780702070280" NDATA IMAGE><!ENTITY f024-017-9780702070280 SYSTEM "f024-017-9780702070280" NDATA IMAGE><!ENTITY f024-018-9780702070280 SYSTEM "f024-018-9780702070280" NDATA IMAGE><!ENTITY f024-019a-9780702070280 SYSTEM "f024-019a-9780702070280" NDATA IMAGE><!ENTITY f024-019b-9780702070280 SYSTEM "f024-019b-9780702070280" NDATA IMAGE><!ENTITY f024-020-9780702070280 SYSTEM "f024-020-9780702070280" NDATA IMAGE><!ENTITY f024-021-9780702070280 SYSTEM "f024-021-9780702070280" NDATA IMAGE><!ENTITY f024-022-9780702070280 SYSTEM "f024-022-9780702070280" NDATA IMAGE><!ENTITY f024-023-9780702070280 SYSTEM "f024-023-9780702070280" NDATA IMAGE><!ENTITY f024-024-9780702070280 SYSTEM "f024-024-9780702070280" NDATA IMAGE><!ENTITY f024-025-9780702070280 SYSTEM "f024-025-9780702070280" NDATA IMAGE><!ENTITY f024-026-9780702070280 SYSTEM "f024-026-9780702070280" NDATA IMAGE><!ENTITY f024-027-9780702070280 SYSTEM "f024-027-9780702070280" NDATA IMAGE><!ENTITY f024-028-9780702070280 SYSTEM "f024-028-9780702070280" NDATA IMAGE><!ENTITY f024-029-9780702070280 SYSTEM "f024-029-9780702070280" NDATA IMAGE><!ENTITY f024-030-9780702070280 SYSTEM "f024-030-9780702070280" NDATA IMAGE><!ENTITY f024-031-9780702070280 SYSTEM "f024-031-9780702070280" NDATA IMAGE><!ENTITY f024-032-9780702070280 SYSTEM "f024-032-9780702070280" NDATA IMAGE><!ENTITY f024-033a-9780702070280 SYSTEM "f024-033a-9780702070280" NDATA IMAGE><!ENTITY f024-033b-9780702070280 SYSTEM "f024-033b-9780702070280" NDATA IMAGE><!ENTITY f024-034-9780702070280 SYSTEM "f024-034-9780702070280" NDATA IMAGE><!ENTITY f024-035a-9780702070280 SYSTEM "f024-035a-9780702070280" NDATA IMAGE><!ENTITY f024-035b-9780702070280 SYSTEM "f024-035b-9780702070280" NDATA IMAGE><!ENTITY f024-036-9780702070280 SYSTEM "f024-036-9780702070280" NDATA IMAGE><!ENTITY f024-037-9780702070280 SYSTEM "f024-037-9780702070280" NDATA IMAGE><!ENTITY f024-038-9780702070280 SYSTEM "f024-038-9780702070280" NDATA IMAGE><!ENTITY f024-039-9780702070280 SYSTEM "f024-039-9780702070280" NDATA IMAGE><!ENTITY f024-040a-9780702070280 SYSTEM "f024-040a-9780702070280" NDATA IMAGE><!ENTITY f024-040b-9780702070280 SYSTEM "f024-040b-9780702070280" NDATA IMAGE><!ENTITY f024-041-9780702070280 SYSTEM "f024-041-9780702070280" NDATA IMAGE><!ENTITY f024-042-9780702070280 SYSTEM "f024-042-9780702070280" NDATA IMAGE><!ENTITY f024-043a-9780702070280 SYSTEM "f024-043a-9780702070280" NDATA IMAGE><!ENTITY f024-043b-9780702070280 SYSTEM "f024-043b-9780702070280" NDATA IMAGE><!ENTITY f024-044-9780702070280 SYSTEM "f024-044-9780702070280" NDATA IMAGE><!ENTITY f024-045-9780702070280 SYSTEM "f024-045-9780702070280" NDATA IMAGE><!ENTITY f024-046-9780702070280 SYSTEM "f024-046-9780702070280" NDATA IMAGE><!ENTITY f024-047-9780702070280 SYSTEM "f024-047-9780702070280" NDATA IMAGE><!ENTITY f024-048-9780702070280 SYSTEM "f024-048-9780702070280" NDATA IMAGE><!ENTITY f024-049-9780702070280 SYSTEM "f024-049-9780702070280" NDATA IMAGE><!ENTITY f024-050-9780702070280 SYSTEM "f024-050-9780702070280" NDATA IMAGE><!ENTITY f024-051-9780702070280 SYSTEM "f024-051-9780702070280" NDATA IMAGE><!ENTITY f024-052-9780702070280 SYSTEM "f024-052-9780702070280" NDATA IMAGE><!ENTITY f024-053-9780702070280 SYSTEM "f024-053-9780702070280" NDATA IMAGE><!ENTITY f024-054-9780702070280 SYSTEM "f024-054-9780702070280" NDATA IMAGE><!ENTITY f024-055af-9780702070280 SYSTEM "f024-055af-9780702070280" NDATA IMAGE><!ENTITY f024-056-9780702070280 SYSTEM "f024-056-9780702070280" NDATA IMAGE><!ENTITY f024-057-9780702070280 SYSTEM "f024-057-9780702070280" NDATA IMAGE><!ENTITY f024-058-9780702070280 SYSTEM "f024-058-9780702070280" NDATA IMAGE><!ENTITY f024-059-9780702070280 SYSTEM "f024-059-9780702070280" NDATA IMAGE><!ENTITY f024-060-9780702070280 SYSTEM "f024-060-9780702070280" NDATA IMAGE><!ENTITY f024-061-9780702070280 SYSTEM "f024-061-9780702070280" NDATA IMAGE><!ENTITY f024-062a-9780702070280 SYSTEM "f024-062a-9780702070280" NDATA IMAGE><!ENTITY f024-062b-9780702070280 SYSTEM "f024-062b-9780702070280" NDATA IMAGE><!ENTITY f024-063ab-9780702070280 SYSTEM "f024-063ab-9780702070280" NDATA IMAGE><!ENTITY f024-064-9780702070280 SYSTEM "f024-064-9780702070280" NDATA IMAGE><!ENTITY f024-065-9780702070280 SYSTEM "f024-065-9780702070280" NDATA IMAGE><!ENTITY f024-066-9780702070280 SYSTEM "f024-066-9780702070280" NDATA IMAGE><!ENTITY f024-067-9780702070280 SYSTEM "f024-067-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY icon03-9780702070280 SYSTEM "icon03-9780702070280" NDATA IMAGE><!ENTITY icon04-9780702070280 SYSTEM "icon04-9780702070280" NDATA IMAGE><!ENTITY icon05-9780702070280 SYSTEM "icon05-9780702070280" NDATA IMAGE><!ENTITY icon06-9780702070280 SYSTEM "icon06-9780702070280" NDATA IMAGE><!ENTITY u024-001-9780702070280 SYSTEM "u024-001-9780702070280" NDATA IMAGE><!ENTITY u024-002-9780702070280 SYSTEM "u024-002-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00024" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00024-X</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00024-X</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0020"><ce:label>Fig. 24.1</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">Structure of the major musculoskeletal tissues.</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 24.1</ce:alt-text><ce:link id="ln0020" locator="f024-001-9780702070280" xlink:href="pii:B978070207028000024X/f024-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 24.2</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0015" role="title">The bone remodelling cycle.</ce:simple-para><ce:simple-para id="sp0020" role="caption">Bone is renewed and repaired by the process of bone remodelling. This begins by removal of old and damaged bone by osteoclasts during the phase of bone resorption. After about 10 days, the osteoclasts undergo programmed cell death (apoptosis) and during the reversal phase are replaced by osteoblasts, which begin to fill in the resorbed area with new bone matrix, heralding the start of bone formation. The bone matrix is initially uncalcified (osteoid) but then becomes mineralised to form mature bone.</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 24.2</ce:alt-text><ce:link id="ln0025" locator="f024-002-9780702070280" xlink:href="pii:B978070207028000024X/f024-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 24.3</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0025" role="title">Cellular and molecular regulators of bone remodelling</ce:simple-para><ce:simple-para id="sp0030" role="caption">Osteoclast precursors are derived from haematopoietic stem cells. They differentiate into mature osteoclasts in response to the receptor activator of nuclear factor kappa B ligand (RANKL), which is produced by osteocytes, bone marrow stromal cells, osteoblasts and activated T cells (not shown), and macrophage colony-stimulating factor (M-CSF), which is produced by bone marrow stromal cells. Osteoprotegerin (OPG) is also produced in the bone microenvironment, where it inhibits osteoclastic bone resorption by blocking the effect of RANKL. Osteoblasts, which are derived from bone marrow stromal cells, are responsible for bone formation. Osteoblast activity is stimulated by signalling molecules in the Wnt family but inhibited by sclerostin (SOST), which is produced by osteocytes. In addition to their role in regulating osteoclast and osteoblast activity, osteocytes have an endocrine function in regulating phosphate homeostasis by producing fibroblast growth factor 23 (FGF23), which acts on the kidney to promote phosphate excretion.</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 24.3</ce:alt-text><ce:link id="ln0030" locator="f024-003-9780702070280" xlink:href="pii:B978070207028000024X/f024-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 24.4</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0040" role="title">Structure of a synovial joint.</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 24.4</ce:alt-text><ce:link id="ln0045" locator="f024-004-9780702070280" xlink:href="pii:B978070207028000024X/f024-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 24.5</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0045" role="title">Ultrastructure of articular cartilage.</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 24.5</ce:alt-text><ce:link id="ln0050" locator="f024-005-9780702070280" xlink:href="pii:B978070207028000024X/f024-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 24.6</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0050" role="title">Compensated polarised light microscopy of synovial fluids (× 400).</ce:simple-para><ce:simple-para id="sp0055" role="caption"><ce:bold>A</ce:bold> Monosodium urate crystals show bright negative birefringence under polarised light and needle-shaped morphology. <ce:bold>B</ce:bold> Calcium pyrophosphate crystals show weak positive birefringence under polarised light and are few in number. They are more difficult to detect than urate crystals.</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 24.6</ce:alt-text><ce:link id="ln0055" locator="f024-006a-9780702070280" xlink:href="pii:B978070207028000024X/f024-006a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0060" locator="f024-006b-9780702070280" xlink:href="pii:B978070207028000024X/f024-006b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 24.7</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0060" role="title">Magnetic resonance image showing joint synovitis.</ce:simple-para><ce:simple-para id="sp0065" role="caption">Coronal post-contrast T1-weighted image shows extensive enhancement consistent with synovitis (white areas, arrowed) in both wrists, at the second metacarpophalangeal joint and proximal interphalangeal joints of the right hand.</ce:simple-para></ce:caption><ce:alt-text id="atte0040" role="short">Fig. 24.7</ce:alt-text><ce:source>Courtesy of Dr I. Beggs.</ce:source><ce:link id="ln0080" locator="f024-007-9780702070280" xlink:href="pii:B978070207028000024X/f024-007-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0055"><ce:label>Fig. 24.8</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0070" role="title">Ultrasound image showing synovitis.</ce:simple-para><ce:simple-para id="sp0075" role="caption">Lateral image of a metacarpophalangeal joint in inflammatory arthritis. The periosteum (P) of the phalanx shows as a white line. The dark, hypo-echoic area indicates an effusion. The coloured areas demonstrated by power Doppler indicate increased vascularity. The inset shows a transverse image of the same joint.</ce:simple-para></ce:caption><ce:alt-text id="atte0045" role="short">Fig. 24.8</ce:alt-text><ce:source>Courtesy of Dr N. McKay.</ce:source><ce:link id="ln0085" locator="f024-008-9780702070280" xlink:href="pii:B978070207028000024X/f024-008-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0060"><ce:label>Fig. 24.9</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0080" role="title">Typical output from a dual X-ray absorptiometry (DXA) scan.</ce:simple-para><ce:simple-para id="sp0085" role="caption"><ce:bold>A</ce:bold> Image from hip DXA scan. <ce:bold>B</ce:bold> Bone mineral density (BMD) values plotted in g/cm<ce:sup loc="post">2</ce:sup> (left axis) and as the T-score values (right axis). The solid line represents the population average plotted against age, and the interrupted lines are ± 2 standard deviations. The BMD T-score result from the patient shown aged 70 years (arrow) is −3.0, indicating osteoporosis. Note that, while the patient's BMD is below average, it lies within the reference range for someone of that age, since BMD normally falls with age.</ce:simple-para></ce:caption><ce:alt-text id="atte0050" role="short">Fig. 24.9</ce:alt-text><ce:link id="ln0090" locator="f024-009-9780702070280" xlink:href="pii:B978070207028000024X/f024-009-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0065"><ce:label>Fig. 24.10</ce:label><ce:caption id="ca0055"><ce:simple-para id="sp0115" role="title">Patterns of joint involvement in different forms of polyarthritis.</ce:simple-para><ce:simple-para id="sp0120" role="caption"><ce:bold>A</ce:bold> Rheumatoid arthritis typically targets the metacarpophalangeal and proximal interphalangeal joints of the hands and metatarsophalangeal joints of the feet, as well as other joints, in a symmetrical pattern. <ce:bold>B</ce:bold> Psoriatic arthritis targets proximal and distal interphalangeal joints of the hands, entheses and larger joints in an asymmetrical pattern. Sacroiliitis (often asymmetrical) may occur. <ce:bold>C</ce:bold> Axial spondyloarthritis/ankylosing spondylitis targets the spine, sacroiliac joints, entheses and large peripheral joints in an asymmetrical pattern. <ce:bold>D</ce:bold> Osteoarthritis targets the proximal and distal interphalangeal joints of the hands, first carpometacarpal joint at the base of the thumb, knees, hips, lumbar and cervical spine.</ce:simple-para></ce:caption><ce:alt-text id="atte0055" role="short">Fig. 24.10</ce:alt-text><ce:link id="ln0135" locator="f024-010ad-9780702070280" xlink:href="pii:B978070207028000024X/f024-010ad-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0070"><ce:label>Fig. 24.11</ce:label><ce:caption id="ca0060"><ce:simple-para id="sp0125" role="title">Initial triage assessment of back pain.</ce:simple-para></ce:caption><ce:alt-text id="atte0060" role="short">Fig. 24.11</ce:alt-text><ce:link id="ln0160" locator="f024-011-9780702070280" xlink:href="pii:B978070207028000024X/f024-011-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0075"><ce:label>Fig. 24.12</ce:label><ce:caption id="ca0065"><ce:simple-para id="sp0130" role="title">Pain patterns around the shoulder.</ce:simple-para><ce:simple-para id="sp0135" role="caption">The dark shading indicates sites of maximum pain.</ce:simple-para></ce:caption><ce:alt-text id="atte0065" role="short">Fig. 24.12</ce:alt-text><ce:link id="ln0190" locator="f024-012-9780702070280" xlink:href="pii:B978070207028000024X/f024-012-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0080"><ce:label>Fig. 24.13</ce:label><ce:caption id="ca0070"><ce:simple-para id="sp0145" role="title">Pain patterns of hip disease and trochanteric pain syndrome.</ce:simple-para><ce:simple-para id="sp0150" role="caption">The dark shading indicates sites of maximum pain.</ce:simple-para></ce:caption><ce:alt-text id="atte0070" role="short">Fig. 24.13</ce:alt-text><ce:link id="ln0200" locator="f024-013-9780702070280" xlink:href="pii:B978070207028000024X/f024-013-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0085"><ce:label>Fig. 24.14</ce:label><ce:caption id="ca0075"><ce:simple-para id="sp0160" role="title">Mechanism of action of non-steroidal anti-inflammatory drugs.</ce:simple-para></ce:caption><ce:alt-text id="atte0075" role="short">Fig. 24.14</ce:alt-text><ce:link id="ln0235" locator="f024-014-9780702070280" xlink:href="pii:B978070207028000024X/f024-014-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0090"><ce:label>Fig. 24.15</ce:label><ce:caption id="ca0080"><ce:simple-para id="sp0170" role="title">Targets for biologic therapies in inflammatory rheumatic diseases.</ce:simple-para><ce:simple-para id="sp0175" role="caption">Biologic treatments for inflammatory rheumatic diseases work by targeting key cytokines and other molecules involved in regulating the immune response. See <ce:intra-ref id="ii0235" xlink:href="pii:B978-0-7020-7028-0.00004-4#p0290">page 64</ce:intra-ref> for more details. (BAFF = B-cell-activating factor of the TNF family; CD = cluster of differentiation; IL = interleukin; TNF-α = tumour necrosis factor alpha; TNFi = inhibitor of tumour necrosis factor)</ce:simple-para></ce:caption><ce:alt-text id="atte0080" role="short">Fig. 24.15</ce:alt-text><ce:link id="ln0270" locator="f024-015-9780702070280" xlink:href="pii:B978070207028000024X/f024-015-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0095"><ce:label>Fig. 24.16</ce:label><ce:caption id="ca0085"><ce:simple-para id="sp0185" role="title">Pathological changes in osteoarthritis.</ce:simple-para><ce:simple-para id="sp0190" role="caption"><ce:bold>A</ce:bold> Abnormal nests of proliferating chondrocytes (arrows) interspersed with matrix devoid of normal chondrocytes. <ce:bold>B</ce:bold> Fibrillation of cartilage in OA. <ce:bold>C</ce:bold> X-ray of knee joint affected by OA, showing osteophytes at joint margin (white arrows), subchondral sclerosis (black arrows) and a subchondral cyst (open arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0085" role="short">Fig. 24.16</ce:alt-text><ce:link id="ln0285" locator="f024-016ac-9780702070280" xlink:href="pii:B978070207028000024X/f024-016ac-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0100"><ce:label>Fig. 24.17</ce:label><ce:caption id="ca0090"><ce:simple-para id="sp0195" role="title">Nodal osteoarthritis.</ce:simple-para><ce:simple-para id="sp0200" role="caption">Heberden's nodes and lateral (radial/ulnar) deviation of distal interphalangeal joints, with mild Bouchard's nodes at the proximal interphalangeal joints.</ce:simple-para></ce:caption><ce:alt-text id="atte0090" role="short">Fig. 24.17</ce:alt-text><ce:link id="ln0300" locator="f024-017-9780702070280" xlink:href="pii:B978070207028000024X/f024-017-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0105"><ce:label>Fig. 24.18</ce:label><ce:caption id="ca0095"><ce:simple-para id="sp0205" role="title">X-ray appearances in hand osteoarthritis.</ce:simple-para><ce:simple-para id="sp0210" role="caption">There is joint space narrowing affecting the proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints in both hands. There are typical articular subchondral and ‘gullwing’ appearances to some osteoarthritis-affected joints, as well as osteophyte formation that is most marked at the second DIP joints bilaterally and the first PIP joint on the right hand (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0095" role="short">Fig. 24.18</ce:alt-text><ce:link id="ln0305" locator="f024-018-9780702070280" xlink:href="pii:B978070207028000024X/f024-018-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0110"><ce:label>Fig. 24.19</ce:label><ce:caption id="ca0100"><ce:simple-para id="sp0215" role="title">X-ray appearances in knee osteoarthritis.</ce:simple-para><ce:simple-para id="sp0220" role="caption"><ce:bold>A</ce:bold> Advanced osteoarthritis showing almost complete loss of joint space affecting both compartments and sclerosis of subchondral bone. <ce:bold>B</ce:bold> Skyline view of the patella femoral joint in a patient with severe patello-femoral osteoarthritis. There is almost complete loss of joint space and lateral displacement of the patella.</ce:simple-para></ce:caption><ce:alt-text id="atte0100" role="short">Fig. 24.19</ce:alt-text><ce:link id="ln0310" locator="f024-019a-9780702070280" xlink:href="pii:B978070207028000024X/f024-019a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0315" locator="f024-019b-9780702070280" xlink:href="pii:B978070207028000024X/f024-019b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0115"><ce:label>Fig. 24.20</ce:label><ce:caption id="ca0105"><ce:simple-para id="sp0225" role="title">Typical varus knee deformity resulting from marked medial tibio-femoral osteoarthritis.</ce:simple-para></ce:caption><ce:alt-text id="atte0105" role="short">Fig. 24.20</ce:alt-text><ce:link id="ln0320" locator="f024-020-9780702070280" xlink:href="pii:B978070207028000024X/f024-020-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0120"><ce:label>Fig. 24.21</ce:label><ce:caption id="ca0110"><ce:simple-para id="sp0230" role="title">X-ray of hip showing changes of osteoarthritis.</ce:simple-para><ce:simple-para id="sp0235" role="caption">Note the superior joint space narrowing (N), subchondral sclerosis (S), marginal osteophytes (O) and cysts (C).</ce:simple-para></ce:caption><ce:alt-text id="atte0110" role="short">Fig. 24.21</ce:alt-text><ce:link id="ln0325" locator="f024-021-9780702070280" xlink:href="pii:B978070207028000024X/f024-021-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0125"><ce:label>Fig. 24.22</ce:label><ce:caption id="ca0115"><ce:simple-para id="sp0240" role="title">X-ray of spine showing typical changes of osteoarthritis.</ce:simple-para><ce:simple-para id="sp0245" role="caption">Cervical spondylosis showing disc space narrowing between C6 and C7, osteophytes at the anterior vertebral body margins (thin arrows) and osteosclerosis at the apophyseal joints (thick arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0115" role="short">Fig. 24.22</ce:alt-text><ce:link id="ln0330" locator="f024-022-9780702070280" xlink:href="pii:B978070207028000024X/f024-022-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0130"><ce:label>Fig. 24.23</ce:label><ce:caption id="ca0120"><ce:simple-para id="sp0250" role="title">Mechanisms of crystal formation.</ce:simple-para></ce:caption><ce:alt-text id="atte0120" role="short">Fig. 24.23</ce:alt-text><ce:link id="ln0350" locator="f024-023-9780702070280" xlink:href="pii:B978070207028000024X/f024-023-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0135"><ce:label>Fig. 24.24</ce:label><ce:caption id="ca0125"><ce:simple-para id="sp0255" role="title">Uric acid metabolism.</ce:simple-para><ce:simple-para id="sp0260" role="caption">The main pathways for uric acid production and elimination are shown, along with the site of action for urate-lowering therapies.</ce:simple-para></ce:caption><ce:alt-text id="atte0125" role="short">Fig. 24.24</ce:alt-text><ce:link id="ln0355" locator="f024-024-9780702070280" xlink:href="pii:B978070207028000024X/f024-024-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0140"><ce:label>Fig. 24.25</ce:label><ce:caption id="ca0130"><ce:simple-para id="sp0270" role="title">Podagra.</ce:simple-para><ce:simple-para id="sp0275" role="caption">Acute gout causing swelling, erythema and extreme pain and tenderness of the first metatarsophalangeal joint.</ce:simple-para></ce:caption><ce:alt-text id="atte0130" role="short">Fig. 24.25</ce:alt-text><ce:link id="ln0365" locator="f024-025-9780702070280" xlink:href="pii:B978070207028000024X/f024-025-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0145"><ce:label>Fig. 24.26</ce:label><ce:caption id="ca0135"><ce:simple-para id="sp0280" role="title">Tophus with white monosodium urate monohydrate crystals visible beneath the skin.</ce:simple-para><ce:simple-para id="sp0285" role="caption">Diuretic-induced gout in a patient with pre-existing nodal osteoarthritis.</ce:simple-para></ce:caption><ce:alt-text id="atte0135" role="short">Fig. 24.26</ce:alt-text><ce:link id="ln0375" locator="f024-026-9780702070280" xlink:href="pii:B978070207028000024X/f024-026-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0150"><ce:label>Fig. 24.27</ce:label><ce:caption id="ca0140"><ce:simple-para id="sp0290" role="title">Erosive arthritis in chronic gout.</ce:simple-para><ce:simple-para id="sp0295" role="caption">Punched-out (‘Lulworth Cove’) erosions (arrows) in association with a destructive arthritis affecting the first metatarsophalangeal joint.</ce:simple-para></ce:caption><ce:alt-text id="atte0140" role="short">Fig. 24.27</ce:alt-text><ce:link id="ln0380" locator="f024-027-9780702070280" xlink:href="pii:B978070207028000024X/f024-027-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0155"><ce:label>Fig. 24.28</ce:label><ce:caption id="ca0145"><ce:simple-para id="sp0300" role="title">Chondrocalcinosis of the knee.</ce:simple-para><ce:simple-para id="sp0305" role="caption">The X-ray shows calcification of the fibrocartilaginous menisci (M) and articular hyaline cartilage (H). There is also narrowing (N) of the medial tibio-femoral compartment and osteophyte (O) formation.</ce:simple-para></ce:caption><ce:alt-text id="atte0145" role="short">Fig. 24.28</ce:alt-text><ce:link id="ln0395" locator="f024-028-9780702070280" xlink:href="pii:B978070207028000024X/f024-028-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0160"><ce:label>Fig. 24.29</ce:label><ce:caption id="ca0150"><ce:simple-para id="sp0315" role="title">Shoulder X-ray showing supraspinatus tendon calcification (arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0150" role="short">Fig. 24.29</ce:alt-text><ce:link id="ln0405" locator="f024-029-9780702070280" xlink:href="pii:B978070207028000024X/f024-029-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0165"><ce:label>Fig. 24.30</ce:label><ce:caption id="ca0155"><ce:simple-para id="sp0320" role="title">Possible causative mechanisms in fibromyalgia.</ce:simple-para></ce:caption><ce:alt-text id="atte0155" role="short">Fig. 24.30</ce:alt-text><ce:link id="ln0410" locator="f024-030-9780702070280" xlink:href="pii:B978070207028000024X/f024-030-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0170"><ce:label>Fig. 24.31</ce:label><ce:caption id="ca0160"><ce:simple-para id="sp0325" role="title">Typical tender points in fibromyalgia.</ce:simple-para></ce:caption><ce:alt-text id="atte0160" role="short">Fig. 24.31</ce:alt-text><ce:link id="ln0420" locator="f024-031-9780702070280" xlink:href="pii:B978070207028000024X/f024-031-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0175"><ce:label>Fig. 24.32</ce:label><ce:caption id="ca0165"><ce:simple-para id="sp0330" role="title">Pathophysiology of rheumatoid arthritis.</ce:simple-para><ce:simple-para id="sp0335" role="caption">Some of the cytokines and cellular interactions believed to be important in rheumatoid arthritis are shown. (ADAMTS5 = aggrecanase; IL = interleukin; M-CSF = macrophage colony-stimulating factor; MMP = matrix metalloproteinase; RANKL = receptor activator of nuclear factor kappa B ligand; TNF = tumour necrosis factor)</ce:simple-para></ce:caption><ce:alt-text id="atte0165" role="short">Fig. 24.32</ce:alt-text><ce:link id="ln0445" locator="f024-032-9780702070280" xlink:href="pii:B978070207028000024X/f024-032-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0180"><ce:label>Fig. 24.33</ce:label><ce:caption id="ca0170"><ce:simple-para id="sp0340" role="title">The hand in rheumatoid arthritis.</ce:simple-para><ce:simple-para id="sp0345" role="caption"><ce:bold>A</ce:bold> Ulnar deviation of the fingers with wasting of the small muscles of the hands and synovial swelling at the wrists, the extensor tendon sheaths, the metacarpophalangeal and proximal interphalangeal joints. <ce:bold>B</ce:bold> ‘Swan neck’ deformity of the fingers.</ce:simple-para></ce:caption><ce:alt-text id="atte0170" role="short">Fig. 24.33</ce:alt-text><ce:link id="ln0455" locator="f024-033a-9780702070280" xlink:href="pii:B978070207028000024X/f024-033a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0460" locator="f024-033b-9780702070280" xlink:href="pii:B978070207028000024X/f024-033b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0185"><ce:label>Fig. 24.34</ce:label><ce:caption id="ca0175"><ce:simple-para id="sp0350" role="title">Rheumatoid nodules and olecranon bursitis.</ce:simple-para><ce:simple-para id="sp0355" role="caption">Nodules were palpable within, as well as outside, the bursa.</ce:simple-para></ce:caption><ce:alt-text id="atte0175" role="short">Fig. 24.34</ce:alt-text><ce:link id="ln0470" locator="f024-034-9780702070280" xlink:href="pii:B978070207028000024X/f024-034-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0190"><ce:label>Fig. 24.35</ce:label><ce:caption id="ca0180"><ce:simple-para id="sp0360" role="title">Subluxation of cervical spine.</ce:simple-para><ce:simple-para id="sp0365" role="caption"><ce:bold>A</ce:bold> Flexion, showing widening of the space (arrow) between the odontoid peg of the axis (behind) and the anterior arch of the atlas (in front). <ce:bold>B</ce:bold> Extension, showing reduction in this space.</ce:simple-para></ce:caption><ce:alt-text id="atte0180" role="short">Fig. 24.35</ce:alt-text><ce:link id="ln0475" locator="f024-035a-9780702070280" xlink:href="pii:B978070207028000024X/f024-035a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0480" locator="f024-035b-9780702070280" xlink:href="pii:B978070207028000024X/f024-035b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0195"><ce:label>Fig. 24.36</ce:label><ce:caption id="ca0185"><ce:simple-para id="sp0370" role="title">Calculation of the Disease Activity Score 28 (DAS28).</ce:simple-para><ce:simple-para id="sp0375" role="caption">*Erythrocyte sedimentation rate or C-reactive protein can be used for the calculation.</ce:simple-para></ce:caption><ce:alt-text id="atte0185" role="short">Fig. 24.36</ce:alt-text><ce:link id="ln0495" locator="f024-036-9780702070280" xlink:href="pii:B978070207028000024X/f024-036-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0200"><ce:label>Fig. 24.37</ce:label><ce:caption id="ca0190"><ce:simple-para id="sp0380" role="title">Algorithm for the management of rheumatoid arthritis.</ce:simple-para><ce:simple-para id="sp0385" role="caption">(DAS28 = Disease Activity Score 28; DMARD = disease-modifying antirheumatic drug; HCQ = hydroxychloroquine; MTX = methotrexate; SSZ = sulfasalazine)</ce:simple-para></ce:caption><ce:alt-text id="atte0190" role="short">Fig. 24.37</ce:alt-text><ce:link id="ln0505" locator="f024-037-9780702070280" xlink:href="pii:B978070207028000024X/f024-037-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0205"><ce:label>Fig. 24.38</ce:label><ce:caption id="ca0195"><ce:simple-para id="sp0400" role="title">Pathophysiology of axial spondyloarthropathy.</ce:simple-para><ce:simple-para id="sp0405" role="caption">In genetically susceptible individuals, it is thought that bacterial components penetrate the mucosal barrier to activate macrophages and dendritic cells in the intestinal submucosa. These cells produce increased amounts of interleukin 23 (IL-23), which acts on T cells, neutrophils and mast cells to make IL-17; IL-17 in turn has a pivotal role in driving inflammation, causing sacroiliitis and enthesitis. Presentation of antigen by dendritic cells also plays a pathogenic part in activating T cells, and tumour necrosis factor (TNF), produced by macrophages and activated T cells, contributes to the pathogenesis of inflammation. Production of IL-22 by T cells is thought to be involved in causing the new bone formation that is typical of axial spondyloarthropathy.</ce:simple-para></ce:caption><ce:alt-text id="atte0195" role="short">Fig. 24.38</ce:alt-text><ce:link id="ln0530" locator="f024-038-9780702070280" xlink:href="pii:B978070207028000024X/f024-038-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0210"><ce:label>Fig. 24.39</ce:label><ce:caption id="ca0210"><ce:simple-para id="sp0430" role="title">Magnetic resonance imaging appearances in sacroiliitis.</ce:simple-para><ce:simple-para id="sp0435" role="caption">Coronal MRI short T1 inversion recovery (STIR) sequence showing bilateral sacroiliitis in axial spondyloarthritis. Bone marrow oedema (circles) is present around both sacroiliac joints, which show irregularities due to erosions (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0200" role="short">Fig. 24.39</ce:alt-text><ce:link id="ln0555" locator="f024-039-9780702070280" xlink:href="pii:B978070207028000024X/f024-039-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0215"><ce:label>Fig. 24.40</ce:label><ce:caption id="ca0200"><ce:simple-para id="sp0410" role="title">Radiographic changes in spondyloarthritis.</ce:simple-para><ce:simple-para id="sp0415" role="caption"><ce:bold>A</ce:bold> Fine symmetrical marginal syndesmophytes typical of ankylosing spondylitis (arrow). <ce:bold>B</ce:bold> Coarse, asymmetrical non-marginal syndesmophytes typical of psoriatic spondylitis (arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0205" role="short">Fig. 24.40</ce:alt-text><ce:link id="ln0540" locator="f024-040a-9780702070280" xlink:href="pii:B978070207028000024X/f024-040a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0545" locator="f024-040b-9780702070280" xlink:href="pii:B978070207028000024X/f024-040b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0220"><ce:label>Fig. 24.41</ce:label><ce:caption id="ca0205"><ce:simple-para id="sp0420" role="title">‘Bamboo’ spine of advanced ankylosing spondylitis.</ce:simple-para><ce:simple-para id="sp0425" role="caption">Note the symmetrical marginal syndesmophytes (arrows), sacroiliac joint fusion and generalised osteopenia.</ce:simple-para></ce:caption><ce:alt-text id="atte0210" role="short">Fig. 24.41</ce:alt-text><ce:link id="ln0550" locator="f024-041-9780702070280" xlink:href="pii:B978070207028000024X/f024-041-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0225"><ce:label>Fig. 24.42</ce:label><ce:caption id="ca0215"><ce:simple-para id="sp0440" role="title">Pathogenesis of psoriatic arthritis.</ce:simple-para><ce:simple-para id="sp0445" role="caption">Some of the cytokines and cellular interactions believed to be important in psoriatic arthritis are shown. (ADAMTS-5 = aggrecanase; IL = interleukin; M-CSF = macrophage colony-stimulating factor; MMP = matrix metalloproteinase; TNF = tumour necrosis factor; RANKL = RANK ligand)</ce:simple-para></ce:caption><ce:alt-text id="atte0215" role="short">Fig. 24.42</ce:alt-text><ce:link id="ln0565" locator="f024-042-9780702070280" xlink:href="pii:B978070207028000024X/f024-042-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0230"><ce:label>Fig. 24.43</ce:label><ce:caption id="ca0220"><ce:simple-para id="sp0450" role="title">Psoriatic arthropathy.</ce:simple-para><ce:simple-para id="sp0455" role="caption"><ce:bold>A</ce:bold> Dactylitis. <ce:bold>B</ce:bold> Distal interphalangeal joint pattern with accompanying nail dystrophy (pitting and onycholysis).</ce:simple-para></ce:caption><ce:alt-text id="atte0220" role="short">Fig. 24.43</ce:alt-text><ce:link id="ln0570" locator="f024-043a-9780702070280" xlink:href="pii:B978070207028000024X/f024-043a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0575" locator="f024-043b-9780702070280" xlink:href="pii:B978070207028000024X/f024-043b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0235"><ce:label>Fig. 24.44</ce:label><ce:caption id="ca0225"><ce:simple-para id="sp0460" role="title">Severe secondary Raynaud's phenomenon leading to digital ulceration.</ce:simple-para></ce:caption><ce:alt-text id="atte0225" role="short">Fig. 24.44</ce:alt-text><ce:link id="ln0580" locator="f024-044-9780702070280" xlink:href="pii:B978070207028000024X/f024-044-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0240"><ce:label>Fig. 24.45</ce:label><ce:caption id="ca0230"><ce:simple-para id="sp0465" role="title">Malar rash of systemic lupus erythematosus, sparing the nasolabial folds.</ce:simple-para><ce:simple-para id="sp0470" role="caption">The rash is notably similar to rosacea, which may itself be associated with inflammatory joint diseases such as psoriatic arthritis.</ce:simple-para></ce:caption><ce:alt-text id="atte0230" role="short">Fig. 24.45</ce:alt-text><ce:link id="ln0585" locator="f024-045-9780702070280" xlink:href="pii:B978070207028000024X/f024-045-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0245"><ce:label>Fig. 24.46</ce:label><ce:caption id="ca0235"><ce:simple-para id="sp0475" role="title">Livedo reticularis (systemic lupus erythematosus and anti-phospholipid syndrome).</ce:simple-para></ce:caption><ce:alt-text id="atte0235" role="short">Fig. 24.46</ce:alt-text><ce:link id="ln0590" locator="f024-046-9780702070280" xlink:href="pii:B978070207028000024X/f024-046-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0250"><ce:label>Fig. 24.47</ce:label><ce:caption id="ca0240"><ce:simple-para id="sp0480" role="title">Systemic sclerosis.</ce:simple-para><ce:simple-para id="sp0485" role="caption">Hands showing tight, shiny skin, sclerodactyly, flexion contractures of the fingers and thickening of the left middle finger extensor tendon sheath.</ce:simple-para></ce:caption><ce:alt-text id="atte0240" role="short">Fig. 24.47</ce:alt-text><ce:link id="ln0600" locator="f024-047-9780702070280" xlink:href="pii:B978070207028000024X/f024-047-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0255"><ce:label>Fig. 24.48</ce:label><ce:caption id="ca0245"><ce:simple-para id="sp0490" role="title">Typical facial appearance showing telangiectasias in localised cutaneous systemic sclerosis.</ce:simple-para></ce:caption><ce:alt-text id="atte0245" role="short">Fig. 24.48</ce:alt-text><ce:link id="ln0605" locator="f024-048-9780702070280" xlink:href="pii:B978070207028000024X/f024-048-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0260"><ce:label>Fig. 24.49</ce:label><ce:caption id="ca0250"><ce:simple-para id="sp0495" role="title">Typical eyelid appearance in dermatomyositis.</ce:simple-para><ce:simple-para id="sp0500" role="caption">Note the oedema and telangiectasia.</ce:simple-para></ce:caption><ce:alt-text id="atte0250" role="short">Fig. 24.49</ce:alt-text><ce:link id="ln0615" locator="f024-049-9780702070280" xlink:href="pii:B978070207028000024X/f024-049-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0265"><ce:label>Fig. 24.50</ce:label><ce:caption id="ca0255"><ce:simple-para id="sp0505" role="title">Muscle biopsy from a patient with polymyositis.</ce:simple-para><ce:simple-para id="sp0510" role="caption">The sample shows an intense inflammatory cell infiltrate in an area of degenerating and regenerating muscle fibres.</ce:simple-para></ce:caption><ce:alt-text id="atte0255" role="short">Fig. 24.50</ce:alt-text><ce:link id="ln0620" locator="f024-050-9780702070280" xlink:href="pii:B978070207028000024X/f024-050-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0270"><ce:label>Fig. 24.51</ce:label><ce:caption id="ca0260"><ce:simple-para id="sp0515" role="title">Types of vasculitis.</ce:simple-para><ce:simple-para id="sp0520" role="caption">The anatomical targets of different forms of vasculitis are shown.</ce:simple-para></ce:caption><ce:alt-text id="atte0260" role="short">Fig. 24.51</ce:alt-text><ce:link id="ln0625" locator="f024-051-9780702070280" xlink:href="pii:B978070207028000024X/f024-051-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0275"><ce:label>Fig. 24.52</ce:label><ce:caption id="ca0265"><ce:simple-para id="sp0525" role="title">Eye involvement in antineutrophil cytoplasmic antibody-associated vasculitis.</ce:simple-para></ce:caption><ce:alt-text id="atte0265" role="short">Fig. 24.52</ce:alt-text><ce:link id="ln0635" locator="f024-052-9780702070280" xlink:href="pii:B978070207028000024X/f024-052-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0280"><ce:label>Fig. 24.53</ce:label><ce:caption id="ca0270"><ce:simple-para id="sp0530" role="title">Rash of systemic vasculitis (palpable purpura).</ce:simple-para></ce:caption><ce:alt-text id="atte0270" role="short">Fig. 24.53</ce:alt-text><ce:link id="ln0640" locator="f024-053-9780702070280" xlink:href="pii:B978070207028000024X/f024-053-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0285"><ce:label>Fig. 24.54</ce:label><ce:caption id="ca0275"><ce:simple-para id="sp0535" role="title">Oral ulceration in Behçet's disease.</ce:simple-para></ce:caption><ce:alt-text id="atte0275" role="short">Fig. 24.54</ce:alt-text><ce:link id="ln0655" locator="f024-054-9780702070280" xlink:href="pii:B978070207028000024X/f024-054-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0290"><ce:label>Fig. 24.55</ce:label><ce:caption id="ca0280"><ce:simple-para id="sp0540" role="title">Fractures associated with osteoporosis.</ce:simple-para><ce:simple-para id="sp0545" role="caption"><ce:bold>A</ce:bold> X-ray of wrist. <ce:bold>B</ce:bold> Vertebrae. <ce:bold>C</ce:bold> Humerus. <ce:bold>D</ce:bold> Hip. <ce:bold>E</ce:bold> and <ce:bold>F</ce:bold> The changing incidence of each of these fractures with age in women and men, respectively.</ce:simple-para></ce:caption><ce:alt-text id="atte0280" role="short">Fig. 24.55</ce:alt-text><ce:source>From Curtis EM, van der Velde R, Moon RJ, et al. Epidemiology of fractures in the United Kingdom 1988–2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 2016; 87:19–26.</ce:source><ce:link id="ln0665" locator="f024-055af-9780702070280" xlink:href="pii:B978070207028000024X/f024-055af-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0300"><ce:label>Fig. 24.56</ce:label><ce:caption id="ca0290"><ce:simple-para id="sp0560" role="title">Changes in bone mass and microstructure with age.</ce:simple-para><ce:simple-para id="sp0565" role="caption">Changes in men (blue line) and women (red line).</ce:simple-para></ce:caption><ce:alt-text id="atte0285" role="short">Fig. 24.56</ce:alt-text><ce:link id="ln0675" locator="f024-056-9780702070280" xlink:href="pii:B978070207028000024X/f024-056-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0305"><ce:label>Fig. 24.57</ce:label><ce:caption id="ca0295"><ce:simple-para id="sp0570" role="title">Relation between bone mineral density (BMD) and fractures.</ce:simple-para><ce:simple-para id="sp0575" role="caption"><ce:bold>A</ce:bold> The relative risk of fracture increases exponentially as BMD falls (blue line), and is 14-fold higher in people with a T-score of &#x003C;−3.5 compared with those with normal BMD. In absolute terms, however, more fractures occur in people with normal BMD or osteopenia (red line). <ce:bold>B</ce:bold> The proportions of fractures that occur in people with normal BMD, osteopenia and osteoporosis.</ce:simple-para></ce:caption><ce:alt-text id="atte0290" role="short">Fig. 24.57</ce:alt-text><ce:link id="ln0685" locator="f024-057-9780702070280" xlink:href="pii:B978070207028000024X/f024-057-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0310"><ce:label>Fig. 24.58</ce:label><ce:caption id="ca0300"><ce:simple-para id="sp0580" role="title">Algorithm for the investigation of patients with suspected osteoporosis.</ce:simple-para><ce:simple-para id="sp0585" role="caption">Fracture risk is assessed using FRAX or QFracture (see ‘<ce:cross-ref id="crf1255" refid="st1905">Further information</ce:cross-ref>’, <ce:cross-ref id="crf9015" refid="s2040">p. 1060</ce:cross-ref>).</ce:simple-para></ce:caption><ce:alt-text id="atte0295" role="short">Fig. 24.58</ce:alt-text><ce:link id="ln0695" locator="f024-058-9780702070280" xlink:href="pii:B978070207028000024X/f024-058-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0315"><ce:label>Fig. 24.59</ce:label><ce:caption id="ca0305"><ce:simple-para id="sp0590" role="title">Mechanism of action of bisphosphonates.</ce:simple-para></ce:caption><ce:alt-text id="atte0300" role="short">Fig. 24.59</ce:alt-text><ce:link id="ln0710" locator="f024-059-9780702070280" xlink:href="pii:B978070207028000024X/f024-059-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0320"><ce:label>Fig. 24.60</ce:label><ce:caption id="ca0310"><ce:simple-para id="sp0600" role="title">Seasonal changes in vitamin D concentrations.</ce:simple-para><ce:simple-para id="sp0605" role="caption">To convert nmol/L to ng/mL, multiply by 2.5.</ce:simple-para></ce:caption><ce:alt-text id="atte0305" role="short">Fig. 24.60</ce:alt-text><ce:source>Adapted from McDonald HM, Mavroeidi A, Fraser WD, et al. Sunlight and dietary contributions to the seasonal vitamin D status of cohorts of healthy postmenopausal women living at northerly latitudes: a major cause for concern? Osteoporosis Int 2011; 22:2461–2472.</ce:source><ce:link id="ln0730" locator="f024-060-9780702070280" xlink:href="pii:B978070207028000024X/f024-060-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0325"><ce:label>Fig. 24.61</ce:label><ce:caption id="ca0315"><ce:simple-para id="sp0610" role="title">Vitamin D metabolism.</ce:simple-para><ce:simple-para id="sp0615" role="caption">Vitamin D is produced in the skin from 7-dehydrocholesterol (7-DHC) by ultraviolet B (UVB) light. The 7-dehydrocholesterol reductase enzyme, which is encoded by the <ce:italic>DHCR7</ce:italic> gene, opposes the effect of UVB by converting 7-DHC to cholesterol. The vitamin D then undergoes hydroxylation steps in the liver and kidney to form the active metabolite 1,25(OH)<ce:inf loc="post">2</ce:inf>D, which regulates calcium homeostasis by stimulating calcium absorption from the diet and bone resorption. See text for details.</ce:simple-para></ce:caption><ce:alt-text id="atte0310" role="short">Fig. 24.61</ce:alt-text><ce:link id="ln0735" locator="f024-061-9780702070280" xlink:href="pii:B978070207028000024X/f024-061-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0330"><ce:label>Fig. 24.62</ce:label><ce:caption id="ca0320"><ce:simple-para id="sp0620" role="title">Osteomalacia.</ce:simple-para><ce:simple-para id="sp0625" role="caption"><ce:bold>A</ce:bold> X-ray of the pelvis showing pseudofractures affecting the inferior and superior pubic rami on the left side (arrows). Healing pseudofractures with callus formation are also visible at the inferior and superior pubic rami on the right side (arrows). <ce:bold>B</ce:bold> Photomicrograph of bone biopsy from an osteomalacic patient showing thick osteoid seams (stained light blue, arrows) that cover almost all of the bone surface. Calcified bone is stained dark blue.</ce:simple-para></ce:caption><ce:alt-text id="atte0315" role="short">Fig. 24.62</ce:alt-text><ce:link id="ln0740" locator="f024-062a-9780702070280" xlink:href="pii:B978070207028000024X/f024-062a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0745" locator="f024-062b-9780702070280" xlink:href="pii:B978070207028000024X/f024-062b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0335"><ce:label>Fig. 24.63</ce:label><ce:caption id="ca0325"><ce:simple-para id="sp0630" role="title">Paget's disease.</ce:simple-para><ce:simple-para id="sp0635" role="caption"><ce:bold>A</ce:bold> <ce:sup loc="post">99m</ce:sup>Tc-labelled bisphosphonate scintigraphy from a patient with Paget's disease, illustrating the intense tracer uptake and deformity of the affected femur. <ce:bold>B</ce:bold> The typical radiographic features with expansion of the femur, alternating areas of osteosclerosis and radiolucency of the trochanter, and pseudofractures breaching the bone cortex (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0320" role="short">Fig. 24.63</ce:alt-text><ce:link id="ln0750" locator="f024-063ab-9780702070280" xlink:href="pii:B978070207028000024X/f024-063ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0340"><ce:label>Fig. 24.64</ce:label><ce:caption id="ca0330"><ce:simple-para id="sp0640" role="title">Complex regional pain syndrome (osteodystrophy).</ce:simple-para><ce:simple-para id="sp0645" role="caption"><ce:sup loc="post">99m</ce:sup>Tc-labelled bisphosphonate scintigraphy showing increased uptake in femoral condyle.</ce:simple-para></ce:caption><ce:alt-text id="atte0325" role="short">Fig. 24.64</ce:alt-text><ce:link id="ln0760" locator="f024-064-9780702070280" xlink:href="pii:B978070207028000024X/f024-064-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0345"><ce:label>Fig. 24.65</ce:label><ce:caption id="ca0335"><ce:simple-para id="sp0650" role="title">McCune–Albright syndrome.</ce:simple-para><ce:simple-para id="sp0655" role="caption">X-ray of tibia in a patient with McCune–Albright syndrome showing expansile osteolytic lesion.</ce:simple-para></ce:caption><ce:alt-text id="atte0330" role="short">Fig. 24.65</ce:alt-text><ce:link id="ln0765" locator="f024-065-9780702070280" xlink:href="pii:B978070207028000024X/f024-065-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0350"><ce:label>Fig. 24.66</ce:label><ce:caption id="ca0340"><ce:simple-para id="sp0665" role="title">Wrist X-ray showing a neuropathic (Charcot) joint in a patient with syringomyelia.</ce:simple-para><ce:simple-para id="sp0670" role="caption">Note the disorganised architecture with complete loss of the proximal carpal row, bony fragments and soft tissue swelling.</ce:simple-para></ce:caption><ce:alt-text id="atte0335" role="short">Fig. 24.66</ce:alt-text><ce:link id="ln0785" locator="f024-066-9780702070280" xlink:href="pii:B978070207028000024X/f024-066-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0355"><ce:label>Fig. 24.67</ce:label><ce:caption id="ca0345"><ce:simple-para id="sp0675" role="title">Diffuse idiopathic skeletal hyperostosis (DISH).</ce:simple-para><ce:simple-para id="sp0680" role="caption">Anteroposterior X-ray of the thoracic spine showing right-sided, flowing new bone joining more than four contiguous vertebrae. The disc spaces are preserved.</ce:simple-para></ce:caption><ce:alt-text id="atte0340" role="short">Fig. 24.67</ce:alt-text><ce:link id="ln0790" locator="f024-067-9780702070280" xlink:href="pii:B978070207028000024X/f024-067-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0010" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0035" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0345" role="short">Image 1</ce:alt-text></ce:inline-figure> 24.1</ce:label><ce:alt-text id="atte0350" role="short">24.1</ce:alt-text><ce:textbox-head><ce:title id="tit0015">Key regulators of bone remodelling</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0340"><ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte0355" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Mediator</entry><entry align="left">Source</entry><entry align="left">Effects</entry><entry align="left">Comment</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>RANKL</ce:bold></entry><entry align="left">Osteocytes<ce:br/>Stromal cells<ce:br/>Osteoblasts<ce:br/>Activated T cells</entry><entry align="left">Stimulates bone resorption</entry><entry align="left">Activates RANK</entry></row><row rowsep="1"><entry align="left"><ce:bold>Osteoprotegerin</ce:bold></entry><entry align="left">Stromal cells<ce:br/>Lymphocytes</entry><entry align="left">Inhibits bone resorption</entry><entry align="left">Acts as decoy receptor for RANKL</entry></row><row rowsep="1"><entry align="left"><ce:bold>Wnt</ce:bold></entry><entry align="left">Stromal cells</entry><entry align="left">Stimulates bone formation</entry><entry align="left">Activates LRP receptors</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sclerostin</ce:bold></entry><entry align="left">Osteocytes</entry><entry align="left">Inhibits bone formation</entry><entry align="left">Blocks effect of Wnt on LRP receptors</entry></row><row rowsep="1"><entry align="left"><ce:bold>Parathyroid hormone</ce:bold></entry><entry align="left">Parathyroid glands</entry><entry align="left">Increases bone resorption and formation</entry><entry align="left"/></row><row rowsep="1"><entry align="left"><ce:bold>Thyroid hormone</ce:bold></entry><entry align="left">Thyroid gland</entry><entry align="left">Increases bone resorption and formation</entry><entry align="left"/></row><row rowsep="1"><entry align="left"><ce:bold>Oestrogen</ce:bold></entry><entry align="left">Ovary</entry><entry align="left">Inhibits bone resorption</entry><entry align="left"/></row><row><entry align="left"><ce:bold>Glucocorticoid</ce:bold></entry><entry align="left">Adrenal gland<ce:br/>Exogenous</entry><entry align="left">Inhibits bone formation</entry><entry align="left"/></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0035">(LRP = lipoprotein receptor-related protein; RANKL = receptor activator of nuclear factor kappa B ligand)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0015" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0040" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0360" role="short">Image 2</ce:alt-text></ce:inline-figure> 24.2</ce:label><ce:alt-text id="atte0365" role="short">24.2</ce:alt-text><ce:textbox-head><ce:title id="tit0020">Types of joint</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0355"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte0370" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Range of movement</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Fibrous</ce:bold></entry><entry align="left">Minimal</entry><entry align="left">Skull sutures</entry></row><row rowsep="1"><entry align="left"><ce:bold>Fibrocartilaginous</ce:bold></entry><entry align="left">Limited</entry><entry align="left">Symphysis pubis<ce:br/>Costochondral junctions<ce:br/>Intervertebral discs<ce:br/>Sacroiliac joints</entry></row><row><entry align="left"><ce:bold>Synovial</ce:bold></entry><entry align="left">Large</entry><entry align="left">Most limb joints<ce:br/>Temporomandibular<ce:br/>Costovertebral</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0020" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0065" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0375" role="short">Image 3</ce:alt-text></ce:inline-figure> 24.3</ce:label><ce:alt-text id="atte0380" role="short">24.3</ce:alt-text><ce:textbox-head><ce:title id="tit0025">Radiographic abnormalities in selected rheumatic diseases</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0435"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte0385" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Rheumatoid arthritis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0055"><ce:list-item id="u0290"><ce:label>•</ce:label><ce:para id="p0440">Periarticular osteoporosis</ce:para></ce:list-item><ce:list-item id="u0295"><ce:label>•</ce:label><ce:para id="p0445">Marginal joint erosions</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0060"><ce:list-item id="u0300"><ce:label>•</ce:label><ce:para id="p0450">Joint subluxation</ce:para></ce:list-item><ce:list-item id="u0305"><ce:label>•</ce:label><ce:para id="p0455">Joint space narrowing</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Osteoporosis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0065"><ce:list-item id="u0310"><ce:label>•</ce:label><ce:para id="p0460">Osteopenia</ce:para></ce:list-item><ce:list-item id="u0315"><ce:label>•</ce:label><ce:para id="p0465">Vertebral fractures</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0070"><ce:list-item id="u0320"><ce:label>•</ce:label><ce:para id="p0470">Non-vertebral fractures</ce:para></ce:list-item><ce:list-item id="u0325"><ce:label>•</ce:label><ce:para id="p0475">Cortical thinning</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Paget's disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0075"><ce:list-item id="u0330"><ce:label>•</ce:label><ce:para id="p0480">Bone expansion</ce:para></ce:list-item><ce:list-item id="u0335"><ce:label>•</ce:label><ce:para id="p0485">Abnormal trabecular pattern</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0080"><ce:list-item id="u0340"><ce:label>•</ce:label><ce:para id="p0490">Osteosclerosis and lysis</ce:para></ce:list-item><ce:list-item id="u0345"><ce:label>•</ce:label><ce:para id="p0495">Pseudofractures</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Psoriatic arthritis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0085"><ce:list-item id="u0350"><ce:label>•</ce:label><ce:para id="p0500">Sacroiliitis</ce:para></ce:list-item><ce:list-item id="u0355"><ce:label>•</ce:label><ce:para id="p0505">Syndesmophytes</ce:para></ce:list-item><ce:list-item id="u0360"><ce:label>•</ce:label><ce:para id="p0510">Bone sclerosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0090"><ce:list-item id="u0365"><ce:label>•</ce:label><ce:para id="p0515">Proliferative enthesis erosions</ce:para></ce:list-item><ce:list-item id="u0370"><ce:label>•</ce:label><ce:para id="p0520">Enthesophytes</ce:para></ce:list-item><ce:list-item id="u0375"><ce:label>•</ce:label><ce:para id="p0525">Juxta-articular new bone</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Osteoarthritis</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0095"><ce:list-item id="u0380"><ce:label>•</ce:label><ce:para id="p0530">Joint space narrowing</ce:para></ce:list-item><ce:list-item id="u0385"><ce:label>•</ce:label><ce:para id="p0535">Osteophytes</ce:para></ce:list-item><ce:list-item id="u0390"><ce:label>•</ce:label><ce:para id="p0540">Subchondral sclerosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0100"><ce:list-item id="u0395"><ce:label>•</ce:label><ce:para id="p0545">Joint deformity</ce:para></ce:list-item><ce:list-item id="u0400"><ce:label>•</ce:label><ce:para id="p0550">Subchondral cysts</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0025" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0070" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0390" role="short">Image 4</ce:alt-text></ce:inline-figure> 24.4</ce:label><ce:alt-text id="atte0395" role="short">24.4</ce:alt-text><ce:textbox-head><ce:title id="tit0030">Conditions identified by <ce:sup loc="post">99m</ce:sup>Tc-labelled bisphosphonate bone scintigraphy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0570"><ce:list id="ulist0105"><ce:list-item id="u0405"><ce:label>•</ce:label><ce:para id="p0575">Skeletal metastases</ce:para></ce:list-item><ce:list-item id="u0410"><ce:label>•</ce:label><ce:para id="p0580">Paget's disease of bone</ce:para></ce:list-item><ce:list-item id="u0415"><ce:label>•</ce:label><ce:para id="p0585">Stress fractures and osteomalacia (e.g. Looser's zones)</ce:para></ce:list-item><ce:list-item id="u0420"><ce:label>•</ce:label><ce:para id="p0590">Complex regional pain syndrome (<ce:cross-ref id="crf9020" refid="s1885">p. 1055</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0425"><ce:label>•</ce:label><ce:para id="p0595">Sclerosing bone disorders (e.g. hypertrophic pulmonary osteoarthropathy; <ce:cross-ref id="crf9025" refid="s1935">p. 1057</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0430"><ce:label>•</ce:label><ce:para id="p0600">Spondyloarthritides (abnormalities at sacroiliac joints and tendon/ligament insertions)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0030" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0075" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0400" role="short">Image 5</ce:alt-text></ce:inline-figure> 24.5</ce:label><ce:alt-text id="atte0405" role="short">24.5</ce:alt-text><ce:textbox-head><ce:title id="tit0035">Conditions detected by magnetic resonance imaging</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0610"><ce:list id="ulist0110"><ce:list-item id="u0435"><ce:label>•</ce:label><ce:para id="p0615">Osteonecrosis</ce:para></ce:list-item><ce:list-item id="u0440"><ce:label>•</ce:label><ce:para id="p0620">Intervertebral disc disease</ce:para></ce:list-item><ce:list-item id="u0445"><ce:label>•</ce:label><ce:para id="p0625">Nerve root entrapment</ce:para></ce:list-item><ce:list-item id="u0450"><ce:label>•</ce:label><ce:para id="p0630">Spinal cord compression</ce:para></ce:list-item><ce:list-item id="u0455"><ce:label>•</ce:label><ce:para id="p0635">Spinal stenosis</ce:para></ce:list-item><ce:list-item id="u0460"><ce:label>•</ce:label><ce:para id="p0640">Sepsis</ce:para></ce:list-item><ce:list-item id="u0465"><ce:label>•</ce:label><ce:para id="p0645">Complex regional pain syndrome</ce:para></ce:list-item><ce:list-item id="u0470"><ce:label>•</ce:label><ce:para id="p0650">Malignancy</ce:para></ce:list-item><ce:list-item id="u0475"><ce:label>•</ce:label><ce:para id="p0655">Fractures</ce:para></ce:list-item><ce:list-item id="u0480"><ce:label>•</ce:label><ce:para id="p0660">Meniscal disease</ce:para></ce:list-item><ce:list-item id="u0485"><ce:label>•</ce:label><ce:para id="p0665">Synovitis</ce:para></ce:list-item><ce:list-item id="u0490"><ce:label>•</ce:label><ce:para id="p0670">Sacroiliitis and enthesitides</ce:para></ce:list-item><ce:list-item id="u0495"><ce:label>•</ce:label><ce:para id="p0675">Inflammatory myositis</ce:para></ce:list-item><ce:list-item id="u0500"><ce:label>•</ce:label><ce:para id="p0680">Rotator cuff tears, bursitis and tenosynovitis</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0035" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0095" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0410" role="short">Image 6</ce:alt-text></ce:inline-figure> 24.6</ce:label><ce:alt-text id="atte0415" role="short">24.6</ce:alt-text><ce:textbox-head><ce:title id="tit0040">Typical biochemical abnormalities in various skeletal diseases (in serum)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0710"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0420" role="short">Unlabelled table</ce:alt-text><tgroup cols="7"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><colspec colname="col6" colnum="6"/><colspec colname="col7" colnum="7"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Calcium</entry><entry align="left">Phosphate</entry><entry align="left">ALP</entry><entry align="left">PTH</entry><entry align="left">FGF23</entry><entry align="left">25(OH)D</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Osteoporosis</ce:bold></entry><entry align="left">N</entry><entry align="left">N</entry><entry align="left">N (↑ after fracture)</entry><entry align="left">N or ↑</entry><entry align="left">N</entry><entry align="left">N or ↓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Paget's disease</ce:bold></entry><entry align="left">N</entry><entry align="left">N</entry><entry align="left">↑↑</entry><entry align="left">N or ↑</entry><entry align="left">N</entry><entry align="left">N or ↓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Renal osteodystrophy</ce:bold></entry><entry align="left">N or ↓</entry><entry align="left">N or ↑</entry><entry align="left">↑</entry><entry align="left">↑↑</entry><entry align="left">↑↑</entry><entry align="left">N or ↓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Vitamin D-deficient osteomalacia</ce:bold></entry><entry align="left">N or ↓</entry><entry align="left">N or ↓</entry><entry align="left">↑</entry><entry align="left">↑↑</entry><entry align="left">N or ↓</entry><entry align="left">↓↓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Hypophosphataemic rickets</ce:bold></entry><entry align="left">N</entry><entry align="left">↓↓</entry><entry align="left">↑</entry><entry align="left">N or ↑</entry><entry align="left">↑↑</entry><entry align="left">N or ↓</entry></row><row><entry align="left"><ce:bold>Primary hyperparathyroidism</ce:bold></entry><entry align="left">↑/↑↑</entry><entry align="left">N or ↓</entry><entry align="left">N or ↑</entry><entry align="left">↑↑</entry><entry align="left">N or ↑</entry><entry align="left">N or ↓</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0090">(ALP = alkaline phosphatase; FGF23 = fibroblast growth factor 23; PTH = parathyroid hormone)</ce:simple-para><ce:simple-para id="sp0095">(N = normal; single arrow = increased or decreased; double arrow = greatly increased or decreased)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0040" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0100" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0425" role="short">Image 7</ce:alt-text></ce:inline-figure> 24.7</ce:label><ce:alt-text id="atte0430" role="short">24.7</ce:alt-text><ce:textbox-head><ce:title id="tit0045">Causes of an elevated serum creatinine phosphokinase (CPK)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0715"><ce:list id="ulist0115"><ce:list-item id="u0505"><ce:label>•</ce:label><ce:para id="p0720">Inflammatory myositis ± vasculitis</ce:para></ce:list-item><ce:list-item id="u0510"><ce:label>•</ce:label><ce:para id="p0725">Muscular dystrophy</ce:para></ce:list-item><ce:list-item id="u0515"><ce:label>•</ce:label><ce:para id="p0730">Motor neuron disease</ce:para></ce:list-item><ce:list-item id="u0520"><ce:label>•</ce:label><ce:para id="p0735">Alcohol, drugs (especially statins)</ce:para></ce:list-item><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0745">Myocardial infarction<ce:cross-ref id="crf0385" refid="fn0010">*</ce:cross-ref><ce:footnote id="fn0010"><ce:label>*</ce:label><ce:note-para id="np0010">The CK-MB cardiac-specific isoform is disproportionately elevated compared with total CPK.</ce:note-para></ce:footnote></ce:para></ce:list-item><ce:list-item id="u0525"><ce:label>•</ce:label><ce:para id="p0740">Trauma, strenuous exercise, prolonged immobilisation after a fall</ce:para></ce:list-item><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p0750">Hypothyroidism, metabolic myopathy</ce:para></ce:list-item><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p0755">Viral myositis</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0105" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0435" role="short">Image 8</ce:alt-text></ce:inline-figure> 24.8</ce:label><ce:alt-text id="atte0440" role="short">24.8</ce:alt-text><ce:textbox-head><ce:title id="tit0050">Conditions associated with a positive rheumatoid factor<ce:cross-ref id="crf0395" refid="fn0015">*</ce:cross-ref><ce:footnote id="fn0015"><ce:label>*</ce:label><ce:note-para id="np0015">Normal healthy people can be positive for rheumatoid factor.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0770"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0445" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Condition</entry><entry align="left">Approximate frequency (%)</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Rheumatoid arthritis with nodules and extra-articular manifestations</ce:bold></entry><entry align="left">100</entry></row><row rowsep="1"><entry align="left"><ce:bold>Rheumatoid arthritis (overall)</ce:bold></entry><entry align="left">70</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sjögren's syndrome</ce:bold></entry><entry align="left">90</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mixed essential cryoglobulinaemia</ce:bold></entry><entry align="left">90</entry></row><row rowsep="1"><entry align="left"><ce:bold>Primary biliary cholangitis</ce:bold></entry><entry align="left">50</entry></row><row rowsep="1"><entry align="left"><ce:bold>Infective endocarditis</ce:bold></entry><entry align="left">40</entry></row><row rowsep="1"><entry align="left"><ce:bold>Systemic lupus erythematosus</ce:bold></entry><entry align="left">30</entry></row><row rowsep="1"><entry align="left"><ce:bold>Tuberculosis</ce:bold></entry><entry align="left">15</entry></row><row><entry align="left"><ce:bold>Age &#x003E; 65 years</ce:bold></entry><entry align="left">20</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0110" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0450" role="short">Image 9</ce:alt-text></ce:inline-figure> 24.9</ce:label><ce:alt-text id="atte0455" role="short">24.9</ce:alt-text><ce:textbox-head><ce:title id="tit0055">Conditions associated with a positive antinuclear antibody<ce:cross-ref id="crf0405" refid="fn0020">*</ce:cross-ref><ce:footnote id="fn0020"><ce:label>*</ce:label><ce:note-para id="np0020">Low-titre positive antinuclear antibody can occur in people without autoimmune disease, without obvious clinical consequences, particularly in the elderly.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0785"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0460" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Condition</entry><entry align="left">Approximate frequency (%)</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Systemic lupus erythematosus</ce:bold></entry><entry align="left">100%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Systemic sclerosis</ce:bold></entry><entry align="left">60–80%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sjögren's syndrome</ce:bold></entry><entry align="left">40–70%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Dermatomyositis or polymyositis</ce:bold></entry><entry align="left">30–80%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mixed connective tissue disease</ce:bold></entry><entry align="left">100%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Autoimmune hepatitis</ce:bold></entry><entry align="left">100%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Rheumatoid arthritis</ce:bold></entry><entry align="left">30–50%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Autoimmune thyroid disease</ce:bold></entry><entry align="left">30–50%</entry></row><row rowsep="1"><entry align="left"><ce:bold>Malignancy</ce:bold></entry><entry align="left">Varies widely</entry></row><row><entry align="left"><ce:bold>Infectious diseases</ce:bold></entry><entry align="left">Varies widely</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0115" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0465" role="short">Image 10</ce:alt-text></ce:inline-figure> 24.10</ce:label><ce:alt-text id="atte0470" role="short">24.10</ce:alt-text><ce:textbox-head><ce:title id="tit0060">Conditions associated with antibodies to extractable nuclear antigens</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0800"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0475" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Antibody (target/other name)</entry><entry align="left">Disease association</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Anti-centromere antibody</ce:bold></entry><entry align="left">Localised cutaneous systemic sclerosis (sensitivity 60%, specificity 98%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-histone antibody</ce:bold></entry><entry align="left">Drug-induced lupus (80%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-Jo-1</ce:bold><ce:br/><ce:bold>(anti-histidyl-tRNA synthetase)</ce:bold></entry><entry align="left">Polymyositis, dermatomyositis or polymyositis–systemic sclerosis overlap (20–30%)<ce:br/>Particularly associated with interstitial lung disease</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-La antibody</ce:bold><ce:br/><ce:bold>(anti-SS-B)</ce:bold></entry><entry align="left">Sjögren's syndrome (60%)<ce:br/>SLE (20–60%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-ribonucleoprotein antibody</ce:bold><ce:br/><ce:bold>(anti-RNP)</ce:bold></entry><entry align="left">Mixed connective tissue disease (100%)<ce:br/>SLE (25–50%), usually in conjunction with anti-Sm antibodies</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-Ro antibody</ce:bold><ce:br/><ce:bold>(anti-SS-A)</ce:bold></entry><entry align="left">SLE (35–60%): associated with photosensitivity, thrombocytopenia and subacute cutaneous lupus<ce:br/>Maternal anti-Ro antibodies associated with neonatal lupus and congenital heart block<ce:br/>Sjögren's syndrome (40–80%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-RNA polymerase</ce:bold></entry><entry align="left">Diffuse systemic sclerosis (15%)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti Sm</ce:bold><ce:br/><ce:bold>(anti-Smith antibody)</ce:bold></entry><entry align="left">SLE (15–30%); associated with renal disease</entry></row><row><entry align="left"><ce:bold>Anti-Scl-70</ce:bold><ce:br/><ce:bold>(anti-topoisomerase I antibody)</ce:bold></entry><entry align="left">Diffuse systemic sclerosis (15%); associated with more severe organ involvement, including pulmonary fibrosis</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0100">(SLE = systemic lupus erythematosus)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0060" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0120" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0480" role="short">Image 11</ce:alt-text></ce:inline-figure> 24.11</ce:label><ce:alt-text id="atte0485" role="short">24.11</ce:alt-text><ce:textbox-head><ce:title id="tit0065">Causes of acute monoarthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0870"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0490" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Common</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0125"><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p0875">Gout</ce:para></ce:list-item><ce:list-item id="u0565"><ce:label>•</ce:label><ce:para id="p0880">Pseudogout</ce:para></ce:list-item><ce:list-item id="u0570"><ce:label>•</ce:label><ce:para id="p0885">Trauma</ce:para></ce:list-item><ce:list-item id="u0575"><ce:label>•</ce:label><ce:para id="p0890">Haemarthrosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0130"><ce:list-item id="u0580"><ce:label>•</ce:label><ce:para id="p0895">Spondyloarthritis</ce:para></ce:list-item><ce:list-item id="u0585"><ce:label>•</ce:label><ce:para id="p0900">Psoriatic arthritis</ce:para></ce:list-item><ce:list-item id="u0590"><ce:label>•</ce:label><ce:para id="p0905">Reactive arthritis</ce:para></ce:list-item><ce:list-item id="u0595"><ce:label>•</ce:label><ce:para id="p0910">Enteropathic arthritis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Less common</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0135"><ce:list-item id="u0600"><ce:label>•</ce:label><ce:para id="p0915">Rheumatoid arthritis</ce:para></ce:list-item><ce:list-item id="u0605"><ce:label>•</ce:label><ce:para id="p0920">Juvenile idiopathic arthritis</ce:para></ce:list-item><ce:list-item id="u0610"><ce:label>•</ce:label><ce:para id="p0925">Pigmented villonodular synovitis</ce:para></ce:list-item><ce:list-item id="u0615"><ce:label>•</ce:label><ce:para id="p0930">Foreign body reaction</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0140"><ce:list-item id="u0620"><ce:label>•</ce:label><ce:para id="p0935">Tuberculosis</ce:para></ce:list-item><ce:list-item id="u0625"><ce:label>•</ce:label><ce:para id="p0940">Leukaemia<ce:cross-ref id="crf0420" refid="tn0010">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0630"><ce:label>•</ce:label><ce:para id="p0945">Gonococcal infection</ce:para></ce:list-item><ce:list-item id="u0635"><ce:label>•</ce:label><ce:para id="p0950">Osteomyelitis<ce:cross-ref id="crf0425" refid="tn0010">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0010"><ce:label>*</ce:label><ce:note-para id="np0025">In children, both leukaemia and osteomyelitis may present with monoarthritis.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0065" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0125" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0495" role="short">Image 12</ce:alt-text></ce:inline-figure> 24.12</ce:label><ce:alt-text id="atte0500" role="short">24.12</ce:alt-text><ce:textbox-head><ce:title id="tit0070">Common causes of polyarthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0975"><ce:display><ce:table frame="topbot" id="t0050"><ce:alt-text id="atte0505" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Cause</entry><entry align="left">Characteristics</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Rheumatoid arthritis</ce:bold></entry><entry align="left">Symmetrical, small and large joints, upper and lower limbs</entry></row><row rowsep="1"><entry align="left"><ce:bold>Viral arthritis</ce:bold></entry><entry align="left">Symmetrical, small joints; may be associated with rash and prodromal illness; self-limiting</entry></row><row rowsep="1"><entry align="left"><ce:bold>Osteoarthritis</ce:bold></entry><entry align="left">Symmetrical, targets PIP, DIP and first CMC joints in hands, knees, hips, back and neck; associated with Heberden's and Bouchard's nodes</entry></row><row rowsep="1"><entry align="left"><ce:bold>Psoriatic arthritis</ce:bold></entry><entry align="left">Asymmetrical, targets all joints and entheses; associated with nail pitting/onycholysis, dactylitis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Axial spondyloarthritis and enteropathic arthritis</ce:bold></entry><entry align="left">Tends to affect midsize and large joints and entheses, lower more than upper limbs; history of inflammatory back pain</entry></row><row rowsep="1"><entry align="left"><ce:bold>Systemic lupus erythematosus</ce:bold></entry><entry align="left">Symmetrical, typically affecting small joints; clinical evidence of synovitis unusual</entry></row><row rowsep="1"><entry align="left"><ce:bold>Juvenile idiopathic arthritis</ce:bold></entry><entry align="left">Various patterns (<ce:cross-ref id="crf9030" refid="p4230">p. 1026</ce:cross-ref>): polyarticular, oligoarticular and systemic but also enthesitis-predominant</entry></row><row rowsep="1"><entry align="left"><ce:bold>Chronic gout</ce:bold></entry><entry align="left">Affects distal more than proximal joints; history of acute attacks</entry></row><row rowsep="1"><entry align="left"><ce:bold>Chronic sarcoidosis</ce:bold> (<ce:intra-ref id="ii0120" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1590">p. 608</ce:intra-ref>)</entry><entry align="left">Varies: small and large joints, often involves ankles</entry></row><row><entry align="left"><ce:bold>Calcium pyrophosphate arthritis</ce:bold></entry><entry align="left">Chronic polyarthritis with involvement of wrists, ankles, knees and oligoarticular small hand joints</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0105">(CMC = carpometacarpal; DIP = distal interphalangeal; PIP = proximal interphalangeal)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0070" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0130" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0510" role="short">Image 13</ce:alt-text></ce:inline-figure> 24.13</ce:label><ce:alt-text id="atte0515" role="short">24.13</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Extra-articular features of inflammatory arthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0985"><ce:display><ce:table frame="topbot" id="t0055"><ce:alt-text id="atte0520" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Clinical feature</entry><entry align="left">Disease association</entry></row></thead><tbody><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Skin, nails and mucous membranes</ce:bold></entry></row><row rowsep="0"><entry align="left">Psoriasis, nail pitting and dystrophy</entry><entry align="left">Psoriatic arthritis</entry></row><row rowsep="0"><entry align="left">Raynaud's phenomenon</entry><entry align="left">Systemic sclerosis, antiphospholipid syndrome, SLE</entry></row><row rowsep="0"><entry align="left">Photosensitivity</entry><entry align="left">SLE</entry></row><row rowsep="0"><entry align="left">Livedo reticularis</entry><entry align="left">SLE, antiphospholipid syndrome</entry></row><row rowsep="0"><entry align="left">Splinter haemorrhages, nail-fold infarcts, purpuric lesions</entry><entry align="left">Vasculitis</entry></row><row rowsep="0"><entry align="left">Urticaria and erythemas</entry><entry align="left">SLE, adult-onset Still's disease, systemic JIA, rheumatic fever</entry></row><row rowsep="0"><entry align="left">Oral ulcers</entry><entry align="left">SLE, reactive arthritis, Behçet's disease</entry></row><row rowsep="0"><entry align="left">Nodules</entry><entry align="left">RA (mainly extensor surfaces), gout (tophi; eccentric, white deposits within), rheumatic fever</entry></row><row rowsep="1"><entry align="left">Xerostomia, dry skin, various rashes</entry><entry align="left">Primary Sjögren's syndrome</entry></row><row rowsep="0"><entry align="left"><ce:bold>Eyes</ce:bold></entry><entry align="left"/></row><row rowsep="0"><entry align="left">Uveitis</entry><entry align="left">SpA, sarcoid, JIA, Behçet's disease</entry></row><row rowsep="0"><entry align="left">Conjunctivitis</entry><entry align="left">Reactive arthritis</entry></row><row rowsep="1"><entry align="left">Episcleritis, scleritis</entry><entry align="left">RA, vasculitis</entry></row><row rowsep="0"><entry align="left"><ce:bold>Heart, lungs</ce:bold></entry><entry align="left"/></row><row rowsep="0"><entry align="left">Pleuro-pericarditis</entry><entry align="left">SLE, RA, rheumatic fever</entry></row><row rowsep="0"><entry align="left">Aortic valve/root disease</entry><entry align="left">HLA-B27-related SpA</entry></row><row rowsep="1"><entry align="left">Interstitial lung disease</entry><entry align="left">RA, SLE, primary Sjögren's syndrome</entry></row><row rowsep="0"><entry align="left"><ce:bold>Abdominal organs</ce:bold></entry><entry align="left"/></row><row rowsep="0"><entry align="left">Hepatosplenomegaly</entry><entry align="left">RA, SLE</entry></row><row rowsep="0"><entry align="left">Haematuria, proteinuria</entry><entry align="left">SLE, vasculitis, systemic sclerosis</entry></row><row rowsep="1"><entry align="left">Urethritis</entry><entry align="left">Reactive arthritis and SpA (sterile)</entry></row><row><entry align="left"><ce:bold>Fever, lymphadenopathy</ce:bold></entry><entry align="left">Infection, systemic JIA, rheumatic fever</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0110">(HLA = human leucocyte antigen; JIA = juvenile idiopathic arthritis; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; SpA = spondyloarthritis)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0075" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0140" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0525" role="short">Image 14</ce:alt-text></ce:inline-figure> 24.14</ce:label><ce:alt-text id="atte0530" role="short">24.14</ce:alt-text><ce:textbox-head><ce:title id="tit0080">Characteristics of different fracture types</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1015"><ce:display><ce:table frame="topbot" id="t0060"><ce:alt-text id="atte0535" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Fracture type</entry><entry align="left">Precipitation factor</entry><entry align="left">Disease</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Fragility fracture</ce:bold></entry><entry align="left">Fall from standing height or less</entry><entry align="left">Osteoporosis<ce:br/>Osteopenia</entry></row><row rowsep="1"><entry align="left"><ce:bold>Vertebral fracture</ce:bold></entry><entry align="left">Bending, lifting, falling</entry><entry align="left">Osteoporosis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Stress fracture</ce:bold></entry><entry align="left">Running, excessive training</entry><entry align="left">Normal</entry></row><row rowsep="1"><entry align="left"><ce:bold>High-energy fracture</ce:bold></entry><entry align="left">Major trauma</entry><entry align="left">Normal</entry></row><row><entry align="left"><ce:bold>Pathological fracture</ce:bold></entry><entry align="left">Spontaneous, minimal trauma</entry><entry align="left">Malignancy<ce:br/>Paget's disease<ce:br/>Osteomalacia</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0080" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0145" locator="icon03-9780702070280" xlink:href="pii:B978070207028000024X/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0540" role="short">Image 15</ce:alt-text></ce:inline-figure> 24.15</ce:label><ce:alt-text id="atte0545" role="short">24.15</ce:alt-text><ce:textbox-head><ce:title id="tit0085">How to investigate a suspected fracture</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1025"><ce:list id="ulist0145"><ce:list-item id="u0640"><ce:label>•</ce:label><ce:para id="p1030">Order X-rays in two projections at right angles to one another</ce:para></ce:list-item><ce:list-item id="u0645"><ce:label>•</ce:label><ce:para id="p1035">Include the whole bone and the joints at either end (this may reveal an additional unsuspected fracture)</ce:para></ce:list-item><ce:list-item id="u0650"><ce:label>•</ce:label><ce:para id="p1040">Check for evidence of displacement</ce:para></ce:list-item><ce:list-item id="u0655"><ce:label>•</ce:label><ce:para id="p1045">Check for a break in the cortex</ce:para></ce:list-item><ce:list-item id="u0660"><ce:label>•</ce:label><ce:para id="p1050">In suspected vertebral fracture, check for depression of the end plate</ce:para></ce:list-item><ce:list-item id="u0665"><ce:label>•</ce:label><ce:para id="p1055">If clinical suspicion is high but no fracture is seen, request magnetic resonance imaging</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0085" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0150" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0550" role="short">Image 16</ce:alt-text></ce:inline-figure> 24.16</ce:label><ce:alt-text id="atte0555" role="short">24.16</ce:alt-text><ce:textbox-head><ce:title id="tit0090">Some common causes of generalised pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1070"><ce:list id="ulist0150"><ce:list-item id="u0670"><ce:label>•</ce:label><ce:para id="p1075">Myopathies</ce:para></ce:list-item><ce:list-item id="u0675"><ce:label>•</ce:label><ce:para id="p1080">Psoriatic arthritis (enthesopathic)</ce:para></ce:list-item><ce:list-item id="u0680"><ce:label>•</ce:label><ce:para id="p1085">Fibromyalgia</ce:para></ce:list-item><ce:list-item id="u0685"><ce:label>•</ce:label><ce:para id="p1090">Parvovirus arthromyalgia</ce:para></ce:list-item><ce:list-item id="u0690"><ce:label>•</ce:label><ce:para id="p1095">Rheumatic fever/post-streptococcal infection</ce:para></ce:list-item><ce:list-item id="u0695"><ce:label>•</ce:label><ce:para id="p1100">Metastatic cancer</ce:para></ce:list-item><ce:list-item id="u0700"><ce:label>•</ce:label><ce:para id="p1105">Severe osteomalacia</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0090" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0155" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0560" role="short">Image 17</ce:alt-text></ce:inline-figure> 24.17</ce:label><ce:alt-text id="atte0565" role="short">24.17</ce:alt-text><ce:textbox-head><ce:title id="tit0095">Causes of low back pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1125"><ce:list id="ulist0155"><ce:list-item id="u0705"><ce:label>•</ce:label><ce:para id="p1130">Mechanical (soft-tissue lesion) back pain</ce:para></ce:list-item><ce:list-item id="u0710"><ce:label>•</ce:label><ce:para id="p1135">Intervertebral disc lesions (e.g. prolapse, disc degeneration)</ce:para></ce:list-item><ce:list-item id="u0715"><ce:label>•</ce:label><ce:para id="p1140">Facet joint disease (osteoarthritis, psoriatic arthritis)</ce:para></ce:list-item><ce:list-item id="u0720"><ce:label>•</ce:label><ce:para id="p1145">Vertebral fracture (<ce:cross-ref id="crf9035" refid="s0245">p. 994</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0725"><ce:label>•</ce:label><ce:para id="p1150">Paget's disease</ce:para></ce:list-item><ce:list-item id="u0730"><ce:label>•</ce:label><ce:para id="p1155">Axial spondyloarthritis</ce:para></ce:list-item><ce:list-item id="u0735"><ce:label>•</ce:label><ce:para id="p1160">Spondylodiscitis</ce:para></ce:list-item><ce:list-item id="u0740"><ce:label>•</ce:label><ce:para id="p1165">Bone metastases</ce:para></ce:list-item><ce:list-item id="u0745"><ce:label>•</ce:label><ce:para id="p1170">Spondylolisthesis (<ce:cross-ref id="crf9040" refid="s2005">p. 1059</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0750"><ce:label>•</ce:label><ce:para id="p1175">Scheuermann's disease (<ce:cross-ref id="crf9045" refid="s1885">p. 1055</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0095" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0165" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0570" role="short">Image 18</ce:alt-text></ce:inline-figure> 24.18</ce:label><ce:alt-text id="atte0575" role="short">24.18</ce:alt-text><ce:textbox-head><ce:title id="tit0100">Features of mechanical low back pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1185"><ce:list id="ulist0160"><ce:list-item id="u0755"><ce:label>•</ce:label><ce:para id="p1190">Pain varies with physical activity (improved with rest)</ce:para></ce:list-item><ce:list-item id="u0760"><ce:label>•</ce:label><ce:para id="p1195">Onset often sudden and precipitated by lifting or bending</ce:para></ce:list-item><ce:list-item id="u0765"><ce:label>•</ce:label><ce:para id="p1200">Recurrent episodes</ce:para></ce:list-item><ce:list-item id="u0770"><ce:label>•</ce:label><ce:para id="p1205">Pain limited to back or upper leg</ce:para></ce:list-item><ce:list-item id="u0775"><ce:label>•</ce:label><ce:para id="p1210">No clear-cut nerve root distribution</ce:para></ce:list-item><ce:list-item id="u0780"><ce:label>•</ce:label><ce:para id="p1215">No systemic features</ce:para></ce:list-item><ce:list-item id="u0785"><ce:label>•</ce:label><ce:para id="p1220">Prognosis good (90% recovery at 6 weeks)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0100" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0170" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0580" role="short">Image 19</ce:alt-text></ce:inline-figure> 24.19</ce:label><ce:alt-text id="atte0585" role="short">24.19</ce:alt-text><ce:textbox-head><ce:title id="tit0105">Red flags for possible spinal pathology</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0310"><ce:section-title id="st0280">History</ce:section-title><ce:para id="p1230"><ce:list id="ulist0165"><ce:list-item id="u0790"><ce:label>•</ce:label><ce:para id="p1235">Age: presentation &#x003C; 20 years or &#x003E; 55 years</ce:para></ce:list-item><ce:list-item id="u0795"><ce:label>•</ce:label><ce:para id="p1240">Character: constant, progressive pain unrelieved by rest</ce:para></ce:list-item><ce:list-item id="u0800"><ce:label>•</ce:label><ce:para id="p1245">Location: thoracic pain</ce:para></ce:list-item><ce:list-item id="u0805"><ce:label>•</ce:label><ce:para id="p1250">Past medical history: carcinoma, tuberculosis, HIV, systemic glucocorticoid use, osteoporosis</ce:para></ce:list-item><ce:list-item id="u0810"><ce:label>•</ce:label><ce:para id="p1255">Constitutional: systemic upset, sweats, weight loss</ce:para></ce:list-item><ce:list-item id="u0815"><ce:label>•</ce:label><ce:para id="p1260">Major trauma</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0315"><ce:section-title id="st0285">Examination</ce:section-title><ce:para id="p1265"><ce:list id="ulist0170"><ce:list-item id="u0820"><ce:label>•</ce:label><ce:para id="p1270">Painful spinal deformity</ce:para></ce:list-item><ce:list-item id="u0825"><ce:label>•</ce:label><ce:para id="p1275">Severe/symmetrical spinal deformity</ce:para></ce:list-item><ce:list-item id="u0830"><ce:label>•</ce:label><ce:para id="p1280">Saddle anaesthesia</ce:para></ce:list-item><ce:list-item id="u0835"><ce:label>•</ce:label><ce:para id="p1285">Progressive neurological signs/muscle-wasting</ce:para></ce:list-item><ce:list-item id="u0840"><ce:label>•</ce:label><ce:para id="p1290">Multiple levels of root signs</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0105" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0175" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0590" role="short">Image 20</ce:alt-text></ce:inline-figure> 24.20</ce:label><ce:alt-text id="atte0595" role="short">24.20</ce:alt-text><ce:textbox-head><ce:title id="tit0110">Clinical features of radicular pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0320"><ce:section-title id="st0290">Nerve root pain</ce:section-title><ce:para id="p1295"><ce:list id="ulist0175"><ce:list-item id="u0845"><ce:label>•</ce:label><ce:para id="p1300">Unilateral leg pain worse than low back pain</ce:para></ce:list-item><ce:list-item id="u0850"><ce:label>•</ce:label><ce:para id="p1305">Pain radiates beyond knee</ce:para></ce:list-item><ce:list-item id="u0855"><ce:label>•</ce:label><ce:para id="p1310">Paraesthesia in same distribution</ce:para></ce:list-item><ce:list-item id="u0860"><ce:label>•</ce:label><ce:para id="p1315">Nerve irritation signs (reduced straight leg raising that reproduces leg pain)</ce:para></ce:list-item><ce:list-item id="u0865"><ce:label>•</ce:label><ce:para id="p1320">Motor, sensory or reflex signs (limited to one or adjacent nerve roots)</ce:para></ce:list-item><ce:list-item id="u0870"><ce:label>•</ce:label><ce:para id="p1325">Prognosis reasonable (50% recovery at 6 weeks)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0325"><ce:section-title id="st0295">Cauda equina syndrome</ce:section-title><ce:para id="p1330"><ce:list id="ulist0180"><ce:list-item id="u0875"><ce:label>•</ce:label><ce:para id="p1335">Difficulty with micturition</ce:para></ce:list-item><ce:list-item id="u0880"><ce:label>•</ce:label><ce:para id="p1340">Loss of anal sphincter tone or faecal incontinence</ce:para></ce:list-item><ce:list-item id="u0885"><ce:label>•</ce:label><ce:para id="p1345">Saddle anaesthesia</ce:para></ce:list-item><ce:list-item id="u0890"><ce:label>•</ce:label><ce:para id="p1350">Gait disturbance</ce:para></ce:list-item><ce:list-item id="u0895"><ce:label>•</ce:label><ce:para id="p1355">Pain, numbness or weakness affecting one or both legs</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0110" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0180" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0600" role="short">Image 21</ce:alt-text></ce:inline-figure> 24.21</ce:label><ce:alt-text id="atte0605" role="short">24.21</ce:alt-text><ce:textbox-head><ce:title id="tit0115">Typical causes of neck pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1395"><ce:display><ce:table frame="topbot" id="t0065"><ce:alt-text id="atte0610" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Mechanical</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0185"><ce:list-item id="u0900"><ce:label>•</ce:label><ce:para id="p1400">Postural</ce:para></ce:list-item><ce:list-item id="u0905"><ce:label>•</ce:label><ce:para id="p1405">Whiplash injury</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0190"><ce:list-item id="u0910"><ce:label>•</ce:label><ce:para id="p1410">Facet joint</ce:para></ce:list-item><ce:list-item id="u0915"><ce:label>•</ce:label><ce:para id="p1415">Cervical spondylosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0195"><ce:list-item id="u0920"><ce:label>•</ce:label><ce:para id="p1420">Infections</ce:para></ce:list-item><ce:list-item id="u0925"><ce:label>•</ce:label><ce:para id="p1425">Axial spondyloarthritis</ce:para></ce:list-item><ce:list-item id="u0930"><ce:label>•</ce:label><ce:para id="p1430">Psoriatic arthritis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0200"><ce:list-item id="u0935"><ce:label>•</ce:label><ce:para id="p1435">Rheumatoid arthritis</ce:para></ce:list-item><ce:list-item id="u0940"><ce:label>•</ce:label><ce:para id="p1440">Polymyalgia rheumatica</ce:para></ce:list-item><ce:list-item id="u0945"><ce:label>•</ce:label><ce:para id="p1445">Discitis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0205"><ce:list-item id="u0950"><ce:label>•</ce:label><ce:para id="p1450">Axial calcium pyrophosphate dihydrate disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0210"><ce:list-item id="u0955"><ce:label>•</ce:label><ce:para id="p1455">Fibrous dysplasia</ce:para></ce:list-item><ce:list-item id="u0960"><ce:label>•</ce:label><ce:para id="p1460">Paget's disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neoplastic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0215"><ce:list-item id="u0965"><ce:label>•</ce:label><ce:para id="p1465">Metastases</ce:para></ce:list-item><ce:list-item id="u0970"><ce:label>•</ce:label><ce:para id="p1470">Myeloma</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0220"><ce:list-item id="u0975"><ce:label>•</ce:label><ce:para id="p1475">Lymphoma</ce:para></ce:list-item><ce:list-item id="u0980"><ce:label>•</ce:label><ce:para id="p1480">Intrathecal tumours</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0225"><ce:list-item id="u0985"><ce:label>•</ce:label><ce:para id="p1485">Fibromyalgia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0230"><ce:list-item id="u0990"><ce:label>•</ce:label><ce:para id="p1490">Torticollis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Referred</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0235"><ce:list-item id="u0995"><ce:label>•</ce:label><ce:para id="p1495">Pharynx</ce:para></ce:list-item><ce:list-item id="u1000"><ce:label>•</ce:label><ce:para id="p1500">Cervical lymph nodes</ce:para></ce:list-item><ce:list-item id="u1005"><ce:label>•</ce:label><ce:para id="p1505">Teeth</ce:para></ce:list-item><ce:list-item id="u1010"><ce:label>•</ce:label><ce:para id="p1510">Angina pectoris</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0240"><ce:list-item id="u1015"><ce:label>•</ce:label><ce:para id="p1515">Aortic aneurysm</ce:para></ce:list-item><ce:list-item id="u1020"><ce:label>•</ce:label><ce:para id="p1520">Pancoast tumour</ce:para></ce:list-item><ce:list-item id="u1025"><ce:label>•</ce:label><ce:para id="p1525">Diaphragm</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0115" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0185" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0615" role="short">Image 22</ce:alt-text></ce:inline-figure> 24.22</ce:label><ce:alt-text id="atte0620" role="short">24.22</ce:alt-text><ce:textbox-head><ce:title id="tit0120">Clinical findings in shoulder pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0355"><ce:section-title id="st0325">Rotator cuff and subacromial lesions</ce:section-title><ce:para id="p1535"><ce:list id="ulist0245"><ce:list-item id="u1030"><ce:label>•</ce:label><ce:para id="p1540">Pain reproduced by resisted active movement:<ce:list id="ulist0250"><ce:list-item id="u1035"><ce:para id="p1545">Abduction: supraspinatus</ce:para></ce:list-item><ce:list-item id="u1040"><ce:para id="p1550">External rotation: infraspinatus, teres minor</ce:para></ce:list-item><ce:list-item id="u1045"><ce:para id="p1555">Internal rotation: subscapularis</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0360"><ce:section-title id="st0330">Acromioclavicular joint</ce:section-title><ce:para id="p1560"><ce:list id="ulist0255"><ce:list-item id="u1050"><ce:label>•</ce:label><ce:para id="p1565">Pain on full abduction and adduction (at 90° of forward elevation)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0365"><ce:section-title id="st0335">Bicipital (long head) tendinitis</ce:section-title><ce:para id="p1570"><ce:list id="ulist0260"><ce:list-item id="u1055"><ce:label>•</ce:label><ce:para id="p1575">Tenderness over bicipital groove</ce:para></ce:list-item><ce:list-item id="u1060"><ce:label>•</ce:label><ce:para id="p1580">Pain reproduced by resisted active wrist supination or elbow flexion</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0120" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0195" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0625" role="short">Image 23</ce:alt-text></ce:inline-figure> 24.23</ce:label><ce:alt-text id="atte0630" role="short">24.23</ce:alt-text><ce:textbox-head><ce:title id="tit0125">Typical local causes of elbow pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1590"><ce:display><ce:table frame="topbot" id="t0070"><ce:alt-text id="atte0635" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Lesion</entry><entry align="left">Pain</entry><entry align="left">Examination findings</entry></row></thead><tbody><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Lateral humeral epicondylitis</ce:bold><ce:br/>(e.g. traumatic ‘tennis elbow’ or SpA-related enthesitis)</entry><entry rowsep="0" align="left">Lateral epicondyle</entry><entry rowsep="0" align="left">Tenderness over epicondyle</entry></row><row rowsep="1"><entry align="left">Radiation to extensor forearm</entry><entry align="left">Pain reproduced by resisted active wrist extension</entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Medial humeral epicondylitis</ce:bold><ce:br/>(e.g. traumatic ‘golfer's elbow’ or SpA-related enthesitis)</entry><entry rowsep="0" align="left">Medial epicondyle</entry><entry rowsep="0" align="left">Tenderness over epicondyle</entry></row><row rowsep="1"><entry align="left">Radiation to flexor forearm</entry><entry align="left">Pain reproduced by resisted active wrist flexion</entry></row><row><entry align="left"><ce:bold>Olecranon bursitis</ce:bold> (e.g. gout, rheumatoid arthritis or infective, as in tuberculosis)</entry><entry align="left">Olecranon</entry><entry align="left">Tender swelling</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0140">(SpA = spondyloarthritis)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0125" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0205" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0640" role="short">Image 24</ce:alt-text></ce:inline-figure> 24.24</ce:label><ce:alt-text id="atte0645" role="short">24.24</ce:alt-text><ce:textbox-head><ce:title id="tit0130">Local causes of hip pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1625"><ce:display><ce:table frame="topbot" id="t0075"><ce:alt-text id="atte0650" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Lesion</entry><entry align="left">Pain</entry><entry align="left">Examination findings</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Gluteus medius enthesitis</ce:bold></entry><entry align="left">Upper lateral thigh, worse on lying on that side at night</entry><entry align="left">Tenderness over greater trochanter</entry></row><row rowsep="1"><entry align="left"><ce:bold>Trochanteric bursitis</ce:bold></entry><entry align="left">As above</entry><entry align="left">As above</entry></row><row rowsep="1"><entry align="left"><ce:bold>Adductor tendinitis</ce:bold><ce:br/>(usually an SpA-enthesitis or sports-related trauma lesion)</entry><entry align="left">Upper inner thigh</entry><entry align="left">Tenderness over adductor origin/tendon/muscle<ce:br/>Pain reproduced by resisted active hip adduction</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ischiogluteal enthesitis/bursitis</ce:bold></entry><entry align="left">Buttock, worse on sitting</entry><entry align="left">Tenderness over ischial prominence</entry></row><row><entry align="left"><ce:bold>Pubic symphysitis</ce:bold><ce:br/>(can mimic intra-articular hip lesions)</entry><entry align="left">Medial groin pain, can radiate to inner or even outer upper thighs</entry><entry align="left">Tenderness over symphysis joint<ce:br/>If pain is worse on trunk curl/rectus activation under symphysis-resting hand, it may be insertional rectus enthesitis (SpAs)</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0155">(SpA = spondyloarthritis)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0130" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0210" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0655" role="short">Image 25</ce:alt-text></ce:inline-figure> 24.25</ce:label><ce:alt-text id="atte0660" role="short">24.25</ce:alt-text><ce:textbox-head><ce:title id="tit0135">Local causes of knee pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1635"><ce:display><ce:table frame="topbot" id="t0080"><ce:alt-text id="atte0665" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Lesion</entry><entry align="left">Pain</entry><entry align="left">Examination findings</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Pre-patellar bursitis</ce:bold></entry><entry align="left">Over patella</entry><entry align="left">Tender fluctuant swelling in front of patella</entry></row><row rowsep="1"><entry align="left"><ce:bold>Superficial and deep infrapatellar bursitis and fat-pad syndrome</ce:bold></entry><entry align="left">Anterior knee, inferior to patella</entry><entry align="left">Tenderness in front of (superficial) or behind (deep) patellar tendon<ce:br/>Pain on full flexion</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anserine bursitis/enthesitis</ce:bold></entry><entry align="left">Upper medial tibia</entry><entry align="left">Tenderness (± swelling) over upper medial tibia</entry></row><row rowsep="1"><entry align="left"><ce:bold>Medial collateral ligament lesions</ce:bold> (e.g. enthesitis)</entry><entry align="left">Upper medial tibia</entry><entry align="left">Localised tenderness of upper medial tibia<ce:br/>Pain reproduced by valgus stress on partly flexed knee</entry></row><row rowsep="1"><entry align="left"><ce:bold>Popliteal cyst (Baker's cyst)</ce:bold></entry><entry align="left">Popliteal fossa</entry><entry align="left">Tender swelling of popliteal fossa</entry></row><row rowsep="1"><entry align="left"><ce:bold>Patellar ligament enthesopathy</ce:bold></entry><entry align="left">Anterior upper tibia</entry><entry align="left">Tenderness over tibial tubercle</entry></row><row><entry align="left"><ce:bold>Osteochondritis of patellar ligament (Osgood–Schlatter disease)</ce:bold></entry><entry align="left">Anterior upper tibia</entry><entry align="left">Adolescents are affected<ce:br/>Pain on resisted active knee extension</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0135" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0215" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0670" role="short">Image 26</ce:alt-text></ce:inline-figure> 24.26</ce:label><ce:alt-text id="atte0675" role="short">24.26</ce:alt-text><ce:textbox-head><ce:title id="tit0140">Causes of proximal muscle pain or weakness</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1655"><ce:display><ce:table frame="topbot" id="t0085"><ce:alt-text id="atte0680" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0270"><ce:list-item id="u1085"><ce:label>•</ce:label><ce:para id="p1660">Polymyositis</ce:para></ce:list-item><ce:list-item id="u1090"><ce:label>•</ce:label><ce:para id="p1665">Dermatomyositis</ce:para></ce:list-item><ce:list-item id="u1095"><ce:label>•</ce:label><ce:para id="p1670">Other autoimmune connective tissue disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0275"><ce:list-item id="u1100"><ce:label>•</ce:label><ce:para id="p1675">Inclusion body myositis</ce:para></ce:list-item><ce:list-item id="u1105"><ce:label>•</ce:label><ce:para id="p1680">Sarcoid</ce:para></ce:list-item><ce:list-item id="u1110"><ce:label>•</ce:label><ce:para id="p1685">Myasthenia gravis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Endocrine (</ce:bold><ce:intra-ref id="ii0190" xlink:href="pii:B978-0-7020-7028-0.00018-4#c00018"><ce:bold>Ch. 18</ce:bold></ce:intra-ref><ce:bold>)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0280"><ce:list-item id="u1115"><ce:label>•</ce:label><ce:para id="p1690">Hypothyroidism</ce:para></ce:list-item><ce:list-item id="u1120"><ce:label>•</ce:label><ce:para id="p1695">Hyperthyroidism</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0285"><ce:list-item id="u1125"><ce:label>•</ce:label><ce:para id="p1700">Cushing's syndrome</ce:para></ce:list-item><ce:list-item id="u1130"><ce:label>•</ce:label><ce:para id="p1705">Addison's disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic (</ce:bold><ce:intra-ref id="ii0195" xlink:href="pii:B978-0-7020-7028-0.00014-7#c00014"><ce:bold>Ch. 14</ce:bold></ce:intra-ref><ce:bold>)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0290"><ce:list-item id="u1135"><ce:label>•</ce:label><ce:para id="p1710">Myophosphorylase deficiency</ce:para></ce:list-item><ce:list-item id="u1140"><ce:label>•</ce:label><ce:para id="p1715">Phosphofructokinase deficiency</ce:para></ce:list-item><ce:list-item id="u1145"><ce:label>•</ce:label><ce:para id="p1720">Hypokalaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0295"><ce:list-item id="u1150"><ce:label>•</ce:label><ce:para id="p1725">Carnitine deficiency</ce:para></ce:list-item><ce:list-item id="u1160"><ce:label>•</ce:label><ce:para id="p1735">Osteomalacia (<ce:cross-ref id="crf9050" refid="s9005">p. 1049</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u1155"><ce:label>•</ce:label><ce:para id="p1730">Hypercalcaemia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Genetic</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="olist9000"><ce:list-item id="o9000"><ce:label>•</ce:label><ce:para id="p9000">Muscular dystrophy (various; <ce:intra-ref id="ii9010" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2215">p. 1143</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs/toxins</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0300"><ce:list-item id="u1165"><ce:label>•</ce:label><ce:para id="p1740">Alcohol</ce:para></ce:list-item><ce:list-item id="u1170"><ce:label>•</ce:label><ce:para id="p1745">Cocaine</ce:para></ce:list-item><ce:list-item id="u1175"><ce:label>•</ce:label><ce:para id="p1750">Glucocorticoids</ce:para></ce:list-item><ce:list-item id="u1180"><ce:label>•</ce:label><ce:para id="p1755">Statins and fibrates</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0305"><ce:list-item id="u1185"><ce:label>•</ce:label><ce:para id="p1760">Tumour necrosis factor inhibitors</ce:para></ce:list-item><ce:list-item id="u1190"><ce:label>•</ce:label><ce:para id="p1765">Zidovudine</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infections (</ce:bold><ce:intra-ref id="ii0205" xlink:href="pii:B978-0-7020-7028-0.00011-1#c00011"><ce:bold>Ch. 11</ce:bold></ce:intra-ref><ce:bold>)</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0310"><ce:list-item id="u1195"><ce:label>•</ce:label><ce:para id="p1770">Viral (HIV, cytomegalovirus, rubella, Epstein–Barr, echo)</ce:para></ce:list-item><ce:list-item id="u1200"><ce:label>•</ce:label><ce:para id="p1775">Parasitic (schistosomiasis, cysticercosis, toxoplasmosis)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0315"><ce:list-item id="u1205"><ce:label>•</ce:label><ce:para id="p1780">Bacterial (<ce:italic>Clostridium perfringens</ce:italic>, staphylococci, tuberculosis, <ce:italic>Mycoplasma</ce:italic>)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0140" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0220" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0685" role="short">Image 27</ce:alt-text></ce:inline-figure> 24.27</ce:label><ce:alt-text id="atte0690" role="short">24.27</ce:alt-text><ce:textbox-head><ce:title id="tit0145">Interventions for patients with rheumatic diseases</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1870"><ce:display><ce:table frame="topbot" id="t0090"><ce:alt-text id="atte0695" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Core interventions</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0330"><ce:list-item id="u1265"><ce:label>•</ce:label><ce:para id="p1875">Education</ce:para></ce:list-item><ce:list-item id="u1270"><ce:label>•</ce:label><ce:para id="p1880">Aerobic conditioning</ce:para></ce:list-item><ce:list-item id="u1275"><ce:label>•</ce:label><ce:para id="p1885">Muscle strengthening</ce:para></ce:list-item><ce:list-item id="u1280"><ce:label>•</ce:label><ce:para id="p1890">Simple analgesics</ce:para></ce:list-item><ce:list-item id="u1285"><ce:label>•</ce:label><ce:para id="p1895">Disease-modifying therapy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0335"><ce:list-item id="u1290"><ce:label>•</ce:label><ce:para id="p1900">Reduction of adverse mechanical factors</ce:para></ce:list-item><ce:list-item id="u1295"><ce:label>•</ce:label><ce:para id="p1905">Pacing of activities</ce:para></ce:list-item><ce:list-item id="u1300"><ce:label>•</ce:label><ce:para id="p1910">Appropriate footwear</ce:para></ce:list-item><ce:list-item id="u1305"><ce:label>•</ce:label><ce:para id="p1915">Weight reduction if obese</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other options</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0340"><ce:list-item id="u1310"><ce:label>•</ce:label><ce:para id="p1920">Other analgesic drugs:<ce:list id="ulist0345"><ce:list-item id="u1315"><ce:para id="p1925">Oral non-steroidal anti-inflammatory drugs</ce:para></ce:list-item><ce:list-item id="u1320"><ce:para id="p1930">Topical agents</ce:para></ce:list-item><ce:list-item id="u1325"><ce:para id="p1935">Opioid analgesics</ce:para></ce:list-item><ce:list-item id="u1330"><ce:para id="p1940">Amitriptyline</ce:para></ce:list-item><ce:list-item id="u1335"><ce:para id="p1945">Gabapentin/pregabalin</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0350"><ce:list-item id="u1340"><ce:label>•</ce:label><ce:para id="p1950">Local glucocorticoid injections</ce:para></ce:list-item><ce:list-item id="u1345"><ce:label>•</ce:label><ce:para id="p1955">Physical treatments:<ce:list id="olist9005"><ce:list-item id="o9005"><ce:para id="p9005">Heat, cold, aids, appliances</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1355"><ce:label>•</ce:label><ce:para id="p1965">Surgery</ce:para></ce:list-item><ce:list-item id="u1360"><ce:label>•</ce:label><ce:para id="p1970">Coping strategies (see <ce:cross-ref id="crf0545" refid="b0145">Box 24.28</ce:cross-ref>)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0145" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0225" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0700" role="short">Image 28</ce:alt-text></ce:inline-figure> 24.28</ce:label><ce:alt-text id="atte0705" role="short">24.28</ce:alt-text><ce:textbox-head><ce:title id="tit0150">Self-help and coping strategies</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2035"><ce:list id="ulist0360"><ce:list-item id="u1380"><ce:label>•</ce:label><ce:para id="p2040">Yoga and relaxation techniques to reduce stress</ce:para></ce:list-item><ce:list-item id="u1385"><ce:label>•</ce:label><ce:para id="p2045">Avoidance of negative situations or activities that produce stress and increase in pleasant activities that give satisfaction</ce:para></ce:list-item><ce:list-item id="u1390"><ce:label>•</ce:label><ce:para id="p2050">Information and discussion to alter beliefs about and perspectives on disease</ce:para></ce:list-item><ce:list-item id="u1395"><ce:label>•</ce:label><ce:para id="p2055">Reduction or avoidance of catastrophising and maladaptive pain behaviour</ce:para></ce:list-item><ce:list-item id="u1400"><ce:label>•</ce:label><ce:para id="p2060">Imagery and distraction techniques for pain</ce:para></ce:list-item><ce:list-item id="u1405"><ce:label>•</ce:label><ce:para id="p2065">Expansion of social contact and better use of social services</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0150" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0230" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0710" role="short">Image 29</ce:alt-text></ce:inline-figure> 24.29</ce:label><ce:alt-text id="atte0715" role="short">24.29</ce:alt-text><ce:textbox-head><ce:title id="tit0155">Surgical procedures in rheumatology and bone disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2090"><ce:display><ce:table frame="topbot" id="t0095"><ce:alt-text id="atte0720" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Procedure</entry><entry align="left">Indication</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Soft tissue release</ce:bold></entry></row><row rowsep="0"><entry align="left">Carpal tunnel</entry><entry align="left">Median nerve compression</entry></row><row rowsep="0"><entry align="left">Tarsal tunnel</entry><entry align="left">Posterior tibial nerve entrapment</entry></row><row rowsep="0"><entry align="left">Flexor tenosynovectomy</entry><entry align="left">Relief of ‘trigger’ fingers</entry></row><row rowsep="0"><entry align="left">Ulnar nerve transposition</entry><entry align="left">Ulnar nerve entrapment at elbow</entry></row><row rowsep="1"><entry align="left">Fasciotomy</entry><entry align="left">Severe Dupuytren's contracture</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Tendon repairs and transfers</ce:bold></entry></row><row rowsep="0"><entry align="left">Hand extensor tendons</entry><entry align="left">Extensor tendon rupture</entry></row><row rowsep="1"><entry align="left">Thumb and finger flexor tendons</entry><entry align="left">Flexor tendon rupture</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Synovectomy</ce:bold></entry></row><row rowsep="0"><entry align="left">Wrist and extensor tendon sheath (+ excision of radial head)</entry><entry align="left">Pain relief and prevention of extensor tendon rupture in RA, resistant inflammatory synovitis</entry></row><row rowsep="1"><entry align="left">Knee synovectomy</entry><entry align="left">Resistant inflammatory synovitis</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Osteotomy</ce:bold></entry></row><row rowsep="0"><entry align="left">Femoral osteotomy</entry><entry align="left">Early OA of hip</entry></row><row><entry morerows="1" rowsep="1" align="left">Tibial osteotomy</entry><entry rowsep="0" align="left">Unicompartmental knee OA</entry></row><row rowsep="1"><entry align="left">Deformed tibia in OA or Paget's disease</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Excision arthroplasty</ce:bold></entry></row><row rowsep="0"><entry align="left">First metatarsophalangeal joint (Keller's procedure)</entry><entry align="left">Painful hallux valgus</entry></row><row rowsep="0"><entry align="left">Radial head</entry><entry align="left">Painful distal radio-ulnar joint</entry></row><row rowsep="0"><entry align="left">Lateral end of clavicle</entry><entry align="left">Painful acromioclavicular joint</entry></row><row rowsep="1"><entry align="left">Metatarsal head</entry><entry align="left">Painful subluxed metatarsophalangeal joints</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Joint replacement arthroplasty</ce:bold></entry></row><row rowsep="1"><entry align="left">Knee, hip, shoulder, elbow</entry><entry align="left">Painful damaged joints in OA and RA</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Arthrodesis</ce:bold></entry></row><row rowsep="0"><entry align="left">Wrist</entry><entry align="left">Damaged joint: pain relief, improvement of grip</entry></row><row rowsep="1"><entry align="left">Ankle/subtalar joints</entry><entry align="left">Damaged joint: pain relief, stabilisation of hindfoot</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fracture repair</ce:bold></entry></row><row rowsep="0"><entry align="left">Hip arthroplasty</entry><entry align="left">Fractured neck of femur</entry></row><row rowsep="0"><entry align="left">External fixation</entry><entry align="left">Multiple fractures, open fractures</entry></row><row rowsep="0"><entry align="left">Intramedullary nailing</entry><entry align="left">Tibial and femur fractures</entry></row><row rowsep="1"><entry align="left">Screw, plating and wiring</entry><entry align="left">Wrist and other fractures</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other procedures</ce:bold></entry></row><row rowsep="0"><entry align="left">Nerve root decompression</entry><entry align="left">Spinal stenosis, nerve entrapment</entry></row><row rowsep="0"><entry align="left">Kyphoplasty</entry><entry align="left">Painful vertebral fracture (evidence base poor)</entry></row><row><entry align="left">Vertebroplasty</entry><entry align="left">Painful vertebral fracture (evidence base poor)</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0155" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0240" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0725" role="short">Image 30</ce:alt-text></ce:inline-figure> 24.30</ce:label><ce:alt-text id="atte0730" role="short">24.30</ce:alt-text><ce:textbox-head><ce:title id="tit0160">Commonly used NSAIDs and their risk of gastrointestinal bleeding and perforation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2115"><ce:display><ce:table frame="topbot" id="t0100"><ce:alt-text id="atte0735" role="short">Unlabelled table</ce:alt-text><ce:link id="ln0245" locator="b024-030-9780702070280" xlink:href="pii:B978070207028000024X/b024-030-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:legend><ce:simple-para id="sp0165">(CNS = central nervous system; COX = cyclo-oxygenase; PPI = proton pump inhibitor)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0160" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0250" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0740" role="short">Image 31</ce:alt-text></ce:inline-figure> 24.31</ce:label><ce:alt-text id="atte0745" role="short">24.31</ce:alt-text><ce:textbox-head><ce:title id="tit0165">Risk factors for NSAID-induced ulcers</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2120"><ce:list id="ulist0365"><ce:list-item id="u1410"><ce:label>•</ce:label><ce:para id="p2125">Age &#x003E; 60 years<ce:cross-ref id="crf0580" refid="fn0025">*</ce:cross-ref><ce:footnote id="fn0025"><ce:label>*</ce:label><ce:note-para id="np0030">The most important risk factors.</ce:note-para></ce:footnote></ce:para></ce:list-item><ce:list-item id="u1415"><ce:label>•</ce:label><ce:para id="p2130">Past history of peptic ulcer<ce:cross-ref id="crf0585" refid="fn0025">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1420"><ce:label>•</ce:label><ce:para id="p2135">Past history of adverse event with NSAID</ce:para></ce:list-item><ce:list-item id="u1425"><ce:label>•</ce:label><ce:para id="p2140">Concomitant glucocorticoid use</ce:para></ce:list-item><ce:list-item id="u1430"><ce:label>•</ce:label><ce:para id="p2145">High-dose or multiple NSAIDs</ce:para></ce:list-item><ce:list-item id="u1435"><ce:label>•</ce:label><ce:para id="p2150">High-risk NSAID (see <ce:cross-ref id="crf0590" refid="b0155">Box 24.30</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0165" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0255" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0750" role="short">Image 32</ce:alt-text></ce:inline-figure> 24.32</ce:label><ce:alt-text id="atte0755" role="short">24.32</ce:alt-text><ce:textbox-head><ce:title id="tit0170">Recommendations for the use of NSAIDs</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2160"><ce:list id="ulist0370"><ce:list-item id="u1440"><ce:label>•</ce:label><ce:para id="p2165">Use the lowest dose for the shortest time possible to control symptoms</ce:para></ce:list-item><ce:list-item id="u1445"><ce:label>•</ce:label><ce:para id="p2170">Avoid NSAIDs in patients on warfarin</ce:para></ce:list-item><ce:list-item id="u1450"><ce:label>•</ce:label><ce:para id="p2175">Allow 2–3 weeks to assess efficacy. If response is inadequate, consider a trial of another NSAID</ce:para></ce:list-item><ce:list-item id="u1455"><ce:label>•</ce:label><ce:para id="p2180">Never prescribe more than one NSAID at a time</ce:para></ce:list-item><ce:list-item id="u1460"><ce:label>•</ce:label><ce:para id="p2185">Co-prescribe a proton pump inhibitor for patients with risk factors for gastrointestinal adverse effects (see <ce:cross-ref id="crf0600" refid="b0160">Box 24.31</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u1465"><ce:label>•</ce:label><ce:para id="p2190">Avoid in patients with vascular disease</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0170" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0260" locator="icon02-9780702070280" xlink:href="pii:B978070207028000024X/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0760" role="short">Image 33</ce:alt-text></ce:inline-figure> 24.33</ce:label><ce:alt-text id="atte0765" role="short">24.33</ce:alt-text><ce:textbox-head><ce:title id="tit0175">Use of oral NSAIDs in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2195"><ce:list id="ulist0375"><ce:list-item id="u1470"><ce:label>•</ce:label><ce:para id="p2200"><ce:bold>Gastrointestinal complications</ce:bold>: age is a strong risk factor for bleeding and perforation, and for peptic ulceration. Elderly patients are more likely to die if they suffer NSAID-associated bleeding or perforation.</ce:para></ce:list-item><ce:list-item id="u1475"><ce:label>•</ce:label><ce:para id="p2205"><ce:bold>Cardiovascular disease</ce:bold>: use NSAIDs with caution in patients with cardiovascular disease. Therapy with NSAIDs may exacerbate hypertension and heart failure.</ce:para></ce:list-item><ce:list-item id="u1480"><ce:label>•</ce:label><ce:para id="p2210"><ce:bold>Renal disease</ce:bold>: use of NSAIDs may cause renal impairment.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0175" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0265" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0770" role="short">Image 34</ce:alt-text></ce:inline-figure> 24.34</ce:label><ce:alt-text id="atte0775" role="short">24.34</ce:alt-text><ce:textbox-head><ce:title id="tit0180">Disease-modifying antirheumatic drugs</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2225"><ce:display><ce:table frame="topbot" id="t0105"><ce:alt-text id="atte0780" role="short">Unlabelled table</ce:alt-text><tgroup cols="6"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><colspec colname="col6" colnum="6"/><thead><row rowsep="1"><entry morerows="1" align="left">Drug</entry><entry morerows="1" align="left">Maintenance dose</entry><entry namest="col3" nameend="col5" align="center">Monitoring<ce:cross-ref id="crf0615" refid="tn0015">*</ce:cross-ref></entry><entry morerows="1" align="left">Indications</entry></row><row role="tcolhead1" rowsep="1"><entry align="left">FBC</entry><entry align="left">LFTs</entry><entry align="left">Other</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Methotrexate</ce:bold></entry><entry align="left">10–25 mg weekly orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left"/><entry align="left">RA, PsA, AxSpA, JIA</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sulfasalazine</ce:bold></entry><entry align="left">2–4 g daily orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left"/><entry align="left">RA, PsA, AxSpA, JIA</entry></row><row rowsep="1"><entry align="left"><ce:bold>Hydroxychloroquine</ce:bold></entry><entry align="left">200–400 mg daily orally</entry><entry align="left">–</entry><entry align="left">–</entry><entry align="left">Visual function</entry><entry align="left">RA, SLE</entry></row><row rowsep="1"><entry align="left"><ce:bold>Leflunomide</ce:bold></entry><entry align="left">10–20 mg daily orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">BP</entry><entry align="left">RA, JIA, PsA</entry></row><row rowsep="1"><entry align="left"><ce:bold>Azathioprine</ce:bold></entry><entry align="left">1–2.5 mg/kg daily orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left"/><entry align="left">SLE, SV</entry></row><row rowsep="1"><entry align="left"><ce:bold>Apremilast</ce:bold></entry><entry align="left">30 mg twice daily orally</entry><entry align="left">–</entry><entry align="left">–</entry><entry align="left">–</entry><entry align="left">PsA</entry></row><row rowsep="1"><entry align="left"><ce:bold>Tofacitinib</ce:bold></entry><entry align="left">5 mg twice daily orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">Infection</entry><entry align="left">RA</entry></row><row rowsep="1"><entry align="left"><ce:bold>Baricitinib</ce:bold></entry><entry align="left">2–4 mg daily orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">Infection</entry><entry align="left">RA</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cyclophosphamide</ce:bold></entry><entry align="left">2 mg/kg daily orally<ce:br/>15 mg/kg IV</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">eGFR</entry><entry align="left">SLE, SV</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mycophenolate mofetil (MMF)</ce:bold></entry><entry align="left">2–4 g daily orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">–</entry><entry align="left">SLE, SV</entry></row><row rowsep="1"><entry align="left"><ce:bold>Gold (myocrisin)</ce:bold></entry><entry align="left">50 mg 4-weekly IM</entry><entry align="left">✓</entry><entry align="left">–</entry><entry align="left">Urinalysis</entry><entry align="left">RA</entry></row><row rowsep="1"><entry align="left"><ce:bold>Penicillamine</ce:bold></entry><entry align="left">500–1500 mg daily orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">Urinalysis</entry><entry align="left">RA</entry></row><row><entry align="left"><ce:bold>Ciclosporin A</ce:bold></entry><entry align="left">3–5 mg/kg daily orally</entry><entry align="left">–</entry><entry align="left">–</entry><entry align="left">BP, eGFR</entry><entry align="left">RA, PsA</entry></row></tbody></tgroup><ce:table-footnote id="tn0015"><ce:label>*</ce:label><ce:note-para id="np0035">Monitoring tests are usually done every 2 weeks on initiation of treatment for 6 weeks, then monthly for 3 months, then 3-monthly. (AxSpA = axial spondyloarthritis; BP = blood pressure; eGFR = estimated glomerular filtration rate; FBC = full blood count; IM = intramuscular; IV = intravenous; JIA = juvenile idiopathic arthritis; LFTs = liver function tests; PsA = psoriatic arthritis; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; SV = systemic vasculitis)</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0180" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0275" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0785" role="short">Image 35</ce:alt-text></ce:inline-figure> 24.35</ce:label><ce:alt-text id="atte0790" role="short">24.35</ce:alt-text><ce:textbox-head><ce:title id="tit0185">Biological drugs for inflammatory rheumatic disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2300"><ce:display><ce:table frame="topbot" id="t0110"><ce:alt-text id="atte0795" role="short">Unlabelled table</ce:alt-text><ce:link id="ln9000" locator="b024-035-9780702070280" xlink:href="pii:B978070207028000024X/b024-035-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:legend><ce:simple-para id="sp0180">(AOSD = adult-onset Still's disease; AxSpA = axial spondyloarthritis; BAFF = B-cell-activating factor of the TNF family; CAPS = cryopyrin-associated periodic syndromes; CD = cluster of differentiation; IL = interleukin; IV = intravenous; JIA = juvenile idiopathic arthritis; PsA = psoriatic arthritis; RA = rheumatoid arthritis; SC = subcutaneous; sJIA = systemic juvenile inflammatory arthritis; SLE = systemic lupus erythematosus; TNF-α = tumour necrosis factor alpha)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0185" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0280" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0800" role="short">Image 36</ce:alt-text></ce:inline-figure> 24.36</ce:label><ce:alt-text id="atte0805" role="short">24.36</ce:alt-text><ce:textbox-head><ce:title id="tit0190">Risk factors for osteoarthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s9000"><ce:section id="s0635"><ce:section-title id="st0590">Genetics</ce:section-title><ce:para id="p2365"><ce:list id="ulist0380"><ce:list-item id="u1485"><ce:label>•</ce:label><ce:para id="p2370">Skeletal dysplasias</ce:para></ce:list-item><ce:list-item id="u1490"><ce:label>•</ce:label><ce:para id="p2375">Polygenic inheritance</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0640"><ce:section-title id="st0595">Developmental abnormalities</ce:section-title><ce:para id="p2380"><ce:list id="ulist0385"><ce:list-item id="u1495"><ce:label>•</ce:label><ce:para id="p2385">Developmental dysplasia of the hip</ce:para></ce:list-item><ce:list-item id="u1500"><ce:label>•</ce:label><ce:para id="p2390">Slipped femoral epiphysis</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0645"><ce:section-title id="st0600">Repetitive loading</ce:section-title><ce:para id="p2395"><ce:list id="ulist0390"><ce:list-item id="u1505"><ce:label>•</ce:label><ce:para id="p2400">Farmers</ce:para></ce:list-item><ce:list-item id="u1510"><ce:label>•</ce:label><ce:para id="p2405">Miners</ce:para></ce:list-item><ce:list-item id="u1515"><ce:label>•</ce:label><ce:para id="p2410">Elite athletes</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0650"><ce:section-title id="st0605">Adverse biomechanics</ce:section-title><ce:para id="p2415"><ce:list id="ulist0395"><ce:list-item id="u1520"><ce:label>•</ce:label><ce:para id="p2420">Meniscectomy</ce:para></ce:list-item><ce:list-item id="u1525"><ce:label>•</ce:label><ce:para id="p2425">Ligament rupture</ce:para></ce:list-item><ce:list-item id="u1530"><ce:label>•</ce:label><ce:para id="p2430">Paget's disease</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0655"><ce:section-title id="st0610">Obesity</ce:section-title><ce:para id="p2435"><ce:bold>Trauma</ce:bold></ce:para><ce:para id="p2440"><ce:bold>Hormonal</ce:bold></ce:para><ce:para id="p2445"><ce:list id="ulist0400"><ce:list-item id="u1535"><ce:label>•</ce:label><ce:para id="p2450">Oestrogen deficiency</ce:para></ce:list-item><ce:list-item id="u1540"><ce:label>•</ce:label><ce:para id="p2455">Aromatase inhibitors</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0190" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0290" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0810" role="short">Image 37</ce:alt-text></ce:inline-figure> 24.37</ce:label><ce:alt-text id="atte0815" role="short">24.37</ce:alt-text><ce:textbox-head><ce:title id="tit0195">Symptoms and signs of osteoarthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0665"><ce:section-title id="st0620">Pain</ce:section-title><ce:para id="p2485"><ce:list id="ulist0405"><ce:list-item id="u1545"><ce:label>•</ce:label><ce:para id="p2490">Insidious onset over months or years</ce:para></ce:list-item><ce:list-item id="u1550"><ce:label>•</ce:label><ce:para id="p2495">Variable or intermittent nature over time (‘good days, bad days’)</ce:para></ce:list-item><ce:list-item id="u1555"><ce:label>•</ce:label><ce:para id="p2500">Mainly related to movement and weight-bearing, relieved by rest</ce:para></ce:list-item><ce:list-item id="u1560"><ce:label>•</ce:label><ce:para id="p2505">Only brief (&#x003C; 15 mins) morning stiffness and brief (&#x003C; 5 mins) ‘gelling’ after rest</ce:para></ce:list-item><ce:list-item id="u1565"><ce:label>•</ce:label><ce:para id="p2510">Usually only one or a few joints painful</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0670"><ce:section-title id="st0625">Clinical signs</ce:section-title><ce:para id="p2515"><ce:list id="ulist0410"><ce:list-item id="u1570"><ce:label>•</ce:label><ce:para id="p2520">Restricted movement due to capsular thickening or blocking by osteophyte</ce:para></ce:list-item><ce:list-item id="u1575"><ce:label>•</ce:label><ce:para id="p2525">Palpable, sometimes audible, coarse crepitus due to rough articular surfaces</ce:para></ce:list-item><ce:list-item id="u1580"><ce:label>•</ce:label><ce:para id="p2530">Bony swelling around joint margins</ce:para></ce:list-item><ce:list-item id="u1585"><ce:label>•</ce:label><ce:para id="p2535">Deformity, usually without instability</ce:para></ce:list-item><ce:list-item id="u1590"><ce:label>•</ce:label><ce:para id="p2540">Joint-line or periarticular tenderness</ce:para></ce:list-item><ce:list-item id="u1595"><ce:label>•</ce:label><ce:para id="p2545">Muscle weakness and wasting</ce:para></ce:list-item><ce:list-item id="u1600"><ce:label>•</ce:label><ce:para id="p2550">Mild or absent synovitis</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0195" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0295" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0820" role="short">Image 38</ce:alt-text></ce:inline-figure> 24.38</ce:label><ce:alt-text id="atte0825" role="short">24.38</ce:alt-text><ce:textbox-head><ce:title id="tit0200">Characteristics of generalised nodal osteoarthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2570"><ce:list id="ulist0415"><ce:list-item id="u1605"><ce:label>•</ce:label><ce:para id="p2575">Polyarticular finger interphalangeal joint osteoarthritis</ce:para></ce:list-item><ce:list-item id="u1610"><ce:label>•</ce:label><ce:para id="p2580">Heberden's (± Bouchard's) nodes</ce:para></ce:list-item><ce:list-item id="u1615"><ce:label>•</ce:label><ce:para id="p2585">Marked female preponderance</ce:para></ce:list-item><ce:list-item id="u1620"><ce:label>•</ce:label><ce:para id="p2590">Peak onset in middle age</ce:para></ce:list-item><ce:list-item id="u1625"><ce:label>•</ce:label><ce:para id="p2595">Good functional outcome for hands</ce:para></ce:list-item><ce:list-item id="u1630"><ce:label>•</ce:label><ce:para id="p2600">Predisposition to osteoarthritis at other joints, especially knees</ce:para></ce:list-item><ce:list-item id="u1635"><ce:label>•</ce:label><ce:para id="p2605">Strong genetic predisposition</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0200" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0335" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0830" role="short">Image 39</ce:alt-text></ce:inline-figure> 24.39</ce:label><ce:alt-text id="atte0835" role="short">24.39</ce:alt-text><ce:textbox-head><ce:title id="tit0205">Causes of early-onset osteoarthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0700"><ce:section-title id="st0655">Monoarticular</ce:section-title><ce:para id="p2715"><ce:list id="ulist0430"><ce:list-item id="u1700"><ce:label>•</ce:label><ce:para id="p2720">Previous trauma, localised instability</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0705"><ce:section-title id="st0660">Pauciarticular or polyarticular</ce:section-title><ce:para id="p2725"><ce:list id="ulist0435"><ce:list-item id="u1705"><ce:label>•</ce:label><ce:para id="p2730">Juvenile idiopathic arthritis (<ce:cross-ref id="crf9055" refid="p4230">p. 1026</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u1710"><ce:label>•</ce:label><ce:para id="p2735">Metabolic or endocrine disease:<ce:list id="ulist0440"><ce:list-item id="u1715"><ce:para id="p2740">Haemochromatosis (<ce:intra-ref id="ii0275" xlink:href="pii:B978-0-7020-7028-0.00022-6#s1265">p. 895</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u1720"><ce:para id="p2745">Ochronosis</ce:para></ce:list-item><ce:list-item id="u1725"><ce:para id="p2750">Acromegaly (<ce:intra-ref id="ii0280" xlink:href="pii:B978-0-7020-7028-0.00018-4#p5050">p. 685</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1730"><ce:label>•</ce:label><ce:para id="p2755">Spondylo-epiphyseal dysplasia</ce:para></ce:list-item><ce:list-item id="u1735"><ce:label>•</ce:label><ce:para id="p2760">Late avascular necrosis</ce:para></ce:list-item><ce:list-item id="u1740"><ce:label>•</ce:label><ce:para id="p2765">Neuropathic joint</ce:para></ce:list-item><ce:list-item id="u1745"><ce:label>•</ce:label><ce:para id="p2770">Kashin–Beck disease</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0205" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0340" locator="icon02-9780702070280" xlink:href="pii:B978070207028000024X/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0840" role="short">Image 40</ce:alt-text></ce:inline-figure> 24.40</ce:label><ce:alt-text id="atte0845" role="short">24.40</ce:alt-text><ce:textbox-head><ce:title id="tit0210">Osteoarthritis in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2800"><ce:list id="ulist0445"><ce:list-item id="u1750"><ce:label>•</ce:label><ce:para id="p2805"><ce:bold>Pain and disability</ce:bold>: osteoarthritis is the principal cause in old age.</ce:para></ce:list-item><ce:list-item id="u1755"><ce:label>•</ce:label><ce:para id="p2810"><ce:bold>Calcium phosphate deposition disease</ce:bold>: may cause acute attacks of synovitis (pseudogout) on a background of chronic osteoarthritis.</ce:para></ce:list-item><ce:list-item id="u1760"><ce:label>•</ce:label><ce:para id="p2815"><ce:bold>Falls</ce:bold>: reduced muscle strength and pain associated with lower limb osteoarthritis increase the risk.</ce:para></ce:list-item><ce:list-item id="u1765"><ce:label>•</ce:label><ce:para id="p2820"><ce:bold>Muscle-strengthening exercises</ce:bold>: safely reduce the pain and disability of knee osteoarthritis with accompanying improvements in balance and reduced tendency to fall.</ce:para></ce:list-item><ce:list-item id="u1770"><ce:label>•</ce:label><ce:para id="p2825"><ce:bold>Oral paracetamol and topical non-steroidal anti-inflammatory drugs</ce:bold>: safe in older people, with no important drug interactions or contraindications.</ce:para></ce:list-item><ce:list-item id="u1775"><ce:label>•</ce:label><ce:para id="p2830"><ce:bold>Intra-articular injection of glucocorticoid</ce:bold>: a very safe and often effective treatment, particularly useful for tiding a patient over a special event.</ce:para></ce:list-item><ce:list-item id="u1780"><ce:label>•</ce:label><ce:para id="p2835"><ce:bold>Total joint replacement</ce:bold>: an excellent cost-effective treatment for severe disabling knee or hip osteoarthritis in older people. There is no age limit for joint replacement surgery.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0210" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0345" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0850" role="short">Image 41</ce:alt-text></ce:inline-figure> 24.41</ce:label><ce:alt-text id="atte0855" role="short">24.41</ce:alt-text><ce:textbox-head><ce:title id="tit0215">Crystal-associated arthritis and deposition in connective tissue</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2885"><ce:display><ce:table frame="topbot" id="t0115"><ce:alt-text id="atte0860" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Crystal</entry><entry align="left">Associations</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Common</ce:bold></entry></row><row rowsep="0"><entry align="left">Monosodium urate monohydrate</entry><entry align="left">Acute gout<ce:br/>Chronic tophaceous gout</entry></row><row rowsep="0"><entry align="left">Calcium pyrophosphate dihydrate</entry><entry align="left">Acute ‘pseudogout’<ce:br/>Chronic (pyrophosphate) arthropathy<ce:br/>Chondrocalcinosis</entry></row><row rowsep="1"><entry align="left">Basic calcium phosphates</entry><entry align="left">Calcific periarthritis<ce:br/>Calcinosis</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Uncommon</ce:bold></entry></row><row rowsep="0"><entry align="left">Cholesterol</entry><entry align="left">Chronic effusions in rheumatoid arthritis</entry></row><row rowsep="0"><entry align="left">Calcium oxalate</entry><entry align="left">Acute arthritis in dialysis patients</entry></row><row rowsep="0"><entry align="left">Extrinsic crystals/semi-crystalline particles:</entry><entry align="left"/></row><row rowsep="0"><entry align="left"><ce:hsp sp="1"/>Synthetic crystals</entry><entry align="left">Acute synovitis</entry></row><row><entry align="left"><ce:hsp sp="1"/>Plant thorns/sea urchin spines</entry><entry align="left">Chronic monoarthritis, tenosynovitis</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0215" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0360" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0865" role="short">Image 42</ce:alt-text></ce:inline-figure> 24.42</ce:label><ce:alt-text id="atte0870" role="short">24.42</ce:alt-text><ce:textbox-head><ce:title id="tit0220">Causes of hyperuricaemia and gout</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2910"><ce:display><ce:table frame="topbot" id="t0120"><ce:alt-text id="atte0875" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Diminished renal excretion</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0450"><ce:list-item id="u1785"><ce:label>•</ce:label><ce:para id="p2915">Increased renal tubular reabsorption<ce:cross-ref id="crf0745" refid="tn0020">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1790"><ce:label>•</ce:label><ce:para id="p2920">Renal failure</ce:para></ce:list-item><ce:list-item id="u1795"><ce:label>•</ce:label><ce:para id="p2925">Lead toxicity</ce:para></ce:list-item><ce:list-item id="u1800"><ce:label>•</ce:label><ce:para id="p2930">Lactic acidosis</ce:para></ce:list-item><ce:list-item id="u1805"><ce:label>•</ce:label><ce:para id="p2935">Alcohol</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0455"><ce:list-item id="u1810"><ce:label>•</ce:label><ce:para id="p2940">Drugs:<ce:list id="ulist0460"><ce:list-item id="u1815"><ce:para id="p2945">Thiazide and loop diuretics</ce:para></ce:list-item><ce:list-item id="u1820"><ce:para id="p2950">Low-dose aspirin</ce:para></ce:list-item><ce:list-item id="u1825"><ce:para id="p2955">Ciclosporin</ce:para></ce:list-item><ce:list-item id="u1830"><ce:para id="p2960">Pyrazinamide</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Increased intake</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0465"><ce:list-item id="u1835"><ce:label>•</ce:label><ce:para id="p2965">Game</ce:para></ce:list-item><ce:list-item id="u1840"><ce:label>•</ce:label><ce:para id="p2970">Seafood</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0470"><ce:list-item id="u1845"><ce:label>•</ce:label><ce:para id="p2975">Offal</ce:para></ce:list-item><ce:list-item id="u1850"><ce:label>•</ce:label><ce:para id="p2980">Red meat</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Increased production</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0475"><ce:list-item id="u1855"><ce:label>•</ce:label><ce:para id="p2985">Myeloproliferative and lymphoproliferative disease</ce:para></ce:list-item><ce:list-item id="u1860"><ce:label>•</ce:label><ce:para id="p2990">Psoriasis</ce:para></ce:list-item><ce:list-item id="u1865"><ce:label>•</ce:label><ce:para id="p2995">High fructose intake</ce:para></ce:list-item><ce:list-item id="u1870"><ce:label>•</ce:label><ce:para id="p3000">Glycogen storage disease (<ce:intra-ref id="ii0300" xlink:href="pii:B978-0-7020-7028-0.00014-7#p2775">p. 370</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0480"><ce:list-item id="u1875"><ce:label>•</ce:label><ce:para id="p3005">Inherited disorders:<ce:list id="ulist0485"><ce:list-item id="u1880"><ce:para id="p3010">Lesch–Nyhan syndrome (HPRT mutations)</ce:para></ce:list-item><ce:list-item id="u1885"><ce:para id="p3015">Phosphoribosyl pyrophosphate synthetase 1 mutations</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0265">(HPRT = hypoxanthine guanine phosphoribosyl transferase)</ce:simple-para></ce:legend><ce:table-footnote id="tn0020"><ce:label>*</ce:label><ce:note-para id="np0040">Usually genetically determined (see text).</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0220" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0370" locator="icon02-9780702070280" xlink:href="pii:B978070207028000024X/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0880" role="short">Image 43</ce:alt-text></ce:inline-figure> 24.43</ce:label><ce:alt-text id="atte0885" role="short">24.43</ce:alt-text><ce:textbox-head><ce:title id="tit0225">Gout in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3075"><ce:list id="ulist0495"><ce:list-item id="u1915"><ce:label>•</ce:label><ce:para id="p3080"><ce:bold>Aetiology</ce:bold>: a higher proportion of older patients have gout secondary to diuretic use and chronic kidney disease. Gout is often associated with osteoarthritis.</ce:para></ce:list-item><ce:list-item id="u1920"><ce:label>•</ce:label><ce:para id="p3085"><ce:bold>Presentation</ce:bold>: may be atypical, with painful tophi and chronic symptoms, rather than acute attacks. Joints of the upper limbs are more frequently affected.</ce:para></ce:list-item><ce:list-item id="u1925"><ce:label>•</ce:label><ce:para id="p3090"><ce:bold>Management</ce:bold>: acute attacks are best treated by aspiration and intra-articular injection of glucocorticoids, followed by early mobilisation. Non-steroidal anti-inflammatory drugs and colchicine should be used with caution because of increased risk of toxicity. Low doses of allopurinol (50 mg/day) should be given and increased gradually to avoid toxicity.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0225" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0385" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0890" role="short">Image 44</ce:alt-text></ce:inline-figure> 24.44</ce:label><ce:alt-text id="atte0895" role="short">24.44</ce:alt-text><ce:textbox-head><ce:title id="tit0230">Indications for urate-lowering drugs</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3135"><ce:list id="ulist0500"><ce:list-item id="u1930"><ce:label>•</ce:label><ce:para id="p3140">Recurrent attacks of acute gout</ce:para></ce:list-item><ce:list-item id="u1940"><ce:label>•</ce:label><ce:para id="p3150">Evidence of bone or joint damage</ce:para></ce:list-item><ce:list-item id="u1935"><ce:label>•</ce:label><ce:para id="p3145">Tophi</ce:para></ce:list-item><ce:list-item id="u1945"><ce:label>•</ce:label><ce:para id="p3155">Renal impairment</ce:para></ce:list-item><ce:list-item id="u1950"><ce:label>•</ce:label><ce:para id="p3160">Nephrolithiasis</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0230" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0390" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0900" role="short">Image 45</ce:alt-text></ce:inline-figure> 24.45</ce:label><ce:alt-text id="atte0905" role="short">24.45</ce:alt-text><ce:textbox-head><ce:title id="tit0235">Risk factors for chondrocalcinosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0815"><ce:section-title id="st0765">Common</ce:section-title><ce:para id="p3195"><ce:list id="ulist0505"><ce:list-item id="u1955"><ce:label>•</ce:label><ce:para id="p3200">Age</ce:para></ce:list-item><ce:list-item id="u1960"><ce:label>•</ce:label><ce:para id="p3205">Osteoarthritis<ce:cross-ref id="crf0800" refid="fn0030">*</ce:cross-ref><ce:footnote id="fn0030"><ce:label>*</ce:label><ce:note-para id="np0045">May be associated with structural damage to affected joints.</ce:note-para></ce:footnote></ce:para></ce:list-item><ce:list-item id="u1965"><ce:label>•</ce:label><ce:para id="p3210">Primary hyperparathyroidism</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0820"><ce:section-title id="st0770">Rare</ce:section-title><ce:para id="p3215"><ce:list id="ulist0510"><ce:list-item id="u1970"><ce:label>•</ce:label><ce:para id="p3220">Familial factors<ce:cross-ref id="crf0805" refid="fn0030">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1975"><ce:label>•</ce:label><ce:para id="p3225">Haemochromatosis<ce:cross-ref id="crf0810" refid="fn0030">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1980"><ce:label>•</ce:label><ce:para id="p3230">Hypophosphatasia</ce:para></ce:list-item><ce:list-item id="u1985"><ce:label>•</ce:label><ce:para id="p3235">Hypomagnesaemia</ce:para></ce:list-item><ce:list-item id="u1990"><ce:label>•</ce:label><ce:para id="p3240">Wilson's disease</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0235" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0400" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0910" role="short">Image 46</ce:alt-text></ce:inline-figure> 24.46</ce:label><ce:alt-text id="atte0915" role="short">24.46</ce:alt-text><ce:textbox-head><ce:title id="tit0240">Rheumatic diseases associated with basic calcium phosphate deposition</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3285"><ce:display><ce:table frame="topbot" id="t0125"><ce:alt-text id="atte0920" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Disease</entry><entry align="left">Site of calcification</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Calcific periarthritis</ce:bold></entry><entry align="left">Tendons and ligaments</entry></row><row rowsep="1"><entry align="left"><ce:bold>Dermatomyositis and polymyositis</ce:bold></entry><entry align="left">Subcutaneous tissue</entry></row><row rowsep="1"><entry align="left"><ce:bold>Systemic sclerosis (lcSScl)</ce:bold></entry><entry align="left">Subcutaneous tissue</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mixed connective tissue disease</ce:bold></entry><entry align="left">Subcutaneous tissue</entry></row><row rowsep="1"><entry align="left"><ce:bold>Paget's disease of bone</ce:bold></entry><entry align="left">Blood vessels</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ankylosing spondylitis</ce:bold></entry><entry align="left">Ligaments</entry></row><row rowsep="1"><entry align="left"><ce:bold>Fibrodysplasia ossificans progressiva</ce:bold></entry><entry align="left">Subcutaneous tissues and muscle</entry></row><row rowsep="1"><entry align="left"><ce:bold>Milwaukee shoulder syndrome</ce:bold></entry><entry align="left">Tendons and ligaments</entry></row><row><entry align="left"><ce:bold>Albright's hereditary osteodystrophy</ce:bold> (<ce:intra-ref id="ii0330" xlink:href="pii:B978-0-7020-7028-0.00018-4#p3085">p. 664</ce:intra-ref>)</entry><entry align="left">Muscle</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0310">(lcSScl = localised cutaneous systemic sclerosis)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0240" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0415" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0925" role="short">Image 47</ce:alt-text></ce:inline-figure> 24.47</ce:label><ce:alt-text id="atte0930" role="short">24.47</ce:alt-text><ce:textbox-head><ce:title id="tit0245">The spectrum of symptoms in fibromyalgia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0905"><ce:section-title id="st0840">Usual symptoms</ce:section-title><ce:para id="p3330"><ce:list id="ulist0515"><ce:list-item id="u1995"><ce:label>•</ce:label><ce:para id="p3335">Widespread pain</ce:para></ce:list-item><ce:list-item id="u2000"><ce:label>•</ce:label><ce:para id="p3340">Fatiguability</ce:para></ce:list-item><ce:list-item id="u2005"><ce:label>•</ce:label><ce:para id="p3345">Disability</ce:para></ce:list-item><ce:list-item id="u2010"><ce:label>•</ce:label><ce:para id="p3350">Broken, non-restorative sleep</ce:para></ce:list-item><ce:list-item id="u2015"><ce:label>•</ce:label><ce:para id="p3355">Low affect, irritability, poor concentration</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0910"><ce:section-title id="st0845">Variable locomotor symptoms</ce:section-title><ce:para id="p3360"><ce:list id="ulist0520"><ce:list-item id="u2020"><ce:label>•</ce:label><ce:para id="p3365">Early-morning stiffness</ce:para></ce:list-item><ce:list-item id="u2025"><ce:label>•</ce:label><ce:para id="p3370">Feeling of swelling in hands</ce:para></ce:list-item><ce:list-item id="u2030"><ce:label>•</ce:label><ce:para id="p3375">Distal finger tingling</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0915"><ce:section-title id="st0850">Additional, variable, non-locomotor symptoms</ce:section-title><ce:para id="p3380"><ce:list id="ulist0525"><ce:list-item id="u2035"><ce:label>•</ce:label><ce:para id="p3385">Non-throbbing bifrontal headache (tension headache)</ce:para></ce:list-item><ce:list-item id="u2040"><ce:label>•</ce:label><ce:para id="p3390">Colicky abdominal pain, bloating, variable bowel habit (irritable bowel syndrome)</ce:para></ce:list-item><ce:list-item id="u2045"><ce:label>•</ce:label><ce:para id="p3395">Bladder fullness, nocturnal frequency (irritable bladder)</ce:para></ce:list-item><ce:list-item id="u2050"><ce:label>•</ce:label><ce:para id="p3400">Hyperacusis, dyspareunia, discomfort when touched (allodynia)</ce:para></ce:list-item><ce:list-item id="u2055"><ce:label>•</ce:label><ce:para id="p3405">Frequent side-effects with drugs (chemical sensitivity)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0245" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0425" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0935" role="short">Image 48</ce:alt-text></ce:inline-figure> 24.48</ce:label><ce:alt-text id="atte0940" role="short">24.48</ce:alt-text><ce:textbox-head><ce:title id="tit0250">Laboratory investigations recommended before finalising a diagnosis of fibromyalgia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3420"><ce:display><ce:table frame="topbot" id="t0130"><ce:alt-text id="atte0945" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Test</entry><entry align="left">Condition screened for</entry></row></thead><tbody><row rowsep="1"><entry align="left">Full blood count, liver and renal function tests</entry><entry align="left">General disease indicators</entry></row><row rowsep="1"><entry align="left">Erythrocyte sedimentation rate, C-reactive protein, serum amyloid A, immunoglobulins</entry><entry align="left">Inflammatory disease</entry></row><row rowsep="1"><entry align="left">Thyroid function</entry><entry align="left">Hypo-/hyperthyroidism</entry></row><row rowsep="1"><entry align="left">Calcium, albumin, phosphate, alkaline phosphatase, parathyroid hormone, 25-hydroxyvitamin-D, serum angiotensin-converting enzyme</entry><entry align="left">Hyperparathyroidism, osteomalacia, sarcoid</entry></row><row><entry align="left">Antinuclear antibodies, extractable nuclear antigens, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, complement C3 and C4, lupus anticoagulant, anti-cardiolipin antibodies, streptococcal antibodies</entry><entry align="left">Autoinflammatory and autoimmune diseases</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0250" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0430" locator="icon02-9780702070280" xlink:href="pii:B978070207028000024X/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0950" role="short">Image 49</ce:alt-text></ce:inline-figure> 24.49</ce:label><ce:alt-text id="atte0955" role="short">24.49</ce:alt-text><ce:textbox-head><ce:title id="tit0255">Joint and bone infection in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3445"><ce:list id="ulist0530"><ce:list-item id="u2060"><ce:label>•</ce:label><ce:para id="p3450"><ce:bold>Vertebral infection</ce:bold>: more common. Recognition may be delayed, as symptoms may be attributed to compression fractures caused by osteoporosis.</ce:para></ce:list-item><ce:list-item id="u2065"><ce:label>•</ce:label><ce:para id="p3455"><ce:bold>Peripheral vascular disease</ce:bold>: leads to more frequent involvement of the bones of the feet, and diabetic foot ulcers are also commonly complicated by osteomyelitis.</ce:para></ce:list-item><ce:list-item id="u2070"><ce:label>•</ce:label><ce:para id="p3460"><ce:bold>Prosthetic joint infections</ce:bold>: now more common because of the increased frequency of prosthetic joint insertion in older people.</ce:para></ce:list-item><ce:list-item id="u2075"><ce:label>•</ce:label><ce:para id="p3465"><ce:bold>Gram-negative bacilli</ce:bold>: more frequent pathogens than in younger people.</ce:para></ce:list-item><ce:list-item id="u2080"><ce:label>•</ce:label><ce:para id="p3470"><ce:bold>Cephalosporins:</ce:bold> contraindicated due to the high risk of <ce:italic>Clostridium difficile</ce:italic>.</ce:para></ce:list-item><ce:list-item id="u2085"><ce:label>•</ce:label><ce:para id="p3475"><ce:bold>Septic arthritis:</ce:bold> mortality is high in elderly patients.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0255" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0435" locator="icon06-9780702070280" xlink:href="pii:B978070207028000024X/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0960" role="short">Image 50</ce:alt-text></ce:inline-figure> 24.50</ce:label><ce:alt-text id="atte0965" role="short">24.50</ce:alt-text><ce:textbox-head><ce:title id="tit0260">Emergency management of suspected septic arthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0960"><ce:section id="s0965"><ce:section-title id="st0890">Admit patient to hospital</ce:section-title><ce:para id="p3505"><ce:bold>Perform urgent investigations</ce:bold></ce:para><ce:para id="p3510"><ce:list id="ulist0535"><ce:list-item id="u2090"><ce:label>•</ce:label><ce:para id="p3515">Aspirate joint:<ce:list id="ulist0540"><ce:list-item id="u2095"><ce:para id="p3520">Send synovial fluid for Gram stain and culture</ce:para></ce:list-item><ce:list-item id="u2100"><ce:para id="p3525">Use imaging guidance if required</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2105"><ce:label>•</ce:label><ce:para id="p3530">Send blood for culture, routine biochemistry and haematology, including erythrocyte sedimentation rate and C-reactive protein</ce:para></ce:list-item><ce:list-item id="u2110"><ce:label>•</ce:label><ce:para id="p3535">Consider sending other samples (sputum, urine, wound swab) for culture, depending on patient history, to determine primary source of infection</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0970"><ce:section-title id="st0895">Commence intravenous antibiotic<ce:cross-ref id="crf0880" refid="fn0035">*</ce:cross-ref><ce:footnote id="fn0035"><ce:label>*</ce:label><ce:note-para id="np0050">The evidence base for choice of antibiotic selection is poor. Local guidelines should be followed where available.</ce:note-para></ce:footnote></ce:section-title><ce:para id="p3540"><ce:list id="ulist0545"><ce:list-item id="u2115"><ce:label>•</ce:label><ce:para id="p3545">Flucloxacillin (2 g 4 times daily)</ce:para></ce:list-item><ce:list-item id="u2120"><ce:label>•</ce:label><ce:para id="p3550">If penicillin-allergic:<ce:list id="ulist0550"><ce:list-item id="u2125"><ce:para id="p3555">Clindamycin (450–600 mg 4 times daily in younger patients)</ce:para></ce:list-item><ce:list-item id="u2130"><ce:para id="p3560">Intravenous vancomycin (1 g twice daily if age &#x003E; 65 years)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2135"><ce:label>•</ce:label><ce:para id="p3565">If high risk of Gram-negative sepsis:<ce:list id="ulist0555"><ce:list-item id="u2140"><ce:para id="p3570">Use antibiotic(s) active against <ce:italic>Staph. aureus</ce:italic> and locally-encountered Gram-negative organisms (seek expert guidance locally)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0975"><ce:section-title id="st0900">Relieve pain</ce:section-title><ce:para id="p3575"><ce:list id="ulist0560"><ce:list-item id="u2145"><ce:label>•</ce:label><ce:para id="p3580">Oral and/or intravenous analgesics</ce:para></ce:list-item><ce:list-item id="u2150"><ce:label>•</ce:label><ce:para id="p3585">Consider local ice-packs</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0980"><ce:section-title id="st0905">Aspirate joint</ce:section-title><ce:para id="p3590"><ce:list id="ulist0565"><ce:list-item id="u2155"><ce:label>•</ce:label><ce:para id="p3595">Perform serial needle aspiration to dryness (1–3 times daily or as required)</ce:para></ce:list-item><ce:list-item id="u2160"><ce:label>•</ce:label><ce:para id="p3600">Consider arthroscopic drainage if needle aspiration difficult</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0985"><ce:section-title id="st0910">Arrange physiotherapy</ce:section-title><ce:para id="p3605"><ce:list id="ulist0570"><ce:list-item id="u2165"><ce:label>•</ce:label><ce:para id="p3610">Early regular passive movement, progressing to active movements once pain controlled and effusion not re-accumulating</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0260" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0440" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0970" role="short">Image 51</ce:alt-text></ce:inline-figure> 24.51</ce:label><ce:alt-text id="atte0975" role="short">24.51</ce:alt-text><ce:textbox-head><ce:title id="tit0265">Musculoskeletal manifestations of HIV</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3625"><ce:display><ce:table frame="topbot" id="t0135"><ce:alt-text id="atte0980" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Condition</entry><entry align="left">Comment</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Non-specific arthralgia</ce:bold></entry><entry align="left">Most common; intermittent and polyarticular</entry></row><row rowsep="1"><entry align="left"><ce:bold>Reactive arthritis</ce:bold><ce:br/><ce:bold>Psoriatic arthritis</ce:bold><ce:br/><ce:bold>Idiopathic lower limb inflammatory arthritis</ce:bold></entry><entry align="left">Especially in men who have sex with men</entry></row><row><entry align="left"><ce:bold>Osteonecrosis</ce:bold><ce:br/><ce:bold>Myositis</ce:bold><ce:br/><ce:bold>Vasculitis</ce:bold><ce:br/><ce:bold>Sjögren's-like disease</ce:bold></entry><entry align="left">Unclear if related to HIV, its treatment or intercurrent disease</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0265" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0450" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0985" role="short">Image 52</ce:alt-text></ce:inline-figure> 24.52</ce:label><ce:alt-text id="atte0990" role="short">24.52</ce:alt-text><ce:textbox-head><ce:title id="tit0270">Criteria for diagnosis of rheumatoid arthritis<ce:cross-ref id="crf0910" refid="fn0040">*</ce:cross-ref><ce:footnote id="fn0040"><ce:label>*</ce:label><ce:note-para id="np0055">European League Against Rheumatism/American College of Rheumatology 2010 criteria.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3695"><ce:display><ce:table frame="topbot" id="t0140"><ce:alt-text id="atte0995" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Criterion</entry><entry align="left">Score</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Joints affected</ce:bold></entry></row><row rowsep="0"><entry align="left">1 large joint</entry><entry align="left">0</entry></row><row rowsep="0"><entry align="left">2–10 large joints</entry><entry align="left">1</entry></row><row rowsep="0"><entry align="left">1–3 small joints</entry><entry align="left">2</entry></row><row rowsep="0"><entry align="left">4–10 small joints</entry><entry align="left">3</entry></row><row rowsep="1"><entry align="justify">&#x003E; 10 joints (at least 1 small joint)</entry><entry align="justify">5</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Serology</ce:bold></entry></row><row rowsep="0"><entry align="left">Negative RF and ACPA</entry><entry align="left">0</entry></row><row rowsep="0"><entry align="left">Low positive RF or ACPA</entry><entry align="left">2</entry></row><row rowsep="1"><entry align="left">High positive RF or ACPA</entry><entry align="left">3</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Duration of symptoms</ce:bold></entry></row><row rowsep="0"><entry align="left">&#x003C; 6 weeks</entry><entry align="left">0</entry></row><row rowsep="1"><entry align="left">&#x003E; 6 weeks</entry><entry align="left">1</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Acute phase reactants</ce:bold></entry></row><row rowsep="0"><entry align="left">Normal CRP and ESR</entry><entry align="left">0</entry></row><row rowsep="1"><entry align="left">Abnormal CRP or ESR</entry><entry align="left">1</entry></row><row><entry namest="col1" nameend="col2" align="center">Patients with a score ≥ 6 are considered to have definite RA.</entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p3700">(ACPA = anti-citrullinated peptide antibody; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0270" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0465" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1000" role="short">Image 53</ce:alt-text></ce:inline-figure> 24.53</ce:label><ce:alt-text id="atte1005" role="short">24.53</ce:alt-text><ce:textbox-head><ce:title id="tit0275">Extra-articular manifestations of rheumatoid disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3720"><ce:display><ce:table frame="topbot" id="t0145"><ce:alt-text id="atte1010" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Systemic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0575"><ce:list-item id="u2170"><ce:label>•</ce:label><ce:para id="p3725">Fever</ce:para></ce:list-item><ce:list-item id="u2175"><ce:label>•</ce:label><ce:para id="p3730">Weight loss</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0580"><ce:list-item id="u2180"><ce:label>•</ce:label><ce:para id="p3735">Fatigue</ce:para></ce:list-item><ce:list-item id="u2185"><ce:label>•</ce:label><ce:para id="p3740">Susceptibility to infection</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Musculoskeletal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0585"><ce:list-item id="u2190"><ce:label>•</ce:label><ce:para id="p3745">Muscle-wasting</ce:para></ce:list-item><ce:list-item id="u2195"><ce:label>•</ce:label><ce:para id="p3750">Tenosynovitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0590"><ce:list-item id="u2200"><ce:label>•</ce:label><ce:para id="p3755">Bursitis</ce:para></ce:list-item><ce:list-item id="u2205"><ce:label>•</ce:label><ce:para id="p3760">Osteoporosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haematological</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0595"><ce:list-item id="u2210"><ce:label>•</ce:label><ce:para id="p3765">Anaemia</ce:para></ce:list-item><ce:list-item id="u2215"><ce:label>•</ce:label><ce:para id="p3770">Thrombocytosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0600"><ce:list-item id="u2220"><ce:label>•</ce:label><ce:para id="p3775">Eosinophilia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Lymphatic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0605"><ce:list-item id="u2225"><ce:label>•</ce:label><ce:para id="p3780">Felty's syndrome (see <ce:cross-ref id="crf0925" refid="b0275">Box 24.54</ce:cross-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0610"><ce:list-item id="u2230"><ce:label>•</ce:label><ce:para id="p3785">Splenomegaly</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Nodules</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0615"><ce:list-item id="u2235"><ce:label>•</ce:label><ce:para id="p3790">Sinuses</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0620"><ce:list-item id="u2240"><ce:label>•</ce:label><ce:para id="p3795">Fistulae</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Ocular</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0625"><ce:list-item id="u2245"><ce:label>•</ce:label><ce:para id="p3800">Episcleritis</ce:para></ce:list-item><ce:list-item id="u2250"><ce:label>•</ce:label><ce:para id="p3805">Scleritis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0630"><ce:list-item id="u2255"><ce:label>•</ce:label><ce:para id="p3810">Scleromalacia</ce:para></ce:list-item><ce:list-item id="u2260"><ce:label>•</ce:label><ce:para id="p3815">Keratoconjunctivitis sicca</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Vasculitis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0635"><ce:list-item id="u2265"><ce:label>•</ce:label><ce:para id="p3820">Digital arteritis</ce:para></ce:list-item><ce:list-item id="u2270"><ce:label>•</ce:label><ce:para id="p3825">Ulcers</ce:para></ce:list-item><ce:list-item id="u2275"><ce:label>•</ce:label><ce:para id="p3830">Pyoderma gangrenosum</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0640"><ce:list-item id="u2280"><ce:label>•</ce:label><ce:para id="p3835">Mononeuritis multiplex</ce:para></ce:list-item><ce:list-item id="u2285"><ce:label>•</ce:label><ce:para id="p3840">Visceral arteritis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cardiac</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0645"><ce:list-item id="u2290"><ce:label>•</ce:label><ce:para id="p3845">Pericarditis</ce:para></ce:list-item><ce:list-item id="u2295"><ce:label>•</ce:label><ce:para id="p3850">Myocarditis</ce:para></ce:list-item><ce:list-item id="u2300"><ce:label>•</ce:label><ce:para id="p3855">Endocarditis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0650"><ce:list-item id="u2305"><ce:label>•</ce:label><ce:para id="p3860">Conduction defects</ce:para></ce:list-item><ce:list-item id="u2310"><ce:label>•</ce:label><ce:para id="p3865">Coronary vasculitis</ce:para></ce:list-item><ce:list-item id="u2315"><ce:label>•</ce:label><ce:para id="p3870">Granulomatous aortitis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Pulmonary</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0655"><ce:list-item id="u2320"><ce:label>•</ce:label><ce:para id="p3875">Nodules</ce:para></ce:list-item><ce:list-item id="u2325"><ce:label>•</ce:label><ce:para id="p3880">Pleural effusions</ce:para></ce:list-item><ce:list-item id="u2330"><ce:label>•</ce:label><ce:para id="p3885">Pulmonary fibrosis</ce:para></ce:list-item><ce:list-item id="o9010"><ce:label>•</ce:label><ce:para id="p9015">Obliterative Bronchiolitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0660"><ce:list-item id="u2340"><ce:label>•</ce:label><ce:para id="p3895">Caplan's syndrome (<ce:intra-ref id="ii0380" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1655">p. 611</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="o9015"><ce:label>•</ce:label><ce:para id="p9020">Bronchiectasis</ce:para></ce:list-item><ce:list-item id="o9020"><ce:label>•</ce:label><ce:para id="p9025">Pneumothorax</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neurological</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0665"><ce:list-item id="u2345"><ce:label>•</ce:label><ce:para id="p3900">Cervical cord compression</ce:para></ce:list-item><ce:list-item id="u2350"><ce:label>•</ce:label><ce:para id="p3905">Compression neuropathies</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0670"><ce:list-item id="u2355"><ce:label>•</ce:label><ce:para id="p3910">Peripheral neuropathy</ce:para></ce:list-item><ce:list-item id="u2360"><ce:label>•</ce:label><ce:para id="p3915">Mononeuritis multiplex</ce:para></ce:list-item></ce:list></entry></row><row role="thead1"><entry namest="col1" nameend="col2" align="left"><ce:bold>Amyloidosis (</ce:bold><ce:intra-ref id="ii0385" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0470"><ce:bold>p. 81</ce:bold></ce:intra-ref><ce:bold>)</ce:bold></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0275" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0485" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1015" role="short">Image 54</ce:alt-text></ce:inline-figure> 24.54</ce:label><ce:alt-text id="atte1020" role="short">24.54</ce:alt-text><ce:textbox-head><ce:title id="tit0280">Felty's syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3965"><ce:display><ce:table frame="topbot" id="t0150"><ce:alt-text id="atte1025" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Risk factors</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0675"><ce:list-item id="u2365"><ce:label>•</ce:label><ce:para id="p3970">Age of onset 50–70 years</ce:para></ce:list-item><ce:list-item id="u2370"><ce:label>•</ce:label><ce:para id="p3975">Female &#x003E; male</ce:para></ce:list-item><ce:list-item id="u2375"><ce:label>•</ce:label><ce:para id="p3980">Caucasians &#x003E; blacks</ce:para></ce:list-item><ce:list-item id="u2380"><ce:label>•</ce:label><ce:para id="p3985">Long-standing rheumatoid arthritis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0680"><ce:list-item id="u2385"><ce:label>•</ce:label><ce:para id="p3990">Deforming but inactive disease</ce:para></ce:list-item><ce:list-item id="u2390"><ce:label>•</ce:label><ce:para id="p3995">Seropositive for rheumatoid factor</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Common clinical features</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0685"><ce:list-item id="u2395"><ce:label>•</ce:label><ce:para id="p4000">Splenomegaly</ce:para></ce:list-item><ce:list-item id="u2400"><ce:label>•</ce:label><ce:para id="p4005">Lymphadenopathy</ce:para></ce:list-item><ce:list-item id="u2405"><ce:label>•</ce:label><ce:para id="p4010">Weight loss</ce:para></ce:list-item><ce:list-item id="u2410"><ce:label>•</ce:label><ce:para id="p4015">Skin pigmentation</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0690"><ce:list-item id="u2415"><ce:label>•</ce:label><ce:para id="p4020">Keratoconjunctivitis sicca</ce:para></ce:list-item><ce:list-item id="u2420"><ce:label>•</ce:label><ce:para id="p4025">Vasculitis, leg ulcers</ce:para></ce:list-item><ce:list-item id="u2425"><ce:label>•</ce:label><ce:para id="p4030">Recurrent infections</ce:para></ce:list-item><ce:list-item id="u2430"><ce:label>•</ce:label><ce:para id="p4035">Nodules</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Laboratory findings</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0695"><ce:list-item id="u2435"><ce:label>•</ce:label><ce:para id="p4040">Normochromic, normocytic anaemia</ce:para></ce:list-item><ce:list-item id="u2440"><ce:label>•</ce:label><ce:para id="p4045">Neutropenia</ce:para></ce:list-item><ce:list-item id="u2445"><ce:label>•</ce:label><ce:para id="p4050">Abnormal liver function</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0700"><ce:list-item id="u2450"><ce:label>•</ce:label><ce:para id="p4055">Thrombocytopenia</ce:para></ce:list-item><ce:list-item id="u2455"><ce:label>•</ce:label><ce:para id="p4060">Impaired T- and B-cell immunity</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0280" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0490" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1030" role="short">Image 55</ce:alt-text></ce:inline-figure> 24.55</ce:label><ce:alt-text id="atte1035" role="short">24.55</ce:alt-text><ce:textbox-head><ce:title id="tit0285">Investigations and monitoring of rheumatoid arthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4070"><ce:display><ce:table frame="topbot" id="t0155"><ce:alt-text id="atte1040" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>To establish diagnosis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0705"><ce:list-item id="u2460"><ce:label>•</ce:label><ce:para id="p4075">Clinical criteria</ce:para></ce:list-item><ce:list-item id="u2465"><ce:label>•</ce:label><ce:para id="p4080">Erythrocyte sedimentation rate and C-reactive protein</ce:para></ce:list-item><ce:list-item id="u2470"><ce:label>•</ce:label><ce:para id="p4085">Ultrasound or magnetic resonance imaging</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0710"><ce:list-item id="u2475"><ce:label>•</ce:label><ce:para id="p4090">Rheumatoid factor and anti-citrullinated peptide antibodies</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>To monitor disease activity and drug efficacy</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0715"><ce:list-item id="u2480"><ce:label>•</ce:label><ce:para id="p4095">Pain (visual analogue scale)</ce:para></ce:list-item><ce:list-item id="u2485"><ce:label>•</ce:label><ce:para id="p4100">Early morning stiffness (minutes)</ce:para></ce:list-item><ce:list-item id="u2490"><ce:label>•</ce:label><ce:para id="p4105">Joint tenderness</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0720"><ce:list-item id="u2495"><ce:label>•</ce:label><ce:para id="p4110">Joint swelling</ce:para></ce:list-item><ce:list-item id="u2500"><ce:label>•</ce:label><ce:para id="p4115">DAS28 score (see <ce:cross-ref id="crf0950" refid="f0195">Fig. 24.36</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u2505"><ce:label>•</ce:label><ce:para id="p4120">Erythrocyte sedimentation rate and C-reactive protein</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>To monitor disease damage</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0725"><ce:list-item id="u2510"><ce:label>•</ce:label><ce:para id="p4125">X-rays</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0730"><ce:list-item id="u2515"><ce:label>•</ce:label><ce:para id="p4130">Functional assessment</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>To monitor drug safety</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0735"><ce:list-item id="u2520"><ce:label>•</ce:label><ce:para id="p4135">Urinalysis</ce:para></ce:list-item><ce:list-item id="u2525"><ce:label>•</ce:label><ce:para id="p4140">Full blood count</ce:para></ce:list-item><ce:list-item id="u2530"><ce:label>•</ce:label><ce:para id="p4145">Chest X-ray</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0740"><ce:list-item id="u2535"><ce:label>•</ce:label><ce:para id="p4150">Urea and creatinine</ce:para></ce:list-item><ce:list-item id="u2540"><ce:label>•</ce:label><ce:para id="p4155">Liver function tests</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0285" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0500" locator="icon05-9780702070280" xlink:href="pii:B978070207028000024X/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1045" role="short">Image 56</ce:alt-text></ce:inline-figure> 24.56</ce:label><ce:alt-text id="atte1050" role="short">24.56</ce:alt-text><ce:textbox-head><ce:title id="tit0290">Rheumatoid arthritis in pregnancy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4175"><ce:list id="ulist0745"><ce:list-item id="u2545"><ce:label>•</ce:label><ce:para id="p4180"><ce:bold>Immunological changes in pregnancy</ce:bold>: many patients with rheumatoid arthritis go into remission during pregnancy.</ce:para></ce:list-item><ce:list-item id="u2550"><ce:label>•</ce:label><ce:para id="p4185"><ce:bold>Conception</ce:bold>: methotrexate should be discontinued for at least 3 months and leflunomide discontinued for at least 24 months before trying to conceive.</ce:para></ce:list-item><ce:list-item id="u2555"><ce:label>•</ce:label><ce:para id="p4190"><ce:bold>Paracetamol</ce:bold>: the oral analgesic of choice during pregnancy.</ce:para></ce:list-item><ce:list-item id="u2560"><ce:label>•</ce:label><ce:para id="p4195"><ce:bold>Oral non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase 2 (COX-2) inhibitors</ce:bold>: can be used from implantation to 20 weeks' gestation.</ce:para></ce:list-item><ce:list-item id="u2565"><ce:label>•</ce:label><ce:para id="p4200"><ce:bold>Glucocorticoids</ce:bold>: may be used to control disease flares; the main maternal risks are hypertension, glucose intolerance and osteoporosis.</ce:para></ce:list-item><ce:list-item id="u2570"><ce:label>•</ce:label><ce:para id="p4205"><ce:bold>Disease-modifying antirheumatic drugs (DMARDs) that may be used</ce:bold>: sulfasalazine, hydroxychloroquine and azathioprine if required to control inflammation.</ce:para></ce:list-item><ce:list-item id="u2575"><ce:label>•</ce:label><ce:para id="p4210"><ce:bold>DMARDs that must be avoided</ce:bold>: methotrexate, leflunomide, cyclophosphamide, mycophenolate and gold.</ce:para></ce:list-item><ce:list-item id="u2580"><ce:label>•</ce:label><ce:para id="p4215"><ce:bold>Biologic therapies</ce:bold>: experience is limited but they may be relatively safe during pregnancy. The main theoretical risk is immunosuppression in the neonate, except for certolizumab, which does cross the placenta in negligible amounts.</ce:para></ce:list-item><ce:list-item id="u2585"><ce:label>•</ce:label><ce:para id="p4220"><ce:bold>Breastfeeding</ce:bold>: methotrexate, leflunomide and cyclophosphamide are contraindicated.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0290" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0510" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1055" role="short">Image 57</ce:alt-text></ce:inline-figure> 24.57</ce:label><ce:alt-text id="atte1060" role="short">24.57</ce:alt-text><ce:textbox-head><ce:title id="tit0295">Clinical features of juvenile idiopathic arthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4250"><ce:display><ce:table frame="topbot" id="t0160"><ce:alt-text id="atte1065" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Subtype</entry><entry align="left">Frequency</entry><entry align="left">Clinical features</entry><entry align="left">Immunology</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Systemic juvenile idiopathic arthritis</ce:bold></entry><entry align="left">5%</entry><entry align="left">Fever, rash, arthralgia, hepatosplenomegaly</entry><entry align="left">Autoantibody-negative</entry></row><row rowsep="1"><entry align="left"><ce:bold>Oligoarthritis (≤</ce:bold> <ce:bold>4 joints)</ce:bold></entry><entry align="left">60%</entry><entry align="left">Large-joint arthritis, uveitis</entry><entry align="left">ANA-positive</entry></row><row rowsep="1"><entry align="left"><ce:bold>Polyarthritis (≥</ce:bold> <ce:bold>5 joints)</ce:bold></entry><entry align="left">20%</entry><entry align="left">Polyarthritis; may be extended form of oligoarthritis</entry><entry align="left">ANA-positive</entry></row><row rowsep="1"><entry align="left"><ce:bold>Enthesis-related</ce:bold></entry><entry align="left">5%</entry><entry align="left">Sacroiliitis, enthesopathy</entry><entry align="left">HLA-B27-positive</entry></row><row rowsep="1"><entry align="left"><ce:bold>RF-positive</ce:bold></entry><entry align="left">5%</entry><entry align="left">Polyarthritis, similar to RA</entry><entry align="left">RF-positive, ACPA-positive</entry></row><row><entry align="left"><ce:bold>Psoriatic arthritis</ce:bold></entry><entry align="left">5%</entry><entry align="left">Same as adult disease (<ce:cross-ref id="crf9060" refid="p4645">p. 1032</ce:cross-ref>)</entry><entry align="left">Autoantibody-negative</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0390">(ACPA = anti-citrullinated peptide antibody; ANA = antinuclear antibody; HLA = human leucocyte antigen; RA = rheumatoid arthritis; RF = rheumatoid factor)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0295" role="alt4"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0515" locator="icon04-9780702070280" xlink:href="pii:B978070207028000024X/icon04-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1070" role="short">Image 58</ce:alt-text></ce:inline-figure> 24.58</ce:label><ce:alt-text id="atte1075" role="short">24.58</ce:alt-text><ce:textbox-head><ce:title id="tit0300">Juvenile idiopathic arthritis in adolescence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4290"><ce:list id="ulist0750"><ce:list-item id="u2590"><ce:label>•</ce:label><ce:para id="p4295"><ce:bold>Uveitis</ce:bold>: may be clinically silent and persist into adulthood. All (not just those who are ANA-positive) need ophthalmic screening for eye involvement.</ce:para></ce:list-item><ce:list-item id="u2595"><ce:label>•</ce:label><ce:para id="p4300"><ce:bold>Persistence into adulthood</ce:bold>: occurs in 50% of cases, especially in systemic disease. Specific supportive management through transition from adolescence to adulthood should be planned.</ce:para></ce:list-item><ce:list-item id="u2600"><ce:label>•</ce:label><ce:para id="p4305"><ce:bold>Reduced peak bone mass</ce:bold>: common in polyarthritis and systemic juvenile idiopathic arthritis but there are few data on fracture risk and the evidence base for treatment is poor.</ce:para></ce:list-item><ce:list-item id="u2605"><ce:label>•</ce:label><ce:para id="p4310"><ce:bold>Therapy</ce:bold>: methotrexate is standard treatment, used after NSAIDs alone are insufficient. Anti-TNF therapy is effective in all forms of juvenile idiopathic arthritis but long-term safety remains unclear.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4315">(ANA = antinuclear antibody; NSAIDs = non-steroidal anti-inflammatory drugs; TNF = tumour necrosis factor)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0300" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0520" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1080" role="short">Image 59</ce:alt-text></ce:inline-figure> 24.59</ce:label><ce:alt-text id="atte1085" role="short">24.59</ce:alt-text><ce:textbox-head><ce:title id="tit0305">Features common to spondyloarthropathies</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4325"><ce:list id="ulist0755"><ce:list-item id="u2610"><ce:label>•</ce:label><ce:para id="p4330">Asymmetrical inflammatory oligoarthritis (lower &#x003E; upper limb)</ce:para></ce:list-item><ce:list-item id="u2615"><ce:label>•</ce:label><ce:para id="p4335">History of inflammatory back pain</ce:para></ce:list-item><ce:list-item id="u2620"><ce:label>•</ce:label><ce:para id="p4340">Sacroiliitis and spinal osteitis</ce:para></ce:list-item><ce:list-item id="u2625"><ce:label>•</ce:label><ce:para id="p4345">Enthesitis (e.g. gluteus medius insertion, plantar fascia origin)</ce:para></ce:list-item><ce:list-item id="u2630"><ce:label>•</ce:label><ce:para id="p4350">Tendency for familial aggregation</ce:para></ce:list-item><ce:list-item id="u2635"><ce:label>•</ce:label><ce:para id="p4355">HLA-B27 association</ce:para></ce:list-item><ce:list-item id="u2640"><ce:label>•</ce:label><ce:para id="p4360">Psoriasis (of skin and/or nails)</ce:para></ce:list-item><ce:list-item id="u2645"><ce:label>•</ce:label><ce:para id="p4365">Uveitis</ce:para></ce:list-item><ce:list-item id="u2650"><ce:label>•</ce:label><ce:para id="p4370">Sterile urethritis and/or prostatitis</ce:para></ce:list-item><ce:list-item id="u2655"><ce:label>•</ce:label><ce:para id="p4375">Inflammatory bowel disease</ce:para></ce:list-item><ce:list-item id="u2660"><ce:label>•</ce:label><ce:para id="p4380">Aortic root lesions (aortic incompetence, conduction defects)</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4385">(HLA = human leucocyte antigen)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0305" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0525" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1090" role="short">Image 60</ce:alt-text></ce:inline-figure> 24.60</ce:label><ce:alt-text id="atte1095" role="short">24.60</ce:alt-text><ce:textbox-head><ce:title id="tit0310">Comparison of diagnostic criteria for axial spondyloarthritis (ASAS) and ankylosing spondylitis (modified New York)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4430"><ce:display><ce:table frame="topbot" id="t0165"><ce:alt-text id="atte1100" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Axial spondyloarthritis</entry><entry align="left">Ankylosing spondylitis</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Imaging</ce:bold></entry><entry align="left">Sacroiliitis on MRI only</entry><entry align="left">Bilateral sacroiliitis on X-ray, even if changes are mild<ce:br/>Unilateral sacroiliitis on X-ray if changes are definite</entry></row><row rowsep="1"><entry align="left"><ce:bold>History</ce:bold></entry><entry align="left">Back pain &#x003E; 3 months that has four of the following characteristics:<ce:br/><ce:list id="olist0765"><ce:list-item id="o2690"><ce:label>1</ce:label><ce:para id="p4435">improved by exercise</ce:para></ce:list-item><ce:list-item id="o2695"><ce:label>2</ce:label><ce:para id="p4440">not relieved by rest</ce:para></ce:list-item><ce:list-item id="o2700"><ce:label>3</ce:label><ce:para id="p4445">insidious onset</ce:para></ce:list-item><ce:list-item id="o2705"><ce:label>4</ce:label><ce:para id="p4450">night pain</ce:para></ce:list-item><ce:list-item id="o2710"><ce:label>5</ce:label><ce:para id="p4455">age at onset &#x003C; 45</ce:para></ce:list-item></ce:list><ce:br/>Good response of back pain to NSAID<ce:br/>Family history of spondyloarthritis<ce:br/>History of inflammatory bowel disease</entry><entry align="left">Low back pain &#x003E; 3 months improved by exercise and not relieved by rest</entry></row><row rowsep="1"><entry align="left"><ce:bold>Clinical examination</ce:bold></entry><entry align="left">Arthritis<ce:br/>Enthesitis<ce:br/>Uveitis<ce:br/>Dactylitis<ce:br/>Psoriasis</entry><entry align="left">Limitation of lumbar spine movement in sagittal and frontal planes<ce:br/>Chest expansion reduced</entry></row><row rowsep="1"><entry align="left"><ce:bold>Investigations</ce:bold></entry><entry align="left">HLA-B27-positive<ce:br/>Elevated CRP</entry><entry align="left"/></row><row><entry namest="col1" nameend="col3" align="center"><ce:italic>Axial spondyloarthritis</ce:italic> is diagnosed from: sacroiliitis on MRI + one other feature on history, clinical examination or investigation. The diagnosis can also be made in HLA-B27-positive patients with &#x003E;1 clinical feature in the absence of sacroiliitis<ce:br/><ce:italic>Ankylosing spondylitis</ce:italic> can be diagnosed on X-ray evidence of sacroiliitis with one other feature on history or examination</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0395">(ASAS = Assessment of Spondylitis International Society; CRP = C-reactive protein; HLA = human leucocyte antigen; MRI = magnetic resonance imaging; NSAID = non-steroidal anti-inflammatory drug)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0310" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0535" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1105" role="short">Image 61</ce:alt-text></ce:inline-figure> 24.61</ce:label><ce:alt-text id="atte1110" role="short">24.61</ce:alt-text><ce:textbox-head><ce:title id="tit0315">Extra-articular features of axial spondyloarthritis and ankylosing spondylitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4515"><ce:list id="ulist0770"><ce:list-item id="u2715"><ce:label>•</ce:label><ce:para id="p4520">Fatigue, anaemia</ce:para></ce:list-item><ce:list-item id="u2720"><ce:label>•</ce:label><ce:para id="p4525">Anterior uveitis (25%)</ce:para></ce:list-item><ce:list-item id="u2725"><ce:label>•</ce:label><ce:para id="p4530">Prostatitis (80% of men) and sterile urethritis</ce:para></ce:list-item><ce:list-item id="u2730"><ce:label>•</ce:label><ce:para id="p4535">Inflammatory bowel disease (up to 50% have IBD lesions)</ce:para></ce:list-item><ce:list-item id="u2735"><ce:label>•</ce:label><ce:para id="p4540">Osteoporosis</ce:para></ce:list-item><ce:list-item id="u2740"><ce:label>•</ce:label><ce:para id="p4545">Cardiovascular disease (aortic valve disease 20%)</ce:para></ce:list-item><ce:list-item id="u2745"><ce:label>•</ce:label><ce:para id="p4550">Amyloidosis (rare)</ce:para></ce:list-item><ce:list-item id="u2750"><ce:label>•</ce:label><ce:para id="p4555">Atypical upper lobe pulmonary fibrosis (very rare)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0315" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0560" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1115" role="short">Image 62</ce:alt-text></ce:inline-figure> 24.62</ce:label><ce:alt-text id="atte1120" role="short">24.62</ce:alt-text><ce:textbox-head><ce:title id="tit0320">The CASPAR criteria for psoriatic arthritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4660">Inflammatory articular disease (joint, spine or enthesis) with ≥ 3 points from the following (1 point each unless stated):<ce:list id="ulist0780"><ce:list-item id="u2790"><ce:label>•</ce:label><ce:para id="p4665">Current psoriasis (scores 2 points)</ce:para></ce:list-item><ce:list-item id="u2795"><ce:label>•</ce:label><ce:para id="p4670">History of psoriasis in first- or second-degree relative</ce:para></ce:list-item><ce:list-item id="u2800"><ce:label>•</ce:label><ce:para id="p4675">Psoriatic nail dystrophy</ce:para></ce:list-item><ce:list-item id="u2805"><ce:label>•</ce:label><ce:para id="p4680">Negative IgM rheumatoid factor<ce:cross-ref id="crf1050" refid="fn0045"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:footnote id="fn0045"><ce:label>1</ce:label><ce:note-para id="np0060">Established by any method except latex.</ce:note-para></ce:footnote></ce:para></ce:list-item><ce:list-item id="u2810"><ce:label>•</ce:label><ce:para id="p4685">Current dactylitis</ce:para></ce:list-item><ce:list-item id="u2815"><ce:label>•</ce:label><ce:para id="p4690">History of dactylitis</ce:para></ce:list-item><ce:list-item id="u2820"><ce:label>•</ce:label><ce:para id="p4695">Juxta-articular new bone<ce:cross-ref id="crf1055" refid="fn0050"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:footnote id="fn0050"><ce:label>2</ce:label><ce:note-para id="np0065">Ill-defined ossification near joint margins (excluding osteophytes) on X-rays of hands or feet.</ce:note-para></ce:footnote></ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4700">(CASPAR = <ce:bold>C</ce:bold>l<ce:bold>AS</ce:bold>sification for <ce:bold>P</ce:bold>soriatic <ce:bold>AR</ce:bold>thritis)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0320" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0595" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1125" role="short">Image 63</ce:alt-text></ce:inline-figure> 24.63</ce:label><ce:alt-text id="atte1130" role="short">24.63</ce:alt-text><ce:textbox-head><ce:title id="tit0325">Criteria for the classification of systemic lupus erythematosus</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4870"><ce:display><ce:table frame="topbot" id="t0170"><ce:alt-text id="atte1135" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Features</entry><entry align="left">Characteristics</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Malar rash</ce:bold></entry><entry align="left">Fixed erythema, flat or raised, sparing the nasolabial folds</entry></row><row rowsep="1"><entry align="left"><ce:bold>Discoid rash</ce:bold></entry><entry align="left">Erythematous raised patches with adherent keratotic scarring and follicular plugging</entry></row><row rowsep="1"><entry align="left"><ce:bold>Photosensitivity</ce:bold></entry><entry align="left">Rash due to unusual reaction to sunlight</entry></row><row rowsep="1"><entry align="left"><ce:bold>Oral ulcers</ce:bold></entry><entry align="left">Oral or nasopharyngeal ulceration, which may be painless</entry></row><row rowsep="1"><entry align="left"><ce:bold>Arthritis</ce:bold></entry><entry align="left">Non-erosive, involving two or more peripheral joints</entry></row><row rowsep="1"><entry align="left"><ce:bold>Serositis</ce:bold></entry><entry align="left">Pleuritis (history of pleuritic pain or rub, or pleural effusion) <ce:italic>or</ce:italic> pericarditis (rub, electrocardiogram evidence or effusion)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Renal disorder</ce:bold></entry><entry align="left">Persistent proteinuria &#x003E; 0.5 g/24 hrs <ce:italic>or</ce:italic> cellular casts (red cell, granular or tubular)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Neurological disorder</ce:bold></entry><entry align="left">Seizures or psychosis, in the absence of provoking drugs or metabolic derangement</entry></row><row rowsep="1"><entry align="left"><ce:bold>Haematological disorder</ce:bold></entry><entry align="left">Haemolytic anaemia <ce:italic>or</ce:italic> leucopenia<ce:cross-ref id="crf1100" refid="tn0025">*</ce:cross-ref> (&#x003C; 4 × 10<ce:sup loc="post">9</ce:sup>/L) <ce:italic>or</ce:italic> lymphopenia<ce:cross-ref id="crf1105" refid="tn0025">*</ce:cross-ref> (&#x003C; 1 × 10<ce:sup loc="post">9</ce:sup>/L) <ce:italic>or</ce:italic> thrombocytopenia<ce:cross-ref id="crf1110" refid="tn0025">*</ce:cross-ref> (&#x003C; 100 × 10<ce:sup loc="post">9</ce:sup>/L) in the absence of offending drugs</entry></row><row rowsep="1"><entry align="left"><ce:bold>Immunological</ce:bold></entry><entry align="left">Anti-DNA antibodies in abnormal titre <ce:italic>or</ce:italic> presence of antibody to Sm antigen <ce:italic>or</ce:italic> positive antiphospholipid antibodies</entry></row><row rowsep="1"><entry align="left"><ce:bold>Antinuclear antibody (ANA)</ce:bold></entry><entry align="left">Abnormal titre of ANA by immunofluorescence</entry></row><row><entry namest="col1" nameend="col2" align="center">An adult has SLE if any 4 of 11 features are present serially or simultaneously</entry></row></tbody></tgroup><ce:table-footnote id="tn0025"><ce:label>*</ce:label><ce:note-para id="np0070">On two separate occasions.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0325" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0610" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1140" role="short">Image 64</ce:alt-text></ce:inline-figure> 24.64</ce:label><ce:alt-text id="atte1145" role="short">24.64</ce:alt-text><ce:textbox-head><ce:title id="tit0330">Features of primary Sjögren's syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5005"><ce:display><ce:table frame="topbot" id="t0175"><ce:alt-text id="atte1150" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Risk factors</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0795"><ce:list-item id="u2880"><ce:label>•</ce:label><ce:para id="p5010">Age of onset 40–60</ce:para></ce:list-item><ce:list-item id="u2885"><ce:label>•</ce:label><ce:para id="p5015">Female &#x003E; male</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0800"><ce:list-item id="u2890"><ce:label>•</ce:label><ce:para id="p5020">HLA-B8/DR3</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Common clinical features</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0805"><ce:list-item id="u2895"><ce:label>•</ce:label><ce:para id="p5025">Keratoconjunctivitis sicca</ce:para></ce:list-item><ce:list-item id="u2900"><ce:label>•</ce:label><ce:para id="p5030">Xerostomia</ce:para></ce:list-item><ce:list-item id="u2905"><ce:label>•</ce:label><ce:para id="p5035">Salivary gland enlargement</ce:para></ce:list-item><ce:list-item id="u2910"><ce:label>•</ce:label><ce:para id="p5040">Rashes/skin irritation</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0810"><ce:list-item id="u2915"><ce:label>•</ce:label><ce:para id="p5045">Non-erosive arthralgia</ce:para></ce:list-item><ce:list-item id="u2920"><ce:label>•</ce:label><ce:para id="p5050">Generalised osteoarthritis</ce:para></ce:list-item><ce:list-item id="u2925"><ce:label>•</ce:label><ce:para id="p5055">Raynaud's phenomenon</ce:para></ce:list-item><ce:list-item id="u2930"><ce:label>•</ce:label><ce:para id="p5060">Fatigue</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Less common features</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0815"><ce:list-item id="u2935"><ce:label>•</ce:label><ce:para id="p5065">Low-grade fever</ce:para></ce:list-item><ce:list-item id="u2940"><ce:label>•</ce:label><ce:para id="p5070">Interstitial lung disease</ce:para></ce:list-item><ce:list-item id="u2945"><ce:label>•</ce:label><ce:para id="p5075">Anaemia, leucopenia</ce:para></ce:list-item><ce:list-item id="u2950"><ce:label>•</ce:label><ce:para id="p5080">Thrombocytopenia</ce:para></ce:list-item><ce:list-item id="u2955"><ce:label>•</ce:label><ce:para id="p5085">Cryoglobulinaemia</ce:para></ce:list-item><ce:list-item id="u2960"><ce:label>•</ce:label><ce:para id="p5090">Vasculitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0820"><ce:list-item id="u2965"><ce:label>•</ce:label><ce:para id="p5095">Peripheral neuropathy</ce:para></ce:list-item><ce:list-item id="u2970"><ce:label>•</ce:label><ce:para id="p5100">Lymphadenopathy</ce:para></ce:list-item><ce:list-item id="u2975"><ce:label>•</ce:label><ce:para id="p5105">Lymphoreticular lymphoma</ce:para></ce:list-item><ce:list-item id="u2980"><ce:label>•</ce:label><ce:para id="p5110">Glomerulonephritis</ce:para></ce:list-item><ce:list-item id="u2985"><ce:label>•</ce:label><ce:para id="p5115">Interstitial nephritis</ce:para></ce:list-item><ce:list-item id="u2990"><ce:label>•</ce:label><ce:para id="p5120">Renal tubular acidosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Autoantibodies frequently detected</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0825"><ce:list-item id="u2995"><ce:label>•</ce:label><ce:para id="p5125">Rheumatoid factor</ce:para></ce:list-item><ce:list-item id="u3000"><ce:label>•</ce:label><ce:para id="p5130">Antinuclear antibody</ce:para></ce:list-item><ce:list-item id="u3005"><ce:label>•</ce:label><ce:para id="p5135">SS-A (anti-Ro)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0830"><ce:list-item id="u3010"><ce:label>•</ce:label><ce:para id="p5140">SS-B (anti-La)</ce:para></ce:list-item><ce:list-item id="u3015"><ce:label>•</ce:label><ce:para id="p5145">Gastric parietal cell</ce:para></ce:list-item><ce:list-item id="u3020"><ce:label>•</ce:label><ce:para id="p5150">Thyroid</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Associated autoimmune disorders</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0835"><ce:list-item id="u3025"><ce:label>•</ce:label><ce:para id="p5155">Systemic lupus erythematosus</ce:para></ce:list-item><ce:list-item id="u3030"><ce:label>•</ce:label><ce:para id="p5160">Systemic sclerosis</ce:para></ce:list-item><ce:list-item id="u3035"><ce:label>•</ce:label><ce:para id="p5165">Coeliac disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0840"><ce:list-item id="u3040"><ce:label>•</ce:label><ce:para id="p5170">Primary biliary cholangitis</ce:para></ce:list-item><ce:list-item id="u3045"><ce:label>•</ce:label><ce:para id="p5175">Chronic active hepatitis</ce:para></ce:list-item><ce:list-item id="u3050"><ce:label>•</ce:label><ce:para id="p5180">Myasthenia gravis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p5185">(HLA = human leucocyte antigen)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0330" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0630" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1155" role="short">Image 65</ce:alt-text></ce:inline-figure> 24.65</ce:label><ce:alt-text id="atte1160" role="short">24.65</ce:alt-text><ce:textbox-head><ce:title id="tit0335">Clinical features of systemic vasculitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5250"><ce:display><ce:table frame="topbot" id="t0180"><ce:alt-text id="atte1165" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Systemic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0845"><ce:list-item id="u3055"><ce:label>•</ce:label><ce:para id="p5255">Malaise</ce:para></ce:list-item><ce:list-item id="u3060"><ce:label>•</ce:label><ce:para id="p5260">Fever</ce:para></ce:list-item><ce:list-item id="u3065"><ce:label>•</ce:label><ce:para id="p5265">Night sweats</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0850"><ce:list-item id="u3070"><ce:label>•</ce:label><ce:para id="p5270">Weight loss with arthralgia and myalgia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Rashes</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0855"><ce:list-item id="u3075"><ce:label>•</ce:label><ce:para id="p5275">Palpable purpura</ce:para></ce:list-item><ce:list-item id="u3080"><ce:label>•</ce:label><ce:para id="p5280">Pulp infarcts</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0860"><ce:list-item id="u3085"><ce:label>•</ce:label><ce:para id="p5285">Ulceration</ce:para></ce:list-item><ce:list-item id="u3090"><ce:label>•</ce:label><ce:para id="p5290">Livedo reticularis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Ear, nose and throat</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0865"><ce:list-item id="u3095"><ce:label>•</ce:label><ce:para id="p5295">Epistaxis</ce:para></ce:list-item><ce:list-item id="u3100"><ce:label>•</ce:label><ce:para id="p5300">Recurrent sinusitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0870"><ce:list-item id="u3105"><ce:label>•</ce:label><ce:para id="p5305">Deafness</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Respiratory</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0875"><ce:list-item id="u3110"><ce:label>•</ce:label><ce:para id="p5310">Haemoptysis</ce:para></ce:list-item><ce:list-item id="u3115"><ce:label>•</ce:label><ce:para id="p5315">Cough</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0880"><ce:list-item id="u3120"><ce:label>•</ce:label><ce:para id="p5320">Poorly controlled asthma</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gastrointestinal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0885"><ce:list-item id="u3125"><ce:label>•</ce:label><ce:para id="p5325">Abdominal pain (due to mucosal inflammation or enteric ischaemia)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0890"><ce:list-item id="u3130"><ce:label>•</ce:label><ce:para id="p5330">Mouth ulcers</ce:para></ce:list-item><ce:list-item id="u3135"><ce:label>•</ce:label><ce:para id="p5335">Diarrhoea</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neurological</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0895"><ce:list-item id="u3140"><ce:label>•</ce:label><ce:para id="p5340">Sensory or motor neuropathy</ce:para></ce:list-item></ce:list></entry><entry align="left"/></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0335" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0645" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1170" role="short">Image 66</ce:alt-text></ce:inline-figure> 24.66</ce:label><ce:alt-text id="atte1175" role="short">24.66</ce:alt-text><ce:textbox-head><ce:title id="tit0340">Conditions that can mimic polymyalgia rheumatica</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5390"><ce:list id="ulist0900"><ce:list-item id="u3145"><ce:label>•</ce:label><ce:para id="p5395">Calcium pyrophosphate disease</ce:para></ce:list-item><ce:list-item id="u3150"><ce:label>•</ce:label><ce:para id="p5400">Spondyloarthritis</ce:para></ce:list-item><ce:list-item id="u3155"><ce:label>•</ce:label><ce:para id="p5405">Hyper-/hypothyroidism</ce:para></ce:list-item><ce:list-item id="u3160"><ce:label>•</ce:label><ce:para id="p5410">Psoriatic arthritis (enthesopathic)</ce:para></ce:list-item><ce:list-item id="u3165"><ce:label>•</ce:label><ce:para id="p5415">Systemic vasculitis</ce:para></ce:list-item><ce:list-item id="u3170"><ce:label>•</ce:label><ce:para id="p5420">Myeloma</ce:para></ce:list-item><ce:list-item id="u3175"><ce:label>•</ce:label><ce:para id="p5425">Inflammatory myopathy (particularly inclusion body myositis, <ce:cross-ref id="crf9065" refid="s2005">p. 1059</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u3180"><ce:label>•</ce:label><ce:para id="p5430">Lambert–Eaton syndrome (<ce:intra-ref id="ii0510" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2215">p. 1143</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u3185"><ce:label>•</ce:label><ce:para id="p5435">Multiple separate lesions (cervical spondylosis, cervical radiculopathy, bilateral subacromial impingement, facet joint arthritis, osteoarthritis of the acromioclavicular joint)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0340" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0650" locator="icon06-9780702070280" xlink:href="pii:B978070207028000024X/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1180" role="short">Image 67</ce:alt-text></ce:inline-figure> 24.67</ce:label><ce:alt-text id="atte1185" role="short">24.67</ce:alt-text><ce:textbox-head><ce:title id="tit0345">Emergency management of giant cell arteritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5450"><ce:list id="ulist0905"><ce:list-item id="u3190"><ce:label>•</ce:label><ce:para id="p5455">Take blood for CRP, ESR, FBC, bone/liver/renal function, serum protein electrophoresis, CPK, RF, ACPA, ANA, ANCA, complement C3 and C4, immunoglobulins, PTH, TSH, vitamin D and urine electrophoresis</ce:para></ce:list-item><ce:list-item id="u3195"><ce:label>•</ce:label><ce:para id="p5460">Commence prednisolone (40–60 mg daily), and simultaneously, a weekly oral bisphosphonate and calcium with vitamin D supplements</ce:para></ce:list-item><ce:list-item id="u3200"><ce:label>•</ce:label><ce:para id="p5465">Consider urgent ophthalmology examination and temporal artery biopsy in patients with visual symptoms</ce:para></ce:list-item><ce:list-item id="u3205"><ce:label>•</ce:label><ce:para id="p5470">Consider obtaining temporal artery ultrasound or <ce:sup loc="post">19</ce:sup>FDG-PET scan</ce:para></ce:list-item><ce:list-item id="u3210"><ce:label>•</ce:label><ce:para id="p5475">Review within 1 week and adjust glucocorticoid doses according to clinical response and results of investigations</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5480">(ACPA = anti-citrullinated peptide antibody; ANA = antinuclear antibody; ANCA = antineutrophil cytoplasmic antibody; CPK = creatine phosphokinase; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; FBC = full blood count; <ce:sup loc="post">19</ce:sup>FDG-PET = <ce:sup loc="post">19</ce:sup>fluorodeoxyglucose positron emission tomography; PTH = parathyroid hormone; RF = rheumatoid factor; TSH = thyroid-stimulating hormone)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0345" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0660" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1190" role="short">Image 68</ce:alt-text></ce:inline-figure> 24.68</ce:label><ce:alt-text id="atte1195" role="short">24.68</ce:alt-text><ce:textbox-head><ce:title id="tit0350">Criteria for the diagnosis of Behçet's disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5515">Recurrent oral ulceration: minor aphthous, major aphthous or herpetiform ulceration at least three times in 12 months <ce:italic>plus</ce:italic> two of the following:<ce:list id="ulist0910"><ce:list-item id="u3215"><ce:label>•</ce:label><ce:para id="p5520">Recurrent genital ulceration</ce:para></ce:list-item><ce:list-item id="u3220"><ce:label>•</ce:label><ce:para id="p5525">Eye lesions: anterior uveitis, posterior uveitis, cells in vitreous on slit-lamp examination, retinal vasculitis</ce:para></ce:list-item><ce:list-item id="u3225"><ce:label>•</ce:label><ce:para id="p5530">Skin lesions: erythema nodosum, pseudofolliculitis, papulopustular lesions, acneiform nodules</ce:para></ce:list-item><ce:list-item id="u3230"><ce:label>•</ce:label><ce:para id="p5535">Positive pathergy test</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0350" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0680" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1200" role="short">Image 69</ce:alt-text></ce:inline-figure> 24.69</ce:label><ce:alt-text id="atte1205" role="short">24.69</ce:alt-text><ce:textbox-head><ce:title id="tit0355">Risk factors for osteoporosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5565"><ce:display><ce:table frame="topbot" id="t0185"><ce:alt-text id="atte1210" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Genetics</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0925"><ce:list-item id="u3245"><ce:label>•</ce:label><ce:para id="p5580">Single-gene disorders:<ce:list id="ulist0930"><ce:list-item id="u3250"><ce:para id="p5585"><ce:italic>LRP5</ce:italic> mutations</ce:para></ce:list-item><ce:list-item id="u3255"><ce:para id="p5590">Oestrogen receptor mutations</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0915"><ce:list-item id="u3235"><ce:label>•</ce:label><ce:para id="p5570">Polygenic inheritance:<ce:list id="ulist0920"><ce:list-item id="u3240"><ce:para id="p5575">Common variants in many pathways</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Endocrine disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0935"><ce:list-item id="u3260"><ce:label>•</ce:label><ce:para id="p5595">Hypogonadism</ce:para></ce:list-item><ce:list-item id="u3265"><ce:label>•</ce:label><ce:para id="p5600">Hyperthyroidism</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0940"><ce:list-item id="u3270"><ce:label>•</ce:label><ce:para id="p5605">Hyperparathyroidism</ce:para></ce:list-item><ce:list-item id="u3275"><ce:label>•</ce:label><ce:para id="p5610">Cushing's syndrome</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0945"><ce:list-item id="u3280"><ce:label>•</ce:label><ce:para id="p5615">Inflammatory bowel disease</ce:para></ce:list-item><ce:list-item id="u3285"><ce:label>•</ce:label><ce:para id="p5620">Ankylosing spondylitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0950"><ce:list-item id="u3290"><ce:label>•</ce:label><ce:para id="p5625">Rheumatoid arthritis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0955"><ce:list-item id="u3295"><ce:label>•</ce:label><ce:para id="p5630">Glucocorticoids</ce:para></ce:list-item><ce:list-item id="u3300"><ce:label>•</ce:label><ce:para id="p5635">Gonadotrophin-releasing hormone (GnRH) agonists</ce:para></ce:list-item><ce:list-item id="u3310"><ce:label>•</ce:label><ce:para id="p5645">Levothyroxine over-replacement</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0960"><ce:list-item id="u3305"><ce:label>•</ce:label><ce:para id="p5640">Aromatase inhibitors</ce:para></ce:list-item><ce:list-item id="u3315"><ce:label>•</ce:label><ce:para id="p5650">Thiazolidinediones</ce:para></ce:list-item><ce:list-item id="u3320"><ce:label>•</ce:label><ce:para id="p5655">Anticonvulsants</ce:para></ce:list-item><ce:list-item id="u3325"><ce:label>•</ce:label><ce:para id="p5660">Alcohol intake &#x003E; 3 U/day</ce:para></ce:list-item><ce:list-item id="u3330"><ce:label>•</ce:label><ce:para id="p5665">Heparin</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gastrointestinal disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0965"><ce:list-item id="u3335"><ce:label>•</ce:label><ce:para id="p5670">Malabsorption</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0970"><ce:list-item id="u3340"><ce:label>•</ce:label><ce:para id="p5675">Chronic liver disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Lung disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0975"><ce:list-item id="u3345"><ce:label>•</ce:label><ce:para id="p5680">Chronic obstructive pulmonary disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0980"><ce:list-item id="u3350"><ce:label>•</ce:label><ce:para id="p5685">Cystic fibrosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Miscellaneous</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0985"><ce:list-item id="u3355"><ce:label>•</ce:label><ce:para id="p5690">Myeloma</ce:para></ce:list-item><ce:list-item id="u3360"><ce:label>•</ce:label><ce:para id="p5695">Homocystinuria</ce:para></ce:list-item><ce:list-item id="u3365"><ce:label>•</ce:label><ce:para id="p5700">Anorexia nervosa<ce:cross-ref id="crf1215" refid="tn0030">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u3370"><ce:label>•</ce:label><ce:para id="p5705">Highly trained athletes<ce:cross-ref id="crf1220" refid="tn0030">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u3375"><ce:label>•</ce:label><ce:para id="p5710">HIV infection</ce:para></ce:list-item><ce:list-item id="u3380"><ce:label>•</ce:label><ce:para id="p5715">Gaucher's disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0990"><ce:list-item id="u3385"><ce:label>•</ce:label><ce:para id="p5720">Systemic mastocytosis</ce:para></ce:list-item><ce:list-item id="u3390"><ce:label>•</ce:label><ce:para id="p5725">Immobilisation</ce:para></ce:list-item><ce:list-item id="u3395"><ce:label>•</ce:label><ce:para id="p5730">Body mass index &#x003C; 18</ce:para></ce:list-item><ce:list-item id="u3400"><ce:label>•</ce:label><ce:para id="p5735">Heavy smoking</ce:para></ce:list-item><ce:list-item id="u3405"><ce:label>•</ce:label><ce:para id="p5740">Autoantibodies to osteoprotegerin (OPG)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0030"><ce:label>*</ce:label><ce:note-para id="np0075">Hypogonadism also plays a role in osteoporosis associated with these conditions.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0355" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0690" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1215" role="short">Image 70</ce:alt-text></ce:inline-figure> 24.70</ce:label><ce:alt-text id="atte1220" role="short">24.70</ce:alt-text><ce:textbox-head><ce:title id="tit0360">Indications for dual X-ray absorptiometry (DXA)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5775"><ce:list id="ulist0995"><ce:list-item id="u3410"><ce:label>•</ce:label><ce:para id="p5780">Low-trauma fracture, age &#x003E; 50 years</ce:para></ce:list-item><ce:list-item id="u3415"><ce:label>•</ce:label><ce:para id="p5785">Clinical risk factors and 10-year fracture risk &#x003E; 10%</ce:para></ce:list-item><ce:list-item id="u3420"><ce:label>•</ce:label><ce:para id="p5790">Glucocorticoid therapy (&#x003E; 7.5 mg prednisolone daily for &#x003E; 3 months)</ce:para></ce:list-item><ce:list-item id="u3425"><ce:label>•</ce:label><ce:para id="p5795">Assessment of response of osteoporosis to treatment</ce:para></ce:list-item><ce:list-item id="u3430"><ce:label>•</ce:label><ce:para id="p5800">Assessment of progression of osteopenia to osteoporosis</ce:para></ce:list-item><ce:list-item id="u3435"><ce:label>•</ce:label><ce:para id="p5805">Age &#x003C; 50 years and very strong risk factors for osteoporosis</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0360" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0700" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1225" role="short">Image 71</ce:alt-text></ce:inline-figure> 24.71</ce:label><ce:alt-text id="atte1230" role="short">24.71</ce:alt-text><ce:textbox-head><ce:title id="tit0365">Investigations in osteoporosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5815"><ce:display><ce:table frame="topbot" id="t0190"><ce:alt-text id="atte1235" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Investigation</entry><entry align="left">Secondary cause of osteoporosis</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Urea, creatinine and electrolytes</ce:bold></entry><entry align="left">Chronic kidney disease</entry></row><row rowsep="1"><entry align="left"><ce:bold>Liver function tests and albumin</ce:bold></entry><entry align="left">Chronic liver disease</entry></row><row rowsep="1"><entry align="left"><ce:bold>Full blood count, erythrocyte sedimentation rate</ce:bold></entry><entry align="left">Inflammatory disease<ce:br/>Myeloma</entry></row><row rowsep="1"><entry align="left"><ce:bold>Tissue transglutaminase antibodies</ce:bold></entry><entry align="left">Coeliac disease</entry></row><row rowsep="1"><entry align="left"><ce:bold>Serum calcium and phosphate</ce:bold></entry><entry align="left">Primary hyperparathyroidism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Serum 25(OH)D and alkaline phosphatase</ce:bold></entry><entry align="left">Vitamin D deficiency<ce:br/>Osteomalacia</entry></row><row rowsep="1"><entry align="left"><ce:bold>Serum parathyroid hormone</ce:bold></entry><entry align="left">Primary hyperparathyroidism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Thyroid function tests</ce:bold></entry><entry align="left">Hyperthyroidism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Serum protein electrophoresis</ce:bold></entry><entry align="left">Myeloma<ce:br/>Monoclonal gammopathy of uncertain significance</entry></row><row rowsep="1"><entry align="left"><ce:bold>Urinary Bence Jones protein</ce:bold></entry><entry align="left">Myeloma</entry></row><row rowsep="1"><entry align="left"><ce:bold>Testosterone and gonadotrophins</ce:bold></entry><entry align="left">Male hypogonadism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Oestrogen and gonadotrophins</ce:bold></entry><entry align="left">Female hypogonadism<ce:cross-ref id="crf1265" refid="tn0035"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry></row><row><entry align="left"><ce:bold>Bone biopsy</ce:bold></entry><entry align="left">Unexplained early-onset osteoporosis<ce:cross-ref id="crf1270" refid="tn0040"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:br/>Renal disease<ce:br/>Multiple possible causes of low bone mass</entry></row></tbody></tgroup><ce:table-footnote id="tn0035"><ce:label>1</ce:label><ce:note-para id="np0080">Only required for unexplained osteoporosis in young women who are amenorrhoeic.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0040"><ce:label>2</ce:label><ce:note-para id="np0085">Seldom required.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0365" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0705" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1240" role="short">Image 72</ce:alt-text></ce:inline-figure> 24.72</ce:label><ce:alt-text id="atte1245" role="short">24.72</ce:alt-text><ce:textbox-head><ce:title id="tit0370">Drug treatments for osteoporosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5835"><ce:display><ce:table frame="topbot" id="t0195"><ce:alt-text id="atte1250" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Drug</entry><entry align="left">Regimen</entry><entry align="left">Postmenopausal osteoporosis</entry><entry align="left">Glucocorticoid osteoporosis</entry><entry align="left">Male osteoporosis</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Alendronic acid</ce:bold></entry><entry align="left">70 mg/week orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">✓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Risedronate</ce:bold></entry><entry align="left">35 mg/week orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">✓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ibandronate</ce:bold></entry><entry align="left">150 mg/monthly orally<ce:br/>3 mg/3-monthly IV</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">✓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Zoledronic acid</ce:bold></entry><entry align="left">5 mg annually IV</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">✓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Denosumab</ce:bold></entry><entry align="left">60 mg 6-monthly SC</entry><entry align="left">✓</entry><entry align="left">–</entry><entry align="left">✓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Calcium/vitamin D</ce:bold></entry><entry align="left">Calcium 500–1000 mg daily<ce:br/>Vitamin D 400–800 IU orally</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">✓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Teriparatide</ce:bold></entry><entry align="left">20 µg/day SC</entry><entry align="left">✓</entry><entry align="left">✓</entry><entry align="left">✓</entry></row><row rowsep="1"><entry align="left"><ce:bold>Abaloparatide</ce:bold></entry><entry align="left">80 µg/day SC</entry><entry align="left">✓</entry><entry align="left">–</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left"><ce:bold>Hormone replacement therapy</ce:bold></entry><entry align="left">Various preparations</entry><entry align="left">✓</entry><entry align="left">–</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left"><ce:bold>Raloxifene</ce:bold></entry><entry align="left">60 mg/day orally</entry><entry align="left">✓</entry><entry align="left">–</entry><entry align="left">–</entry></row><row><entry align="left"><ce:bold>Tibolone</ce:bold></entry><entry align="left">1.25 mg/day orally</entry><entry align="left">✓</entry><entry align="left">–</entry><entry align="left">–</entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p5840">(IV = intravenous; SC = subcutaneous)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0370" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0715" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1255" role="short">Image 73</ce:alt-text></ce:inline-figure> 24.73</ce:label><ce:alt-text id="atte1260" role="short">24.73</ce:alt-text><ce:textbox-head><ce:title id="tit0375">Adverse effects of bisphosphonates</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1675"><ce:section-title id="st1550">Common</ce:section-title><ce:para id="p5860"><ce:list id="ulist1000"><ce:list-item id="u3440"><ce:label>•</ce:label><ce:para id="p5865">Upper gastrointestinal intolerance (oral)</ce:para></ce:list-item><ce:list-item id="u3445"><ce:label>•</ce:label><ce:para id="p5870">Acute phase response (intravenous)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1680"><ce:section-title id="st1555">Less common</ce:section-title><ce:para id="p5875"><ce:list id="ulist1005"><ce:list-item id="u3450"><ce:label>•</ce:label><ce:para id="p5880">Atrial fibrillation (intravenous zoledronic acid)</ce:para></ce:list-item><ce:list-item id="u3455"><ce:label>•</ce:label><ce:para id="p5885">Hypocalcaemia (intravenous bisphosphonates)</ce:para></ce:list-item><ce:list-item id="u3460"><ce:label>•</ce:label><ce:para id="p5890">Atypical subtrochanteric fractures</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1685"><ce:section-title id="st1560">Rare</ce:section-title><ce:para id="p5895"><ce:list id="ulist1010"><ce:list-item id="u3465"><ce:label>•</ce:label><ce:para id="p5900">Uveitis</ce:para></ce:list-item><ce:list-item id="u3470"><ce:label>•</ce:label><ce:para id="p5905">Osteonecrosis of the jaw</ce:para></ce:list-item><ce:list-item id="u3475"><ce:label>•</ce:label><ce:para id="p5910">Oesophageal ulceration</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0375" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0720" locator="icon02-9780702070280" xlink:href="pii:B978070207028000024X/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1265" role="short">Image 74</ce:alt-text></ce:inline-figure> 24.74</ce:label><ce:alt-text id="atte1270" role="short">24.74</ce:alt-text><ce:textbox-head><ce:title id="tit0380">Osteoporosis in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5925"><ce:list id="ulist1015"><ce:list-item id="u3480"><ce:label>•</ce:label><ce:para id="p5930"><ce:bold>Bone loss</ce:bold>: due to increased bone turnover, with an age-related defect switch in differentiation of bone marrow stromal cells to form adipocytes as opposed to osteoblasts.</ce:para></ce:list-item><ce:list-item id="u3485"><ce:label>•</ce:label><ce:para id="p5935"><ce:bold>Fractures due to osteoporosis</ce:bold>: common cause of morbidity and mortality, although fracture healing is not delayed by age.</ce:para></ce:list-item><ce:list-item id="u3490"><ce:label>•</ce:label><ce:para id="p5940"><ce:bold>Recurrent fractures</ce:bold>: those who suffer a fragility fracture are at increased risk of further fracture, so should be investigated for osteoporosis and treated if this is confirmed.</ce:para></ce:list-item><ce:list-item id="u3495"><ce:label>•</ce:label><ce:para id="p5945"><ce:bold>Falls</ce:bold>: risk factors for falls (such as visual and neuromuscular impairments) are independent risk factors for hip fracture in elderly individuals, so intervention to prevent falls is as important as treatment of osteoporosis (<ce:intra-ref id="ii0590" xlink:href="pii:B978-0-7020-7028-0.00032-9#s0135">p. 1308</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u3500"><ce:label>•</ce:label><ce:para id="p5950"><ce:bold>Intravenous zoledronic acid</ce:bold>: reduces mortality and subsequent fracture in selected elderly patients with hip fractures.</ce:para></ce:list-item><ce:list-item id="u3505"><ce:label>•</ce:label><ce:para id="p5955"><ce:bold>Calcium and vitamin D</ce:bold>: reduce the risk of fractures in those who are housebound or living in care homes.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0380" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0725" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1275" role="short">Image 75</ce:alt-text></ce:inline-figure> 24.75</ce:label><ce:alt-text id="atte1280" role="short">24.75</ce:alt-text><ce:textbox-head><ce:title id="tit0385">Causes of osteomalacia and rickets</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6000"><ce:display><ce:table frame="topbot" id="t0200"><ce:alt-text id="atte1285" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Cause</entry><entry align="left">Predisposing factor</entry><entry align="left">Mechanism</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Vitamin D deficiency</ce:bold></entry></row><row rowsep="0"><entry align="left">Classical</entry><entry align="left">Lack of sunlight exposure and poor diet</entry><entry align="left">Reduced cholecalciferol synthesis in the skin/low levels of vitamin D in the diet</entry></row><row rowsep="1"><entry align="left">Gastrointestinal disease</entry><entry align="left">Malabsorption</entry><entry align="left">Malabsorption of dietary vitamin D and calcium</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Failure of 1,25 vitamin D synthesis</ce:bold></entry></row><row rowsep="0"><entry align="left">Chronic renal failure</entry><entry align="left">Hyperphosphataemia and kidney damage</entry><entry align="left">Impaired conversion of 25(OH)D<ce:inf loc="post">3</ce:inf> to 1,25(OH)<ce:inf loc="post">2</ce:inf>D<ce:inf loc="post">3</ce:inf></entry></row><row rowsep="1"><entry align="left">Vitamin D-resistant rickets type I (autosomal recessive)</entry><entry align="left">Loss-of-function mutations in renal 25(OH)D 1α-hydroxylase enzyme</entry><entry align="left">Impaired conversion of 25(OH)D<ce:inf loc="post">3</ce:inf> to 1,25(OH)<ce:inf loc="post">2</ce:inf>D<ce:inf loc="post">3</ce:inf></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Vitamin D receptor defects</ce:bold></entry></row><row rowsep="1"><entry align="left">Vitamin D-resistant rickets type II (autosomal recessive)</entry><entry align="left">Loss-of-function mutations in vitamin D receptor</entry><entry align="left">Impaired response to 1,25(OH)<ce:inf loc="post">2</ce:inf>D<ce:inf loc="post">3</ce:inf></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Defects in phosphate and pyrophosphate metabolism</ce:bold></entry></row><row rowsep="0"><entry align="left">Hypophosphataemic rickets (X-linked dominant)</entry><entry align="left">Mutations in <ce:italic>PHEX</ce:italic></entry><entry align="left">Increased FGF23 production (mechanism unclear)</entry></row><row rowsep="0"><entry align="left">Autosomal dominant hypophosphataemic rickets</entry><entry align="left">Mutation in <ce:italic>FGF23</ce:italic></entry><entry align="left">Mutant FGF23 is resistant to degradation</entry></row><row rowsep="0"><entry align="left">Autosomal recessive hypophosphataemic rickets</entry><entry align="left">Mutations in <ce:italic>DMP1</ce:italic></entry><entry align="left">Increased production of FGF23<ce:br/>Local deficiency of DMP1 inhibits mineralisation</entry></row><row rowsep="0"><entry align="left">Tumour-induced hypophosphataemic osteomalacia</entry><entry align="left">Ectopic production of FGF23 by tumour</entry><entry align="left">Over-production of FGF23</entry></row><row rowsep="1"><entry align="left">Hypophosphatasia</entry><entry align="left">Mutations in <ce:italic>ALPL</ce:italic>, which encodes alkaline phosphatase</entry><entry align="left">Inhibition of bone mineralisation due to accumulation of pyrophosphate in bone</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Iatrogenic and other causes</ce:bold></entry></row><row rowsep="0"><entry align="left">Bisphosphonate therapy</entry><entry align="left">High-dose etidronate/pamidronate</entry><entry align="left">Drug-induced impairment of mineralisation</entry></row><row rowsep="0"><entry align="left">Aluminium</entry><entry align="left">Use of aluminium-containing phosphate binders or aluminium in dialysis fluid</entry><entry align="left">Aluminium-induced impairment of mineralisation</entry></row><row><entry align="left">Fluoride</entry><entry align="left">High fluoride in water</entry><entry align="left">Inhibition of mineralisation by fluoride</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0595">(FGF23 = fibroblast growth factor 23)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0385" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0755" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1290" role="short">Image 76</ce:alt-text></ce:inline-figure> 24.76</ce:label><ce:alt-text id="atte1295" role="short">24.76</ce:alt-text><ce:textbox-head><ce:title id="tit0390">Medical management of Paget's disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6145"><ce:display><ce:table frame="topbot" id="t0205"><ce:alt-text id="atte1300" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Drug</entry><entry align="left">Route of administration</entry><entry align="left">Dose</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Etidronate</ce:bold></entry><entry align="left">Oral</entry><entry align="left">400 mg daily for 3–6 months</entry></row><row rowsep="1"><entry align="left"><ce:bold>Tiludronate</ce:bold></entry><entry align="left">Oral</entry><entry align="left">400 mg daily for 3–6 months</entry></row><row rowsep="1"><entry align="left"><ce:bold>Risedronate</ce:bold></entry><entry align="left">Oral</entry><entry align="left">30 mg daily for 2 months</entry></row><row rowsep="1"><entry align="left"><ce:bold>Pamidronate</ce:bold></entry><entry align="left">IV</entry><entry align="left">1–3 × 60 mg infusions</entry></row><row rowsep="1"><entry align="left"><ce:bold>Zoledronic acid</ce:bold></entry><entry align="left">IV</entry><entry align="left">1 × 5 mg infusion</entry></row><row><entry align="left"><ce:bold>Calcitonin</ce:bold></entry><entry align="left">SC</entry><entry align="left">100–200 IU 3 times weekly for 2–3 months</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0390" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0770" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1305" role="short">Image 77</ce:alt-text></ce:inline-figure> 24.77</ce:label><ce:alt-text id="atte1310" role="short">24.77</ce:alt-text><ce:textbox-head><ce:title id="tit0395">Primary tumours of the musculoskeletal system</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6195"><ce:display><ce:table frame="topbot" id="t0210"><ce:alt-text id="atte1315" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Cell type</entry><entry align="left">Benign</entry><entry align="left">Malignant</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Osteoblast</ce:bold></entry><entry align="left">Osteoid osteoma</entry><entry align="left">Osteosarcoma</entry></row><row rowsep="1"><entry align="left"><ce:bold>Chondrocyte</ce:bold></entry><entry align="left">Chondroma<ce:br/>Osteochondroma</entry><entry align="left">Chondrosarcoma</entry></row><row rowsep="1"><entry align="left"><ce:bold>Fibroblast</ce:bold></entry><entry align="left">Fibroma</entry><entry align="left">Fibrosarcoma</entry></row><row rowsep="1"><entry align="left"><ce:bold>Bone marrow cell</ce:bold></entry><entry align="left">Eosinophilic granuloma</entry><entry align="left">Ewing's sarcoma</entry></row><row rowsep="1"><entry align="left"><ce:bold>Endothelial cell</ce:bold></entry><entry align="left">Haemangioma</entry><entry align="left">Angiosarcoma</entry></row><row><entry align="left"><ce:bold>Osteoclast precursor</ce:bold></entry><entry align="left">Giant cell tumour</entry><entry align="left">Malignant giant cell tumour</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0395" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0775" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1320" role="short">Image 78</ce:alt-text></ce:inline-figure> 24.78</ce:label><ce:alt-text id="atte1325" role="short">24.78</ce:alt-text><ce:textbox-head><ce:title id="tit0400">Drug-induced effects on the musculoskeletal system</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6225"><ce:display><ce:table frame="topbot" id="t0215"><ce:alt-text id="atte1330" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Musculoskeletal problem</entry><entry align="left">Principal drug</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Secondary gout</ce:bold></entry><entry align="left">Thiazides, furosemide, alcohol</entry></row><row rowsep="1"><entry align="left"><ce:bold>Osteoporosis</ce:bold></entry><entry align="left">Glucocorticoids, heparin, glitazones, aromatase inhibitors, GnRH agonists</entry></row><row rowsep="1"><entry align="left"><ce:bold>Osteomalacia</ce:bold></entry><entry align="left">Anticonvulsants, etidronate and pamidronate (high-dose)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Osteonecrosis</ce:bold></entry><entry align="left">Glucocorticoids, alcohol</entry></row><row rowsep="1"><entry align="left"><ce:bold>Drug-induced lupus syndrome</ce:bold></entry><entry align="left">Procainamide, hydralazine, isoniazid, chlorpromazine</entry></row><row rowsep="1"><entry align="left"><ce:bold>Arthralgias, arthritis</ce:bold></entry><entry align="left">Glucocorticoid withdrawal, glibenclamide, methyldopa, ciclosporin, isoniazid, barbiturates</entry></row><row rowsep="1"><entry align="left"><ce:bold>Myalgia</ce:bold></entry><entry align="left">Glucocorticoid withdrawal, L-tryptophan, fibrates, statins</entry></row><row rowsep="1"><entry align="left"><ce:bold>Myopathy</ce:bold></entry><entry align="left">Glucocorticoids, chloroquine</entry></row><row rowsep="1"><entry align="left"><ce:bold>Myositis, myasthenia</ce:bold></entry><entry align="left">Penicillamine, statins</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cramps</ce:bold></entry><entry align="left">Glucocorticoids, ACTH, diuretics, carbenoxolone</entry></row><row><entry align="left"><ce:bold>Vasculitis</ce:bold></entry><entry align="left">Amphetamines, thiazides</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0660">(ACTH = adrenocorticotrophic hormone; GnRH = gonadotrophin-releasing hormone)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0400" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0780" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1335" role="short">Image 79</ce:alt-text></ce:inline-figure> 24.79</ce:label><ce:alt-text id="atte1340" role="short">24.79</ce:alt-text><ce:textbox-head><ce:title id="tit0405">Rheumatological manifestations of malignancy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6235"><ce:list id="ulist1020"><ce:list-item id="u3510"><ce:label>•</ce:label><ce:para id="p6240">Polyarthritis</ce:para></ce:list-item><ce:list-item id="u3515"><ce:label>•</ce:label><ce:para id="p6245">Dermatomyositis and polymyositis</ce:para></ce:list-item><ce:list-item id="u3520"><ce:label>•</ce:label><ce:para id="p6250">Hypophosphataemic osteomalacia</ce:para></ce:list-item><ce:list-item id="u3525"><ce:label>•</ce:label><ce:para id="p6255">Hypertrophic osteoarthropathy</ce:para></ce:list-item><ce:list-item id="u3530"><ce:label>•</ce:label><ce:para id="p6260">Vasculitis, connective tissue disease</ce:para></ce:list-item><ce:list-item id="u3535"><ce:label>•</ce:label><ce:para id="p6265">Raynaud's syndrome</ce:para></ce:list-item><ce:list-item id="u3540"><ce:label>•</ce:label><ce:para id="p6270">Polymyalgia rheumatica-like syndrome</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0405" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0795" locator="icon01-9780702070280" xlink:href="pii:B978070207028000024X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1345" role="short">Image 80</ce:alt-text></ce:inline-figure> 24.80</ce:label><ce:alt-text id="atte1350" role="short">24.80</ce:alt-text><ce:textbox-head><ce:title id="tit0410">Modified Beighton score for joint hypermobility</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6355"><ce:display><ce:table frame="topbot" id="t0220"><ce:alt-text id="atte1355" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Clinical test</entry><entry align="left">Score</entry></row></thead><tbody><row rowsep="1"><entry align="left">Extend little finger &#x003E; 90°</entry><entry align="left">1 point each side</entry></row><row rowsep="1"><entry align="left">Bring thumb back parallel to/touching forearm</entry><entry align="left">1 point each side</entry></row><row rowsep="1"><entry align="left">Extend elbow &#x003E; 10°</entry><entry align="left">1 point each side</entry></row><row rowsep="1"><entry align="left">Extend knee &#x003E; 10°</entry><entry align="left">1 point each side</entry></row><row rowsep="1"><entry align="left">Touch floor with flat of hands, legs straight</entry><entry align="left">1 point</entry></row><row><entry namest="col1" nameend="col2" align="center">Hypermobile = a score of 6 or more points out of a possible 9 for epidemiological studies, or 4 or more points (with arthralgia in four or more joints) for a clinical diagnosis of the benign joint hypermobility syndrome</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>24</ce:label><ce:title id="tit0010">Rheumatology and bone disease</ce:title><ce:author-group id="aug0010"><ce:author author-id="B978070207028000024X-1ba1d74558d64dee28c2a648c462ee84" id="au0010"><ce:given-name>GPR</ce:given-name><ce:surname>Clunie</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0015"><ce:author author-id="B978070207028000024X-07b5e9e1a194ee62bc3696fe17f854df" id="au0015"><ce:given-name>SH</ce:given-name><ce:surname>Ralston</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Clinical examination of the musculoskeletal system</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>982</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>Functional anatomy and physiology</ce:bold> <ce:cross-ref id="crf0015" refid="s0025"><ce:bold>984</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0020"><ce:para id="p0020">Bone <ce:cross-ref id="crf0020" refid="s0030">984</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025">Joints <ce:cross-ref id="crf0025" refid="s0045">986</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0030"><ce:para id="p0030">Skeletal muscle <ce:cross-ref id="crf0030" refid="s0080">987</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0035"><ce:para id="p0035"><ce:bold>Investigation of musculoskeletal disease</ce:bold> <ce:cross-ref id="crf0035" refid="s0085"><ce:bold>988</ce:bold></ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0040"><ce:para id="p0040">Joint aspiration <ce:cross-ref id="crf0040" refid="s0090">988</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0045"><ce:para id="p0045">Imaging <ce:cross-ref id="crf0045" refid="s0095">988</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0050"><ce:para id="p0050">Blood tests <ce:cross-ref id="crf0050" refid="s0130">990</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0055"><ce:para id="p0055">Tissue biopsy <ce:cross-ref id="crf0055" refid="s0180">992</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060">Electromyography <ce:cross-ref id="crf0060" refid="s0185">992</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0065"><ce:para id="p0065"><ce:bold>Presenting problems in musculoskeletal disease</ce:bold> <ce:cross-ref id="crf0065" refid="s0190"><ce:bold>992</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0070"><ce:para id="p0070">Acute monoarthritis <ce:cross-ref id="crf0070" refid="s0195">992</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0075"><ce:para id="p0075">Polyarthritis <ce:cross-ref id="crf0075" refid="s0220">993</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0080"><ce:para id="p0080">Fracture <ce:cross-ref id="crf0080" refid="s0245">994</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0085"><ce:para id="p0085">Generalised musculoskeletal pain <ce:cross-ref id="crf0085" refid="s0270">995</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0090"><ce:para id="p0090">Back pain <ce:cross-ref id="crf0090" refid="s0295">995</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095">Regional musculoskeletal pain <ce:cross-ref id="crf0095" refid="s0340">997</ce:cross-ref><ce:list id="ulist0030"><ce:list-item id="u0100"><ce:para id="p0100">Neck pain <ce:cross-ref id="crf0100" refid="s0345">997</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0105"><ce:para id="p0105">Shoulder pain <ce:cross-ref id="crf0105" refid="s0350">997</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Elbow pain <ce:cross-ref id="crf0110" refid="s0370">998</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0115"><ce:para id="p0115">Hand and wrist pain <ce:cross-ref id="crf0115" refid="s0375">998</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0120"><ce:para id="p0120">Hip pain <ce:cross-ref id="crf0120" refid="s0380">998</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0125"><ce:para id="p0125">Knee pain <ce:cross-ref id="crf0125" refid="s0385">998</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0130"><ce:para id="p0130">Ankle and foot pain <ce:cross-ref id="crf0130" refid="s0390">999</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0135"><ce:para id="p0135">Muscle pain and weakness <ce:cross-ref id="crf0135" refid="s0395">1000</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0140"><ce:para id="p0140"><ce:bold>Principles of management</ce:bold> <ce:cross-ref id="crf0140" refid="s0420"><ce:bold>1000</ce:bold></ce:cross-ref><ce:list id="ulist0035"><ce:list-item id="u0145"><ce:para id="p0145">Education and lifestyle interventions <ce:cross-ref id="crf0145" refid="s0425">1000</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0150"><ce:para id="p0150">Non-pharmacological interventions <ce:cross-ref id="crf0150" refid="s0445">1001</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0155"><ce:para id="p0155">Pharmacological treatment <ce:cross-ref id="crf0155" refid="s0470">1002</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0160"><ce:para id="p0160"><ce:bold>Osteoarthritis</ce:bold> <ce:cross-ref id="crf0160" refid="s0610"><ce:bold>1007</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0165"><ce:para id="p0165"><ce:bold>Crystal-induced arthritis</ce:bold> <ce:cross-ref id="crf0165" refid="s0760"><ce:bold>1012</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0170"><ce:para id="p0170"><ce:bold>Fibromyalgia</ce:bold> <ce:cross-ref id="crf0170" refid="s0880"><ce:bold>1018</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0175"><ce:para id="p0175"><ce:bold>Bone and joint infections</ce:bold> <ce:cross-ref id="crf0175" refid="s0925"><ce:bold>1019</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0180"><ce:para id="p0180"><ce:bold>Rheumatoid arthritis</ce:bold> <ce:cross-ref id="crf0180" refid="s1030"><ce:bold>1021</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0185"><ce:para id="p0185"><ce:bold>Juvenile idiopathic arthritis</ce:bold> <ce:cross-ref id="crf0185" refid="s1130"><ce:bold>1026</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0190"><ce:para id="p0190"><ce:bold>Spondyloarthropathies</ce:bold> <ce:cross-ref id="crf0190" refid="s1160"><ce:bold>1027</ce:bold></ce:cross-ref><ce:list id="ulist0040"><ce:list-item id="u0195"><ce:para id="p0195">Axial spondyloarthropathy <ce:cross-ref id="crf0195" refid="s1165">1028</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0200"><ce:para id="p0200">Reactive arthritis <ce:cross-ref id="crf0200" refid="s1225">1031</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0205"><ce:para id="p0205">Psoriatic arthritis <ce:cross-ref id="crf0205" refid="s1250">1032</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0210"><ce:para id="p0210">Enteropathic (spondylo)arthritis <ce:cross-ref id="crf0210" refid="s1310">1034</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0215"><ce:para id="p0215"><ce:bold>Autoimmune connective tissue diseases</ce:bold> <ce:cross-ref id="crf0215" refid="s1315"><ce:bold>1034</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0220"><ce:para id="p0220"><ce:bold>Vasculitis</ce:bold> <ce:cross-ref id="crf0220" refid="s1530"><ce:bold>1040</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0225"><ce:para id="p0225"><ce:bold>Diseases of bone</ce:bold> <ce:cross-ref id="crf0225" refid="s1605"><ce:bold>1044</ce:bold></ce:cross-ref><ce:list id="ulist0045"><ce:list-item id="u0230"><ce:para id="p0230">Osteoporosis <ce:cross-ref id="crf0230" refid="s1610">1044</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0235"><ce:para id="p0235">Osteomalacia, rickets and vitamin D deficiency <ce:cross-ref id="crf0235" refid="s1730">1049</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0240"><ce:para id="p0240">Paget's disease of bone <ce:cross-ref id="crf0240" refid="s1850">1053</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0245"><ce:para id="p0245">Other bone diseases <ce:cross-ref id="crf0245" refid="s1880">1055</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0250"><ce:para id="p0250"><ce:bold>Bone and joint tumours</ce:bold> <ce:cross-ref id="crf0250" refid="s1920"><ce:bold>1056</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0255"><ce:para id="p0255"><ce:bold>Rheumatological involvement in other diseases</ce:bold> <ce:cross-ref id="crf0255" refid="s1950"><ce:bold>1057</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0260"><ce:para id="p0260"><ce:bold>Miscellaneous conditions</ce:bold> <ce:cross-ref id="crf0260" refid="s1980"><ce:bold>1058</ce:bold></ce:cross-ref></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:section id="s0010"><ce:section-title id="st0010">Clinical examination of the musculoskeletal system</ce:section-title><ce:para id="p0265"><ce:display><ce:figure id="f0010"><ce:alt-text id="atte1360" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0010" locator="u024-001-9780702070280" xlink:href="pii:B978070207028000024X/u024-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para><ce:section id="s0015"><ce:section id="s0020"><ce:section-title id="st0015">General Assessment of Locomotor System (GALS) and Schöber's test</ce:section-title><ce:para id="p0270"><ce:display><ce:figure id="f0015"><ce:alt-text id="atte1365" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0015" locator="u024-002-9780702070280" xlink:href="pii:B978070207028000024X/u024-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:section></ce:section></ce:section><ce:para id="p0275">Disorders of the musculoskeletal system affect all ages and ethnic groups. In the UK, about 25% of new consultations in general practice are for musculoskeletal symptoms. Musculoskeletal diseases may arise from processes affecting bones, joints, muscles, or connective tissues such as skin and tendon. The principal manifestations are pain and impairment of locomotor function.</ce:para><ce:para id="p0280">Diseases of the musculoskeletal system tend to be more common in women and most increase in frequency with increasing age. They are the most common cause of physical disability in older people and account for one-third of physical disability at all ages.</ce:para><ce:section id="s0025"><ce:section-title id="st0020">Functional anatomy and physiology</ce:section-title><ce:para id="p0285">The musculoskeletal system is responsible for movement of the body, provides a structural framework to protect internal organs, and acts as a reservoir for storage of calcium and phosphate in the regulation of mineral homeostasis. The main components of the musculoskeletal system are depicted in <ce:cross-ref id="crf0265" refid="f0020">Figure 24.1</ce:cross-ref><ce:float-anchor refid="f0020"/>.</ce:para><ce:section id="s0030"><ce:section-title id="st0025">Bone</ce:section-title><ce:para id="p0290">Bones fall into two main types, based on their embryonic development. Flat bones, such as the skull, develop by intramembranous ossification, in which embryonic fibroblasts differentiate directly into bone within condensations of mesenchymal tissue during early fetal life. Long bones, such as the femur and radius, develop by endochondral ossification from a cartilage template. During development, the cartilage is invaded by vascular tissue containing osteoprogenitor cells and is gradually replaced by bone from centres of ossification situated in the middle and at the ends of the bone. A thin remnant of cartilage called the growth plate or epiphysis remains at each end of long bones, and chondrocyte proliferation here is responsible for skeletal growth during childhood and adolescence. At the end of puberty, the increased levels of sex hormones halt cell division in the growth plate. The cartilage remnant then disappears as the epiphysis fuses and longitudinal bone growth ceases.</ce:para><ce:para id="p0295">Two types of bone tissue are present in the normal skeleton (<ce:cross-ref id="crf0270" refid="f0020">Fig. 24.1</ce:cross-ref>). Cortical bone is formed from Haversian systems, comprising concentric lamellae of bone tissue surrounding a central canal that contains blood vessels. Cortical bone is dense and forms a hard envelope around the long bones. Trabecular or cancellous bone fills the centre of the bone and consists of an interconnecting meshwork of trabeculae, separated by spaces filled with bone marrow. The most important cell types in bone are:<ce:list id="ulist0050"><ce:list-item id="u0265"><ce:label>•</ce:label><ce:para id="p0300"><ce:italic>Osteoclasts</ce:italic>: multinucleated cells of haematopoietic origin, responsible for bone resorption.</ce:para></ce:list-item><ce:list-item id="u0270"><ce:label>•</ce:label><ce:para id="p0305"><ce:italic>Osteoblasts</ce:italic>: mononuclear cells of derived from marrow stromal cells responsible for bone formation.</ce:para></ce:list-item><ce:list-item id="u0275"><ce:label>•</ce:label><ce:para id="p0310"><ce:italic>Osteocytes</ce:italic>: cells that differentiate from osteoblasts that become embedded in bone matrix during bone formation. They are responsible for sensing and responding to mechanical stimuli and for coordinating osteoclast and osteoblast activity.</ce:para></ce:list-item><ce:list-item id="u0280"><ce:label>•</ce:label><ce:para id="p0315"><ce:italic>Bone marrow stromal cells</ce:italic>: cells that produce receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF), which stimulate osteoclast formation, and other cytokines that support haematopoiesis (<ce:intra-ref id="ii0010" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0060">p. 914</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u0285"><ce:label>•</ce:label><ce:para id="p0320"><ce:italic>Bone lining cells</ce:italic>: flattened cells lining the bone surface that differentiate from osteoblasts when bone formation is complete.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0035"><ce:section-title id="st0030">Bone matrix and mineral</ce:section-title><ce:para id="p0325">The most abundant protein of bone is type I collagen, which is formed from two α1 peptide chains and one α2 chain wound together in a triple helix. Type I collagen is proteolytically processed inside the cell before being laid down in the extracellular space, releasing propeptide fragments that can be used as biochemical markers of bone formation. Subsequently, the collagen fibrils become ‘cross-linked’ to one another by pyridinium molecules, a process that enhances bone strength. When bone is broken down by osteoclasts, the cross-links are released into the circulation. These can be measured biochemically and are sometimes used clinically to assess levels of bone resorption. Bone is normally laid down in an orderly fashion, but when bone turnover is high, as in Paget's disease or severe hyperparathyroidism, it is laid down in a chaotic pattern, giving rise to ‘woven bone’ that is mechanically weak. Bone matrix also contains growth factors, other structural proteins and proteoglycans, thought to be involved in helping bone cells attach to bone matrix and in regulating bone cell activity. The other major component of bone is mineral, comprised of calcium and phosphate crystals deposited between the collagen fibrils in the form of hydroxyapatite [Ca<ce:inf loc="post">10</ce:inf> (PO<ce:inf loc="post">4</ce:inf>)<ce:inf loc="post">6</ce:inf> (OH)<ce:inf loc="post">2</ce:inf>]. Mineralisation is essential for bone's rigidity and strength but over-mineralisation causes the bone to become brittle. In clinical practice, increased mineralisation can occur in some types of osteogenesis imperfecta and in response to long-term bisphosphonate therapy.</ce:para></ce:section><ce:section id="s0040"><ce:section-title id="st0035">Bone remodelling</ce:section-title><ce:para id="p0330">Bone remodelling is required for renewal and repair of the skeleton throughout life. This is a cyclical process that has four phases; quiescence, resorption, reversal and formation, as illustrated in <ce:cross-ref id="crf0275" refid="f0025">Figure 24.2</ce:cross-ref><ce:float-anchor refid="f0025"/>. Remodelling starts with the attraction of osteoclast precursors in peripheral blood to the target site, probably by local release of chemotactic factors from areas of microdamage. The osteoclasts resorb bone and, after about 10 days, undergo programmed cell death (apoptosis), heralding the start of the reversal phase, when osteoblast precursors are recruited to the resorption site. The osteoblast precursors differentiate into mature osteoblasts and form new bone during the formation phase. Initially, the matrix is unmineralised (osteoid) but eventually becomes mineralised to form mature bone. Some osteoblasts become trapped in bone matrix and differentiate into osteocytes, which play a key regulatory role in coordinating bone formation and resorption, whereas others differentiate into bone-lining cells.</ce:para><ce:para id="p0335">The cellular and molecular mediators of this bone remodelling are shown in more detail in <ce:cross-ref id="crf0280" refid="f0030">Figure 24.3</ce:cross-ref><ce:float-anchor refid="f0030"/>. Osteoclast precursors are derived from haematopoietic stem cells and differentiate into mature osteoclasts in response to M-CSF, produced by bone marrow stromal cells, and RANKL, produced by osteocytes, bone marrow stromal cells and osteoblasts. The RANKL binds to and activates a receptor called RANK (receptor activator of nuclear factor kappa B) on osteoclast precursors, promoting osteoclast differentiation and bone resorption. This effect is blocked by osteoprotegerin (OPG), which is a decoy receptor for RANKL that inhibits osteoclast formation. Once formed, mature osteoclasts attach to the bone surface by a tight sealing zone and secrete hydrochloric acid and proteolytic enzymes, including cathepsin K, into the space underneath, which is known as the Howship's lacuna. The acid dissolves the mineral and cathepsin K degrades collagen. Osteocytes also produce sclerostin (SOST), which is a potent inhibitor of bone formation. Under conditions of mechanical loading, sclerostin production by osteocytes is inhibited, allowing bone formation to proceed, stimulated by members of the Wnt family of signalling proteins. The Wnt molecules stimulate bone formation by activating members of the lipoprotein receptor-related protein (LRP) family, the most important of which are LRP4, LRP5 and LRP6. Sclerostin antagonises the effects of Wnt family members by blocking their interaction with LRP family members. Finally, osteocytes play a critical role in phosphate homeostasis by producing the hormone FGF23, which regulates renal tubular phosphate reabsorption. Key regulators of bone remodelling are summarised in <ce:cross-ref id="crf0285" refid="b0010">Box 24.1</ce:cross-ref><ce:float-anchor refid="b0010"/>.</ce:para><ce:para id="p0345">Mineralisation of bone is critically dependent on the enzyme alkaline phosphatase (ALP), which is produced by osteoblasts and degrades pyrophosphate, an inhibitor of mineralisation. Bone remodelling is predominantly regulated at a local level but can be influenced by circulating hormones or mechanical loading, which can up-regulate or down-regulate remodelling across the whole skeleton (<ce:cross-ref id="crf0290" refid="b0010">Box 24.1</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0045"><ce:section-title id="st0040">Joints</ce:section-title><ce:para id="p0350">There are three main types of joint: fibrous, fibrocartilaginous and synovial (<ce:cross-ref id="crf0295" refid="b0015">Box 24.2</ce:cross-ref><ce:float-anchor refid="b0015"/>).</ce:para><ce:section id="s0050"><ce:section-title id="st0045">Fibrous and fibrocartilaginous joints</ce:section-title><ce:para id="p0360">These comprise a simple bridge of fibrous or fibrocartilaginous tissue joining two bones together where there is little requirement for movement. The intervertebral disc is a special type of fibrocartilaginous joint in which an amorphous area, called the nucleus pulposus, lies in the centre of the fibrocartilaginous bridge. The nucleus has a high water content and acts as a cushion to improve the disc's shock-absorbing properties.</ce:para></ce:section><ce:section id="s0055"><ce:section-title id="st0050">Synovial joints</ce:section-title><ce:para id="p0365">These are complex structures containing several cell types. They are found where a wide range of movement is needed (<ce:cross-ref id="crf0300" refid="f0035">Fig. 24.4</ce:cross-ref><ce:float-anchor refid="f0035"/>).</ce:para><ce:section id="s0060"><ce:section-title id="st0055">Articular cartilage</ce:section-title><ce:para id="p0370">This avascular tissue covers the bone ends in synovial joints. Cartilage cells (chondrocytes) are responsible for synthesis and turnover of cartilage, which consists of a mesh of type II collagen fibrils that extend through a hydrated ‘gel’ of proteoglycan molecules. The most important proteoglycan is aggrecan, which consists of a core protein to which several glycosaminoglycan (GAG) side chains are attached (<ce:cross-ref id="crf0305" refid="f0040">Fig. 24.5</ce:cross-ref><ce:float-anchor refid="f0040"/>). The GAGs are polysaccharides that consist of long chains of disaccharide repeats comprising one normal sugar and an amino sugar. The most abundant GAGs in aggrecan are chondroitin sulphate and keratan sulphate. Hyaluronan is another important GAG that binds to aggrecan molecules to form very large complexes with a total molecular weight of more than 100 million. Aggrecan has a strong negative charge and avidly binds water molecules to assume a shape that occupies the maximum possible volume available. The expansive force of the hydrated aggrecan, combined with the restrictive strength of the collagen mesh, gives articular cartilage excellent shock-absorbing properties.</ce:para><ce:para id="p0375">With ageing, the concentration of chondroitin sulphate decreases, whereas that of keratan sulphate increases, resulting in reduced water content and shock-absorbing properties. These changes differ from those found in osteoarthritis (<ce:cross-ref id="crf9070" refid="s0580">p. 1007</ce:cross-ref>), where there is abnormal chondrocyte division, loss of proteoglycan from matrix and an increase in water content. Cartilage matrix is constantly turning over and in health there is a perfect balance between synthesis and degradation. Degradation of cartilage matrix is carried out by aggrecanases and matrix metalloproteinases, responsible for the breakdown of proteins and proteoglycans, and by glycosidases, responsible for the breakdown of GAGs. Pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumour necrosis factor (TNF), which are released during inflammation, stimulate production of aggrecanase and metalloproteinases, causing cartilage degradation.</ce:para></ce:section><ce:section id="s0065"><ce:section-title id="st0060">Synovial fluid</ce:section-title><ce:para id="p0380">The surfaces of articular cartilage are separated by a space filled with synovial fluid (SF), a viscous liquid that lubricates the joint. It is an ultrafiltrate of plasma, into which synovial cells secrete hyaluronan and proteoglycans.</ce:para></ce:section><ce:section id="s0070"><ce:section-title id="st0065">Intra-articular discs</ce:section-title><ce:para id="p0385">Some joints contain fibrocartilaginous discs within the joint space that act as shock absorbers. The most clinically important are the menisci of the knee. These are avascular structures that remain viable because of diffusion of oxygen and nutrients from the SF.</ce:para></ce:section><ce:section id="s0075"><ce:section-title id="st0070">Synovial membrane, joint capsule and bursae</ce:section-title><ce:para id="p0390">The bones of synovial joints are connected by the joint capsule, a fibrous structure richly supplied with blood vessels, nerves and lymphatics that encases the joint. Ligaments are discrete, regional thickenings of the capsule that act to stabilise joints (see <ce:cross-ref id="crf0310" refid="f0035">Fig. 24.4</ce:cross-ref>). The inner surface of the joint capsule is the synovial membrane, comprising an outer layer of blood vessels and loose connective tissue that is rich in type I collagen, and an inner layer 1–4 cells thick consisting of two main cell types. Type A synoviocytes are phagocytic cells derived from the monocyte/macrophage lineage and are responsible for removing particulate matter from the joint cavity; type B synoviocytes are fibroblast-like cells that secrete SF. Most inflammatory and degenerative joint diseases associate with thickening of the synovial membrane and infiltration by lymphocytes, polymorphs and macrophages.</ce:para><ce:para id="p0395">Bursae are hollow sacs lined with synovium and contain a small amount of SF. They help tendons and muscles move smoothly in relation to bones and other articular structures.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0080"><ce:section-title id="st0075">Skeletal muscle</ce:section-title><ce:para id="p0400">Skeletal muscles are responsible for body movements and respiration. Muscle consists of bundles of cells (myocytes) embedded in fine connective tissue containing nerves and blood vessels. Myocytes are large, elongated, multinucleated cells formed by fusion of mononuclear precursors (myoblasts) in early embryonic life. The nuclei lie peripherally and the centre of the cell contains actin and myosin molecules, which interdigitate with one another to form the myofibrils that are responsible for muscle contraction. The molecular mechanisms of skeletal muscle contraction are the same as for cardiac muscle (<ce:intra-ref id="ii0025" xlink:href="pii:B978-0-7020-7028-0.00016-0#s0055">p. 446</ce:intra-ref>). Myocytes contain many mitochondria that provide the large amounts of adenosine triphosphate (ATP) necessary for muscle contraction and are rich in the protein myoglobin, which acts as a reservoir for oxygen during contraction.</ce:para><ce:para id="p0405">Individual myofibrils are organised into bundles (fasciculi) that are bound together by a thin layer of connective tissue (the perimysium). The surface of the muscle is surrounded by a thicker layer of connective tissue, the epimysium, which merges with the perimysium to form the muscle tendon. Tendons are tough, fibrous structures that attach muscles to a point of insertion on the bone surface called the enthesis.</ce:para></ce:section></ce:section><ce:section id="s0085"><ce:section-title id="st0080">Investigation of musculoskeletal disease</ce:section-title><ce:para id="p0410">Clinical history and examination usually provide sufficient information for the diagnosis and management of many musculoskeletal diseases. Investigations are helpful in confirming the diagnosis, assessing disease activity and indicating prognosis.</ce:para><ce:section id="s0090"><ce:section-title id="st0085">Joint aspiration</ce:section-title><ce:para id="p0415">Joint aspiration with examination of SF is pivotal in patients suspected of having septic arthritis, crystal arthritis or intra-articular bleeding. It should be carried out in all individuals with acute monoarthritis, and samples should be sent for microbiology and clinical chemistry.</ce:para><ce:para id="p0420">It is possible to obtain SF by aspiration from most peripheral joints and only a small amount is required for diagnostic purposes. Normal SF is present in small volume, is clear and either colourless or pale yellow, and has a high viscosity. It contains few cells. With joint inflammation, the volume increases, the cell count and the proportion of neutrophils rise (causing turbidity), and the viscosity reduces (due to enzymatic degradation of hyaluronan and aggrecan). Turbid fluid with a high neutrophil count occurs in sepsis, crystal arthritis and reactive arthritis. High concentrations of urate crystals or cholesterol can make SF appear white. Non-uniform blood-staining usually reflects needle trauma to the synovium. Uniform blood-staining is most commonly due to a bleeding diathesis, trauma or pigmented villonodular synovitis (<ce:cross-ref id="crf9075" refid="s2005">p. 1059</ce:cross-ref>) but can occur in severe inflammatory synovitis. A lipid layer floating above blood-stained fluid is diagnostic of intra-articular fracture and is caused by release of bone marrow fat into the joint.</ce:para><ce:para id="p0425">Crystals can be identified by compensated polarised light microscopy of fresh SF (to avoid crystal dissolution and post-aspiration crystallisation). Urate crystals are long and needle-shaped, and show a strong light intensity and negative birefringence (<ce:cross-ref id="crf0315" refid="f0045">Fig. 24.6A</ce:cross-ref><ce:float-anchor refid="f0045"/>). Calcium pyrophosphate crystals are smaller, rhomboid in shape and usually less numerous than urate crystals; they have weak intensity and positive birefringence (<ce:cross-ref id="crf0320" refid="f0045">Fig. 24.6B</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0095"><ce:section-title id="st0090">Imaging</ce:section-title><ce:section id="s0100"><ce:section-title id="st0095">Plain X-rays</ce:section-title><ce:para id="p0430">X-rays show structural changes that are of value in the differential diagnosis and monitoring of many bone and joint diseases (<ce:cross-ref id="crf0325" refid="b0020">Box 24.3</ce:cross-ref><ce:float-anchor refid="b0020"/>).</ce:para><ce:para id="p0555">They are of diagnostic value in osteoarthritis (OA), where they demonstrate joint space narrowing that tends to be focal rather than widespread, as in inflammatory arthritis. Other features of OA detected on X-rays include osteophytes, subchondral sclerosis, bone cysts and calcified loose bodies within the synovium (see <ce:cross-ref id="crf0330" refid="f0120">Fig. 24.21</ce:cross-ref>, <ce:cross-ref id="crf9080" refid="s0685">p. 1010</ce:cross-ref>). Erosions and sclerosis of the sacroiliac joints and syndesmophytes in the spine may be observed in patients with spondyloarthritis (SpA; see <ce:cross-ref id="crf0335" refid="f0215">Fig. 24.40</ce:cross-ref>, <ce:cross-ref id="crf9085" refid="s1205">p. 1030</ce:cross-ref>). In peripheral joints, proliferative erosions, associated with new bone formation and periosteal reaction, occur in SpA. In tophaceous gout, well-defined punched-out erosions may occur (see <ce:cross-ref id="crf0340" refid="f0150">Fig. 24.27</ce:cross-ref>, <ce:cross-ref id="crf9090" refid="p3115">p. 1015</ce:cross-ref>). Calcification of cartilage, tendons and soft tissues or muscle occurs mainly in chondrocalcinosis (see <ce:cross-ref id="crf0345" refid="f0155">Fig. 24.28</ce:cross-ref>, <ce:cross-ref id="crf9095" refid="p3170">p. 1016</ce:cross-ref>), calcium-containing crystal diseases, tumoral calcinosis and autoimmune connective tissue diseases.</ce:para><ce:para id="p0560">X-rays are of limited value in the diagnosis of rheumatoid arthritis (RA) because features such as erosions, joint space narrowing and periarticular osteoporosis may be detectable only after several months or even years. The main indication for X-rays in RA is in the assessment of disease over time when structural damage to the joints is suspected.</ce:para></ce:section><ce:section id="s0105"><ce:section-title id="st0100">Bone scintigraphy</ce:section-title><ce:para id="p0565">Bone scintigraphy is useful in the diagnosis of metastatic bone disease and Paget's disease of bone. Abnormalities may also be observed in primary bone tumours, complex regional pain syndrome, osteoarthritis and inflammatory arthritis. It involves gamma-camera imaging following an intravenous injection of <ce:sup loc="post">99m</ce:sup>Tc-labelled bisphosphonate. Early post-injection images reflect blood flow and can show increased perfusion of inflamed synovium, Pagetic bone or primary or secondary bone tumours. Delayed images taken a few hours later reflect bone remodelling as the <ce:sup loc="post">99m</ce:sup>Tc-labelled bisphosphonate localises to sites of active bone turnover. Scintigraphy has a high sensitivity for detecting important bone and joint pathology that is not apparent on X-rays (<ce:cross-ref id="crf0350" refid="b0025">Box 24.4</ce:cross-ref><ce:float-anchor refid="b0025"/>). Single photon emission computed tomography (SPECT) combines radionuclide imaging with computed tomography. It can provide accurate anatomical localisation of abnormal tracer uptake within the bone and is of particular value in the assessment of patients with chronic low back pain of unknown cause.</ce:para></ce:section><ce:section id="s0110"><ce:section-title id="st0105">Magnetic resonance imaging</ce:section-title><ce:para id="p0605">Magnetic resonance imaging (MRI) gives detailed information on anatomy, allowing three-dimensional visualisation of bone and soft tissues that cannot be adequately assessed by plain X-rays. The technique is valuable in the assessment and diagnosis of many musculoskeletal diseases (<ce:cross-ref id="crf0355" refid="b0030">Box 24.5</ce:cross-ref><ce:float-anchor refid="b0030"/>). T1-weighted sequences are useful for defining anatomy, whereas T2-weighted sequences are useful for assessing tissue water content, which is often increased in synovitis and other inflammatory disorders (<ce:cross-ref id="crf0360" refid="f0050">Fig. 24.7</ce:cross-ref><ce:float-anchor refid="f0050"/>). MRI sequences that suppress signal from fat, such as short TI inversion recovery (STIR), are helpful when evaluating inflammatory disease. Contrast agents, such as gadolinium, can be administered to increase sensitivity in detecting erosions and synovitis.</ce:para></ce:section><ce:section id="s0115"><ce:section-title id="st0110">Ultrasonography</ce:section-title><ce:para id="p0685">Ultrasonography is a useful investigation for confirmation of small joint synovitis and erosions, for anatomical location of periarticular lesions, for characterisation of tendon lesions and for guided injection of joints and bursae. Ultrasound is more sensitive than clinical examination for the detection of early synovitis and is used increasingly in the diagnosis and assessment of patients with suspected inflammatory arthritis. In addition to locating synovial thickening and effusions, ultrasound can detect increased blood flow within synovium using power Doppler imaging, an option that is available on most modern ultrasound machines (<ce:cross-ref id="crf0365" refid="f0055">Fig. 24.8</ce:cross-ref><ce:float-anchor refid="f0055"/>).</ce:para></ce:section><ce:section id="s0120"><ce:section-title id="st0115">Computed tomography</ce:section-title><ce:para id="p0690">Computed tomography (CT) is used selectively for assessing patients with bone and joint disease. CT may be used when skeletal configuration needs defining, when calcific lesions are being assessed (crowned dens syndrome, <ce:cross-ref id="crf9100" refid="p3265">p. 1017</ce:cross-ref>), when MRI is contraindicated, or when articular regions are being evaluated in which an adjacent joint replacement creates signal artefacts on MRI, using specific metal artefact reduction algorithms.</ce:para></ce:section><ce:section id="s0125"><ce:section-title id="st0120">Dual X-ray absorptiometry</ce:section-title><ce:para id="p0695">Estimation of bone mineral density (BMD) has a key role in the diagnosis and management of osteoporosis and is best made using dual X-ray absorptiometry (DXA). Measurements at lumbar spine, hip and sometimes forearm are obtained. DXA works on the principle that calcium in bone attenuates passage of X-rays through the tissue in proportion to the amount of mineral present: the more bone mineral present, the higher the BMD value. Bone density measurements are often presented as T-scores, which measure of the number of standard deviations by which the patient's BMD value differs from that in a young healthy control (<ce:cross-ref id="crf0370" refid="f0060">Fig. 24.9</ce:cross-ref><ce:float-anchor refid="f0060"/>). Osteoporosis is defined in postmenopausal women and men of more than 50 years old by a T-score of −2.5 or below (shaded red in the figure); osteopenia is diagnosed when the T-score lies between −1.0 and −2.5 (shaded pink). BMD values above −1.0 and below +2.5 are considered normal (yellow/green), whereas values above +2.5 indicate high bone mass, the most common cause being OA. The results need to be interpreted carefully and in reference to coexisting conditions, such as aortic calcification, vertebral fractures, degenerative disc disease and OA, all of which can artefactually raise BMD results. Radiographic correlation is then advisable.</ce:para></ce:section></ce:section><ce:section id="s0130"><ce:section-title id="st0125">Blood tests</ce:section-title><ce:section id="s0135"><ce:section-title id="st0130">Haematology</ce:section-title><ce:para id="p0700">Abnormalities in the full blood count (FBC) often occur in inflammatory rheumatic diseases but changes are usually non-specific. Examples include neutrophilia in crystal arthritides and sepsis; neutropenia in lupus; and lymphopenia in autoimmune rheumatic and connective tissue diseases. Reduced levels of haemoglobin and raised platelets are a common and important finding in active inflammatory rheumatological disorders. Many synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) can cause marrow toxicity and require regular monitoring of the FBC. Additional tests that are useful in assessing rheumatic diseases include the direct antiglobulin test (which can indicate intravascular haemolysis in systemic lupus erythematosus (SLE); <ce:intra-ref id="ii0070" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0860">p. 948</ce:intra-ref>) and the dilute Russell viper venom test (a functional assay for a lupus anticoagulant; <ce:intra-ref id="ii0075" xlink:href="pii:B978-0-7020-7028-0.00023-8#u4055">p. 978</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0140"><ce:section-title id="st0135">Biochemistry</ce:section-title><ce:para id="p0705">Routine biochemistry is useful for assessing metabolic bone disease, muscle diseases and gout, and is essential in monitoring DMARDs and biologic drugs (renal and hepatic function). Several bone diseases, including Paget's disease, renal bone disease and osteomalacia, give a characteristic pattern that can be helpful diagnostically (<ce:cross-ref id="crf0375" refid="b0035">Box 24.6</ce:cross-ref><ce:float-anchor refid="b0035"/>). Serum levels of uric acid are usually raised in gout but a normal level does not exclude it, especially during an acute attack, when urate levels temporarily fall. Equally, an elevated serum uric acid does not confirm the diagnosis, since most hyperuricaemic people never develop gout. Levels of C-reactive protein (CRP) are a useful marker of infection and inflammation, and are more specific than the erythrocyte sedimentation rate (ESR). An exception is in autoimmune connective tissue diseases, such as SLE and systemic sclerosis, where CRP may be normal but the ESR raised in active disease. Accordingly, an elevated CRP in a patient with lupus or systemic sclerosis suggests an intercurrent illness, such as sepsis, rather than active disease. More detail on the interpretation of CRP and ESR changes is given on <ce:intra-ref id="ii0080" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0185">page 72</ce:intra-ref>. Serum creatine phosphokinase levels are useful in the diagnosis of myopathy or myositis, but specificity and sensitivity are poor and raised levels may occur in some conditions (<ce:cross-ref id="crf0380" refid="b0040">Box 24.7</ce:cross-ref><ce:float-anchor refid="b0040"/>).</ce:para></ce:section><ce:section id="s0145"><ce:section-title id="st0140">Immunology</ce:section-title><ce:para id="p0760">Autoantibody tests are widely used in the diagnosis of rheumatic diseases. Whatever test is used, the results must be interpreted in light of the clinical picture and the different detection and assay systems used in different hospitals.</ce:para><ce:section id="s0150"><ce:section-title id="st0145">Rheumatoid factor</ce:section-title><ce:para id="p0765">Rheumatoid factor (RF) is an antibody directed against the Fc fragment of human immunoglobulin. In routine clinical practice, immunoglobulin M (IgM) RF is usually measured, although different methodologies allow measurement of IgG and IgA RFs too. Positive RF occurs in a wide variety of diseases and some normal adults (<ce:cross-ref id="crf0390" refid="b0045">Box 24.8</ce:cross-ref><ce:float-anchor refid="b0045"/>), particularly with increasing age. Although the specificity is poor, about 70% of patients with RA test positive. High RF titres are associated with more severe disease and extra-articular disease.</ce:para></ce:section><ce:section id="s0155"><ce:section-title id="st0150">Anti-citrullinated peptide antibodies</ce:section-title><ce:para id="p0775">Anti-citrullinated peptide antibodies (ACPAs) recognise peptides in which the amino acid arginine has been converted to citrulline by peptidylarginine deiminase, an enzyme abundant in inflamed synovium and in a variety of mucosal structures. ACPAs have similar sensitivity to RF for RA (70%) but much higher specificity (&#x003E; 95%), and should be used in preference to RF in the diagnosis of RA. ACPAs are associated with more severe disease progression and can be detected in asymptomatic patients several years before the development of RA. Their pathological role is still debated but it is likely that they amplify the synovial response to an inflammatory stimulus.</ce:para></ce:section><ce:section id="s0160"><ce:section-title id="st0155">Antinuclear antibodies</ce:section-title><ce:para id="p0780">Antinuclear antibodies (ANAs) are directed against one or more components of the cell nucleus, including nucleic acids themselves and the proteins concerned with the processing of DNA or RNA. They occur in many inflammatory rheumatic diseases but are also found at low titre in normal individuals and in other diseases (<ce:cross-ref id="crf0400" refid="b0050">Box 24.9</ce:cross-ref><ce:float-anchor refid="b0050"/>). ANAs are not associated with disease severity or activity. The most common indication for ANA testing is in patients suspected of having SLE or other autoimmune connective tissue diseases. ANA has high sensitivity for SLE (100%) but low specificity (10–40%). A negative ANA virtually excludes SLE but a positive result does not confirm it.</ce:para><ce:para id="p0790">Anti-DNA antibodies bind to double-stranded DNA (dsDNA) and are useful in SLE monitoring as very high titres are associated with more severe disease, including renal or central nervous system (CNS) involvement, and an increase in antibody titre may precede relapse. Anti-DNA antibodies are routinely tested by enzyme-linked immunosorbent assay (ELISA; see also <ce:cross-ref id="crf9105" refid="p4855">p. 1036</ce:cross-ref>).</ce:para><ce:para id="p0795">Antibodies to extractable nuclear antigens (ENAs) act as markers for certain autoimmune connective tissue diseases and some complications of SLE but sensitivity and specificity are poor (<ce:cross-ref id="crf0410" refid="b0055">Box 24.10</ce:cross-ref><ce:float-anchor refid="b0055"/>). For example, antibodies to Sm are found in a minority of patients with SLE but are associated with renal involvement. Antibodies to Ro occur in SLE and in Sjögren's syndrome (in association with anti-La antibodies), and are associated with a photosensitive rash and congenital heart block. Antibodies to ribonucleoprotein (RNP) occur in SLE and also in mixed connective tissue disease, where features of lupus, myositis and systemic sclerosis coexist. Anti-topoisomerase 1 (also termed Scl-70) antibodies occur in diffuse systemic sclerosis, whereas anti-centromere antibodies are more specific for limited systemic sclerosis.</ce:para></ce:section><ce:section id="s0165"><ce:section-title id="st0160">Antiphospholipid antibodies</ce:section-title><ce:para id="p0805">Antiphospholipid antibodies bind to a number of phospholipid binding proteins but the most clinically relevant are those that target beta<ce:inf loc="post">2</ce:inf>-glycoprotein 1 (β<ce:inf loc="post">2</ce:inf>GP1). They may be detected in SLE and other autoimmune connective tissue diseases and are key in diagnosing antiphospholipid antibody syndrome (<ce:intra-ref id="ii0090" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1775">p. 977</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0170"><ce:section-title id="st0165">Antineutrophil cytoplasmic antibodies</ce:section-title><ce:para id="p0810">Antineutrophil cytoplasmic antibodies (ANCAs) are IgG antibodies directed against the cytoplasmic constituents of granulocytes and are useful in the diagnosis and monitoring of systemic vasculitis. Two common patterns are described by immunofluorescence: cytoplasmic fluorescence (c-ANCA), which is caused by antibodies to proteinase-3 (PR3); and perinuclear fluorescence (p-ANCA), which is caused by antibodies to myeloperoxidase (MPO) and other proteins, such as lactoferrin and elastase. These antibodies are not specific for vasculitis and positive results may be found in autoimmune liver disease, malignancy, infection (bacterial and human immunodeficiency virus, HIV), inflammatory bowel disease, RA, SLE and pulmonary fibrosis.</ce:para></ce:section><ce:section id="s0175"><ce:section-title id="st0170">Complement</ce:section-title><ce:para id="p0815">Low complement C3 is an indicator of active SLE, owing to ‘consumption’ of complement by immune complexes (see <ce:intra-ref id="ii9005" xlink:href="pii:B978-0-7020-7028-0.00004-4#f0025">Fig. 4.4</ce:intra-ref>, <ce:intra-ref id="ii9015" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0070">p. 66</ce:intra-ref>). Low C4 is less specific for SLE activity. High C3 and functional measures of complement activation are non-specific features of inflammation.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0180"><ce:section-title id="st0175">Tissue biopsy</ce:section-title><ce:para id="p0820">Tissue biopsy is useful in confirming the diagnosis in certain musculoskeletal diseases.</ce:para><ce:para id="p0825">Synovial biopsy can be useful in selected patients with chronic inflammatory monoarthritis or tenosynovitis to rule out chronic infectious causes, especially mycobacterial infections. Synovial biopsy can be obtained arthroscopically (by conventional means or by use of needle arthroscope) or by using ultrasound guidance under local anaesthetic.</ce:para><ce:para id="p0830">Temporal artery biopsy can be of value in patients suspected of having temporal arteritis, especially when the presentation is atypical, but a negative result does not exclude the diagnosis. Biopsies of affected tissues, such as skin, lung, nasopharynx, gut, kidney and muscle, should be sought by default in confirming a diagnosis of systemic vasculitis.</ce:para><ce:para id="p0835">Muscle biopsy plays an important role in the investigation of myopathy and inflammatory myositis. It is usually taken from the quadriceps or deltoid through a small skin incision under local anaesthetic. Since myositis can be patchy in nature, MRI is sometimes used to localise the best site for biopsy. Immunohistochemical staining, together with plain histology, gives information on primary and secondary muscle and neuromuscular disease. Repeat biopsies are sometimes used to monitor the response to treatment.</ce:para><ce:para id="p0840">Bone biopsy is occasionally required where non-invasive tests give inconclusive results, in the diagnosis of infiltrative disorders, in patients with renal bone disease, suspected chronic infection or malignancy, and rarely to confirm or exclude the presence of osteomalacia. Bone is taken from the iliac crest using a large-diameter (8 mm) trephine needle under local anaesthetic and processed without demineralisation. For focal lesions, the biopsy should be taken under X-ray guidance or at open surgery, from an affected site.</ce:para></ce:section><ce:section id="s0185"><ce:section-title id="st0180">Electromyography</ce:section-title><ce:para id="p0845">Electromyography (<ce:intra-ref id="ii0095" xlink:href="pii:B978-0-7020-7028-0.00025-1#p1480">p. 1076</ce:intra-ref>) is of value in the investigation of suspected myopathy and inflammatory myositis, when it shows the diagnostic triad of:<ce:list id="ulist0120"><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p0850">spontaneous fibrillation</ce:para></ce:list-item><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p0855">short-duration action potentials in a polyphasic disorganised outline</ce:para></ce:list-item><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p0860">repetitive bouts of high-voltage oscillations on needle contact with diseased muscle.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0190"><ce:section-title id="st0185">Presenting problems in musculoskeletal disease</ce:section-title><ce:section id="s0195"><ce:section-title id="st0190">Acute monoarthritis</ce:section-title><ce:para id="p0865">The most important causes of acute arthritis in a single joint are crystal arthritis, sepsis, SpA and oligoarticular juvenile idiopathic arthritis (JIA; <ce:cross-ref id="crf9110" refid="p4230">p. 1026</ce:cross-ref>). Other potential causes are shown in <ce:cross-ref id="crf0415" refid="b0060">Box 24.11</ce:cross-ref><ce:float-anchor refid="b0060"/>.</ce:para><ce:section id="s0200"><ce:section id="s0205"><ce:section-title id="st0195">Clinical assessment</ce:section-title><ce:para id="p0955">The clinical history, pattern of joint involvement, speed of onset, and age and gender of the patient all give clues to the most likely diagnosis. Gout classically affects the first metatarsophalangeal (MTP) joint, whereas pseudogout, which can be a presenting feature of calcium pyrophosphate dihydrate (CPPD) disease, can affect the hand/wrist, ankle, knee or hip. A very rapid onset (6–12 hours) is suggestive of crystal arthritis; joint sepsis develops more slowly and continues to progress until treated. Haemarthrosis typically causes a large effusion, in the absence of periarticular swelling or skin change, in a patient who has suffered an injury. Pigmented villonodular synovitis (<ce:cross-ref id="crf9115" refid="s2005">p. 1059</ce:cross-ref>) also presents with synovial swelling and a large effusion, although the onset is gradual. A previous diarrhoeal illness or genital infection suggests reactive arthritis, whereas intercurrent illness, dehydration or surgery may act as a trigger for crystal-induced arthritis. Rheumatoid arthritis seldom presents with monoarthritis but psoriatic arthritis (PsA) can typically present this way. Osteoarthritis can present with pain and stiffness affecting a single joint, but the onset is gradual and there is usually no evidence of significant joint swelling unless it is complicated by crystal-induced inflammation.</ce:para></ce:section><ce:section id="s0210"><ce:section-title id="st0200">Investigations</ce:section-title><ce:para id="p0960">Aspiration of the affected joint is mandatory. If sepsis is suspected in a large joint, arthroscopic washout is advisable. The fluid should be sent for culture and Gram stain to seek the presence of organisms and should be checked by polarised light microscopy for crystals. Blood cultures should also be taken in patients suspected of having septic arthritis. CRP levels and ESR are raised in sepsis, crystal arthritis and reactive arthritis, and this can be useful in assessing the response to treatment. Serum uric acid measurements may be raised in gout but a normal level does not exclude the diagnosis. Ruling out primary hyperparathyroidism is essential if there is pseudogout.</ce:para></ce:section><ce:section id="s0215"><ce:section-title id="st0205">Management</ce:section-title><ce:para id="p0965">If there is any suspicion of sepsis, intravenous antibiotics (see <ce:cross-ref id="crf0430" refid="b0255">Box 24.50</ce:cross-ref>, <ce:cross-ref id="crf9120" refid="p3485">p. 1020</ce:cross-ref>) should be given promptly, pending the results of cultures. Unless atypical infections/tuberculosis (requiring prolonged or special culture) are suspected, intra-articular glucocorticoid injection may be considered after 48 hours of negative synovial fluid culture. Otherwise, management should be directed towards the underlying cause.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0220"><ce:section-title id="st0210">Polyarthritis</ce:section-title><ce:para id="p0970">This term is used to describe pain and swelling affecting five or more joints or joint groups. The possible causes are listed in <ce:cross-ref id="crf0435" refid="b0065">Box 24.12</ce:cross-ref><ce:float-anchor refid="b0065"/>.</ce:para><ce:section id="s0225"><ce:section id="s0230"><ce:section-title id="st0215">Clinical assessment</ce:section-title><ce:para id="p0980">The hallmarks of inflammatory arthritis are early-morning stiffness and worsening of symptoms with inactivity, along with synovial swelling and tenderness on examination. Clinical features in other systems can be helpful in determining the underlying cause (<ce:cross-ref id="crf0440" refid="b0070">Box 24.13</ce:cross-ref><ce:float-anchor refid="b0070"/>). The most important diagnoses to consider are PsA, RA and inflammatory small joint OA. RA is characterised by symmetrical involvement of the small joints of the hands and feet, wrists, ankles and knees. PsA is strongly associated with enthesitis. Viral arthritis (<ce:cross-ref id="crf9125" refid="p3485">p. 1020</ce:cross-ref>), Poncet's disease (in regions where tuberculosis is highly prevalent; <ce:intra-ref id="ii0125" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1030">p. 588</ce:intra-ref>), polyarticular JIA (in children) and post-streptococcal arthritis should also be considered.</ce:para><ce:para id="p0990">The pattern of involvement can be helpful in reaching a diagnosis (<ce:cross-ref id="crf0445" refid="f0065">Fig. 24.10</ce:cross-ref><ce:float-anchor refid="f0065"/>). Asymmetry, lower limb predominance, enthesitis and greater involvement of large joints are characteristic of the SpAs. In PsA there may be involvement of the proximal and distal interphalangeal (PIP and DIP) joints, as opposed to the metacarpophalangeal (MCP) and PIP joints in RA. Inflammatory OA can appear similar to small-joint PsA in the pattern of joint involvement. In PsA there may be nail pitting or early onycholysis. Psoriasis may not be present. SLE can be associated with polyarthritis but more usually causes polyarthralgia and tenosynovitis, mainly of distal limb joints/tendons (<ce:cross-ref id="crf9130" refid="s1335">p. 1035</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0235"><ce:section-title id="st0220">Investigations</ce:section-title><ce:para id="p0995">Blood samples should be taken for routine haematology, biochemistry, ESR, CRP, viral serology and an immunological screen, including ANA, RF and ACPA. Ultrasound examination or MRI may be required to confirm the presence of synovitis, if this is not obvious clinically.</ce:para></ce:section><ce:section id="s0240"><ce:section-title id="st0225">Management</ce:section-title><ce:para id="p1000">Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics will help. Systemic glucocorticoids can be considered if symptoms are very severe or having a great functional impact, but early immunotherapy (DMARDs) is required in RA and in some cases of PsA. An early accurate and specific diagnosis is very important.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0245"><ce:section-title id="st0230">Fracture</ce:section-title><ce:para id="p1005">Fractures are a common presenting symptom of osteoporosis but they also occur in other bone diseases, in osteopenia and in some patients with normal bone.</ce:para><ce:section id="s0250"><ce:section id="s0255"><ce:section-title id="st0235">Clinical assessment</ce:section-title><ce:para id="p1010">The presentation is with localised bone pain, which is worsened by movement of the affected limb or region. There is usually a history of trauma but spontaneous fractures can occur in the absence of trauma in severe osteoporosis. Fractures can be divided into several subtypes, based on the precipitating event and presence or absence of an underlying disease (<ce:cross-ref id="crf0450" refid="b0075">Box 24.14</ce:cross-ref><ce:float-anchor refid="b0075"/>). The main differential diagnosis is soft tissue injury but fracture should be suspected when there is marked pain and swelling, abnormal movement of the affected limb, crepitus or deformity. Femoral neck fractures typically produce a shortened, externally rotated leg that is painful to move. The pain from vertebral fracture is variable and a high index of suspicion is key to making the diagnosis by imaging, as discussed below.</ce:para></ce:section><ce:section id="s0260"><ce:section-title id="st0240">Investigations</ce:section-title><ce:para id="p1020">X-rays of the affected site should be taken in at least two planes and examined for discontinuity of the cortical outline (<ce:cross-ref id="crf0455" refid="b0080">Box 24.15</ce:cross-ref><ce:float-anchor refid="b0080"/>). In addition to demonstrating the fracture, X-rays may also show evidence of an underlying disorder, such as osteoporosis, Paget's disease or osteomalacia. If the X-ray fails to show evidence of a fracture but clinical suspicion remains high, MRI should be obtained. Patients who are over the age of 50 and present with fragility fractures should be screened for osteoporosis by DXA.</ce:para></ce:section><ce:section id="s0265"><ce:section-title id="st0245">Management</ce:section-title><ce:para id="p1060">Management of fracture in the acute stage requires adequate pain relief, with opiates if necessary, reduction of the fracture to restore normal anatomy, and immobilisation of the affected limb to promote healing. This can be achieved either by the use of an external cast or splint, or by internal fixation. Femoral neck fractures present a special management problem since non-union and avascular necrosis are common. This is especially true with intracapsular hip fractures, which should be treated by joint replacement surgery. Following the fracture, rehabilitation is required with physiotherapy and a supervised exercise programme. If the DXA scan shows evidence of osteoporosis or other metabolic bone disease, this should be treated appropriately (<ce:cross-ref id="crf9135" refid="s1650">p. 1046</ce:cross-ref>). Options for management of painful vertebral fracture are discussed on <ce:cross-ref id="crf9140" refid="s0465">page 1002</ce:cross-ref>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0270"><ce:section-title id="st0250">Generalised musculoskeletal pain</ce:section-title><ce:section id="s0275"><ce:section id="s0280"><ce:section-title id="st0255">Clinical assessment</ce:section-title><ce:para id="p1065">Clinical history and examination need to be wide-ranging (<ce:cross-ref id="crf0460" refid="b0085">Box 24.16</ce:cross-ref><ce:float-anchor refid="b0085"/>). Relentlessly progressive pain occurring in association with weight loss suggests malignant disease with bone metastases. Generalised bone pain may also arise in severe osteomalacia, primary hyperparathyroidism and polyostotic Paget's disease. Widespread pain can occur in PsA if there is enthesial as well as, or instead of, joint involvement; fatigue is also often present. Polyarticular RA or OA pains tend to be localised to sites of involvement, such as the lumbar spine, hips, knees and hands. Fibromyalgia (FM) syndrome (<ce:cross-ref id="crf9145" refid="s0875">p. 1018</ce:cross-ref>) presents with generalised pain that particularly affects the trunk, back and neck. Accompanying features include fatigue, poor concentration and focal areas of hyperalgesia. Widespread pain may also occur in association with hypermobility, most notably Ehlers–Danlos syndrome hypermobility subtype (hEDS; <ce:cross-ref id="crf9150" refid="s2005">p. 1059</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0285"><ce:section-title id="st0260">Investigations</ce:section-title><ce:para id="p1110">Bone scintigraphy is of value in patients suspected of having osteomalacia, bone metastases or Paget's disease, and in characterising lesions at joints and/or entheses in SpAs, including PsA. Myeloma (<ce:intra-ref id="ii0145" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1400">p. 966</ce:intra-ref>) should be screened for with an FBC, measurement of CRP, and plasma and urinary protein electrophoresis. If these results are positive, a radiological skeletal survey should be obtained. Routine biochemistry, vitamin D and parathyroid hormone (PTH) should be measured if osteomalacia is suspected. In Paget's disease, ALP may be elevated but can be normal in localised disease. Any persistently elevated ESR, CRP, angiotensin-converting enzyme (ACE), immunoglobulins, C3/C4 or platelets invariably indicates inflammatory disease. Laboratory investigations are normal in patients with FM alone and in hEDS.</ce:para></ce:section><ce:section id="s0290"><ce:section-title id="st0265">Management</ce:section-title><ce:para id="p1115">Management should be directed towards the underlying cause. Chronic pain of unknown cause and that associated with FM respond poorly to analgesics and NSAIDs, but may respond partially to antineuropathic agents, such as amitriptyline, duloxetine, gabapentin and pregabalin.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0295"><ce:section-title id="st0270">Back pain</ce:section-title><ce:para id="p1120">Back pain is a common symptom that affects 60–80% of people at some time in their lives. Although the prevalence has not increased, reported disability from back pain has risen significantly in the last 30 years. In Western countries, back pain is the most common cause of sickness-related work absence. In the UK, 7% of adults consult their GP each year with back pain. Globally, low back pain is thought to affect about 9% of the population. The most important causes are summarised in <ce:cross-ref id="crf0465" refid="b0090">Box 24.17</ce:cross-ref><ce:float-anchor refid="b0090"/>.</ce:para><ce:section id="s0300"><ce:section id="s0305"><ce:section-title id="st0275">Clinical assessment</ce:section-title><ce:para id="p1180">The main purpose of clinical assessment is to differentiate the self-limiting disorder of acute mechanical back pain from serious spinal pathology, as summarised in <ce:cross-ref id="crf0470" refid="f0070">Figure 24.11</ce:cross-ref><ce:float-anchor refid="f0070"/>. Mechanical back pain is the most common cause of acute back pain in people aged 20–55. This accounts for more than 90% of episodes, and is usually acute and associated with lifting or bending. It is exacerbated by activity and is generally relieved by rest (<ce:cross-ref id="crf0475" refid="b0095">Box 24.18</ce:cross-ref><ce:float-anchor refid="b0095"/>). It is usually confined to the lumbar–sacral region, buttock or thigh, is asymmetrical and does not radiate beyond the knee (which would imply nerve root irritation). On examination, there may be asymmetric local paraspinal muscle spasm and tenderness, and painful restriction of some, but not all, movements. Low back pain is more common in manual workers, particularly those in occupations that involve heavy lifting and twisting. The prognosis is generally good. After 2 days, 30% are better and 90% have recovered by 6 weeks. Recurrences of pain may occur and about 10–15% of patients go on to develop chronic back pain that may be difficult to treat. Psychological elements, such as job dissatisfaction, depression and anxiety, are important risk factors for the transition to chronic pain and disability.</ce:para><ce:para id="p1225">Back pain secondary to serious spinal pathology has different characteristics (<ce:cross-ref id="crf0480" refid="b0100">Box 24.19</ce:cross-ref><ce:float-anchor refid="b0100"/>). If there is clinical evidence of spinal cord or nerve root compression, sepsis including tuberculosis, or a cauda equina lesion (<ce:cross-ref id="crf0485" refid="b0105">Box 24.20</ce:cross-ref><ce:float-anchor refid="b0105"/>), urgent investigation is needed. Spinal stenosis presents insidiously with leg discomfort on walking that is relieved by rest, bending forwards or walking uphill. Patients may adopt a characteristic simian posture, with a forward stoop and slight flexion at hips and knees. The most common cause is the gradual development of coexisting contributing lesions such as facet joint arthritis, ligament flavum thickening or degenerative spondylolisthesis.</ce:para><ce:para id="p1360">Degenerative disc disease is a common cause of chronic low back pain in middle-aged adults. Prolapse of an intervertebral disc presents when discs are still well hydrated (in young and early middle age) with nerve root pain, which can be accompanied by a sensory deficit, motor weakness and asymmetrical reflexes. Examination may reveal a positive sciatic or femoral stretch test. About 70% of patients improve by 4 weeks. Inflammatory back pain (IBP) due to axial spondyloarthritis (axSpA) or PsA has a gradual onset and almost always occurs before the age of 40. It is associated with morning stiffness and improves with movement. Spondylolisthesis (<ce:cross-ref id="crf9155" refid="s2005">p. 1059</ce:cross-ref>) may cause back pain that is typically aggravated by standing and walking. Occasionally, diffuse idiopathic skeletal hyperostosis (DISH; <ce:cross-ref id="crf9160" refid="s1970">p. 1058</ce:cross-ref>) can cause back pain but it is usually asymptomatic. Arachnoiditis is a rare cause of chronic severe low back pain. It is caused by chronic inflammation of the nerve root sheaths in the spinal canal and can complicate meningitis, spinal surgery or myelography with oil-based contrast agents.</ce:para></ce:section><ce:section id="s0330"><ce:section-title id="st0300">Investigations</ce:section-title><ce:para id="p1365">Investigations are not required in patients with acute mechanical back pain. Those with persistent pain (&#x003E; 6 weeks) or red flags (see <ce:cross-ref id="crf0490" refid="b0100">Box 24.19</ce:cross-ref>) should undergo further investigation. MRI is the investigation of choice because it can demonstrate spinal stenosis, cord compression or nerve root compression, as well as inflammatory changes in axSpA, malignancy and sepsis. Plain X-rays can be of value in patients suspected of having vertebral compression fractures, OA and degenerative disc disease. If metastatic disease is suspected, bone scintigraphy should be considered. Additional investigations that may be required include routine biochemistry and haematology, ESR and CRP (to screen for sepsis and inflammatory disease), protein and urinary electrophoresis (for myeloma), human leucocyte antigen (HLA)-B27 status in IBP and prostate-specific antigen (for prostate carcinoma).</ce:para></ce:section><ce:section id="s0335"><ce:section-title id="st0305">Management</ce:section-title><ce:para id="p1370">Education is important in patients with mechanical back pain. It should emphasise the self-limiting nature of the condition and the fact that exercise is helpful rather than damaging. Regular analgesia and/or NSAIDs may be required to improve mobility and facilitate exercise. Return to work and normal activity should take place as soon as possible. Bed rest is not helpful and may increase the risk of chronic disability. Referral for physical therapy should be considered if a return to normal activities has not been achieved by 6 weeks. Low-dose tricyclic antidepressant drugs may help pain, sleep and mood.</ce:para><ce:para id="p1375">Other treatment modalities that are occasionally used include epidural and facet joint injection, traction and lumbar supports, though there is limited randomised controlled trial evidence to support their use. Malignant disease, osteoporosis, Paget's disease and SpAs require specific treatment of the underlying condition.</ce:para><ce:para id="p1380">Surgery is required in less than 1% of patients with low back pain but may be needed in progressive spinal stenosis, in spinal cord compression and in some patients with nerve root compression.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0340"><ce:section-title id="st0310">Regional musculoskeletal pain</ce:section-title><ce:para id="p1385">Regional musculoskeletal pain is a common presenting complaint, usually occurring as the result of age-related degenerative disease of tendons and ligaments, OA and trauma.</ce:para><ce:section id="s0345"><ce:section-title id="st0315">Neck pain</ce:section-title><ce:para id="p1390">Neck pain is a common symptom that can occur following an injury or falling asleep in an awkward position, as a result of stress or in association with OA of the spine. The causes are shown in <ce:cross-ref id="crf0495" refid="b0110">Box 24.21</ce:cross-ref><ce:float-anchor refid="b0110"/>. Most cases resolve spontaneously or with a short course of NSAIDs or analgesics and some exercise therapy. Patients with persistent pain that follows a nerve root distribution and those with upper or lower limb neurological signs should be investigated by MRI and, if necessary, referred for a neurosurgical opinion.</ce:para></ce:section><ce:section id="s0350"><ce:section-title id="st0320">Shoulder pain</ce:section-title><ce:para id="p1530">Shoulder pain is a common complaint over the age of 40 (<ce:cross-ref id="crf0500" refid="b0115">Box 24.22</ce:cross-ref><ce:float-anchor refid="b0115"/>). Varying pain patterns associated with common lesions are shown in <ce:cross-ref id="crf0505" refid="f0075">Figure 24.12</ce:cross-ref><ce:float-anchor refid="f0075"/>. For most shoulder lesions, general management is with analgesics, NSAIDs, local glucocorticoid injections and physiotherapy aimed at restoring normal movement and function. Surgery may be required in patients who have debilitating or persistent symptoms in association with rotator cuff lesions or severe acromioclavicular joint arthritis. If there is subacromial impingement, without evidence of a rotator cuff tear on MRI, subacromial glucocorticoid injection and physiotherapy constitute a reasonable first step. Calcific supraspinatus tendonitis unresponsive to glucocorticoid injection can be treated with barbotage (needle disruption of deposit under ultrasound guidance). Complete rotator cuff tears in people under 40 years of age may respond well to full surgical repair but results are less good in older people. Adhesive capsulitis (frozen shoulder) presents with pain associated with marked restriction of elevation and external rotation. Adhesive capsulitis is commonly associated with diabetes mellitus and neck/radicular lesions. Treatment in the early stage is with analgesia, intra- and extracapsular glucocorticoid injection, and regular ‘pendulum’ exercises of the arm to mobilise. Complete recovery sometimes takes up to 2 years. For severe or persistent symptoms, joint distension and manipulation under anaesthesia are surgical options.</ce:para></ce:section><ce:section id="s0370"><ce:section-title id="st0340">Elbow pain</ce:section-title><ce:para id="p1585">The most common causes are repetitive trauma causing lateral epicondylitis (tennis elbow) and medial epicondylitis (golfer's elbow) (<ce:cross-ref id="crf0510" refid="b0120">Box 24.23</ce:cross-ref><ce:float-anchor refid="b0120"/>). SpAs, including psoriatic disease, can present with the same symptoms (tendon insertion enthesitis). Management is by rest, analgesics and topical or systemic NSAIDs. Local glucocorticoid injections may be required in resistant cases. Olecranon bursitis can also follow local repetitive trauma but other causes include infections and gout.</ce:para></ce:section><ce:section id="s0375"><ce:section-title id="st0345">Hand and wrist pain</ce:section-title><ce:para id="p1595">Pain from hand or wrist joints is well localised to the affected joint, except for pain from the first carpometacarpal (CMC) joint, commonly targeted by OA or PsA; although maximal at the thumb base, the pain often radiates down the thumb and to the radial aspect of the wrist. Non-articular causes of hand pain include:<ce:list id="ulist0265"><ce:list-item id="u1065"><ce:label>•</ce:label><ce:para id="p1600"><ce:italic>Tenosynovitis</ce:italic>: affects flexor or extensor digital tendons. Pain and tenderness are well localised to the tendon lesions. There is often early-morning ‘claw-like’ digit stiffness. De Quervain's tenosynovitis involves the tendon sheaths of abductor pollicis longus and extensor pollicis brevis. It produces pain maximal over the radial aspect of the distal forearm and wrist and marked pain on forced ulnar deviation of the wrist with the thumb held across the patient's palm (Finkelstein's sign). This test is not specific for this lesion alone.</ce:para></ce:list-item><ce:list-item id="u1070"><ce:label>•</ce:label><ce:para id="p1605"><ce:italic>Raynaud's phenomenon</ce:italic>: digital vasospasm triggered mostly by cold (<ce:cross-ref id="crf9165" refid="s1335">p. 1035</ce:cross-ref>).</ce:para></ce:list-item><ce:list-item id="u1075"><ce:label>•</ce:label><ce:para id="p1610"><ce:italic>C6, C7 or C8 radiculopath</ce:italic>y.</ce:para></ce:list-item><ce:list-item id="u1080"><ce:label>•</ce:label><ce:para id="p1615"><ce:italic>Carpal tunnel syndrome</ce:italic>: hand position-dependent and/or nocturnal pain, numbness and paraesthesia of thumb and second to fourth digits.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0380"><ce:section-title id="st0350">Hip pain</ce:section-title><ce:para id="p1620">Pain from the hip joint is usually felt deep in the groin, with variable radiation to the buttock, anterolateral thigh or knee (<ce:cross-ref id="crf0515" refid="f0080">Fig. 24.13</ce:cross-ref><ce:float-anchor refid="f0080"/>). Patients who report ‘hip pain’ sometimes point to greater trochanter or buttock areas. Greater trochanter pain syndrome is usually due to either gluteus medius insertional tendonitis/enthesitis, trochanteric bursitis or referred pain (<ce:cross-ref id="crf0520" refid="b0125">Box 24.24</ce:cross-ref><ce:float-anchor refid="b0125"/>). Pain at this site may also be referred from the lumbosacral spine. A differential diagnosis of hip joint conditions (groin pain) is symphysitis (SpAs, including psoriasis disease, need ruling out). Other less common causes of pain in the hip/groin area include inguinal hernia, adductor tendonitis and enthesitis of anterior superior/inferior iliac spines.</ce:para></ce:section><ce:section id="s0385"><ce:section-title id="st0355">Knee pain</ce:section-title><ce:para id="p1630">In middle and older age, the most common cause of knee pain is OA, the features of which are described on <ce:cross-ref id="crf9170" refid="p2460">page 1008</ce:cross-ref>. Pain that is associated with locking of the knee (sudden painful inability to extend fully) is usually due to a meniscal tear or osteochondritis dissecans. Referred pain from the hip may present at the knee and is reproduced by hip, not knee, movement. Pain from periarticular lesions is well localised to the involved structure (<ce:cross-ref id="crf0525" refid="b0130">Box 24.25</ce:cross-ref><ce:float-anchor refid="b0130"/>). Anterior knee pain may be due to patellar ligament or retinacular lesions (enthesitis, tendonitis, fat-pad syndrome) occurring typically from overuse and/or an SpA condition. Anterior knee pain is relatively common in adolescents and may be the result of patellar articular cartilage or ligament insertion osteochondritis.</ce:para></ce:section><ce:section id="s0390"><ce:section-title id="st0360">Ankle and foot pain</ce:section-title><ce:para id="p1640">Pain from the ankle (tibiotalar) joint due to OA or osteochondral defect is felt between the malleoli and is worse on weight-bearing. Pain from the subtalar joint (from the same lesions) is also worse on weight-bearing. Inflammatory arthritis of either of these joints (RA, PsA, CPPD arthritis or gout) often worsens and swells with rest. These diagnoses can be associated with hindfoot tenosynovitis (peroneal or posterior tibial). Pain under the heel is typically due to plantar fasciitis. This can occur as the result of overuse, which case it may respond to rest, padded footwear and local glucocorticoid injections, but can also arise in SpA as a manifestation of enthesitis. Pain affecting the back of the heel may be due to Achilles tendinitis or enthesitis. The MTP joints of the feet are commonly involved symmetrically in RA. The presentation is with pain on walking felt below the metatarsal heads, often described as ‘walking on marbles’. Patients with active inflammation of the MTP joints have pain when the forefoot is squeezed (<ce:cross-ref id="crf9175" refid="s0010">p. 982</ce:cross-ref>). Involvement of the first MTP joint is common in OA or PsA and is associated, respectively, with hallux valgus and dactylitis. The hallux also a classical target in acute gout. Morton's neuroma is a neuropathy of an interdigital nerve and is usually located between the third and fourth metatarsal heads. Women are most commonly affected (tight shoes can be to blame). Local sensory loss and a palpable tender swelling between the metatarsal heads may be detected. Footwear adjustment, with or without a local glucocorticoid injection, often helps but surgical decompression may be required if symptoms persist.</ce:para></ce:section></ce:section><ce:section id="s0395"><ce:section-title id="st0365">Muscle pain and weakness</ce:section-title><ce:para id="p1645">Muscle pain and weakness can arise from a variety of causes. It is important to distinguish between a subjective feeling of generalised weakness occurring with fatigue, and an objective weakness with loss of muscle power and function. The former is a non-specific manifestation of many systemic conditions.</ce:para><ce:section id="s0400"><ce:section id="s0405"><ce:section-title id="st0370">Clinical assessment</ce:section-title><ce:para id="p1650">Proximal muscle weakness suggests the presence of a myopathy or myositis, which typically causes difficulty with standing from a seated position, walking up steps, squatting and lifting overhead. The causes are shown in <ce:cross-ref id="crf0530" refid="b0135">Box 24.26</ce:cross-ref><ce:float-anchor refid="b0135"/>. Worsening of symptoms on exercise and post-exertional cramps suggest a metabolic myopathy, such as glycogen storage disease (<ce:intra-ref id="ii0210" xlink:href="pii:B978-0-7020-7028-0.00014-7#p2775">p. 370</ce:intra-ref>). A strong family history and onset in childhood or early adulthood suggest muscular dystrophy (<ce:intra-ref id="ii0215" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2215">p. 1143</ce:intra-ref>). Alcohol excess can cause an inflammatory myositis and atrophy of type 2 muscle fibres. Proximal myopathy may be a complication of glucocorticoid therapy, prolonged/severe hypercalcaemia and osteomalacia. Myopathy and myositis can also occur in association with many drugs (see ‘<ce:cross-ref id="crf0535" refid="st1905">Further information</ce:cross-ref>’, <ce:cross-ref id="crf9180" refid="s2040">p. 1060</ce:cross-ref>) and viral infections, including HIV; in the latter case, it may be due to HIV itself or to treatment with zidovudine. Polymyositis and dermatomyositis (<ce:cross-ref id="crf9185" refid="p5195">p. 1039</ce:cross-ref>) are associated with coexisting/co-presenting malignancy, especially gonadal tumours. Clinical examination should document the presence, pattern and severity of muscle weakness (<ce:intra-ref id="ii9020" xlink:href="pii:B978-0-7020-7028-0.00025-1#p2195">p. 1081</ce:intra-ref>), assessed using the Medical Research Council (MRC) scale (no power (0) to full power (5)).</ce:para></ce:section><ce:section id="s0410"><ce:section-title id="st0375">Investigations</ce:section-title><ce:para id="p1785">Investigations should include routine biochemistry and haematology, ESR, CRP, creatine kinase, serum 25(OH)-vitamin D, PTH, parvovirus, hepatitis B/C, HIV and streptococcus serology, serum and urine protein electrophoresis, serum ACE, ANAs/ENAs, RF, complement and myositis-specific autoantibodies such as Jo-1. Open muscle biopsy (site guided by MRI detection of abnormal muscle) and electromyography (EMG) are usually required to make the diagnosis. The initial imaging screening for malignancy is usually a CT scan of the chest, abdomen and pelvis; upper gastrointestinal endoscopy and colonoscopy may also be considered.</ce:para></ce:section><ce:section id="s0415"><ce:section-title id="st0380">Management</ce:section-title><ce:para id="p1790">Management is determined by the cause but all patients with muscle disease should benefit from physiotherapy and graded exercises to maximise muscle function after the initial inflammation is controlled.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0420"><ce:section-title id="st0385">Principles of management</ce:section-title><ce:para id="p1795">The management of rheumatological disorders should be tailored to the underlying diagnosis. Certain aspects are common to many disorders, however, and the general principles are discussed here. The therapeutic aims are:<ce:list id="ulist0320"><ce:list-item id="u1210"><ce:label>•</ce:label><ce:para id="p1800">to educate patients about their disease</ce:para></ce:list-item><ce:list-item id="u1215"><ce:label>•</ce:label><ce:para id="p1805">to control pain, if it is present</ce:para></ce:list-item><ce:list-item id="u1220"><ce:label>•</ce:label><ce:para id="p1810">to optimise function</ce:para></ce:list-item><ce:list-item id="u1225"><ce:label>•</ce:label><ce:para id="p1815">to modify the disease process where this is possible</ce:para></ce:list-item><ce:list-item id="u1230"><ce:label>•</ce:label><ce:para id="p1820">to identify and treat comorbidity.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1825">These aims are interrelated and success in one area often benefits others. Successful management requires careful assessment of the person as a whole. The management plan should be individualised and patient-centred, should involve relevant members of the multidisciplinary team, and should be agreed and understood by both the patient and all the practitioners that are involved. It must also take into account:<ce:list id="ulist0325"><ce:list-item id="u1235"><ce:label>•</ce:label><ce:para id="p1830">the patient's activity requirements and occupational and recreational aspirations</ce:para></ce:list-item><ce:list-item id="u1240"><ce:label>•</ce:label><ce:para id="p1835">risk factors that may influence the disease</ce:para></ce:list-item><ce:list-item id="u1245"><ce:label>•</ce:label><ce:para id="p1840">the patient's perceptions and knowledge of the condition</ce:para></ce:list-item><ce:list-item id="u1250"><ce:label>•</ce:label><ce:para id="p1845">medications and coping strategies that have already been tried</ce:para></ce:list-item><ce:list-item id="u1255"><ce:label>•</ce:label><ce:para id="p1850">comorbid disease and its therapy</ce:para></ce:list-item><ce:list-item id="u1260"><ce:label>•</ce:label><ce:para id="p1855">the availability, costs and logistics of appropriate evidence-based interventions.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1860">The simplest and safest interventions should be tried first. Symptoms and signs may change with time, so the management plan for most patients will require regular review and re-adjustment.</ce:para><ce:para id="p1865">Core interventions that should be considered for everyone with a painful musculoskeletal condition are listed in <ce:cross-ref id="crf0540" refid="b0140">Box 24.27</ce:cross-ref><ce:float-anchor refid="b0140"/>. There are also other non-pharmacological and drug options, the choice of which depends on the nature and severity of the diagnosis.</ce:para><ce:section id="s0425"><ce:section-title id="st0390">Education and lifestyle interventions</ce:section-title><ce:section id="s0430"><ce:section-title id="st0395">Education</ce:section-title><ce:para id="p1975">Patients must always be informed about the nature of their condition and its investigation, treatment and prognosis, since education can improve outcome. Information and therapist contact can reduce pain and disability, improve self-efficacy and reduce the health-care costs of many musculoskeletal conditions, including OA and RA. The mechanisms are unclear but in part may result from improved adherence. Benefits are modest but potentially long-lasting, safe and cost-effective. Education can be provided through one-to-one discussion, written literature, patient-led group education classes and interactive computer programs. Inclusion of the patient's partner or carer is often appropriate; this is essential for childhood conditions but also helps in many chronic adult conditions, such as RA and FM.</ce:para><ce:para id="p1980">For children and adolescents with chronic diseases such as JIA, education and support of the whole family, schooling and psychological support is essential and best delivered through a multidisciplinary team.</ce:para></ce:section><ce:section id="s0435"><ce:section-title id="st0400">Exercise</ce:section-title><ce:para id="p1985">Several types of exercise can be prescribed:<ce:list id="ulist0355"><ce:list-item id="u1365"><ce:label>•</ce:label><ce:para id="p1990"><ce:italic>Aerobic fitness training</ce:italic> can produce long-term reduction in pain and disability. It improves well-being, encourages restorative sleep and benefits common comorbidity, such as obesity, diabetes, chronic heart failure and hypertension.</ce:para></ce:list-item><ce:list-item id="u1370"><ce:label>•</ce:label><ce:para id="p1995"><ce:italic>Local strengthening exercise</ce:italic> for muscles that act over compromised joints also reduces pain and disability, with improvements in the reduced muscle strength, proprioception, coordination and balance that associate with chronic arthritis. ‘Small amounts often’ of strengthening exercise are better than protracted sessions performed infrequently.</ce:para></ce:list-item><ce:list-item id="u1375"><ce:label>•</ce:label><ce:para id="p2000"><ce:italic>Weight-bearing exercise</ce:italic> is of value in osteoporosis, where it can result in modest increases in bone density and slow bone loss.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0440"><ce:section-title id="st0405">Joint protection</ce:section-title><ce:para id="p2005">Excessive impact-loading and adverse repetitive use of a compromised joint or periarticular tissue can worsen symptoms in patients with arthritis. This can be mitigated by cessation of contact sports and by pacing of activities by dividing physical tasks into shorter segments with brief breaks in between. Other strategies include adaptations to machinery or tools at the workplace; the use of shock-absorbing footwear with thick soft soles, which can reduce impact-loading through feet, knees, hips and back; and the use of a walking stick on the contralateral side to a painful hip, knee or foot.</ce:para></ce:section></ce:section><ce:section id="s0445"><ce:section-title id="st0410">Non-pharmacological interventions</ce:section-title><ce:section id="s0450"><ce:section-title id="st0415">Physical and occupational therapy</ce:section-title><ce:para id="p2010">Local heat, ice packs, wax baths and other local external applications can induce muscle relaxation and provide temporary relief of symptoms in a range of rheumatic diseases.</ce:para><ce:para id="p2015">Hydrotherapy induces muscle relaxation and facilitates enhanced movement in a warm, pain-relieving environment without the restraints of gravity and normal load-bearing. Various manipulative techniques may also help improve restricted movement. The combination of these with education and therapist contact enhances their benefits.</ce:para><ce:para id="p2020">Splints can give temporary rest and support for painful joints and periarticular tissues, and can prevent harmful involuntary postures during sleep. Prolonged rest must be avoided, however. Orthoses are more permanent appliances used to reduce instability and excessive abnormal movement. They include working wrist splints, knee orthoses, and iron and T-straps to control ankle instability. Orthoses are particularly suited to severely disabled patients in whom a surgical option is inappropriate and often need to be custom-made for the individual.</ce:para><ce:para id="p2025">Aids and appliances can provide dignity and independence for patients with respect to activities of daily living. Common examples are a raised toilet seat, raised chair height, extended handles on taps, a shower instead of a bath, thick-handled cutlery, and extended ‘hands’ to pull on tights and socks. Full assessment and advice from an occupational therapist maximise the benefits of these (<ce:cross-ref id="crf0550" refid="b0140">Box 24.27</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0455"><ce:section-title id="st0420">Self-help and coping strategies</ce:section-title><ce:para id="p2030">These help patients to cope better with, and adjust to, chronic pain and disability. They may be useful at any stage but are particularly so for patients with incurable problems, who have tried all available treatment options. The aim is to increase self-management through self-assessment and problem-solving, so that patients can recognise negative but potentially remediable aspects of their mood (stress, frustration, anger or low self-esteem) and their situation (physical, social, financial). These may then be addressed by changes in attitude and behaviour, as shown in <ce:cross-ref id="crf0555" refid="b0145">Box 24.28</ce:cross-ref><ce:float-anchor refid="b0145"/>.</ce:para><ce:para id="p2070">Involvement of the spouse or partner in mutual goal-setting can improve partnership adjustment. Such approaches are often an element of group education classes and pain clinics but may require more formal clinical psychological input.</ce:para><ce:para id="p2075">Tailored multidisciplinary approaches are required for patients with JIA and other chronic childhood diseases, dependent on age and maturity. Adolescents and young adults have specific demands, different to those of young children and adults, which are influenced by many issues in their lives impinging on the disease process, its impact and their ability to cope with it.</ce:para></ce:section><ce:section id="s0460"><ce:section-title id="st0425">Weight control</ce:section-title><ce:para id="p2080">Obesity aggravates pain at most sites through increased mechanical strain and is a risk factor for progression of joint damage in patients with OA and other types of arthritis. This should be explained to obese patients and strategies offered on how to lose and maintain an appropriate weight (<ce:intra-ref id="ii0225" xlink:href="pii:B978-0-7020-7028-0.00019-6#p0560">p. 700</ce:intra-ref>). Excessive weight loss can be counterproductive and adults with a BMI of &#x003C; 20 kg/m<ce:sup loc="post">2</ce:sup> are at increased risk of fractures. Patients should therefore be advised to maintain BMI within the 20–25 g/m<ce:sup loc="post">2</ce:sup> range.</ce:para></ce:section><ce:section id="s0465"><ce:section-title id="st0430">Surgery</ce:section-title><ce:para id="p2085">A variety of surgical interventions can relieve pain and conserve or restore function in patients with bone, joint and periarticular disease (<ce:cross-ref id="crf0560" refid="b0150">Box 24.29</ce:cross-ref><ce:float-anchor refid="b0150"/>). Soft tissue release and tenosynovectomy can reduce inflammatory symptoms, improve function and prevent or retard tendon damage for variable periods, sometimes indefinitely. Synovectomy does not prevent disease progression but may be indicated for pain relief when drugs, physical therapy and intra-articular injections have provided insufficient relief. The main approaches for damaged joints are osteotomy (cutting bone to alter joint mechanics and load transmission), excision arthroplasty (removing part or all of the joint), joint replacement (insertion of prosthesis in place of the excised joint) and arthrodesis (joint fusion). Surgical fixation of fractures is frequently required in patients with osteoporosis and other bone diseases.</ce:para><ce:para id="p2095">The main aims of surgery are to provide pain relief and improve function and quality of life. If surgery is to be successful, the aims and consequences of each operation should be considered as part of an integrated programme of management and rehabilitation by multidisciplinary teams of surgeons, allied health professionals and physicians, and carefully explained to the patient. Assessment of motivation, social support and environment is no less important than careful consideration of patients' general health, their risks for major surgery, the extent of disease in other joints, and their ability to mobilise following surgery. For some severely compromised people, pain relief and functional independence are better served by provision of a suitable wheelchair, home adjustments and social services than by surgery that is technically successful but following which the patient cannot mobilise.</ce:para></ce:section></ce:section><ce:section id="s0470"><ce:section-title id="st0435">Pharmacological treatment</ce:section-title><ce:section id="s0475"><ce:section-title id="st0440">Analgesics</ce:section-title><ce:para id="p2100">Paracetamol (1 g up to 4 times daily) is the oral analgesic of first choice for mild to moderate pain. It is thought to work by inhibiting prostaglandin synthesis in the brain while having little effect on peripheral prostaglandin production. It is well tolerated and has few adverse effects and drug interactions. An increased risk of gastrointestinal events and cardiovascular disease has been reported with chronic usage in observational studies, but this may be due to channelling of patients at higher risk of these events for treatment with paracetamol rather than NSAID. Paracetamol can be combined with codeine (co-codamol) or dihydrocodeine (co-dydramol). These compound analgesics are more effective than paracetamol but have more side-effects, including constipation, headache and delirium, especially in the elderly. The centrally acting opioid analgesics tramadol and meptazinol may be useful for temporary control of severe pain unresponsive to other measures but can cause nausea, bowel upset, dizziness and somnolence, and withdrawal symptoms after chronic use. The non-opioid analgesic nefopam (30–90 mg 3 times daily) can help moderate pain, though side-effects (nausea, anxiety, dry mouth) often limit its use. Patients with severe or intractable pain may require strong opioid analgesics, such as oxycodone and morphine.</ce:para></ce:section><ce:section id="s0480"><ce:section-title id="st0445">Non-steroidal anti-inflammatory drugs</ce:section-title><ce:para id="p2105">NSAIDs are among the most widely prescribed drugs but their use has declined over recent years because long-term prescription is associated with an increased risk of cardiovascular disease. Oral NSAIDs are useful in the treatment of a range of rheumatic diseases with an inflammatory component. There is variability in response and patients who do not gain benefit from one NSAID may well do so with another. They inhibit the cyclo-oxygenase (COX) and prostaglandin H synthase enzymes, which convert arachidonic acid, derived from membrane phospholipids, to prostaglandins and leukotrienes by the COX and 5-lipoxygenase pathways, respectively (<ce:cross-ref id="crf0565" refid="f0085">Fig. 24.14</ce:cross-ref><ce:float-anchor refid="f0085"/>). There are two COX isoforms, encoded by different genes. The COX-1 enzyme is constitutively expressed in gastric mucosa, platelets and kidneys, and production of prostaglandins at these sites protects against mucosal damage and regulates platelet aggregation and renal blood flow. The COX-2 enzyme is induced at sites of inflammation, producing prostaglandins that cause local pain and swelling. Inflammation also up-regulates COX-2 in the spinal cord, where it modulates pain perception. Ibuprofen, diclofenac and naproxen are non-selective drugs that inhibit both COX enzymes, whereas celecoxib and etoricoxib are selective inhibitors of COX-2. While NSAIDs have anti-inflammatory activity, they are not thought to have a disease-modifying effect in either OA or inflammatory rheumatic diseases.</ce:para><ce:para id="p2110">Non-selective NSAIDs can damage the gastric and duodenal mucosal barrier and are associated with an increased risk of upper gastrointestinal ulceration, bleeding and perforation. The adjusted increased risk (odds ratio) of bleeding or perforation from non-selective NSAIDs is 4–5, though differences exist between NSAIDs (<ce:cross-ref id="crf0570" refid="b0155">Box 24.30</ce:cross-ref><ce:float-anchor refid="b0155"/>). Dyspepsia is a poor guide to the presence of NSAID-associated ulceration and bleeding, and the principal risk factors are shown in <ce:cross-ref id="crf0575" refid="b0160">Box 24.31</ce:cross-ref><ce:float-anchor refid="b0160"/>. Co-prescription of a proton pump inhibitor (PPI) or misoprostol (200 µg twice or 3 times daily) reduces the risk of NSAID-induced ulceration and bleeding but H<ce:inf loc="post">2</ce:inf>-antagonists in standard doses are ineffective. The COX-2 selective NSAIDs are much less likely to cause gastrointestinal toxicity but benefit is attenuated in patients on low-dose aspirin. The National Institute for Health and Care Excellence (NICE) guidelines advise that a PPI should be co-prescribed with all NSAIDs, including COX-2-selective NSAIDs, even though the risk of gastrointestinal events with these is low. Since chronic PPI therapy is associated with an increased risk of hip fracture, the merits of giving PPI therapy with a COX-2-selective drug need to be weighed up carefully.</ce:para><ce:para id="p2155">Other side-effects of NSAIDs include fluid retention and renal impairment due to inhibition of renal prostaglandin production, non-ulcer-associated dyspepsia, abdominal pain and altered bowel habit, and rashes. Interstitial nephritis, asthma and anaphylaxis can also occur but are rare. Recommendations for NSAID prescribing are summarised in <ce:cross-ref id="crf0595" refid="b0165">Box 24.32</ce:cross-ref><ce:float-anchor refid="b0165"/>. Because of the risk of adverse effects, NSAIDs should be used with great care in the elderly (<ce:cross-ref id="crf0605" refid="b0170">Box 24.33</ce:cross-ref><ce:float-anchor refid="b0170"/>).</ce:para></ce:section><ce:section id="s0485"><ce:section-title id="st0450">Topical agents</ce:section-title><ce:para id="p2215">Topical NSAID creams and gels and capsaicin cream (chilli extract; 0.025%) can help in the treatment of OA and superficial periarticular lesions affecting hands, elbows and knees. They may be used as monotherapy or as an adjunct to oral analgesics. Topical NSAIDs can penetrate superficial tissues and even reach the joint capsule, though intrasynovial levels mainly reflect blood-borne drug delivery. Capsaicin selectively binds to the protein transient receptor potential vanilloid type 1 (TRPV1), which is a heat-activated calcium channel on the surface of peripheral type C nociceptor fibres. Initial application causes a burning sensation but continued use depletes presynaptic substance P, with subsequent pain reduction that is optimal after a period of 1–2 weeks.</ce:para></ce:section><ce:section id="s0490"><ce:section-title id="st0455">Disease-modifying antirheumatic drugs</ce:section-title><ce:para id="p2220">Disease-modifying antirheumatic drugs (DMARDs) are a group of small-molecule inhibitors of the immune response. They are employed in a range of inflammatory rheumatic diseases, as well as in other chronic inflammatory conditions. The most common indications are summarised in <ce:cross-ref id="crf0610" refid="b0175">Box 24.34</ce:cross-ref><ce:float-anchor refid="b0175"/>. Most of these drugs have the potential to cause bone marrow suppression or liver dysfunction and they require regular blood monitoring. Monitoring requirements for commonly used DMARDs are also summarised in <ce:cross-ref id="crf0620" refid="b0175">Box 24.34</ce:cross-ref>. If toxicity occurs, treatment may need to be stopped temporarily and resumed at a lower dose. If toxicity is severe, therapy may have to be withdrawn completely and another drug substituted.</ce:para><ce:section id="s0495"><ce:section-title id="st0460">Methotrexate</ce:section-title><ce:para id="p2230">Methotrexate (MTX) is the core DMARD in RA, JIA and PsA. It inhibits folic acid reductase, preventing formation of tetrahydrofolate, which is necessary for DNA synthesis in leucocytes and other cells. It is given orally in a starting dose of 10–15 mg weekly and escalated in 2.5 mg increments every 2–4 weeks to a maximum of 25 mg weekly until benefit or toxicity occurs. Folic acid (5 mg/week) should be co-prescribed to be taken the day after MTX since it reduces adverse effects without impairing efficacy. Benefit is usually observed after 4–8 weeks but treatment should continue for 3 months before the conclusion is reached that MTX has been ineffective. The most common adverse effects are nausea, vomiting and malaise, which usually occur one 1–2 days after the weekly dose. Individuals who experience these effects can sometimes be successfully treated with subcutaneous MTX. Patients should be warned of drug interaction with sulphonamides and the importance of avoiding excess alcohol, which enhances MTX hepatotoxicity. Acute pulmonary toxicity (pneumonitis) is rare but can occur at any time during treatment, and patients should be warned to stop therapy and seek advice if they develop any new respiratory symptoms. If pneumonitis occurs, treatment should be withdrawn and high-dose glucocorticoids given. MTX must be co-prescribed with robust contraception in women of child-bearing potential and treatment must be stopped for 3 months in advance of planning a pregnancy.</ce:para></ce:section><ce:section id="s0500"><ce:section-title id="st0465">Sulfasalazine</ce:section-title><ce:para id="p2235">Sulfasalazine (SSZ) can be used alone and or combination with MTX and another DMARD. Its mechanism of action is incompletely understood. Nausea and gastrointestinal intolerance are the main adverse effects but leucopenia, abnormal LFTs and rashes may also occur. The usual starting dose is 500 mg daily, escalating in 500 mg increments every 2 weeks to a maintenance dose of 2–4 g daily until benefit or toxicity occurs. Benefit may be observed after 4–8 weeks but treatment should be continued for 3 months before the conclusion is reached that it has been ineffective. Orange staining of urine and contact lenses may occur.</ce:para></ce:section><ce:section id="s0505"><ce:section-title id="st0470">Hydroxychloroquine</ce:section-title><ce:para id="p2240">Hydroxychloroquine (HCQ) is used in the treatment of RA and SLE in a dose of 200–400 mg daily. Its mechanism of action is incompletely understood. A wide range of side-effects can potentially occur but HCQ is usually well tolerated in practice. With long-term use, there is a risk of ocular toxicity due to accumulation in the retina, although this is uncommon. It is usual to check visual function before starting treatment and to repeat this periodically while treatment is continued. HCQ is generally considered to be safe during pregnancy</ce:para></ce:section><ce:section id="s0510"><ce:section-title id="st0475">Leflunomide</ce:section-title><ce:para id="p2245">Leflunomide can be used alone or in combination with other drugs in a dose of 10–20 mg/day. It works by inhibiting dihydro-orotate dehydrogenase, an enzyme used by activated lymphocytes to synthesise pyrimidines necessary for DNA synthesis. It has low marrow toxicity but may cause liver dysfunction, hypertension and hirsutism. It must be co-prescribed with robust contraception in women of child-bearing potential. Treatment must be stopped for a period of 2 years in advance of planning a pregnancy.</ce:para></ce:section><ce:section id="s0515"><ce:section-title id="st0480">Azathioprine</ce:section-title><ce:para id="p2250">Azathioprine is most commonly used in vasculitis and SLE. It is metabolised to 6-mercaptopurine (6-MP), which blocks lymphocyte proliferation by inhibiting DNA synthesis. The typical starting dose is 1 mg/kg body weight per day, increasing to 2.5 mg/kg until a response is observed or toxicity occurs. Bone marrow suppression is the most important side-effect but nausea may also occur. Genetic polymorphisms in the enzyme thiopurine S-methyltransferase (TPMT) influence catabolism of 6-MP and sometimes genetic testing for TPMT variants is done to guide dosages. Allopurinol inhibits catabolism of azathioprine, necessitating a 75% reduction in azathioprine dose.</ce:para></ce:section><ce:section id="s0520"><ce:section-title id="st0485">Apremilast</ce:section-title><ce:para id="p2255">Apremilast is used in the treatment of PsA. It works by inhibiting phosphodiesterase D4 in leucocytes, which in turn suppresses production of pro-inflammatory cytokines, thereby reducing inflammation. Apremilast is given orally in a dose of 30 mg twice daily. The main adverse effects are gastrointestinal upset, weight loss and an increased risk of depression.</ce:para></ce:section><ce:section id="s0525"><ce:section-title id="st0490">Janus-activated kinase inhibitors</ce:section-title><ce:para id="p2260">Janus-activated kinase (JAK) inhibitors work by inhibiting JAK enzymes, which are a family of intracellular signalling molecules that play a key role in transducing the effects of several pro-inflammatory cytokines. They are indicated for patients with RA who have responded inadequately to standard DMARDs and provide an alternative to biologic treatments. Two JAK inhibitors are currently available: tofacitinib, which is given orally in a dose of 5 mg twice daily, and baricitinib, which is given orally in a dose of 2–4 mg once daily. The main adverse effects are an increased risk of opportunistic infections, hepatotoxicity and haematological toxicity.</ce:para></ce:section><ce:section id="s0530"><ce:section-title id="st0495">Cyclophosphamide</ce:section-title><ce:para id="p2265">Cyclophosphamide is a cytotoxic alkylating agent that cross-links DNA and halts cell division, causing immunosuppression. It is mainly used to induce remission in life-threatening systemic vasculitis and SLE. It can be given orally in a dose of 2 mg/kg/day for 3–6 months or intravenously in a dose of 15 mg/kg every 3–4 weeks on 6–8 occasions. Adverse effects include nausea, anorexia, vomiting, bone marrow suppression, cardiac toxicity, alopecia and haemorrhagic cystitis. The risk of cystitis can be mitigated by co-administration of mesna (2-mercaptoethane sulfonate, which binds its urotoxic metabolites) and a high fluid intake.</ce:para></ce:section><ce:section id="s0535"><ce:section-title id="st0500">Mycophenolate mofetil</ce:section-title><ce:para id="p2270">Mycophenolate mofetil (MMF) works by inhibiting inosine monophosphate dehydrogenase, a rate-limiting enzyme in the synthesis of guanosine nucleotides in lymphocytes. MMF is frequently used in SLE and vasculitis in doses of 2–4 g daily orally. Haematological toxicity is the main adverse effect.</ce:para></ce:section><ce:section id="s0540"><ce:section-title id="st0505">Other DMARDs</ce:section-title><ce:para id="p2275">Gold, penicillamine and ciclosporin A have been superseded by more effective alternatives but are still occasionally used. Gold (sodium aurothiomalate, myocrisin) is indicated for RA. Its mechanism of action is unknown. It is given by intramuscular injection of 50 mg weekly after an initial test dose of 10 mg. Treatment is continued for up to 6 months until there is clinical benefit or adverse effects occur. If there is benefit, the frequency of injections is reduced to two-weekly and then monthly, providing that the response is maintained. Penicillamine is indicated for RA but is poorly tolerated. It is given in a starting dose of 125–250 mg daily on an empty stomach, and increased in 125 mg increments every 6 weeks to a maximum dose of 1500 mg daily until there is clinical benefit or adverse effects occur. Ciclosporin A is a calcineurin inhibitor that inhibits lymphocyte activation. It is occasionally used in RA at a dose of 2.5–4 mg/kg/day orally.</ce:para></ce:section></ce:section><ce:section id="s0545"><ce:section-title id="st0510">Glucocorticoids</ce:section-title><ce:para id="p2280">Glucocorticoids have powerful anti-inflammatory and immunosuppressive effects. They promote apoptosis of many immune cells and activation of a wide range of pro-inflammatory signalling pathways. They are used orally, intravenously, intramuscularly and by intra-articular injection in the treatment of a wide range of inflammatory rheumatic diseases, as well as by local injection in patients with soft tissue rheumatism (<ce:cross-ref id="crf9190" refid="p4230">p. 1026</ce:cross-ref>).</ce:para><ce:section id="s0550"><ce:section-title id="st0515">Systemic glucocorticoids</ce:section-title><ce:para id="p2285">Systemic glucocorticoids are widely used in moderate to high doses to induce remission in early RA and in systemic and polyarticular JIA. They are also used at lower doses for maintenance therapy and in the treatment of flares in RA, PsA and axSpA with peripheral joint involvement. Glucocorticoids should be used with caution in PsA because of a rebound increase in activity of psoriasis when the effects wear off. Glucocorticoids are also used to induce remission and to maintain disease control in giant cell arteritis, polymyalgia rheumatica, vasculitis and SLE.</ce:para></ce:section><ce:section id="s0555"><ce:section-title id="st0520">Intra-articular and intramuscular glucocorticoids</ce:section-title><ce:para id="p2290">Intra-articular glucocorticoids are employed in the treatment of a wide range of inflammatory arthritides and are primarily indicated when there are one or two problem joints with persistent synovitis despite good general control of the disease. Methylprednisolone is one of the most widely used, typically in doses of 40–80 mg. Intramuscular methylprednisolone (80–120 mg) is a useful way of controlling inflammatory arthritis while waiting for the effects of a newly introduced DMARD to take effect, and is also helpful in patients with stable disease who have a disease flare where a major change in DMARD strategy is not thought to be necessary.</ce:para></ce:section></ce:section><ce:section id="s0560"><ce:section-title id="st0525">Biologics</ce:section-title><ce:para id="p2295">The term ‘biologic’ refers to a group of medications that includes monoclonal antibodies, fusion proteins and decoy receptors, which are used in the treatment of several inflammatory rheumatic diseases. They are targeted towards specific cytokines, receptors and other cell-surface molecules regulating the immune response (<ce:cross-ref id="crf0625" refid="f0090">Fig. 24.15</ce:cross-ref><ce:float-anchor refid="f0090"/>). The main adverse effect of the biologics used in inflammatory diseases is an increased risk of infections. Biologics are not carcinogenic, but patients who develop cancer while on treatment may exhibit accelerated progression of the tumour due to suppression of the immune response. Treatment costs are much higher than with DMARDs and many countries have set guidelines restricting their use to patients who have active disease despite having had an adequate trial of standard therapies. Their mechanisms of action, dosages and indications are summarised in <ce:cross-ref id="crf0630" refid="b0180">Box 24.35</ce:cross-ref><ce:float-anchor refid="b0180"/>.</ce:para><ce:section id="s0565"><ce:section-title id="st0530">Anti-TNF therapy</ce:section-title><ce:para id="p2305">A variety of inhibitors of the pro-inflammatory cytokine TNF have been developed. Most are monoclonal antibodies that bind to and neutralise TNF, but etanercept is a decoy receptor that prevents TNF binding to its receptor. Anti-TNF therapy has traditionally been used as the first-line biological drug in RA when DMARD therapy has been incompletely effective. It has also traditionally been used as the first-line biologic in PsA and AxSpA, but anti IL-17A therapy (see below) has emerged as an equally effective alternative. Anti-TNF therapy is usually co-prescribed with MTX in RA and PsA as this increases efficacy, but TNF inhibitors are also effective as monotherapy. They are usually given as monotherapy in AxSpA unless there is peripheral joint involvement. Anti-TNF therapy is contraindicated in patients with active infections such as untreated tuberculosis and those with indwelling catheters, due to the high risk of infection. Other contraindications are severe heart failure and multiple sclerosis, both of which may be worsened by treatment.</ce:para></ce:section><ce:section id="s0570"><ce:section-title id="st0535">Rituximab</ce:section-title><ce:para id="p2310">Rituximab is an antibody directed against the CD20 receptor, which is expressed on B lymphocytes and immature plasma cells. It causes profound B-cell lymphopenia for several months due to complement-mediated lysis of cells that express CD20. Rituximab is indicated in patients with RA who have not responded adequately to first-line therapy but is typically employed as a third-line treatment when TNF inhibitors have been ineffective. It is also used in place of cyclophosphamide to induce remission in patients with ANCA-positive vasculitis. In RA, the treatment can be repeated when signs of improvement are wearing off (anything from 6 months to 1 year or longer). In ANCA-positive vasculitis, a single cycle of treatment may last for up to 18 months. Rituximab is sometimes used off-label in SLE, even though clinical trials did not show efficacy. Adverse effects include hypogammaglobulinaemia, infusion reactions, an increased risk of infections and, rarely, progressive multifocal leucoencephalopathy (PML; <ce:intra-ref id="ii0240" xlink:href="pii:B978-0-7020-7028-0.00025-1#s1490">p. 1123</ce:intra-ref>), a serious and potentially fatal infection of the CNS caused by reactivation of JC virus.</ce:para></ce:section><ce:section id="s0575"><ce:section-title id="st0540">Belimumab</ce:section-title><ce:para id="p2315">Belimumab is indicated in SLE. It is a monoclonal antibody that blocks the effects of the cytokine B-cell-activating factor of the TNF family (BAFF), which is required for B-cell survival and function. It is usually given when patients have had an inadequate response to glucocorticoids and hydroxychloroquine. The main adverse effects are an increased risk of infection, leucopenia and infusion reactions.</ce:para></ce:section><ce:section id="s0580"><ce:section-title id="st0545">Abatacept</ce:section-title><ce:para id="p2320">Abatacept is a fusion protein in which the Fc domain of IgG has been combined with the extracellular domain of CTLA4, which blocks T-cell activation by acting as a decoy for CD28, a co-stimulatory molecule necessary for T-cell activation (<ce:intra-ref id="ii0245" xlink:href="pii:B978-0-7020-7028-0.00004-4#p0460">p. 69</ce:intra-ref>). It is indicated in patients with RA who have not responded adequately to first-line therapy but is typically employed as a third-line treatment when TNF inhibitors have been ineffective. The main adverse effect is an increased risk of infections.</ce:para></ce:section><ce:section id="s0585"><ce:section-title id="st0550">Tocilizumab</ce:section-title><ce:para id="p2325">Tocilizumab is a monoclonal antibody to the IL-6 receptor. It is indicated in patients with RA who have not responded adequately to first-line therapy or to TNF inhibitors. It is sometimes employed as a third-line treatment when TNF inhibitors have been ineffective. An exception is when patients are MTX-intolerant, in which case it is often used as a first-line therapy, based on a randomised trial in which it showed greater efficacy than the TNF inhibitor adalimumab. Adverse effects include leucopenia, abnormal LFTs, hypercholesterolaemia, hypersensitivity reactions and an increase risk of diverticulitis.</ce:para></ce:section><ce:section id="s0590"><ce:section-title id="st0555">Ustekinumab</ce:section-title><ce:para id="p2330">Ustekinumab is an antibody to the p40 protein, which is a subunit of IL-23 and IL-12. It is indicated in patients with PsA who have not responded adequately to first-line therapy with other biologics. Adverse effects include an increased risk of infections, hypersensitivity reactions and an exfoliative dermatitis.</ce:para></ce:section><ce:section id="s0595"><ce:section-title id="st0560">Secukinumab</ce:section-title><ce:para id="p2335">Secukinumab is a monoclonal antibody to IL-17A. It is indicated in patients with PsA and axSpA, including ankylosing spondylitis, and who have not responded adequately to first-line therapy. Adverse effects include an increased risk of infections, nasopharyngitis and headache.</ce:para></ce:section><ce:section id="s0600"><ce:section-title id="st0565">Anakinra</ce:section-title><ce:para id="p2340">Anakinra is a decoy receptor for IL-1. It is occasionally used in RA but is less effective than other biological drugs. A more frequent indication is for the treatment of adult-onset Still's disease (<ce:cross-ref id="crf9195" refid="p5220">p. 1040</ce:cross-ref>) and in cryopirin-associated periodic syndromes (<ce:intra-ref id="ii0255" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0470">p. 81</ce:intra-ref>). Adverse effects include an increased risk of infections, hypersensitivity reactions and neutropenia.</ce:para></ce:section><ce:section id="s0605"><ce:section-title id="st0570">Canakinumab</ce:section-title><ce:para id="p2345">Canakinumab is indicated for the treatment of systemic JIA (Still's disease), adult-onset Still's disease, familial fever syndromes and acute flares of gout resistant to other treatments. It is a monoclonal antibody directed against the pro-inflammatory cytokine IL-1β. The usual maintenance dose in adults is 150–300 mg SC every 8 weeks. Adverse effects include an increased risk of infections, hypersensitivity reactions and neutropenia.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0610"><ce:section-title id="st0575">Osteoarthritis</ce:section-title><ce:para id="p2350">Osteoarthritis (OA) is by far the most common form of arthritis and is a major cause of pain and disability in older people. It is characterised by focal loss of articular cartilage, subchondral osteosclerosis, osteophyte formation at the joint margin, and remodelling of joint contour with enlargement of affected joints.</ce:para><ce:section id="s0615"><ce:section id="s0620"><ce:section id="s0625"><ce:section-title id="st0580">Epidemiology</ce:section-title><ce:para id="p2355">The prevalence rises progressively with age and it has been estimated that 45% of all people develop knee OA and 25% hip OA at some point during life. Although some are asymptomatic, the lifetime risk of having a total hip or knee replacement for OA in someone aged 50 is about 11% for women and 8% for men in the UK. There are major ethnic differences in susceptibility: the prevalence of hip OA is lower in Africa, China, Japan and the Indian subcontinent than in European countries, and that of knee OA is higher.</ce:para></ce:section><ce:section id="s0630"><ce:section-title id="st0585">Pathophysiology</ce:section-title><ce:para id="p2360">OA is a complex disorder with both genetic and environmental components (<ce:cross-ref id="crf0635" refid="b0185">Box 24.36</ce:cross-ref><ce:float-anchor refid="b0185"/>). Genetic factors are recognised as playing a key role in the pathogenesis of OA. Family-based studies have estimated that the heritability of OA ranges from about 43% at the knee to between 60% and 65% at the hip and hand, respectively. In most cases, the inheritance is polygenic and mediated by several genetic variants of small effect. OA can, however, be a component of multiple epiphyseal dysplasias, which are caused by mutations in the genes that encode components of cartilage matrix. Structural abnormalities, such as slipped femoral epiphysis and developmental dysplasia of the hip, are also associated with a high risk of OA, presumably due to abnormal load distribution across the joint. Similar mechanisms probably explain the increased risk of OA in patients with limb deformity secondary to Paget's disease of bone. Biomechanical factors play an important role in OA related to certain occupations, such as farmers (hip OA), miners (knee OA) and elite or professional athletes (knee and ankle OA). It has been speculated that the higher prevalence of knee OA in the Indian subcontinent and East Asia might be accounted for by squatting. There is also a high risk of OA in people who have had destabilising injuries, such as cruciate ligament rupture, and those who have had meniscetomy. For most individuals, however, participation in recreational sport does not appear to increase the risk significantly. There is a strong association between obesity and OA, particularly of the hip. This is thought to be due partly to biomechanical factors but it has also been speculated that cytokines released from adipose tissue may play a role. Oestrogen appears to play a role; lower rates of OA have been observed in women who use hormone replacement therapy (HRT), and women who receive aromatase inhibitor therapy for breast cancer often experience a flare in symptoms of OA.</ce:para><ce:para id="p2460">Degeneration of articular cartilage is the defining feature of OA. Under normal circumstances, chondrocytes are terminally differentiated cells but in OA they start dividing to produce nests of metabolically active cells (<ce:cross-ref id="crf0640" refid="f0095">Fig. 24.16A</ce:cross-ref><ce:float-anchor refid="f0095"/>). Initially, matrix components are produced by these cells at an increased rate, but at the same time there is accelerated degradation of the major structural components of cartilage matrix, including aggrecan and type II collagen (see <ce:cross-ref id="crf0645" refid="f0040">Fig. 24.5</ce:cross-ref>, <ce:cross-ref id="crf9200" refid="s0055">p. 987</ce:cross-ref>). Eventually, the concentration of aggrecan in cartilage matrix falls and makes the cartilage vulnerable to load-bearing injury. Fissuring of the cartilage surface (‘fibrillation’) then occurs, leading to the development of deep vertical clefts (<ce:cross-ref id="crf0650" refid="f0095">Fig. 24.16B</ce:cross-ref>), localised chondrocyte death and decreased cartilage thickness. This is initially focal, mainly targeting the maximum load-bearing part of the joint, but eventually large parts of the cartilage surface are damaged. Calcium pyrophosphate and basic calcium phosphate crystals often become deposited in the abnormal cartilage.</ce:para><ce:para id="p2465">OA is also accompanied by abnormalities in subchondral bone, which becomes sclerotic and the site of subchondral cysts (<ce:cross-ref id="crf0655" refid="f0095">Fig. 24.16C</ce:cross-ref>). Fibrocartilage is produced at the joint margin, which undergoes endochondral ossification to form osteophytes. Bone remodelling and cartilage thinning slowly alter the shape of the OA joint, increasing its surface area. It is almost as though there is a homeostatic mechanism operative in OA that causes enlargement of the failing joint to spread the mechanical load over a greater surface area.</ce:para><ce:para id="p2470">Patients with OA also have higher BMD values at sites distant from the joint and this is particularly associated with osteophyte formation. This is in keeping with observations made in epidemiological studies that show that patients with OA are partially protected from developing osteoporosis and vice versa. This is likely to be due to the fact that the genetic factors that predispose to osteoporosis might be protective for OA.</ce:para><ce:para id="p2475">The synovium in OA is often hyperplastic and may be the site of inflammatory change, but to a much lesser extent than in RA and other inflammatory arthropathies. Osteochondral bodies commonly occur within the synovium, reflecting chondroid metaplasia or secondary uptake and growth of damaged cartilage fragments. The outer capsule also thickens and contracts, usually retaining the stability of the remodelling joint. The muscles surrounding affected joints commonly show evidence of wasting and non-specific type II fibre atrophy.</ce:para></ce:section><ce:section id="s0660"><ce:section-title id="st0615">Clinical features</ce:section-title><ce:para id="p2480">OA has a characteristic distribution, mainly targeting the hips, knees, PIP and DIP joints of the hands, neck and lumbar spine (see <ce:cross-ref id="crf0660" refid="f0065">Fig. 24.10</ce:cross-ref>). The main presenting symptoms are pain and functional restriction. The causes of pain in OA are not completely understood but may relate to increased pressure in subchondral bone (mainly causing night pain), trabecular microfractures, capsular distension and low-grade synovitis. Pain may also result from bursitis and enthesopathy secondary to altered joint mechanics. Typical OA pain has the characteristics listed in <ce:cross-ref id="crf0665" refid="b0190">Box 24.37</ce:cross-ref><ce:float-anchor refid="b0190"/>. For many people, functional restriction of the hands, knees or hips is an equal, if not greater, problem than pain. The clinical findings vary according to severity but are principally those of joint damage.</ce:para><ce:para id="p2555">The correlation between the presence of structural change, as assessed by imaging, and symptoms such as pain and disability varies markedly according to site. It is stronger at the hip than at the knee, and poor at most small joints. This suggests that the risk factors for pain and disability may differ from those for structural change. At the knee, for example, reduced quadriceps muscle strength and adverse psychosocial factors (anxiety, depression) correlate more strongly with pain and disability than the degree of radiographic change.</ce:para><ce:para id="p2560">Radiological evidence of OA is very common in middle-aged and older people, and the disease may coexist with other conditions, so it is important to remember that pain in a patient with OA may be due to another cause.</ce:para><ce:section id="s0675"><ce:section-title id="st0630">Generalised nodal OA</ce:section-title><ce:para id="p2565">Characteristics of this common form of OA are shown in <ce:cross-ref id="crf0670" refid="b0195">Box 24.38</ce:cross-ref><ce:float-anchor refid="b0195"/>. Some patients are asymptomatic whereas others develop pain, stiffness and swelling of one or more PIP and DIP joints of the hands from the age of about 40 years onwards. Gradually, these develop posterolateral swellings on each side of the extensor tendon, which slowly enlarge and harden to become Heberden's (DIP) and Bouchard's (PIP) nodes (<ce:cross-ref id="crf0675" refid="f0100">Fig. 24.17</ce:cross-ref><ce:float-anchor refid="f0100"/>). Typically, each joint goes through a phase of episodic symptoms (1–5 years) while the node evolves and OA develops. Once OA is fully established, symptoms may subside and hand function often remains good. Affected joints are enlarged as a result of osteophyte formation and often show characteristic lateral deviation, reflecting the asymmetric focal cartilage loss of OA (<ce:cross-ref id="crf0680" refid="f0105">Fig. 24.18</ce:cross-ref><ce:float-anchor refid="f0105"/>). Involvement of the first CMC joint is also common, leading to pain on trying to open bottles and jars, and functional impairment. Clinically, it may be detected by the presence of crepitus on joint movement, and squaring of the thumb base.</ce:para><ce:para id="p2610">Generalised nodal OA has a very strong genetic component: the daughter of an affected mother has a 1 in 3 chance of developing nodal OA herself. People with nodal OA are also at increased risk of OA at other sites, especially the knee.</ce:para></ce:section><ce:section id="s0680"><ce:section-title id="st0635">Knee OA</ce:section-title><ce:para id="p2615">At the knee, OA principally targets the patello-femoral and medial tibio-femoral compartments but eventually spreads to affect the whole of the joint (<ce:cross-ref id="crf0685" refid="f0110">Fig. 24.19</ce:cross-ref><ce:float-anchor refid="f0110"/>). It may be isolated or occur as part of generalised nodal OA. Most patients have bilateral and symmetrical involvement. In men, trauma is often a more important risk factor and may result in unilateral OA.</ce:para><ce:para id="p2620">The pain is usually localised to the anterior or medial aspect of the knee and upper tibia. Patello-femoral pain is usually worse going up and down stairs or inclines. Posterior knee pain suggests the presence of a complicating popliteal cyst (Baker's cyst). Prolonged walking, rising from a chair, getting in or out of a car, or bending to put on shoes and socks may be difficult. Local examination findings may include:<ce:list id="ulist0420"><ce:list-item id="u1640"><ce:label>•</ce:label><ce:para id="p2625">a jerky, asymmetric (antalgic) gait with less time weight-bearing on the painful side</ce:para></ce:list-item><ce:list-item id="u1645"><ce:label>•</ce:label><ce:para id="p2630">a varus (<ce:cross-ref id="crf0690" refid="f0115">Fig. 24.20</ce:cross-ref><ce:float-anchor refid="f0115"/>) or, less commonly, valgus and/or a fixed flexion deformity</ce:para></ce:list-item><ce:list-item id="u1650"><ce:label>•</ce:label><ce:para id="p2635">joint-line and/or periarticular tenderness (secondary anserine bursitis and medial ligament enthesopathy (see <ce:cross-ref id="crf0695" refid="b0130">Box 24.25</ce:cross-ref>), causing tenderness of the upper medial tibia)</ce:para></ce:list-item><ce:list-item id="u1655"><ce:label>•</ce:label><ce:para id="p2640">weakness and wasting of the quadriceps muscle</ce:para></ce:list-item><ce:list-item id="u1660"><ce:label>•</ce:label><ce:para id="p2645">restricted flexion and extension with coarse crepitus</ce:para></ce:list-item><ce:list-item id="u1665"><ce:label>•</ce:label><ce:para id="p2650">bony swelling around the joint line.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2655">CPPD crystal deposition in association with OA is common at the knee. This may result in a more overt inflammatory component (stiffness, effusions) and super-added acute attacks of synovitis (‘pseudogout’; <ce:cross-ref id="crf9205" refid="p3170">p. 1016</ce:cross-ref>), which may be associated with more rapid radiographic and clinical progression.</ce:para></ce:section><ce:section id="s0685"><ce:section-title id="st0640">Hip OA</ce:section-title><ce:para id="p2660">Hip OA most commonly targets the superior aspect of the joint (<ce:cross-ref id="crf0700" refid="f0120">Fig. 24.21</ce:cross-ref><ce:float-anchor refid="f0120"/>). It is often unilateral at presentation, frequently progresses with superolateral migration of the femoral head, and has a poor prognosis. The less common central (medial) OA shows more central cartilage loss and is largely confined to women. It is often bilateral at presentation and can be associated with generalised nodal OA. It has a better prognosis than superior hip OA and progression to axial migration of the femoral head is uncommon.</ce:para><ce:para id="p2665">The hip shows the best correlation between symptoms and radiographic change. Hip pain is usually maximal deep in the anterior groin, with variable radiation to the buttock, anterolateral thigh, knee or shin. Lateral hip pain, worse on lying on that side with tenderness over the greater trochanter, suggests secondary trochanteric bursitis. Common functional difficulties are the same as for knee OA; in addition, restricted hip abduction in women may cause pain during sexual intercourse. Examination may reveal:<ce:list id="ulist0425"><ce:list-item id="u1670"><ce:label>•</ce:label><ce:para id="p2670">an antalgic gait</ce:para></ce:list-item><ce:list-item id="u1675"><ce:label>•</ce:label><ce:para id="p2675">weakness and wasting of quadriceps and gluteal muscles</ce:para></ce:list-item><ce:list-item id="u1680"><ce:label>•</ce:label><ce:para id="p2680">pain and restriction of internal rotation with the hip flexed – the earliest and most sensitive sign of hip OA; other movements may subsequently be restricted and painful</ce:para></ce:list-item><ce:list-item id="u1685"><ce:label>•</ce:label><ce:para id="p2685">anterior groin tenderness just lateral to the femoral pulse</ce:para></ce:list-item><ce:list-item id="u1690"><ce:label>•</ce:label><ce:para id="p2690">fixed flexion, external rotation deformity of the hip</ce:para></ce:list-item><ce:list-item id="u1695"><ce:label>•</ce:label><ce:para id="p2695">ipsilateral leg shortening with severe joint attrition and superior femoral migration.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2700">Obesity is associated with more rapid progression of hip OA.</ce:para></ce:section><ce:section id="s0690"><ce:section-title id="st0645">Spine OA</ce:section-title><ce:para id="p2705">The cervical and lumbar spine are the sites most often targeted by OA, where it is referred to as cervical spondylosis and lumbar spondylosis, respectively (<ce:cross-ref id="crf0705" refid="f0125">Fig. 24.22</ce:cross-ref><ce:float-anchor refid="f0125"/>). Spine OA may occur in isolation or as part of generalised OA. The typical presentation is with pain localised to the low back region or the neck, although radiation of pain to the arms, buttocks and legs may also occur due to nerve root compression. The pain is typically relieved by rest and worse on movement. On physical examination, the range of movement may be limited and loss of lumbar lordosis is typical. The straight leg-raising test or femoral stretch test may be positive and neurological signs may be seen in the legs where there is complicating spinal stenosis or nerve root compression.</ce:para></ce:section><ce:section id="s0695"><ce:section-title id="st0650">Early-onset OA</ce:section-title><ce:para id="p2710">Unusually, typical symptoms and signs of OA may present before the age of 45. In most cases, a single joint is affected and there is a clear history of previous trauma. However, specific causes of OA need to be considered in people with early-onset disease affecting several joints, especially those not normally targeted by OA, in which case rare causes need to be considered (<ce:cross-ref id="crf0710" refid="b0200">Box 24.39</ce:cross-ref><ce:float-anchor refid="b0200"/>). Kashin–Beck disease is a rare form of OA that occurs in children, typically between the ages of 7 and 13, in some regions of China. The cause is unknown but suggested predisposing factors are selenium deficiency and contamination of cereals with mycotoxin-producing fungi.</ce:para></ce:section><ce:section id="s0710"><ce:section-title id="st0665">Erosive OA</ce:section-title><ce:para id="p2775">This term is used to describe an unusual group of patients with hand OA who have a more prolonged symptom phase, more overt inflammation, more disability and worse outcome than those with nodal OA. Distinguishing features include preferential targeting of PIP joints, subchondral erosions on X-rays, occasional ankylosis of affected joints and lack of association with OA elsewhere. It is unclear whether erosive OA is part of the spectrum of hand OA or a discrete subset.</ce:para></ce:section></ce:section><ce:section id="s0715"><ce:section-title id="st0670">Investigations</ce:section-title><ce:para id="p2780">A plain X-ray of the affected joint should be performed and often this will show one or more of the typical features of OA (see <ce:cross-refs id="crfs0010" refid="f0105 f0110 f0115 f0120 f0125">Figs 24.18–24.22</ce:cross-refs>). In addition to providing diagnostic information, X-rays are of value in assessing the severity of structural change, which is helpful if joint replacement surgery is being considered. Non-weight-bearing postero-anterior views of the pelvis are adequate for assessing hip OA. Patients with suspected knee OA should have standing anteroposterior X-rays taken to assess tibio-femoral cartilage loss, and a flexed skyline view to assess patello-femoral involvement. Spine OA can often be diagnosed on a plain X-ray, which typically shows evidence of disc space narrowing and osteophytes. If nerve root compression or spinal stenosis is suspected, MRI should be performed.</ce:para><ce:para id="p2785">Routine biochemistry, haematology and autoantibody tests are usually normal, though OA is associated with a moderate acute phase response. Synovial fluid aspirated from an affected joint is viscous with a low cell count.</ce:para><ce:para id="p2790">Unexplained early-onset OA requires additional investigation, guided by the suspected underlying condition. X-rays may show typical features of dysplasia or avascular necrosis, widening of joint spaces in acromegaly, multiple cysts, chondrocalcinosis and MCP joint involvement in haemochromatosis (<ce:intra-ref id="ii0285" xlink:href="pii:B978-0-7020-7028-0.00022-6#s1265">p. 895</ce:intra-ref>), or disorganised architecture in neuropathic joints.</ce:para></ce:section><ce:section id="s0720"><ce:section-title id="st0675">Management</ce:section-title><ce:para id="p2795">Treatment follows the principles outlined on <ce:cross-ref id="crf9210" refid="s0395">pages 1000–1007</ce:cross-ref>. Measures that are pertinent in older people are summarised in <ce:cross-ref id="crf0715" refid="b0205">Box 24.40</ce:cross-ref><ce:float-anchor refid="b0205"/>.</ce:para><ce:section id="s0725"><ce:section-title id="st0680">Education</ce:section-title><ce:para id="p2840">It is important to explain the nature of the condition fully, outlining the role of relevant risk factors such as obesity, heredity and trauma. The patent should be informed that established structural changes are permanent and that, although a cure is not possible at present, pain and function can often be improved. The prognosis should also be discussed, mentioning that it is generally good for nodal hand OA and better for knee than hip OA.</ce:para></ce:section><ce:section id="s0730"><ce:section-title id="st0685">Lifestyle advice</ce:section-title><ce:para id="p2845">Weight loss has a substantial beneficial effect on symptoms if the patient is obese and is probably one of the most effective treatments available for OA of the lower limbs. Strengthening and aerobic exercises also have beneficial effects in OA and should be advised, preferably with reinforcement by a physiotherapist (see <ce:cross-ref id="crf0720" refid="b0140">Box 24.27</ce:cross-ref>). Quadriceps strengthening exercises are particularly beneficial in knee OA. Shock-absorbing footwear, pacing of activities, use of a walking stick for painful knee or hip OA, and provision of built-up shoes to equalise leg lengths can all improve symptoms.</ce:para></ce:section><ce:section id="s0735"><ce:section-title id="st0690">Non-pharmacological therapy</ce:section-title><ce:para id="p2850">Acupuncture and transcutaneous electrical nerve stimulation (TENS) have been shown to be effective in knee OA. Local physical therapies, such as heat or cold, can sometimes give temporary relief.</ce:para></ce:section><ce:section id="s0740"><ce:section-title id="st0695">Pharmacological therapy</ce:section-title><ce:para id="p2855">If symptoms do not respond to non-pharmacological measures, paracetamol should be tried. Addition of a topical NSAID, and then capsaicin, for knee and hand OA can also be helpful. Oral NSAIDs should be considered in patients who remain symptomatic. These drugs are significantly more effective than paracetamol and can be successfully combined with paracetamol or compound analgesics if the pain is severe. Strong opiates may occasionally be required. Antineuropathic drugs, such as amitriptyline, gabapentin and pregabalin, are sometimes used in patients with symptoms that are difficult to control but the evidence base for their use is poor. Neutralising antibodies to nerve growth factor have been developed and are a highly effective treatment for pain in OA but they are not yet licensed for routine clinical use.</ce:para></ce:section><ce:section id="s0745"><ce:section-title id="st0700">Intra-articular injections</ce:section-title><ce:para id="p2860">Intra-articular glucocorticoid injections are effective in the treatment of knee OA and are also used for symptomatic relief in the treatment of OA at the first CMC joint. The duration of effect is usually short but trials of serial glucocorticoid injections every 3 months in knee OA have shown efficacy for up to 1 year. Intra-articular injections of hyaluronic acid are effective in knee OA but the treatment is expensive and the effect short-lived. In the UK they have not been considered to be cost-effective by NICE.</ce:para></ce:section><ce:section id="s0750"><ce:section-title id="st0705">Neutraceuticals</ce:section-title><ce:para id="p2865">Chondroitin sulphate and glucosamine sulphate have been used alone and in combination for the treatment of knee OA. There is evidence from randomised controlled trials that these agents can improve knee pain to a small extent (3–5%) compared with placebo.</ce:para></ce:section><ce:section id="s0755"><ce:section-title id="st0710">Surgery</ce:section-title><ce:para id="p2870">Surgery should be considered for patients with OA whose symptoms and functional impairment impact significantly on their quality of life despite optimal medical therapy and lifestyle advice. Total joint replacement surgery is by far the most common surgical procedure for patients with OA. It can transform the quality of life for people with severe knee or hip OA and is indicated when there is significant structural damage on X-ray. Although surgery should not be undertaken at an early stage during the development of OA, it is important to consider it before functional limitation has become advanced since this may compromise outcome. Patient-specific factors, such as age, gender, smoking and presence of obesity, should not be barriers to referral for joint replacement.</ce:para><ce:para id="p2875">Only a small proportion of patients with OA progress to the extent that total joint replacement is required but OA is by far the most frequent indication for this. Over 95% of joint replacements continue to function well into the second decade after surgery and most provide life-long, pain-free function. Up to 20% of patients are not satisfied with the outcome, however, and a few experience little or no improvement in pain. Other surgical procedures are performed much less frequently. Osteotomy is occasionally carried out to prolong the life of malaligned joints and to relieve pain by reducing intraosseous pressure. Cartilage repair is sometimes performed to treat focal cartilage defects resulting from joint injury.</ce:para></ce:section></ce:section></ce:section></ce:section></ce:section><ce:section id="s0760"><ce:section-title id="st0715">Crystal-induced arthritis</ce:section-title><ce:para id="p2880">A variety of crystals can deposit in and around joints and cause an acute inflammatory arthritis, as well as a more chronic arthritis associated with progressive joint damage (<ce:cross-ref id="crf0725" refid="b0210">Box 24.41</ce:cross-ref><ce:float-anchor refid="b0210"/>). Crystals can be the primary pathogenic agent, as in gout, or an accessory factor, as in calcium pyrophosphate deposition disease, in which crystals are deposited in joints that are already abnormal. Several factors influence crystal formation (<ce:cross-ref id="crf0730" refid="f0130">Fig. 24.23</ce:cross-ref><ce:float-anchor refid="f0130"/>). There must be sufficient concentration of the chemical components (ionic product), but whether a crystal then forms depends on the balance of tissue factors that promote and inhibit crystal nucleation and growth. The inflammatory potential of crystals resides in their physical irregularity and high negative surface charge, which can induce inflammation and damage cell membranes. Crystals may also cause mechanical damage to tissues and act as wear particles at the joint surface. They can reside in cartilage or tendon for years without causing inflammation or symptoms, and it is only when they are released that they trigger inflammation. This may occur spontaneously but can also result from local trauma, rapid changes in the concentration of the components that form crystals, or in association with an acute phase response triggered by intercurrent illness or surgery. In the longer term, a reduction in concentrations of the solutes that form crystals causes dissolution of crystals and remission of the arthritis.</ce:para><ce:section id="s0765"><ce:section id="s0770"><ce:section-title id="st0720">Gout</ce:section-title><ce:para id="p2890">Gout is the most common inflammatory arthritis in men and in older women. It is caused by deposition of monosodium urate monohydrate crystals in and around synovial joints.</ce:para><ce:section id="s0775"><ce:section-title id="st0725">Epidemiology</ce:section-title><ce:para id="p2895">The prevalence of gout is approximately 1–2%, with a greater than 5 : 1 male preponderance. Gout has become progressively more common over recent years in affluent societies due to the increased prevalence of obesity and metabolic syndrome (<ce:intra-ref id="ii0295" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0205">p. 730</ce:intra-ref>), of which hyperuricaemia is an integral component. The risk of developing gout increases with age and with serum uric acid (SUA) levels. These are normally distributed in the general population and hyperuricaemia is defined as an SUA of more than 2 standard deviations above the mean for the population. SUA levels are higher in men, increase with age and are positively associated with body weight. Levels are higher in some ethnic groups (such as Maoris and Pacific islanders). Although hyperuricaemia is strong risk factor for gout, only a minority of hyperuricaemic individuals actually develop gout.</ce:para></ce:section><ce:section id="s0780"><ce:section-title id="st0730">Pathophysiology</ce:section-title><ce:para id="p2900">About one-third of the body uric acid pool is derived from dietary sources and two-thirds from endogenous purine metabolism (<ce:cross-ref id="crf0735" refid="f0135">Fig. 24.24</ce:cross-ref><ce:float-anchor refid="f0135"/>). The concentration of uric acid in body fluids depends on the balance between endogenous synthesis, and elimination by the kidneys (two-thirds) and gut (one-third). Purine nucleotide synthesis and degradation are regulated by a network of enzyme pathways, but xanthine oxidase plays a pivotal role in catalysing the conversion of hypoxanthine to xanthine and xanthine to uric acid.</ce:para><ce:para id="p2905">The causes of hyperuricaemia are shown in <ce:cross-ref id="crf0740" refid="b0215">Box 24.42</ce:cross-ref><ce:float-anchor refid="b0215"/>. In over 90% of patients, the main abnormality is reduced uric acid excretion by the kidney, which is genetically determined. Impaired renal excretion of urate also accounts for the occurrence of hyperuricaemia in chronic renal failure, and for hyperuricaemia associated with thiazide diuretic therapy.</ce:para><ce:para id="p3020">Other risk factors for gout include metabolic syndrome, high alcohol intake (predominantly beer, which contains guanosine), generalised OA, and a diet relatively high in game, offal, seafood, red meat and fructose, or low in vitamin C. Lead poisoning may cause gout (saturnine gout). The association between OA and gout is thought to be due to a reduction in levels of proteoglycan and other inhibitors of crystal formation in osteoarthritic cartilage, predisposing to crystal formation.</ce:para><ce:para id="p3025">Some patients develop gout because they over-produce uric acid. The mechanisms are poorly understood, except in the case of a few single gene disorders where there are mutations in genes that regulate purine metabolism (<ce:cross-ref id="crf0750" refid="b0215">Box 24.42</ce:cross-ref>). Lesch–Nyhan syndrome is an X-linked recessive form of gout that is also associated with mental retardation, self-mutilation and choreoathetosis. An inherited cause should be suspected if other clinical features are present or there is an early age at onset with a positive family history. Severe hyperuricaemia can also occur in patients with haematological and other cancers who are undergoing chemotherapy due to increased purine turnover (tumour lysis syndrome). This is seldom connected with gout but can be associated with acute kidney injury (<ce:intra-ref id="ii0305" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0660">p. 411</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0785"><ce:section-title id="st0735">Clinical features</ce:section-title><ce:para id="p3030">The classical presentation is with an acute monoarthritis, which affects the first MTP joint in over 50% of cases (<ce:cross-ref id="crf0755" refid="f0140">Fig. 24.25</ce:cross-ref><ce:float-anchor refid="f0140"/>). Other common sites are the ankle, midfoot, knee, small joints of hands, wrist and elbow. The axial skeleton and large proximal joints are rarely involved. Typical features include:<ce:list id="ulist0490"><ce:list-item id="u1890"><ce:label>•</ce:label><ce:para id="p3035">rapid onset, reaching maximum severity in 2–6 hours, and often waking the patient in the early morning</ce:para></ce:list-item><ce:list-item id="u1895"><ce:label>•</ce:label><ce:para id="p3040">severe pain, often described as the ‘worst pain ever’</ce:para></ce:list-item><ce:list-item id="u1900"><ce:label>•</ce:label><ce:para id="p3045">extreme tenderness, such that the patient is unable to wear a sock or to let bedding rest on the joint</ce:para></ce:list-item><ce:list-item id="u1905"><ce:label>•</ce:label><ce:para id="p3050">marked swelling with overlying red, shiny skin</ce:para></ce:list-item><ce:list-item id="u1910"><ce:label>•</ce:label><ce:para id="p3055">self-limiting over 5–14 days, with complete resolution.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p3060">During the attack, the joint shows signs of marked synovitis, swelling and erythema. There may be accompanying fever, malaise and even delirium, especially if a large joint such as the knee is involved. As the attack subsides, pruritus and desquamation of overlying skin are common. The main differential diagnosis is septic arthritis, infective cellulitis or reactive arthritis. Acute attacks may also manifest as bursitis, tenosynovitis or cellulitis, which have the same clinical characteristics. Many patients describe milder episodes lasting just a few days. Some have attacks in more than one joint. Others have further attacks in other joints a few days later (cluster attacks), the first possibly acting as a trigger. Simultaneous polyarticular attacks are unusual.</ce:para><ce:para id="p3065">Some people never have a second episode and in others several years may elapse before the next one. In many, however, a second attack occurs within 1 year and may progress to chronic gout, with chronic pain and joint damage, and occasionally severe deformity and functional impairment. Patients with uncontrolled hyperuricaemia who suffer multiple attacks of acute gout may also progress to chronic gout.</ce:para><ce:para id="p3070">The presentation of gout in the elderly may be atypical with chronic symptoms rather than acute attacks (<ce:cross-ref id="crf0760" refid="b0220">Box 24.43</ce:cross-ref><ce:float-anchor refid="b0220"/>).</ce:para><ce:para id="p3095">Crystals may be deposited in the joints and soft tissues to produce irregular firm nodules called tophi. These have a predilection for the extensor surfaces of fingers, hands, forearm, elbows, Achilles tendons and sometimes the helix of the ear. Tophi have a white colour (<ce:cross-ref id="crf0765" refid="f0145">Fig. 24.26</ce:cross-ref><ce:float-anchor refid="f0145"/>), differentiating them from rheumatoid nodules. Tophi can ulcerate, discharging white gritty material, become infected or induce a local inflammatory response, with erythema and pus in the absence of secondary infection. They are usually a feature of long-standing gout but can sometimes develop within 12 months in patients with chronic renal failure. Occasionally, tophi may develop in the absence of previous acute attacks, especially in patients on thiazide therapy who have coexisting OA.</ce:para><ce:para id="p3100">In addition to causing musculoskeletal disease, chronic hyperuricaemia may be complicated by renal stone formation (<ce:intra-ref id="ii0310" xlink:href="pii:B978-0-7020-7028-0.00015-9#p3375">p. 431</ce:intra-ref>) and, if severe, renal impairment due to the development of interstitial nephritis as a result of urate deposition in the kidney. This is particularly common in patients with chronic tophaceous gout who are on diuretic therapy.</ce:para></ce:section><ce:section id="s0790"><ce:section-title id="st0740">Investigations</ce:section-title><ce:para id="p3105">The diagnosis of gout can be confirmed by the identification of urate crystals in the aspirate from a joint, bursa or tophus (see <ce:cross-ref id="crf0770" refid="f0045">Fig. 24.6A</ce:cross-ref>, <ce:cross-ref id="crf9215" refid="s0085">p. 988</ce:cross-ref>). In acute gout, the synovial fluid may be turbid due to an elevated neutrophil count. In chronic gout, the appearance is more variable but occasionally the fluid appears white due to the presence of urate crystals. Between attacks, aspiration of an asymptomatic first MTP joint or knee may still reveal crystals.</ce:para><ce:para id="p3110">A biochemical screen, including renal function, uric acid, glucose and lipid profile, should be performed because of the association with metabolic syndrome. Hyperuricaemia is usually present in gout but levels may be normal during an attack because serum urate falls during inflammation. Acute gout is characterised by an elevated ESR and CRP and with a neutrophilia, all of which return to normal as the attack subsides. Tophaceous gout may be accompanied by a modest but chronic elevation in ESR and CRP.</ce:para><ce:para id="p3115">X-rays are usually normal in acute gout but well-demarcated erosions may be seen in patients with chronic or tophaceous gout (<ce:cross-ref id="crf0775" refid="f0150">Fig. 24.27</ce:cross-ref><ce:float-anchor refid="f0150"/>). Tophi may also be visible on X-rays as soft tissue swellings. In late disease, destructive changes may occur that are similar to those in other forms of advanced inflammatory arthritis.</ce:para></ce:section><ce:section id="s0795"><ce:section-title id="st0745">Management</ce:section-title><ce:para id="p3120">Management should focus on first dealing with the acute attack and then giving prophylaxis to lower SUA and prevent further attacks.</ce:para><ce:section id="s0800"><ce:section-title id="st0750">Acute gout</ce:section-title><ce:para id="p3125">Oral colchicine given in doses of 0.5 mg twice or 3 times daily is the treatment of first choice in acute gout. It works by inhibiting microtubule assembly in neutrophils. The most common adverse effects are nausea, vomiting and diarrhoea. Oral NSAIDs are also effective but are used less commonly since many patients affected by acute gout have coexisting cardiovascular, cerebrovascular or chronic kidney disease. Oral prednisolone (15–20 mg daily) or intramuscular methylprednisolone (80–120 mg daily) for 2–3 days are highly effective and are a good choice in elderly patients where there is an increased risk of toxicity with colchicine and NSAID (<ce:cross-ref id="crf0780" refid="b0220">Box 24.43</ce:cross-ref>). The IL-1β inhibitor canakinumab (see <ce:cross-ref id="crf0785" refid="b0180">Box 24.35</ce:cross-ref>) is effective but extremely expensive and so seldom given. Local ice packs can also be used for symptomatic relief. Patients with recurrent episodes can keep a supply of an NSAID, colchicine or prednisolone and take it as soon as the first symptoms occur, continuing until the attack resolves. Joint aspiration can give pain relief, particularly if a large joint is affected, and may be combined with an intra-articular glucocorticoid injection if the diagnosis is clear and infection can be excluded.</ce:para></ce:section><ce:section id="s0805"><ce:section-title id="st0755">Prophylaxis</ce:section-title><ce:para id="p3130">Patients who have had a single attack of gout do not necessarily need to be given urate-lowering therapy, but individuals who have more than one acute attack within 12 months and those with complications such as tophi or erosions should be offered it (<ce:cross-ref id="crf0790" refid="b0225">Box 24.44</ce:cross-ref><ce:float-anchor refid="b0225"/>). The long-term therapeutic aim is to prevent attacks occurring by bringing uric acid levels below the level at which monosodium urate monohydrate crystals form. A therapeutic target of 360 µmol/L (6 mg/dL) is recommended in the British Society of Rheumatology guidelines, whereas the European League Against Rheumatism guidelines recommend a threshold of 300 µmol/L (5 mg/dL).</ce:para><ce:para id="p3165">Allopurinol is the drug of first choice. It inhibits xanthine oxidase, which reduces the conversion of hypoxanthine and xanthine to uric acid. The recommended starting dose is 100 mg daily, or 50 mg in older patients and in renal impairment. The dose of allopurinol should be increased by 100 mg every 4 weeks (50 mg in the elderly and those with renal impairment) until the target uric acid level is achieved, side-effects occur or the maximum recommended dose is reached (900 mg/day). Acute flares of gout often follow initiation of urate-lowering therapy. The patient should be warned about this and told to continue therapy, even if an attack occurs. The risk of flares can be reduced by prophylaxis with oral colchicine (0.5 mg twice daily) or an NSAID for the first few months. Alternatively, patients can be given a supply of colchicine, an NSAID or prednisolone to be taken at the first sign of an acute attack. In the longer term, annual monitoring of uric acid levels is recommended. In most patients, urate-lowering therapy needs to be continued indefinitely.</ce:para><ce:para id="p3170">Febuxostat also inhibits xanthine oxidase. It is typically used in patients with an inadequate response to allopurinol, and when allopurinol is contraindicated or causes adverse effects. Febuxostat undergoes hepatic metabolism and no dose adjustment is required for renal impairment. It is more effective than allopurinol but commonly provokes acute attacks when therapy is initiated. The usual starting dose is 80 mg daily, increasing to 120 mg daily in patients with an inadequate response. Prophylaxis against acute attacks should be given on initiating therapy, as described for allopurinol.</ce:para><ce:para id="p3175">Uricosuric drugs, such as probenecid, sulfinpyrazone and benzbromarone, lower urate levels but are seldom used in routine clinical practice. They are contraindicated in over-producers and those with renal impairment or urolithiasis and require patients to maintain a high fluid intake to avoid uric acid crystallisation in the renal tubules.</ce:para><ce:para id="p3180">Pegloticase is a biological treatment in which the enzyme uricase (oxidises uric acid to 5-hydroxyisourate, which is then converted to allantoin) has been conjugated to monomethoxypolyethylene glycol. It is indicated for the treatment of tophaceous gout resistant to standard therapy and is administered as an intravenous infusion every 2 weeks for up to 6 months. It is highly effective at controlling hyperuricaemia and can cause regression of tophi. The main adverse effects are infusion reactions (which can be treated with antihistamines or glucocorticoids) and flares of gout during the first 3 months of therapy. A limiting factor for longer-term treatment is the development of antibodies to pegloticase, which occur in a high proportion of cases and are associated with an impaired therapeutic response.</ce:para><ce:para id="p3185">Lifestyle measures are equally important as drug therapy in the treatment of gout. Patients should be advised to lose weight where appropriate and to reduce excessive alcohol intake, especially beer. Several antihypertensive drugs, including thiazides, β-blockers and ACE inhibitors, increase uric acid levels, whereas losartan has a uricosuric effect and should be substituted for other drugs if possible. Patients should be advised to avoid large amounts of seafood and offal, which have a high purine content, but a highly restrictive diet is not necessary.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0810"><ce:section-title id="st0760">Calcium pyrophosphate dihydrate crystal deposition disease</ce:section-title><ce:para id="p3190">This condition is associated with deposition of calcium pyrophosphate dihydrate (CPPD) crystals within articular and hyaline cartilage and is often referred to as ‘pseudogout’. It is rare under the age of 55 years but occurs in 10–15% of people between 65 and 75 and 30–60% of those over 85. The knee (hyaline cartilage and menisci) is by far the most common site, followed by the wrist (triangular fibrocartilage) and pelvis (symphysis pubis). Risk factors are shown in <ce:cross-ref id="crf0795" refid="b0230">Box 24.45</ce:cross-ref><ce:float-anchor refid="b0230"/>. In many patients, chondrocalcinosis is asymptomatic and an incidental finding on X-ray. A proportion of patients present with an acute inflammatory arthritis (pseudogout) or a chronic inflammatory arthropathy superimposed on a background of OA, especially at the knee (<ce:cross-ref id="crf0815" refid="f0155">Fig. 24.28</ce:cross-ref><ce:float-anchor refid="f0155"/>), associated with joint damage and functional limitation.</ce:para><ce:section id="s0825"><ce:section-title id="st0775">Pathophysiology</ce:section-title><ce:para id="p3245">The underlying mechanisms of crystal deposition are poorly understood. Clinical studies have shown that pyrophosphate levels are raised in patients with CPPD crystal deposition disease, possibly due to over-production, but why this happens is unclear. In hypophosphatasia (see <ce:cross-ref id="crf9000" refid="b0380">Box 24.75</ce:cross-ref>, <ce:cross-ref id="crf9220" refid="f0320">p. 1050</ce:cross-ref>), the predisposing factor is thought to be impaired degradation of pyrophosphate due to deficiency of ALP. In OA, it is thought that a reduction in the amounts of proteoglycan and other natural inhibitors of crystal formation in the abnormal cartilage also predispose to crystal deposition (see <ce:cross-ref id="crf0820" refid="f0130">Fig. 24.23</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0830"><ce:section-title id="st0780">Clinical features</ce:section-title><ce:para id="p3250">The typical presentation is with a swollen tender joint that is warm and erythematous with a large effusion. Fever is common and the patient may appear confused and ill. The knee is most commonly affected, followed by the wrist, shoulder, ankle and elbow. Trigger factors include trauma, intercurrent illness, dehydration and surgery. Septic arthritis and gout are the main differential diagnoses.</ce:para><ce:para id="p3255">Chronic arthropathy may also occur in association with CPPD crystal deposition disease, affecting the same joints that are involved in acute pseudogout. The presentation is with chronic pain, early morning stiffness, inactivity gelling and functional impairment. Acute attacks of pseudogout may be superimposed. Affected joints usually show features of OA, with varying degrees of synovitis. Effusion and synovial thickening are usually most apparent at knees and wrists. Wrist involvement may result in carpal tunnel syndrome and second and third MCP joints can be affected. Inflammatory features may be sufficiently pronounced to suggest RA. Inflammatory changes can occur at entheses and may involve tendons and the ligamentum flavum. Inflammation around the odontoid may occur secondary to CPPD deposition, leading to crowned dens syndrome; this presents clinically with neck pain. Severe damage and instability of knees or shoulders can mimic a neuropathic joint but no neurological abnormalities will be found.</ce:para></ce:section><ce:section id="s0835"><ce:section-title id="st0785">Investigations</ce:section-title><ce:para id="p3260">The pivotal investigation is joint aspiration, followed by examination of synovial fluid using compensated polarised microscopy to demonstrate CPPD crystals (see <ce:cross-ref id="crf0825" refid="f0045">Fig. 24.6B</ce:cross-ref>, <ce:cross-ref id="crf9225" refid="s0085">p. 988</ce:cross-ref>) and to permit distinction from gout. The aspirated fluid is often turbid and may be uniformly blood-stained, reflecting the severity of inflammation. Since sepsis and pseudogout can coexist, Gram stain and culture of the fluid should be performed to exclude sepsis, even if CPPD crystals are identified in synovial fluid.</ce:para><ce:para id="p3265">X-rays of the affected joint may show evidence of calcification in hyaline cartilage and/or fibrocartilage, although absence of calcification does not exclude the diagnosis. Signs of OA are frequently present. Screening for secondary causes (<ce:cross-ref id="crf0830" refid="b0230">Box 24.45</ce:cross-ref>) should be undertaken, especially in patients who present under the age of 25 and those with polyarticular disease.</ce:para></ce:section><ce:section id="s0840"><ce:section-title id="st0790">Management</ce:section-title><ce:para id="p3270">Joint aspiration can sometimes provide symptomatic relief in pseudogout and in a few patients no further treatment is required. People with persistent symptoms can be treated with intra-articular glucocorticoids, colchicine or an NSAID. Since most patients with pseudogout are elderly, NSAIDs and colchicine must be used with caution. Early active mobilisation is also important. Chronic pyrophosphate-induced arthropathy should be managed as for OA (<ce:cross-ref id="crf9230" refid="s0690">p. 1011</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0845"><ce:section-title id="st0795">Basic calcium phosphate deposition disease</ce:section-title><ce:para id="p3275">Basic calcium phosphate (BCP) deposition disease is caused by the deposition of hydroxyapatite or apatite crystals and other basic calcium phosphate salts (octacalcium phosphate, tricalcium phosphate) in soft tissues. The main affected sites are tendons, ligaments and hyaline cartilage in patients with degenerative disease, and skeletal muscle and subcutaneous tissues in connective tissue diseases.</ce:para><ce:section id="s0850"><ce:section id="s0855"><ce:section-title id="st0800">Pathophysiology</ce:section-title><ce:para id="p3280">Under normal circumstances, inhibitors of mineralisation, such as pyrophosphate and proteoglycans, prevent calcification of soft tissues. When these protective mechanisms break down, abnormal calcification occurs. There are many causes (<ce:cross-ref id="crf0835" refid="b0235">Box 24.46</ce:cross-ref><ce:float-anchor refid="b0235"/>). In most situations calcification is of no consequence, but when the crystals are released an inflammatory reaction may be initiated, causing local pain and inflammation.</ce:para></ce:section></ce:section><ce:section id="s0860"><ce:section-title id="st0805">Calcific periarthritis</ce:section-title><ce:para id="p3290">This occurs as the result of deposition of BCP in tendons, which provokes an acute inflammatory response. The most commonly affected site is the supraspinatus tendon (<ce:cross-ref id="crf0840" refid="f0160">Fig. 24.29</ce:cross-ref><ce:float-anchor refid="f0160"/>) but other sites may also be involved, including the tendons around the hip, feet and hands. The presentation is with acute pain, swelling and local tenderness that develops rapidly over 4–6 hours. The overlying skin may be hot and red, raising the possibility of infection. Attacks sometimes occur spontaneously but can also be triggered by trauma. Modest systemic upset and fever are common. Tendon calcification may be seen on X-ray. If the affected joint or bursa is aspirated, inflammatory fluid containing many calcium-staining (alizarin red S) aggregates may be obtained. During an acute attack, there may be a neutrophilia with an elevation in ESR and CRP. Routine biochemistry is normal. Treatment is with analgesics and NSAIDs. Attacks may also respond to a local injection of glucocorticoid. The condition usually resolves spontaneously over 1–3 weeks and this is often accompanied by dispersal and disappearance of calcific deposits on X-ray. Large deposits sometimes accumulate, causing limitation of joint movement, and may require surgical removal.</ce:para></ce:section><ce:section id="s0865"><ce:section-title id="st0810">Acute inflammatory arthritis</ce:section-title><ce:para id="p3295">Deposition of BCP occurs commonly in OA, both alone and in combination with CPPD crystals, in which case it is referred to as mixed crystal deposition disease. It may present with pseudogout or be an incidental finding.</ce:para></ce:section><ce:section id="s0870"><ce:section-title id="st0815">Milwaukee shoulder syndrome</ce:section-title><ce:para id="p3300">This is a rare syndrome, in which extensive deposition of BCP crystals in large joints is associated with progressive joint destruction. It is more common in women than in men. The onset is gradual with joint pain, sometimes precipitated by injury or overuse. The disease progresses over a few months to cause severe pain and disability, associated with joint destruction. X-rays show joint space narrowing, osteophytes and calcification. Aspiration yields large volumes of relatively non-inflammatory fluid containing abundant BCP aggregates and often cartilage fragments. The differential diagnosis is end-stage avascular necrosis, chronic sepsis or neuropathic joint. There is no acute phase response and synovial fluid cultures are negative.</ce:para><ce:para id="p3305">Treatment is with analgesics, intra-articular injection of glucocorticoids, local physical treatments and physiotherapy. The clinical outcome is poor, however, and most patients require joint replacement. The cause is incompletely understood but it has been speculated that deposition of BCP crystals activates collagenase and other proteases in articular cells, which are responsible for the tissue damage.</ce:para></ce:section><ce:section id="s0875"><ce:section-title id="st0820">Autoimmune connective tissue disease</ce:section-title><ce:para id="p3310">Deposition of BCP may occur in the subcutaneous tissues and muscle of patients with systemic sclerosis and other autoimmune connective tissue diseases. Usually, the deposits are asymptomatic but they may be associated with pain and local ulceration. The mechanism by which this occurs is unclear and there is no specific treatment.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0880"><ce:section-title id="st0825">Fibromyalgia</ce:section-title><ce:para id="p3315">Fibromyalgia (FM) is a condition of generalised pain and consequent disability. It is frequently associated with medically unexplained symptoms in other systems (<ce:intra-ref id="ii0335" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0370">p. 1187</ce:intra-ref>). The prevalence in the UK and US is about 2–3%. Although FM can occur at any age, including adolescence, it increases in prevalence with age, to reach a peak of 7% in women aged over 70. There is a strong female predominance of around 10 : 1. Risk factors include life events that cause (unresolved) psychosocial distress relating to previous abuse, marital disharmony, alcoholism or illness in the family, poor sleep health, previous injury or assault, and low income. FM arises in a variety of races and cultures.</ce:para><ce:section id="s0885"><ce:section id="s0890"><ce:section id="s0895"><ce:section-title id="st0830">Pathophysiology</ce:section-title><ce:para id="p3320">The cause of FM is poorly understood but two abnormalities that may be interrelated (<ce:cross-ref id="crf0845" refid="f0165">Fig. 24.30</ce:cross-ref><ce:float-anchor refid="f0165"/>) and have been consistently reported in affected patients are disturbed, non-restorative sleep and pain sensitisation, probably caused by abnormal central pain processing.</ce:para></ce:section><ce:section id="s0900"><ce:section-title id="st0835">Clinical features</ce:section-title><ce:para id="p3325">The main presenting feature is widespread pain, which is often worst in the neck and back (<ce:cross-ref id="crf0850" refid="b0240">Box 24.47</ce:cross-ref><ce:float-anchor refid="b0240"/>). It is characteristically diffuse and unresponsive to analgesics and NSAIDs. Physiotherapy often makes FM pain worse. Fatiguability, most prominent in the morning, is another major problem and disability is often marked. Although people can usually dress, feed and groom themselves, they may be unable to perform tasks such as shopping or housework. They may have experienced major difficulties at work or may even retire because of pain and fatigue.</ce:para><ce:para id="p3410">Examination is unremarkable, apart from the presence of hyperalgesia on moderate digital pressure (enough just to whiten the nail) over multiple sites (<ce:cross-ref id="crf0855" refid="f0170">Fig. 24.31</ce:cross-ref><ce:float-anchor refid="f0170"/>).</ce:para></ce:section><ce:section id="s0920"><ce:section-title id="st0855">Investigations and management</ce:section-title><ce:para id="p3415">There are no abnormalities on routine blood tests or imaging but it is important to screen for other conditions that could account for all or some of the patient's symptoms (<ce:cross-ref id="crf0860" refid="b0245">Box 24.48</ce:cross-ref><ce:float-anchor refid="b0245"/>). Extensive imaging is not recommended but bone scintigraphy can identify many conditions that can contribute to widespread pain and is a useful ‘negative’ test.</ce:para><ce:para id="p3425">The aims of management are to educate the patient about the condition, address unresolved psychological issues, achieve pain control and improve sleep. Wherever possible, education should include the spouse, family or carer. It should be acknowledged that the cause of FM is not fully understood but the widespread pain does not reflect inflammation, tissue damage or disease. The model of a self-perpetuating cycle of poor sleep and pain (see <ce:cross-ref id="crf0865" refid="f0165">Fig. 24.30</ce:cross-ref>) is a useful framework for problem-based management. Understanding the diagnosis can often help the patient come to terms with the symptoms. Repeat or drawn-out investigation may reinforce beliefs in occult serious pathology and should be avoided.</ce:para><ce:para id="p3430">Low-dose amitriptyline (10–75 mg at night), with or without fluoxetine, may help by encouraging delta sleep and reducing spinal cord wind-up. Many people with FM, however, are intolerant of even small doses of amitriptyline. There is limited evidence for the use of tramadol, serotonin–noradrenaline (norepinephrine) re-uptake inhibitors (SNRIs) such as duloxetine, and the anticonvulsants pregabalin and gabapentin. A graded increase in aerobic exercise can improve well-being and sleep quality. The use of self-help strategies and a cognitive behavioural approach with relaxation techniques should be encouraged. Sublimated anxiety relating to distressing life events should be specifically explored with appropriate counselling. There are patient organisations that provide additional information and support. Although treatment may improve quality of life and ability to cope, most people remain symptomatic for many years.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0925"><ce:section-title id="st0860">Bone and joint infections</ce:section-title><ce:section id="s0930"><ce:section id="s0935"><ce:section-title id="st0865">Septic arthritis</ce:section-title><ce:para id="p3435">Septic arthritis is the most rapid and destructive joint disease. The incidence is 2–10 per 100 000 in the general population and 30–70 per 100 000 in those with pre-existing joint disease or joint replacement. Septic arthritis is associated with significant morbidity and still has a mortality of about 10% despite advances in antimicrobial therapy. The most important risk factor for mortality is increasing age.</ce:para><ce:section id="s0940"><ce:section-title id="st0870">Pathogenesis</ce:section-title><ce:para id="p3440">Septic arthritis usually occurs as a result of haematogenous spread from infections of the skin or upper respiratory tract; infection from direct puncture wounds or secondary to joint aspiration is uncommon. Risk factors include increasing age, pre-existing joint disease (principally RA), diabetes mellitus, immunosuppression (by drugs or disease) and intravenous drug misuse. In RA, the skin is a frequent portal of entry because of maceration of skin between the toes due to joint deformity and difficulties with foot hygiene caused by hand deformity. <ce:cross-ref id="crf0870" refid="b0250">Box 24.49</ce:cross-ref><ce:float-anchor refid="b0250"/> describes the particular considerations in old age.</ce:para></ce:section><ce:section id="s0945"><ce:section-title id="st0875">Clinical features</ce:section-title><ce:para id="p3480">The usual presentation is with acute or subacute monoarthritis and fever. The joint is usually swollen, hot and red, with pain at rest and on movement. Although any joint can be affected, lower limb joints, such as the knee and hip, are most commonly targeted. Patients with pre-existing arthritis may present with multiple joint involvement.</ce:para><ce:para id="p3485">In adults, the most likely organism is <ce:italic>Staphylococcus aureus</ce:italic>, particularly in patients with RA and diabetes. In young, sexually active adults, gonococcus may be responsible. Disseminated gonococcal infection occurs in up to 3% of patients with untreated gonorrhoea. This usually presents with migratory arthralgia, low-grade fever and tenosynovitis, which may precede the development of an oligo- or monoarthritis. Painful pustular skin lesions may also be present. Gram-negative bacilli or group B, C and G streptococci are important causes among the elderly and intravenous drug users. Less commonly, septic arthritis may be caused by group A streptococci, pneumococci, meningococci and <ce:italic>Haemophilus influenzae</ce:italic>.</ce:para></ce:section><ce:section id="s0950"><ce:section-title id="st0880">Investigations</ce:section-title><ce:para id="p3490">The pivotal investigation is joint aspiration but blood cultures should also be taken. The synovial fluid is usually turbid or blood-stained but may appear normal. If the joint is not readily accessible, aspiration should be performed under imaging guidance or in theatre. Prosthetic joints should only be aspirated in theatre.</ce:para><ce:para id="p3495">Synovial fluid should be sent for Gram stain and culture; cultures are positive in around 90% of cases but the Gram stain is positive in only 50%. In contrast, synovial fluid culture is positive in only 30% of gonococcal infections, making it important to obtain concurrent cultures from the genital tract (positive in 70–90% of cases). There is a leucocytosis with raised ESR and CRP in most patients, but these features may be absent in elderly or immunocompromised patients, or early in the disease course. Serial measurements of CRP and ESR are useful in following the response to treatment.</ce:para></ce:section><ce:section id="s0955"><ce:section-title id="st0885">Management</ce:section-title><ce:para id="p3500">The principles of management are summarised in <ce:cross-ref id="crf0875" refid="b0255">Box 24.50</ce:cross-ref><ce:float-anchor refid="b0255"/>. The patient should be admitted to hospital for pain relief and administration of parenteral antibiotics. Flucloxacillin (2 g IV 4 times daily) is the antibiotic of first choice pending the results of cultures, since it will cover most staphylococcal and streptococcal infections. If there is reason to suspect meticillin-resistant <ce:italic>Staphylococcus aureus</ce:italic> (such as a known carrier), vancomycin should be used instead while awaiting cultures. If a Gram-negative infection is suspected, gentamicin or vancomycin should be considered as first-line treatments. Cephalosporins are a potential alternative for Gram-negative infections but carry a high risk of <ce:italic>Clostridium difficile</ce:italic> infection in those aged over 65. Whatever antibiotic is chosen, the regimen may need to be changed, depending on the organism that is isolated. Microbiology advice should always be sought in complicated situations, such as when treating intravenous drug users, patients in intensive care and those who might be colonised by resistant organisms. It is traditional to continue intravenous antibiotics for 2 weeks and to follow this with oral treatment for another 4 weeks, but there is no evidence to support the optimal duration of treatment. Joint aspiration should be performed using a large-bore needle once or twice daily. If this is not possible, arthroscopic or open surgical drainage may be needed performed. Regular passive movement should be undertaken from the outset, and active movements encouraged once the condition has stabilised. Infected prosthetic joints require management by the orthopaedic team, but prolonged antibiotic treatment on its own is often ineffective and removal of the prosthesis is required for eradication of the infection.</ce:para><ce:para id="p3615">Arthritis may be a feature of Lyme disease caused by members of the <ce:italic>Borrelia</ce:italic> species of microorganisms (<ce:intra-ref id="ii0340" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1275">p. 255</ce:intra-ref>). It is generally a late manifestation, which usually affects large joints. Brucellosis presents with an acute febrile illness, followed in some cases by the development of localised infection, which can result in arthritis, bursitis, osteomyelitis, sacroiliitis and paravertebral or psoas abscesses. These conditions are discussed on <ce:intra-ref id="ii0345" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1210">pages 254</ce:intra-ref> and <ce:intra-ref id="ii0350" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1275">255</ce:intra-ref>.</ce:para></ce:section></ce:section><ce:section id="s0990"><ce:section-title id="st0915">Viral arthritis</ce:section-title><ce:para id="p3620">The usual presentation is with acute polyarthritis following a febrile illness, which may be accompanied by a rash. Most cases of viral arthritis are self-limiting and settle down within 4–6 weeks. Human parvovirus arthropathy (mainly B19; <ce:intra-ref id="ii0355" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0570">p. 237</ce:intra-ref>) is the most common in Europe; adults may not have the characteristic ‘slapped cheek’ facial rash seen in children. The diagnosis can be confirmed by a rise in specific IgM. Polyarthritis may also occur rarely with hepatitis B and C, rubella (including rubella vaccination) and HIV infection. A variety of mosquito-borne viruses may cause epidemics of acute polyarthritis, including Ross River (Australia, Pacific), Chikungunya and O'nyong-nyong (Asia, Africa), and Mayaro viruses (South America). A wide variety of articular symptoms have been associated with HIV, mainly in the later stages of infection (<ce:cross-ref id="crf0885" refid="b0260">Box 24.51</ce:cross-ref><ce:float-anchor refid="b0260"/>). Management is symptomatic, with NSAIDs and analgesics.</ce:para></ce:section><ce:section id="s0995"><ce:section-title id="st0920">Osteomyelitis</ce:section-title><ce:para id="p3630">In osteomyelitis, the primary sites of infection are bone and bone marrow. Any part of a bone may be involved but there is preferential targeting of the juxta-epiphyseal regions of long bones adjacent to joints. The risk of osteomyelitis increases with age; the incidence is about 8.8 cases per 100 000 person-years in those under 18, rising to 40.8 cases in those aged 60–69 and 88.3 cases in those above the age of 80.</ce:para><ce:section id="s1000"><ce:section-title id="st0925">Pathogenesis</ce:section-title><ce:para id="p3635">Haematogenous spread is the most common cause in children but contiguous spread of infection from adjacent soft tissues or as the result of surgery is more important in adults. Diabetes is a particularly important risk factor, accounting for about 30% of cases in recent series. Other risk factors include immunosuppressive therapy, HIV infection and sickle-cell disease, which particularly increases the risk of <ce:italic>Salmonella</ce:italic> infection. The organisms most frequently implicated are <ce:italic>Staph. aureus</ce:italic>, <ce:italic>Staph. epidermidis</ce:italic> and streptococci. The infection often results in a florid inflammatory response, with a greatly increased intraosseous pressure. If untreated, the condition may cause localised areas of osteonecrosis, leading to the development of a fragment of necrotic bone that is called a sequestrum. Eventual perforation of the cortex by pus stimulates local new bone formation (involucrum) in the periosteum, often leading to the development of sinuses that discharge through the skin.</ce:para></ce:section><ce:section id="s1005"><ce:section-title id="st0930">Clinical features</ce:section-title><ce:para id="p3640">The presentation is with localised bone pain and tenderness, often accompanied by malaise, night sweats and pyrexia. The adjacent joint may be painful to move and may develop a sterile effusion or secondary septic arthritis.</ce:para></ce:section><ce:section id="s1010"><ce:section-title id="st0935">Investigations</ce:section-title><ce:para id="p3645">Patients suspected of having osteomyelitis should have an MRI, which is more sensitive than X-ray for detecting early changes. Where possible, cultures should be obtained by open or imaging-guided biopsy of the lesion. Evidence of osteopenia, localised osteolysis and osteonecrosis may be seen on X-ray. Blood cultures should be taken, which may also reveal the causative organism. Routine bloods typically show evidence of an acute phase response with a neutrophilia and raised ESR and CRP.</ce:para></ce:section><ce:section id="s1015"><ce:section-title id="st0940">Management</ce:section-title><ce:para id="p3650">Early recognition is critical as once osteomyelitis becomes established and chronic, it may prove very hard to eradicate with antibiotics alone. The principles are those followed for septic arthritis, with parenteral antibiotics for 2 weeks, followed by oral antibiotics for at least 4 weeks. An exception is in localised osteomyelitis of the toes and fingers, which can often be treated successfully with a prolonged course of oral antibiotics. Resection of the infected bone and subsequent reconstruction may be required. Complications of chronic osteomyelitis include secondary amyloidosis (<ce:intra-ref id="ii0360" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0470">p. 81</ce:intra-ref>) and skin malignancy at the margin of a discharging sinus (Marjolin's ulcer).</ce:para></ce:section></ce:section><ce:section id="s1020"><ce:section-title id="st0945">Discitis</ce:section-title><ce:para id="p3655">Discitis is an unusual condition in which there is infection of the intervertebral disc, often extending into the epidural space or paravertebral soft tissues. <ce:italic>Staph. aureus</ce:italic> is the most common pathogen. Risk factors include diabetes mellitus, immunodeficiency or immunosuppressive therapy, and intravenous drug use. The presentation is with back pain accompanied by fever, and an acute phase response with high ESR and CRP and a neutrophilia. If the diagnosis is suspected, an MRI should be performed and blood cultures taken. If blood cultures are negative, open or imaging-guided biopsy of the lesion should be performed to try to identify the organism responsible. Management is with supportive care and parenteral antibiotics followed by oral antibiotics, as described for <ce:cross-ref id="crf0890" refid="s0995">osteomyelitis</ce:cross-ref>.</ce:para></ce:section><ce:section id="s1025"><ce:section-title id="st0950">Tuberculosis</ce:section-title><ce:para id="p3660">Tuberculosis can affect the musculoskeletal system, usually targeting the spine (Pott's disease) or large joints such as the hip, knee or ankle. The presentation is with pain, swelling and fever. The X-ray changes are non-specific and mycobacteria are seldom identified in the synovial fluid, so tissue biopsy is required for a definitive diagnosis. Medical management is described on <ce:intra-ref id="ii0365" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1140">page 592</ce:intra-ref>. In some cases, surgical débridement may be required for extensive joint disease, and spinal involvement may require surgical stabilisation and decompression.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1030"><ce:section-title id="st0955">Rheumatoid arthritis</ce:section-title><ce:para id="p3665">Rheumatoid arthritis (RA) is a common form of inflammatory arthritis, occurring throughout the world and in all ethnic groups. The prevalence of RA is approximately 0.8–1.0% in Europe and the Indian subcontinent, with a female-to-male ratio of 3 : 1. The prevalence is lower in South-east Asia (0.4%). The highest prevalence in the world is in Pima Indians (5%). It is a chronic disease characterised by a clinical course of exacerbations and remissions.</ce:para><ce:section id="s1035"><ce:section id="s1040"><ce:section id="s1045"><ce:section-title id="st0960">Pathophysiology</ce:section-title><ce:para id="p3670">RA is a complex disease with both genetic and environmental components. The importance of genetic factors is demonstrated by higher concordance of RA in monozygotic (12–15%) compared with dizygotic twins (3%), and an increased frequency of disease in first-degree relatives of patients. Genome-wide association studies have detected nearly 100 loci that are associated with the risk of developing RA. The strongest association is with variants in the HLA region. Recent studies have shown that the association with HLA is determined by variations in three amino acids in the HLA-DRβ1 molecule (positions 11, 71 and 74) and single variants HLA-B (at position 9) and HLA-DPβ1 (at position 9). The non-HLA loci generally lie within or close to genes involved in regulating the immune response. It is currently believed that RA occurs when an environmental stimulus, such as infection, triggers autoimmunity in a genetically susceptible host by modifying host proteins through processes like citrullination so that they become immunogenic. However, no single specific pathogen has been identified as a cause. An important environmental risk factor is cigarette smoking, which is also associated with more severe disease and reduced responsiveness to treatment. Remission may occur during pregnancy and sometimes RA first presents post-partum. This is likely to be due to suppression of the immune response during pregnancy but hormonal changes may also play a role.</ce:para><ce:para id="p3675">The disease is characterised by infiltration of the synovial membrane with lymphocytes, plasma cells, dendritic cells and macrophages. There is evidence that CD4<ce:sup loc="post">+</ce:sup> T lymphocytes and B cells play important roles in the pathogenesis of RA by interacting with other cells in the synovium, as illustrated in <ce:cross-ref id="crf0895" refid="f0175">Figure 24.32</ce:cross-ref><ce:float-anchor refid="f0175"/>. Lymphoid follicles form within the synovial membrane in which T- and B-cell interactions occur, causing activation of T cells to produce cytokines and activation of B cells to produce autoantibodies, including RF and ACPA. Synovial macrophages are activated by TNF and interferon gamma (IFN-γ), produced by T cells. The macrophages produce several pro-inflammatory cytokines, including TNF, IL-1 and IL-6, which act on synovial fibroblasts to produce further cytokines, setting up a positive feedback loop. The synovial fibroblasts proliferate, causing synovial hypertrophy and producing matrix metalloproteinases and the proteinase ADAMTS-5, which degrade soft tissues and cartilage. Prostaglandins and nitric oxide produced within the inflamed synovium cause vasodilatation, resulting in swelling and pain. Systemic release of IL-6 triggers production of acute phase proteins by the liver. At the joint margin, the inflamed synovium (pannus) directly invades bone and cartilage to cause joint erosions. A key pathogenic factor in bone erosions and periarticular osteoporosis is osteoclast activation, stimulated by the production of M-CSF by synovial cells and RANKL by activated T cells (<ce:cross-ref id="crf0900" refid="f0175">Fig. 24.32</ce:cross-ref>). New blood-vessel formation (angiogenesis) occurs, causing the inflamed synovium to become highly vascular. Within these blood vessels, pro-inflammatory cytokines activate endothelial cells, which support recruitment of yet more leucocytes to perpetuate the inflammatory process.</ce:para><ce:para id="p3680">Later, fibrous or bony ankylosis may occur. Muscles adjacent to inflamed joints atrophy and may be infiltrated with lymphocytes. This leads to progressive biomechanical dysfunction and may further amplify destruction.</ce:para><ce:para id="p3685">Rheumatoid nodules occur in patients who are RF- or ACPA-positive and primarily affect extensor tendons. They consist of a central area of fibrinoid material surrounded by a palisade of proliferating mononuclear cells. Granulomatous lesions may occur in the pleura, lung, pericardium and sclera.</ce:para></ce:section><ce:section id="s1050"><ce:section-title id="st0965">Clinical features</ce:section-title><ce:para id="p3690">The typical presentation is with pain, joint swelling and stiffness affecting the small joints of the hands, feet and wrists in a symmetrical fashion. Large joint involvement, systemic symptoms and extra-articular features may also occur. Clinical criteria for the diagnosis of RA are shown in <ce:cross-ref id="crf0905" refid="b0265">Box 24.52</ce:cross-ref><ce:float-anchor refid="b0265"/>.</ce:para><ce:para id="p3705">Sometimes RA has an acute onset, with severe early morning stiffness, polyarthritis and pitting oedema. This occurs more commonly in old age. Another presentation is with proximal muscle stiffness mimicking polymyalgia rheumatica (<ce:cross-ref id="crf9235" refid="s1555">p. 1042</ce:cross-ref>). Occasionally, the onset is palindromic, with relapsing and remitting episodes of pain, stiffness and swelling that last for only a few hours or days.</ce:para><ce:para id="p3710">Examination typically reveals swelling and tenderness of the affected joints. Erythema is unusual and its presence suggests coexistent sepsis. Characteristic deformities may develop with long-standing uncontrolled disease, although these have become less common over recent years with more aggressive management. They include ulnar deviation of the fingers, ‘swan neck’ deformity, the boutonnière or ‘button hole’ deformity, and a Z deformity of the thumb (<ce:cross-ref id="crf0915" refid="f0180">Fig. 24.33</ce:cross-ref><ce:float-anchor refid="f0180"/>). Dorsal subluxation of the ulna at the distal radio-ulnar joint may occur and contribute to rupture of the fourth and fifth extensor tendons. Triggering of fingers may occur because of nodules in the flexor tendon sheaths. Subluxation of the MTP joints of the feet may result in ‘cock-up’ toe deformities, causing pain on weight-bearing on the exposed MTP heads and the development of secondary adventitious bursae and callosities. In the hindfoot, a valgus deformity of the calcaneus may be observed as the result of damage to the ankle and subtalar joints. This is often associated with loss of the longitudinal arch (flat foot) due to rupture of the tibialis posterior tendon. Popliteal (Baker's) cysts may occur in patients with knee synovitis, in which synovial fluid communicates with the cyst but is prevented from returning to the joint by a valve-like mechanism; this is not specific to RA. Rupture may be induced by knee flexion, leading to calf pain and swelling that may mimic a deep venous thrombosis (DVT). These joint deformities tend to be observed in older patients with long-standing disease but are becoming much less common with more aggressive treatment of RA in its early stages.</ce:para><ce:section id="s1055"><ce:section-title id="st0970">Systemic features</ce:section-title><ce:para id="p3715">Anorexia, weight loss and fatigue may occur throughout the disease course. Osteoporosis is a common complication (<ce:cross-ref id="crf9240" refid="p5510">p. 1044</ce:cross-ref>) and muscle-wasting may occur as the result of systemic inflammation and reduced activity. Extra-articular features are most common in patients with long-standing seropositive erosive disease but may occasionally occur at presentation, especially in men. Most are due to serositis, granuloma and nodule formation or vasculitis (<ce:cross-ref id="crf0920" refid="b0270">Box 24.53</ce:cross-ref><ce:float-anchor refid="b0270"/>).</ce:para></ce:section><ce:section id="s1060"><ce:section-title id="st0975">Nodules</ce:section-title><ce:para id="p3920">Rheumatoid nodules occur almost exclusively in RF- or ACPA-positive patients, usually in extensor tendons (<ce:cross-ref id="crf0930" refid="f0185">Fig. 24.34</ce:cross-ref><ce:float-anchor refid="f0185"/>). They are frequently asymptomatic but some may be complicated by ulceration and secondary infection.</ce:para></ce:section><ce:section id="s1065"><ce:section-title id="st0980">Vasculitis</ce:section-title><ce:para id="p3925">This is uncommon but may occur in seropositive patients. The presentation is with systemic symptoms, such as fatigue and fever and nail-fold infarcts. Rarely, cutaneous ulceration, skin necrosis and mesenteric, renal or coronary artery occlusion may occur.</ce:para></ce:section><ce:section id="s1070"><ce:section-title id="st0985">Ocular involvement</ce:section-title><ce:para id="p3930">The most common symptom is dry eyes (keratoconjunctivitis sicca) due to secondary Sjögren's syndrome (<ce:cross-ref id="crf9245" refid="p4940">p. 1038</ce:cross-ref>). Scleritis and peripheral ulcerative keratitis are uncommon but more serious and potentially sight-threatening complications that usually present with pain and redness. Clinical features and management are discussed in more detail on <ce:intra-ref id="ii0395" xlink:href="pii:B978-0-7020-7028-0.00027-5#s0300">page 1172</ce:intra-ref>.</ce:para></ce:section><ce:section id="s1075"><ce:section-title id="st0990">Serositis</ce:section-title><ce:para id="p3935">Serositis is usually asymptomatic but may present with pleural or pericardial pain and breathlessness. Pericardial effusion and constrictive pericarditis may rarely occur.</ce:para></ce:section><ce:section id="s1080"><ce:section-title id="st0995">Cardiac involvement</ce:section-title><ce:para id="p3940">Heart block, cardiomyopathy, coronary artery occlusion and aortic regurgitation have all been reported but are rare. The risk of cardiovascular disease is increased due to a combination of conventional risk factors, such as high cholesterol, smoking, hypertension, reduced physical activity, NSAIDs, glucocorticoids and the effects of inflammatory cytokines on vascular endothelium.</ce:para></ce:section><ce:section id="s1085"><ce:section-title id="st1000">Pulmonary involvement</ce:section-title><ce:para id="p3945">Pulmonary fibrosis may occur but is often asymptomatic. There is some evidence that the risk of pulmonary fibrosis is increased by anti-TNF therapy, although its uncertain whether this is causal or a marker of more severe disease in patients who require anti-TNF treatment.</ce:para></ce:section><ce:section id="s1090"><ce:section-title id="st1005">Peripheral neuropathy</ce:section-title><ce:para id="p3950">Entrapment neuropathies may result from compression by hypertrophied synovium or by joint subluxation. Median nerve compression is the most common and bilateral carpal tunnel syndrome can occur as a presenting feature of RA. Other syndromes include ulnar nerve compression at the elbow or wrist, compression of the lateral popliteal nerve at the head of the fibula, and tarsal tunnel syndrome (entrapment of the posterior tibial nerve in the flexor retinaculum), which causes burning, tingling and numbness in the distal sole and toes. Diffuse symmetrical peripheral neuropathy and mononeuritis multiplex may occur in patients with rheumatoid vasculitis.</ce:para></ce:section><ce:section id="s1095"><ce:section-title id="st1010">Spinal cord compression</ce:section-title><ce:para id="p3955">This rare complication is caused by compression of the spinal cord from subluxation of the cervical spine at the atlanto-axial joint or at a subaxial level (<ce:cross-ref id="crf0935" refid="f0190">Fig. 24.35</ce:cross-ref><ce:float-anchor refid="f0190"/>). Atlanto-axial subluxation is due to erosion of the transverse ligament posterior to the odontoid peg. It can lead to cord compression or sudden death following minor trauma or manipulation. It should be suspected in any RA patient who describes new onset of occipital headache, particularly if symptoms of paraesthesia or electric shock are present in the arms. The onset is often insidious, with subtle loss of function that may initially be attributed to active disease. Reflexes and power can be difficult to assess in patients with extensive joint disease and therefore sensory or upper motor signs are most important. Patients with evidence of spinal cord compression require urgent neurosurgical referral for stabilisation and fixation.</ce:para></ce:section><ce:section id="s1100"><ce:section-title id="st1015">Other complications</ce:section-title><ce:para id="p3960">Amyloidosis is a rare complication of long-standing disease that usually presents with nephrotic syndrome. Microcytic anaemia can occur due to iron deficiency resulting from NSAID-induced gastrointestinal blood loss, whereas normochromic, normocytic anaemia with thrombocytosis occurs in patients with active disease. Felty's syndrome is a rare complication of seropositive RA in which splenomegaly occurs in combination with neutropenia and thrombocytopenia (<ce:cross-ref id="crf0940" refid="b0275">Box 24.54</ce:cross-ref><ce:float-anchor refid="b0275"/>). Localised or generalised lymphadenopathy can occur in patients with active disease but persistent lymphadenopathy may indicate the development of lymphoma, which is more common in patients with long-standing RA.</ce:para></ce:section></ce:section><ce:section id="s1105"><ce:section-title id="st1020">Investigations</ce:section-title><ce:para id="p4065">The diagnosis of RA is essentially clinical but investigations are useful in confirming the diagnosis and assessing disease activity (<ce:cross-ref id="crf0945" refid="b0280">Box 24.55</ce:cross-ref><ce:float-anchor refid="b0280"/>). The ESR and CRP are usually raised but normal results do not exclude the diagnosis, especially if only a few joints are involved. Tests for ACPA are positive in about 70% of cases and are highly specific for RA, occurring in many patients before clinical onset of the disease. Similarly, RF is also positive in about 70% of cases, most of whom also test positive for ACPA. RF is less specific than ACPA, however, and positive tests can occur in other diseases (<ce:cross-ref id="crf9250" refid="p0760">p. 991</ce:cross-ref>).</ce:para><ce:para id="p4160">Ultrasound examination and MRI are not routinely required but can be value in patients with symptoms suggestive of RA where there is clinical uncertainty about the presence of synovitis. Plain X-rays of the hands, wrist and feet are usually normal in early RA but periarticular osteoporosis and marginal joint erosions may be observed with more advanced disease. The main indication for an X-ray is in the assessment of patients with painful joints to determine whether significant structural damage has occurred. Patients who are suspected of having atlanto-axial disease should have lateral X-rays taken in flexion and extension, and an MRI. In those with suspected Baker's cyst, ultrasound may be required to establish the diagnosis.</ce:para><ce:para id="p4165">DAS28 is widely used to assess disease activity, response to treatment and need for biological therapy. It involves counting the number of swollen and tender joints in the upper limbs and knees, and combining this with the ESR and the patient's assessment of the activity of their arthritis on a visual analogue scale, where 0 indicates no symptoms and 100 the worst symptoms possible. This data are entered into a calculator to generate a numerical score. The higher the value, the more active the disease (<ce:cross-ref id="crf0955" refid="f0195">Fig. 24.36</ce:cross-ref><ce:float-anchor refid="f0195"/>).</ce:para></ce:section><ce:section id="s1110"><ce:section-title id="st1025">Management</ce:section-title><ce:para id="p4170">The treatment goal is to suppress inflammation, control symptoms and prevent joint damage. This involves a combination of pharmacological and non-pharmacological therapies. When RA occurs in women of child-bearing age, additional considerations need to be taken into account and these are summarised in <ce:cross-ref id="crf0960" refid="b0285">Box 24.56</ce:cross-ref><ce:float-anchor refid="b0285"/>.</ce:para><ce:section id="s1115"><ce:section-title id="st1030">Pharmacological therapy</ce:section-title><ce:para id="p4225">DMARD therapy should be introduced in all patients as this improves outcome. A typical algorithm is shown in <ce:cross-ref id="crf0965" refid="f0200">Figure 24.37</ce:cross-ref><ce:float-anchor refid="f0200"/>. On first diagnosis, prednisolone should be started in a dose of 30 mg daily gradually reducing in 5 mg increments every 2 weeks until therapy is withdrawn after about 12 weeks. At the same time, methotrexate should be started in an initial dose of 15 mg weekly, along with folic acid 5 mg weekly, and escalated up to a maximum of 25 mg weekly, depending on the response. If the patient fails to respond adequately or dose-limiting toxicity occurs, then an additional DMARD should be commenced in combination with MTX. The most common combination is triple therapy, in which methotrexate, sulfasalazine and hydroxychloroquine are combined (<ce:cross-ref id="crf0970" refid="f0200">Fig. 24.37</ce:cross-ref>). Other DMARDs can be substituted or added, along with a low-dose glucocorticoid such as prednisolone (5–10 mg daily) if the patient fails to respond fully. If disease activity remains high (DAS28 &#x003E; 5.1) despite triple therapy, however, it is usual to progress to biologic therapy. The most commonly used first-line biologics in RA are TNF inhibitors, although several other options are available (<ce:cross-ref id="crf9255" refid="s0560">p. 1006</ce:cross-ref>). When the patient has been stabilised on biologic treatment for 12 months or more, a reduction in dose should be considered, since it is possible to reduce the dose in up to 50% of patients without loss of therapeutic effect. The JAK inhibitors tofacitinib and baricitinib have efficacy in patients who fail to respond adequately to other DMARDs and provide an alternative to biologic therapies.</ce:para><ce:para id="p4230">RA is a chronic disease and flares can occur even in patients who are established on DMARD and biologic therapy. Transient flares can be dealt with by intra-articular glucocorticoid injections or a short course of oral glucocorticoids, but if a sustained flare occurs, a change in systemic DMARD and/or biologic therapy may need to be considered.</ce:para></ce:section><ce:section id="s1120"><ce:section-title id="st1035">Non-pharmacological therapy</ce:section-title><ce:para id="p4235">Physical and occupational therapy play important roles and it is vital for all patients to be assessed by an occupational therapist and physiotherapist and the appropriate advice and treatment provided.</ce:para></ce:section><ce:section id="s1125"><ce:section-title id="st1040">Surgery</ce:section-title><ce:para id="p4240">Synovectomy can be helpful in joints that have failed to respond adequately to systemic therapy and intra-articular injections. Joint replacement surgery may be required but the need for this has diminished over recent years, presumably as the result of more aggressive medical management. Other surgical procedures that can be helpful are excision of the metatarsal heads in patients with subluxation of the MTP joints; neurosurgery in patients with atlanto-axial subluxation; and fusion or the wrist or ankle in patients with joint damage (see <ce:cross-ref id="crf0975" refid="b0150">Box 24.29</ce:cross-ref>, <ce:cross-ref id="crf9260" refid="s0465">p. 1002</ce:cross-ref>).</ce:para></ce:section></ce:section></ce:section></ce:section></ce:section><ce:section id="s1130"><ce:section-title id="st1045">Juvenile idiopathic arthritis</ce:section-title><ce:para id="p4245">Juvenile idiopathic arthritis (JIA) is the term, accepted by the international community, for several forms of arthritis defined by the International League of Associations for Rheumatology 2001 criteria (<ce:cross-ref id="crf0980" refid="b0290">Box 24.57</ce:cross-ref><ce:float-anchor refid="b0290"/>). This includes juvenile forms of psoriatic arthritis (JPsA), rheumatoid arthritis (JRA) and more undifferentiated forms of inflammatory arthritis. The majority of patients with JIA have a phenotype that is distinct from adult inflammatory arthritis and includes a strong association with uveitis. JIA affects about 1 : 1000 children and young people up to 16 years of age – similar to the prevalence of diabetes (1 : 700). The annual incidence is approximately 1 per 10 000 children and young people.</ce:para><ce:para id="p4255">Whereas joint restriction is attributed to damage in adults, in children it indicates inflammatory activity. Arthritis in children affects limb growth and has a negative effect on height and weight attainment. In young children, effective disease control can repair joint damage before puberty.</ce:para><ce:para id="p4260">Oligoarthritis is the most common form of JIA, accounting for about 60% of cases. It is more common in females and tends to affect large joints in an asymmetrical pattern. There is an association with uveitis and many patients are ANA-positive. Polyarticular JIA is heterogeneous: some patients are RF- and/or ACPA-positive, while others are negative for autoantibodies.</ce:para><ce:para id="p4265">Systemic juvenile idiopathic arthritis (sJIA, formerly known as Still's disease) is characterised by fever, rash, arthritis, hepatosplenomegaly and serositis in association with anaemia and a raised ESR and CRP. Autoantibody tests are negative. This form of JIA is associated with haemophagocytic syndrome.</ce:para><ce:para id="p4270">Many cases of enthesitis-related arthritis (ERA) are likely to be self-limiting forms of spondyloarthritis. ERA can progress over time into a more obviously defined spondyloarthropathy.</ce:para><ce:section id="s1135"><ce:section id="s1140"><ce:section id="s1145"><ce:section-title id="st1050">Investigations</ce:section-title><ce:para id="p4275">ESR and CRP do not correlate well with the extent or severity of inflammation and may be normal. A very high ESR may indicate the presence of inflammatory bowel disease or (very rarely) leukaemia. Low haemoglobin is likely to be due to anaemia of chronic disease rather than iron deficiency. A positive ANA occurs in 40–75% of cases of JIA and indicates an increased risk of eye disease. Ultrasound is the radiological investigation of choice to confirm synovitis or tenosynovitis. The false-negative rate is higher in foot and ankle disease than in other joints. Arthroscopy should be avoided unless a biopsy is required. Synovial fluid aspiration, but not arthroscopy, is essential when considering sepsis and tuberculosis.</ce:para></ce:section><ce:section id="s1150"><ce:section-title id="st1055">Management</ce:section-title><ce:para id="p4280">The key approach is to gain early rapid control of inflammation, minimise the adverse effects of treatment and support the general physical and mental health of the patient, which requires full multidisciplinary team input. The standard immunotherapy is methotrexate (subcutaneous methotrexate is typically used in the young child). Alternative treatment includes leflunomide, sulfasalazine and hydroxychloroquine. Azathioprine and ciclosporin can be used to treat JIA with uveitis. Mycophenolate and tacrolimus are considered to have a specific role in treating uveitis alone. Drug combinations are not well studied in JIA. Biologic therapies, including anti-TNF, are effective in JIA and are now a standard treatment in the presence of refractory disease or intolerance of methotrexate or other non-biologic immunotherapies. Tocilizumab is also effective in sJIA, and has been approved by NICE for use in the UK.</ce:para></ce:section><ce:section id="s1155"><ce:section-title id="st1060">Prognosis</ce:section-title><ce:para id="p4285">Suboptimal outcomes are associated with delayed diagnosis and referral to the specialist multidisciplinary team, inadequate disease control, presentation with uveitis, sJIA in males and poor engagement with services. Psychological support of affected children and their families is associated with improved outcome. Oligo-JIA often resolves at puberty. Polyarticular disease and sJIA remain active into adulthood in about 50% of cases. Common issues around the transition of adolescent patients into adulthood are shown in <ce:cross-ref id="crf0985" refid="b0295">Box 24.58</ce:cross-ref><ce:float-anchor refid="b0295"/>.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1160"><ce:section-title id="st1065">Spondyloarthropathies</ce:section-title><ce:para id="p4320">Spondyloarthropathies (SpAs) comprise a group of related inflammatory musculoskeletal diseases that show overlap in their clinical features and have a shared immunogenetic association with HLA-B27 (<ce:cross-ref id="crf0990" refid="b0300">Box 24.59</ce:cross-ref><ce:float-anchor refid="b0300"/>). They include:<ce:list id="ulist0760"><ce:list-item id="u2665"><ce:label>•</ce:label><ce:para id="p4390">axial spondyloarthritis</ce:para></ce:list-item><ce:list-item id="u2670"><ce:label>•</ce:label><ce:para id="p4395">ankylosing spondylitis</ce:para></ce:list-item><ce:list-item id="u2675"><ce:label>•</ce:label><ce:para id="p4400">reactive arthritis</ce:para></ce:list-item><ce:list-item id="u2680"><ce:label>•</ce:label><ce:para id="p4405">psoriatic arthritis</ce:para></ce:list-item><ce:list-item id="u2685"><ce:label>•</ce:label><ce:para id="p4410">arthritis with inflammatory bowel disease (enteropathic spondyloarthritis).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4415">In axial spondylitis and ankylosing spondylitis, the axial skeleton (i.e. the central core skeleton) is predominantly affected. In contrast to RA, in the SpAs there are frequent and notable non-synovial musculoskeletal lesions – mainly inflammatory in nature – of ligaments, tendons, periosteum and other bone lesions. A hallmark lesion of all SpAs is enthesitis, which is inflammation at the site of a ligament or tendon insertion into bone. Dactylitis, inflammation of a whole finger or toe, may also occur (see <ce:cross-ref id="crf0995" refid="f0230">Fig. 24.43</ce:cross-ref>).</ce:para><ce:para id="p4420">It has been estimated that about 1% of the adult population in the USA may have an SpA (about 2.7 million). There is a striking association with HLA-B27, particularly for ankylosing spondylitis (&#x003E; 95%). Additionally, SpAs are thought to arise as the result of an aberrant host response to infection and abnormal mucosal immunity mediated through changes in the IL-12, IL-23 and Th17 axis (<ce:intra-ref id="ii0425" xlink:href="pii:B978-0-7020-7028-0.00004-4#f0020">p. 65</ce:intra-ref>). In some situations, a triggering organism can be identified, as in reactive arthritis following bacterial dysentery or chlamydial urethritis, but in others the environmental trigger remains obscure. Familial clustering not only is common to the specific condition occurring in the proband, but also may extend to other diseases in the spondyloarthropathy group.</ce:para><ce:section id="s1165"><ce:section-title id="st1070">Axial spondyloarthropathy</ce:section-title><ce:para id="p4425">Axial spondyloarthropathy includes classical ankylosing spondylitis (AS) as well as axial spondyloarthritis (axSpA). Inflammatory changes in the entire axial skeleton are characteristic of axSpA and can be visualised by MRI; structural alterations, such as new bone formation with syndesmophytes and ankylosis, develop later in the course of the disease. Accordingly, the criteria for diagnosing AS (<ce:cross-ref id="crf1000" refid="b0305">Box 24.60</ce:cross-ref><ce:float-anchor refid="b0305"/>), which require evidence of sacroiliitis on X-ray, are often only able to be applied many years after a patient's symptoms started. Not all patients with axSpA will go on to develop AS.</ce:para><ce:section id="s1170"><ce:section id="s1175"><ce:section-title id="st1075">Pathophysiology</ce:section-title><ce:para id="p4460">Axial SpA and AS arise from an interaction between environmental pathogens and the host immune system in genetically susceptible individuals. Increased faecal carriage of <ce:italic>Klebsiella aerogenes</ce:italic> has been reported in patients with established AS and may relate to exacerbation of both joint and eye disease. There is increasing evidence that axSpA and AS are due to an abnormal host response to the intestinal microbiota with involvement of Th17 cells, which have a key role in mucosal immunity. This leads to production of various inflammatory cytokines, including IL-12, IL-23, IL-17 and TNF-α, which play vital roles in the pathogenesis of enthesitis and other inflammatory lesions (<ce:cross-ref id="crf1005" refid="f0205">Fig. 24.38</ce:cross-ref><ce:float-anchor refid="f0205"/>).</ce:para><ce:para id="p4465">There a strong association between axial spondyloarthropathy and carriage of the major histocompatibility complex (MHC) class I molecule HLA-B27. This is particularly striking in patients defined as having AS, more than 95% of whom are positive for HLA-B27. Other susceptibility genes also implicated in susceptibility to AS include <ce:italic>ERAP-1</ce:italic> (an endoplasmic reticulum protein with a role facilitating intracellular antigen processing and binding with its presenting MHC molecule HLA-B27), the IL-23 receptor and downstream signalling molecules involved in directing Th17 cell responses, such as <ce:italic>STAT3</ce:italic> (see <ce:intra-ref id="ii0430" xlink:href="pii:B978-0-7020-7028-0.00004-4#f0020">Fig. 4.3</ce:intra-ref>, <ce:intra-ref id="ii0435" xlink:href="pii:B978-0-7020-7028-0.00004-4#f0020">p. 65</ce:intra-ref>). The HLA-B27 molecule itself is implicated through its antigen-presenting function or because of its propensity to form homodimers that activate leucocytes. HLA-B27 molecules may also misfold, causing increased endoplasmic reticulum stress. This could lead to inflammatory cytokine release by macrophages and dendritic cells, thus triggering inflammatory disease.</ce:para></ce:section></ce:section><ce:section id="s1180"><ce:section-title id="st1080">Axial spondyloarthritis</ce:section-title><ce:section id="s1185"><ce:section-title id="st1085">Clinical features</ce:section-title><ce:para id="p4470">The cardinal feature of axSpA is inflammatory back pain and early morning stiffness, with low back pain radiating to the buttocks or posterior thighs if the sacroiliac joints are involved. Symptoms are exacerbated by inactivity and relieved by movement. Musculoskeletal symptoms may be prominent at entheses, may be episodic and, if persistent, can present as widespread pain and be mistaken for fibromyalgia. Fatigue is common. A history of psoriasis (current, previous or in a first-degree relative) and inflammatory bowel symptoms (current or previous) are important clues. Physical signs include a reduced range of lumbar spine movements in all directions, pain on sacroiliac stressing and a high enthesitis index. Entheses that are typically affected include Achilles' insertion, plantar fascia origin, patellar ligament entheses, gluteus medius insertion at the greater trochanter and tendon attachments at humeral epicondyles. A number of validated clinical questionnaires, such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP), can be used to assess disease activity and functional status in AS, though newer assessment tools are being developed that are more specific to a diagnosis of axSpA, such as the Assessment of Spondyloarthritis International Society Health Index (ASAS-H).</ce:para></ce:section><ce:section id="s1190"><ce:section-title id="st1090">Investigations</ce:section-title><ce:para id="p4475">The diagnosis is aided by ultrasound or MRI of entheses, or by MRI of the sacroiliac joints and spine (<ce:cross-ref id="crf9005" refid="f0210">Fig. 24.39</ce:cross-ref><ce:float-anchor refid="f0210"/>). Other findings may include raised ESR and CRP (although these can be normal), anaemia and positive HLA-B27. Faecal calprotectin is a useful screening test for associated inflammatory bowel disease.</ce:para></ce:section><ce:section id="s1195"><ce:section-title id="st1095">Management</ce:section-title><ce:para id="p4480">Patient education, NSAID use (optimally, once daily or slow release taken at bedtime) and physical therapy are key interventions at the outset. For severe and/or persistent peripheral musculoskeletal features of SpA, both sulfasalazine and methotrexate are reasonable therapy choices. These medications have no impact on spinal symptoms or disease progression. In patients who fail to respond adequately or who cannot tolerate NSAIDs, progression to biologic therapy with either TNF inhibitors or the IL-17A inhibitor secukinumab should be considered (see <ce:cross-ref id="crf1015" refid="b0180">Box 24.35</ce:cross-ref>, <ce:cross-ref id="crf9265" refid="s0580">p. 1007</ce:cross-ref>). Anti-TNF therapy is effective for both the axial and peripheral lesions of axSpA, but it is as yet unclear whether anti-TNF therapy modifies the natural history of the disease.</ce:para></ce:section><ce:section id="s1200"><ce:section-title id="st1100">Prognosis</ce:section-title><ce:para id="p4485">With such a recent definition of disease, the markers of prognosis in patients diagnosed with axSpA are not fully understood. It is clear that axSpA can remain mild and/or episodic in many patients for many years. HLA-B27 positivity, high persistent CRP and high functional incapacity are likely to be markers of poor prognosis, if not markers of extension ultimately to AS.</ce:para></ce:section></ce:section><ce:section id="s1205"><ce:section-title id="st1105">Ankylosing spondylitis</ce:section-title><ce:para id="p4490">Ankylosing spondylitis (AS) is defined by the presence of sacroiliitis on X-ray and other structural changes on spine X-rays, which may eventually progress to bony fusion of the spine. There is a male-to-female ratio of about 3 : 1. In Europe, more than 90% of those affected are HLA-B27-positive (Caucasian HLA-B27 population prevalence is 9%). The overall prevalence of AS is below 0.5% in most populations. Over 75% of patients are able to remain in employment and enjoy a good quality of life. Even if severe ankylosis develops, functional limitation may not be marked, as long as the spine is fused in an erect posture.</ce:para><ce:section id="s1210"><ce:section-title id="st1110">Clinical features</ce:section-title><ce:para id="p4495">Clinical features are the same as in axSpA. AS typically evolves slowly, with fluctuating symptoms of spinal inflammation; ankylosis develops in many patients over a period of many years. Secondary osteoporosis of the vertebral bodies frequently occurs, leading to an increased risk of vertebral fracture.</ce:para><ce:para id="p4500">In AS, spinal fusion varies in its extent and in most cases does not cause a gross flexion deformity, but a few patients develop marked kyphosis of the dorsal and cervical spine that may interfere with forward vision. This may prove incapacitating, especially when associated with fixed flexion contractures of hips or knees.</ce:para><ce:para id="p4505">Up to 40% of patients also have peripheral musculoskeletal lesions (asymmetrical, affecting entheses of large joints, such as the hips, knees, ankles and shoulders).</ce:para><ce:para id="p4510">Fatigue is a major complaint and is common to all SpAs, but its cause is unknown. Acute anterior uveitis is the most common extra-articular feature, which occasionally precedes joint disease. Other extra-articular features are occasionally observed but are rare (<ce:cross-ref id="crf1020" refid="b0310">Box 24.61</ce:cross-ref><ce:float-anchor refid="b0310"/>).</ce:para></ce:section><ce:section id="s1215"><ce:section-title id="st1115">Investigations</ce:section-title><ce:para id="p4560">In AS, X-rays of the sacroiliac joint show irregularity and loss of cortical margins, widening of the joint space and subsequently sclerosis, joint space narrowing and fusion. Lateral thoracolumbar spine X-rays may show anterior ‘squaring’ of vertebrae due to erosion and sclerosis of the anterior corners and periostitis of the waist. Bridging syndesmophytes may also be seen. These are areas of calcification that follow the outermost fibres of the annulus (<ce:cross-ref id="crf1025" refid="f0215">Fig. 24.40</ce:cross-ref><ce:float-anchor refid="f0215"/>). In advanced disease, ossification of the anterior longitudinal ligament and facet joint fusion may also be visible. The combination of these features may result in the typical ‘bamboo’ spine (<ce:cross-ref id="crf1030" refid="f0220">Fig. 24.41</ce:cross-ref><ce:float-anchor refid="f0220"/>). Erosive changes may be seen in the symphysis pubis, ischial tuberosities and peripheral joints. Osteoporosis is common and vertebral fractures may occur. Atlanto-axial dislocation can arise as a late feature. MRI is more sensitive for detection of early sacroiliitis than X-rays (see <ce:cross-ref id="crf1035" refid="f0210">Fig. 24.39</ce:cross-ref>) and can also detect inflammatory changes in the lumbar spine. DXA scanning is important as part of a fragility fracture assessment.</ce:para><ce:para id="p4565">As in axSpA, ESR and CRP are usually raised in active disease but may be normal; anaemia is often present. Autoantibodies, such as RF, ACPA and ANA, are negative.</ce:para></ce:section><ce:section id="s1220"><ce:section-title id="st1120">Management</ce:section-title><ce:para id="p4570">The aims of management are the same as in axSpA: to relieve pain and stiffness, maintain a maximal range of skeletal mobility and avoid the development of deformities. Mobilising exercises are important and are shown on many online resource sites (e.g. National Ankylosing Spondylitis Society, UK). A long-acting NSAID at night is helpful for alleviation of morning stiffness. Anti-TNF or anti-IL-17A therapy should be considered in patients who are inadequately controlled on standard therapy, as described for axSpA. Biologic therapies are often highly effective at improving symptoms but it is not clear whether they prevent ankylosis or alter the natural history of the disease.</ce:para><ce:para id="p4575">Local glucocorticoid injections can be useful for persistent plantar fasciitis, other enthesopathies and peripheral arthritis. Oral glucocorticoids may be required for acute uveitis but do not help spinal disease. Severe hip, knee or shoulder arthritis with secondary OA may require arthroplasty. Spinal osteotomy, to correct stoop and make eyeline/posture ‘more normal’, can make a significant difference to patients with severe ankylosed kyphotic spines.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1225"><ce:section-title id="st1125">Reactive arthritis</ce:section-title><ce:para id="p4580">Reactive (spondylo)arthritis (ReA) is a ‘reaction’ to a number of bacterial triggers with clinical features in keeping with all SpA conditions. The known triggers are <ce:italic>Chlamydia</ce:italic>, <ce:italic>Campylobacter</ce:italic>, <ce:italic>Salmonella</ce:italic>, <ce:italic>Shigella</ce:italic> and <ce:italic>Yersinia</ce:italic>. Notably, non-SpA-related reactive arthritis can occur following infection with many viruses, <ce:italic>Mycoplasma</ce:italic>, <ce:italic>Borrelia</ce:italic>, streptococci and mycobacteria, including <ce:italic>M. leprae</ce:italic>, which causes leprosy (Hansen's disease); however, the ‘reaction’ in these instances consists typically of myoarthralgias, is not associated with HLA-B27 and is generally not chronic. The arthritis associated with rheumatic fever (<ce:intra-ref id="ii0445" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1965">p. 515</ce:intra-ref>) is also an example of a reactive arthritis that is not associated with HLA-B27.</ce:para><ce:para id="p4585">Sexually acquired reactive arthritis (SARA) is predominantly a disease of young men, with a male preponderance of 15 : 1. This may reflect a difficulty in diagnosing the condition in young women, in whom <ce:italic>Chlamydia</ce:italic> infection is often asymptomatic and is hard to detect in practical terms. Between 1% and 2% of patients with non-specific urethritis seen at genitourinary medicine clinics have SARA (<ce:cross-ref id="crf9270" refid="s1220">p. 1031</ce:cross-ref>). The syndrome of chlamydial urethritis, conjunctivitis and reactive arthritis was formerly known as Reiter’s disease.</ce:para><ce:para id="p4590">With enteric triggering infections (enteropathic ReA), HLA-B27 may predict the reactive arthritis and its severity, though the condition occurs in HLA-B27-negative people. The incidence of specific triggering infections causing reactive arthritis around the world varies, depending on the epidemiology of the infection and prevalence of HLA-B27 in the local population.</ce:para><ce:section id="s1230"><ce:section id="s1235"><ce:section-title id="st1130">Clinical features</ce:section-title><ce:para id="p4595">The onset is typically acute, with an inflammatory enthesitis, oligoarthritis and/or spinal inflammation. Lower limb joints and entheses are predominantly affected. In all types of ReA, there may be considerable systemic disturbance, with fever and weight loss. Achilles insertional enthesitis/tendonitis or plantar fasciitis may also be present. The first attack of arthritis is usually self-limiting, but recurrent or chronic arthritis can develop and about 10% still have active disease 20 years after the initial presentation. Low back pain and stiffness due to enthesitis and osteitis are common and 15–20% of patients develop sacroiliitis. Many extra-articular features in ReA involve the skin, especially in SARA:<ce:list id="ulist0775"><ce:list-item id="u2755"><ce:label>•</ce:label><ce:para id="p4600"><ce:italic>circinate balanitis</ce:italic>, which starts as vesicles on the coronal margin of the prepuce and glans penis, later rupturing to form superficial erosions with minimal surrounding erythema, some coalescing to give a circular pattern</ce:para></ce:list-item><ce:list-item id="u2760"><ce:label>•</ce:label><ce:para id="p4605"><ce:italic>keratoderma blennorrhagica</ce:italic>, which begins as discrete waxy, yellow–brown vesico-papules with desquamating margins, occasionally coalescing to form large crusty plaques on the palms and soles of the feet</ce:para></ce:list-item><ce:list-item id="u2765"><ce:label>•</ce:label><ce:para id="p4610"><ce:italic>pustular psoriasis</ce:italic></ce:para></ce:list-item><ce:list-item id="u2770"><ce:label>•</ce:label><ce:para id="p4615"><ce:italic>nail dystrophy</ce:italic> with subungual hyperkeratosis</ce:para></ce:list-item><ce:list-item id="u2775"><ce:label>•</ce:label><ce:para id="p4620"><ce:italic>mouth ulcers</ce:italic></ce:para></ce:list-item><ce:list-item id="u2780"><ce:label>•</ce:label><ce:para id="p4625"><ce:italic>conjunctivitis</ce:italic></ce:para></ce:list-item><ce:list-item id="u2785"><ce:label>•</ce:label><ce:para id="p4630"><ce:italic>uveitis</ce:italic>, which is rare with the first attack but arises in 30% of patients with recurring or chronic arthritis.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4635">Other complications in ReA are very rare but include aortic incompetence, conduction defects, pleuro-pericarditis, peripheral neuropathy, seizures and meningoencephalitis.</ce:para></ce:section><ce:section id="s1240"><ce:section-title id="st1135">Investigations</ce:section-title><ce:para id="p4640">The diagnosis is usually made clinically but joint aspiration may be required to exclude crystal arthritis and articular infection. ESR and CRP are raised, urethritis may be confirmed in the ‘two-glass test’ by demonstration of mucoid threads in the first-void specimen that clear in the second. High vaginal swabs may reveal <ce:italic>Chlamydia</ce:italic> on culture. Except for post-<ce:italic>Salmonella</ce:italic> arthritis, stool cultures are usually negative by the time the arthritis presents but serology may help confirm previous dysentery. RF, ACPA and ANA are negative.</ce:para><ce:para id="p4645">In chronic or recurrent disease, X-rays show periarticular osteoporosis; proliferative erosions, notably at entheses; periostitis, especially of metatarsals, phalanges and pelvis; and large, ‘fluffy’ calcaneal spurs. In contrast to AS, radiographic sacroiliitis is often asymmetrical and sometimes unilateral, and syndesmophytes are predominantly coarse and asymmetrical, often extending beyond the contours of the annulus (‘non-marginal’) (see <ce:cross-ref id="crf1040" refid="f0215">Fig. 24.40B</ce:cross-ref>). Radiographic changes in the peripheral joints and spine are identical to those seen in psoriasis.</ce:para></ce:section><ce:section id="s1245"><ce:section-title id="st1140">Management</ce:section-title><ce:para id="p4650">Acute ReA should be treated with rest, NSAIDs and analgesics. Intra-articular or systemic glucocorticoids may be required in patients with severe monarticular synovitis or polyarticular disease, respectively. There is no convincing evidence for the use of antibiotics unless a triggering infection is identified. If chlamydial urethritis is diagnosed, it should be treated empirically with a short course of doxycycline or a single dose of azithromycin. Treatment with DMARDs (usually sulfasalazine or methotrexate) should be considered for patients with persistent marked symptoms, recurrent arthritis or severe keratoderma blennorrhagica. Anterior uveitis is a medical emergency requiring topical, subconjunctival or systemic glucocorticoids. For DMARD-recalcitrant cases, anti-TNF therapy should be considered.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1250"><ce:section-title id="st1145">Psoriatic arthritis</ce:section-title><ce:para id="p4655">In the UK and Denmark the estimated population prevalence of psoriatic arthritis (PsA) from registry and coding data is approximately 0.2%. It is likely the true prevalence is considerably higher but this has not been extensively studied. The prevalence of PsA in psoriasis patients, based on clinical assessment, is variable but may be up to 40%. Early PsA may present as axSpA. The onset is usually between 25 and 40 years of age but juvenile forms exist. Occasionally, the arthritis and psoriasis develop synchronously but the onset of musculoskeletal and skin disease is frequently separated by many years. Classification of PsA requires key assessments of family history and screening for enthesitis (<ce:cross-ref id="crf1045" refid="b0315">Box 24.62</ce:cross-ref><ce:float-anchor refid="b0315"/>).</ce:para><ce:section id="s1255"><ce:section id="s1260"><ce:section-title id="st1150">Pathophysiology</ce:section-title><ce:para id="p4705">Genetic factors have an important role in PsA and family studies have suggested that heritability may exceed 80%. Variants in the <ce:italic>HLA-B</ce:italic> and <ce:italic>HLA-C</ce:italic> genes are the strongest genetic risk factors but more than 30 other variants also play a part. Many of these variants overlap with those implicated in psoriasis (<ce:intra-ref id="ii0455" xlink:href="pii:B978-0-7020-7028-0.00029-9#s1120">p. 1247</ce:intra-ref>), where there are more than 40 susceptibility loci. These lie within or close to genes in the IL-12, IL-23 and nuclear factor kappa B (NFκB) signalling pathways. It is thought that an environmental trigger, probably infectious in nature, triggers the disease in genetically susceptible individuals, leading to immune activation involving dendritic cells and T cells. CD8<ce:sup loc="post">+</ce:sup> T cells (which recognise antigen presented in the context of HLA class I) are more abundant than CD4<ce:sup loc="post">+</ce:sup> T cells within the joint, which is in keeping with the genetic association between PsA and HLA-C and B variants. There is increasing evidence that the IL-23/IL-17 pathway plays a pivotal role in PsA. It is thought that the triggering stimulus causes over-production of IL-23 by dendritic cells, which in turn promotes differentiation and activation of Th17 cells, which produce the pro-inflammatory cytokine IL-17A. This, along with Th1 cytokines like IFN-γ and TNF-α, acts on macrophages and tissue-resident stromal cells at entheses, in bone and within the joint to produce additional pro-inflammatory cytokines and other mediators, which contribute to inflammation and tissue damage, as shown in <ce:cross-ref id="crf1060" refid="f0225">Figure 24.42</ce:cross-ref><ce:float-anchor refid="f0225"/>.</ce:para></ce:section><ce:section id="s1265"><ce:section-title id="st1155">Clinical features</ce:section-title><ce:para id="p4710">The presentation is with pain and stiffness affecting joints, tendons, spine and entheses. Joints are typically not swollen; however, several patterns of joint involvement are recognised (see below), including an oligoarticular form. These patterns are not mutually exclusive. Marked variation in disease patterns exists, including a disease course of intermittent exacerbation and remission. Destructive arthritis and disability are uncommon, except in the case of arthritis mutilans.</ce:para><ce:section id="s1270"><ce:section-title id="st1160">Asymmetrical inflammatory mono-/oligoarthritis</ce:section-title><ce:para id="p4715">This often presents abruptly with a combination of synovitis and adjacent periarticular inflammation. It occurs most characteristically in the hands and feet, when synovitis of a finger or toe is coupled with tenosynovitis, enthesitis and inflammation of intervening tissue to give a ‘sausage digit’ or dactylitis (<ce:cross-ref id="crf1065" refid="f0230">Fig. 24.43A</ce:cross-ref><ce:float-anchor refid="f0230"/>). Large joints, such as the knee and ankle, may also be involved, sometimes with very large effusions.</ce:para></ce:section><ce:section id="s1275"><ce:section-title id="st1165">Symmetrical polyarthritis</ce:section-title><ce:para id="p4720">This accounts for about 25% of cases. It predominates in women and may resemble RA, with symmetrical involvement of small and large joints in both upper and lower limbs. Nodules and other extra-articular features of RA are absent and arthritis is generally less extensive and more benign.</ce:para></ce:section><ce:section id="s1280"><ce:section-title id="st1170">Distal interphalangeal joint arthritis</ce:section-title><ce:para id="p4725">This is quite a common pattern and can be difficult to distinguish from inflammatory generalised OA. PsA DIP joint disease is associated with psoriatic nail disease (<ce:cross-ref id="crf1070" refid="f0230">Fig. 24.43B</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1285"><ce:section-title id="st1175">Psoriatic spondylitis</ce:section-title><ce:para id="p4730">This type presents with inflammatory back or neck pain and prominent stiffness symptoms. Any structure in the spine can be involved, including intervertebral disc entheses and facet joints. It may occur alone or with any of the other clinical patterns described above and is typically unilateral or asymmetric in severity.</ce:para></ce:section><ce:section id="s1290"><ce:section-title id="st1180">Arthritis mutilans</ce:section-title><ce:para id="p4735">This is a deforming erosive arthritis targeting the fingers and toes; it occurs in 5% of cases of PsA. Prominent cartilage and bone destruction results in marked instability. The encasing skin appears invaginated and ‘telescoped’ (‘main en lorgnette’) and the finger can be pulled back to its original length.</ce:para></ce:section><ce:section id="s1295"><ce:section-title id="st1185">Enthesitis-predominant</ce:section-title><ce:para id="p4740">This form of disease presents with pain and stiffness at the insertion sites of tendons and ligaments into bone (enthesitis). Symptoms can be extensive or localised. Typically affected entheses include Achilles tendon insertions, plantar fascia origins, patellar ligament attachments, hip abductor complex insertion at lateral femoral condyle, gluteus medius insertion at greater trochanter, humeral epicondyle tendon attachments, deltoid origin at acromial edge, intercostal muscle attachments at ribs, and pelvic ligament attachments.</ce:para><ce:para id="p4745">Nail changes include pitting, onycholysis, subungual hyperkeratosis and horizontal ridging, which are found in 85% of patients with PsA and can occur in the absence of skin disease. The characteristic rash of psoriasis (<ce:intra-ref id="ii0460" xlink:href="pii:B978-0-7020-7028-0.00029-9#s1120">p. 1247</ce:intra-ref>) may be widespread, or confined to the scalp, natal cleft, umbilicus and genitals, where it is easily overlooked. Obtaining a history of psoriasis in a first-degree relative can be tricky but is important, given that a positive response contributes to making a diagnosis.</ce:para></ce:section></ce:section><ce:section id="s1300"><ce:section-title id="st1190">Investigations</ce:section-title><ce:para id="p4750">The diagnosis is made on clinical grounds. Autoantibodies are generally negative and acute phase reactants, such as ESR and CRP, are raised in only a proportion of patients with active disease. X-rays may be normal or show erosive change with joint space narrowing. Features that favour PsA over RA include the characteristic distribution (see <ce:cross-ref id="crf1075" refid="f0065">Fig. 24.10</ce:cross-ref>, <ce:cross-ref id="crf9275" refid="s0245">p. 994</ce:cross-ref>) of proliferative erosions with marked new bone formation, absence of periarticular osteoporosis and osteosclerosis. Imaging of the axial skeleton often reveals features similar to those in chronic ReA, with coarse, asymmetrical, non-marginal syndesmophytes and asymmetrical sacroiliitis. MRI and ultrasound with power Doppler are increasingly employed to detect synovial inflammation and inflammation at the entheses.</ce:para></ce:section><ce:section id="s1305"><ce:section-title id="st1195">Management</ce:section-title><ce:para id="p4755">Therapy with NSAIDs and analgesics may be sufficient to manage symptoms in mild disease. Intra-articular glucocorticoid injections can control isolated synovitis or enthesitis. Splints and prolonged rest should be avoided because of the tendency to fibrous and bony ankylosis. Patients with spondylitis should be prescribed the same exercise and posture regime as in axSpA/AS. Therapy with DMARDs should be considered for persistent synovitis unresponsive to conservative treatment. Methotrexate is the drug of first choice and is also effective for skin disease (see EULAR guidelines, ‘Further information’, <ce:cross-ref id="crf9280" refid="s2040">p. 1060</ce:cross-ref>). Other DMARDs may also be helpful, including sulfasalazine, ciclosporin and leflunomide. Particular attention should be paid to monitoring liver function in patients treated with DMARDs, since abnormalities are common in PsA. Hydroxychloroquine is generally avoided, as it can cause exfoliative skin reactions; it may, however, be tried in the small subset of patients who have mild PsA but no psoriasis and are ANA-positive. Anti-TNF treatment should be considered for individuals with active synovitis who respond inadequately to standard DMARDs, and treatment is effective for both PsA and psoriasis. Ustekinumab, a monoclonal antibody that binds to and neutralises the p40 subunit of IL-12 and IL-23, improves joint, dactylitis and enthesitis lesions in PsA. Secukinumab, a monoclonal antibody that targets IL-17A, has similar efficacy to TNF inhibitors in PsA. Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), which is effective in PsA when DMARD therapy fails, although it appears to be less efficacious than biologic treatment. Adverse effects include weight loss, depression and suicidal ideation.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1310"><ce:section-title id="st1200">Enteropathic (spondylo)arthritis</ce:section-title><ce:para id="p4760">The overall prevalence of inflammatory musculoskeletal disease in inflammatory bowel diseases (IBDs: Crohn's disease and ulcerative colitis) is not well known, as studies have not adequately assessed enthesitis and osteitis lesions, but the musculoskeletal manifestations are in keeping with an SpA phenotype. Involvement of the peripheral joints is seen in about 20% of IBD patients. Oligoarticular disease predominantly affects the large lower limb joints (knees, ankles and hips). Radiographic evidence of sacroiliitis is present in about 20–25% of IBD patients. In Crohn's disease, more than in colitis, the arthritis usually coincides with exacerbations of the underlying bowel disease and the arthritis improves with effective treatment of the bowel disease. There is some suggestion that the severity and onset of inflammatory musculoskeletal symptoms can vary in association with changes in the integrity of the ileocaecal valve, raising the possibility that changes in gut flora may act as triggers for the associated SpA.</ce:para><ce:para id="p4765">NSAIDs are best avoided, since they can exacerbate IBD. Instead, judicious use of glucocorticoids, sulfasalazine and methotrexate may be considered. Liaison is necessary between gastroenterologist and rheumatologist with regard to choice of therapy. Anti-TNF therapy is effective in enteropathic arthritis but etanercept should be avoided, as it has no efficacy in IBD. When musculoskeletal symptoms worsen despite anti-TNF therapy, it is wise to exclude bacterial overgrowth as a triggering cause (blind-loop syndrome).</ce:para></ce:section></ce:section><ce:section id="s1315"><ce:section-title id="st1205">Autoimmune connective tissue diseases</ce:section-title><ce:para id="p4770">Autoimmune connective tissue diseases (AICTDs) share many clinical features and are characterised by dysregulation of immune responses, autoantibody production that is often directed at components of the cell nucleus, and tissue damage.</ce:para><ce:section id="s1320"><ce:section id="s1325"><ce:section-title id="st1210">Systemic lupus erythematosus</ce:section-title><ce:para id="p4775">Systemic lupus erythematosus (SLE, ‘lupus’) is a rare disease with a prevalence that ranges from about 0.03% in Caucasians to 0.2% in Afro-Caribbeans. Some 90% of affected patients are female and the peak age at onset is between 20 and 30 years. SLE is associated with considerable morbidity and a fivefold increase in mortality compared to age- and gender-matched controls, mainly because of an increased risk of premature cardiovascular disease.</ce:para><ce:section id="s1330"><ce:section-title id="st1215">Pathophysiology</ce:section-title><ce:para id="p4780">The cause of SLE is incompletely understood but genetic factors play an important role. There is a higher concordance in monozygotic twins and the disease is strongly associated with polymorphic variants at the HLA locus. In a few instances, SLE is associated with inherited mutations in complement components C1q, C2 and C4, in the immunoglobulin receptor FcγRIIIb or in the DNA exonuclease <ce:italic>TREX1.</ce:italic> Genome-wide association studies have identified common polymorphisms near several other genes that predispose to SLE, most of which are involved in regulating immune cell function. From an immunological standpoint, the characteristic feature of SLE is autoantibody production. These autoantibodies have specificity for a wide range of targets but many are directed against antigens present within the cell or within the nucleus. This has led to the hypothesis that SLE may occur because of defects in apoptosis or in the clearance of apoptotic cells, which causes inappropriate exposure of intracellular antigens on the cell surface, leading to polyclonal B- and T-cell activation and autoantibody production. This is supported by the fact that environmental factors that cause flares of lupus, such as ultraviolet light and infections, increase oxidative stress and cause cell damage. Whatever the underlying cause, autoantibody production and immune complex formation are thought to be important mechanisms of tissue damage in active SLE, leading to vasculitis and organ damage.</ce:para></ce:section><ce:section id="s1335"><ce:section-title id="st1220">Clinical features</ce:section-title><ce:para id="p4785">Symptoms such as fever, weight loss and mild lymphadenopathy may occur during flares of disease activity, whereas others such as fatigue and low-grade joint pains can be constant and not particularly associated with active inflammatory disease.</ce:para><ce:section id="s1340"><ce:section-title id="st1225">Arthritis</ce:section-title><ce:para id="p4790">Arthralgia is a common symptom, occurring in 90% of patients, and is often associated with early morning stiffness. Tenosynovitis may also occur but clinically apparent synovitis with joint swelling is rare. Joint deformities may arise (Jaccoud's arthropathy) as the result of tendon damage but joint erosions are not a feature.</ce:para></ce:section><ce:section id="s1345"><ce:section-title id="st1230">Raynaud's phenomenon</ce:section-title><ce:para id="p4795">Raynaud's phenomenon (<ce:intra-ref id="ii0475" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1650">p. 504</ce:intra-ref>) is common and may antedate other symptoms by months or years. SLE can present with Raynaud's phenomenon, along with arthralgia or arthritis. Secondary Raynaud's phenomenon associated with SLE and other AICTDs needs to be differentiated from primary Raynaud's phenomenon, which is common in the general population (up to 5%). Features in favour of secondary Raynaud's phenomenon include age at onset of over 25 years, absence of a family history of Raynaud's phenomenon, and occurrence in a male. Examination of capillary nail-fold loops using an ophthalmoscope (and oil placed on the skin) can show loss of the normal loop pattern, with capillary ‘fallout’ and dilatation and branching of loops; these features support either a diagnosis of systemic sclerosis or severe primary Raynaud's phenomenon. If Raynaud's phenomenon is severe, digital ulceration can occur (<ce:cross-ref id="crf1080" refid="f0235">Fig. 24.44</ce:cross-ref><ce:float-anchor refid="f0235"/>).</ce:para></ce:section><ce:section id="s1350"><ce:section-title id="st1235">Skin</ce:section-title><ce:para id="p4800">The skin is commonly involved in SLE, and many SLE skin eruptions are precipitated by exposure to ultraviolet light. The main types of skin involvement are:<ce:list id="ulist0785"><ce:list-item id="u2825"><ce:label>•</ce:label><ce:para id="p4805">The classic facial rash (up to 20% of patients). This is erythematous, raised and painful or itchy, and occurs over the cheeks with sparing of the nasolabial folds (<ce:cross-ref id="crf1085" refid="f0240">Fig. 24.45</ce:cross-ref><ce:float-anchor refid="f0240"/>). Rosacea is a mimic of this rash.</ce:para></ce:list-item><ce:list-item id="u2830"><ce:label>•</ce:label><ce:para id="p4810">A discoid rash characterised by hyperkeratosis and follicular plugging, with scarring alopecia if it occurs on the scalp.</ce:para></ce:list-item><ce:list-item id="u2835"><ce:label>•</ce:label><ce:para id="p4815">Diffuse, usually non-scarring alopecia, which may also occur with active disease.</ce:para></ce:list-item><ce:list-item id="u2840"><ce:label>•</ce:label><ce:para id="p4820">Urticarial eruptions.</ce:para></ce:list-item><ce:list-item id="u2845"><ce:label>•</ce:label><ce:para id="p4825">Livedo reticularis (<ce:cross-ref id="crf1090" refid="f0245">Fig. 24.46</ce:cross-ref><ce:float-anchor refid="f0245"/>), which is also a feature of antiphospholipid syndrome (<ce:intra-ref id="ii0480" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1775">p. 977</ce:intra-ref>) and can become frankly vasculitic, if severe.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1355"><ce:section-title id="st1240">Kidney</ce:section-title><ce:para id="p4830">Renal involvement is one of the main determinants of prognosis and regular monitoring of urinalysis and blood pressure is essential. The typical renal lesion is a proliferative glomerulonephritis (<ce:intra-ref id="ii0485" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0300">p. 397</ce:intra-ref>), characterised by heavy haematuria, proteinuria and casts on urine microscopy.</ce:para></ce:section><ce:section id="s1360"><ce:section-title id="st1245">Cardiovascular</ce:section-title><ce:para id="p4835">The most common manifestation is pericarditis. Myocarditis and Libman–Sacks endocarditis can also occur. The endocarditis is due to accumulation on the heart valves of sterile fibrin-containing vegetations, which is thought to be a manifestation of hypercoagulability associated with antiphospholipid antibodies. The risk of atherosclerosis is greatly increased, as is the risk of stroke and myocardial infarction. This is thought to be multifactorial due to the adverse effects of inflammation on the endothelium, chronic glucocorticoid therapy and the procoagulant effects of antiphospholipid antibodies.</ce:para></ce:section><ce:section id="s1365"><ce:section-title id="st1250">Lung</ce:section-title><ce:para id="p4840">Lung involvement is common and most frequently manifests as pleuritic pain (serositis) or pleural effusion. Other features include pneumonitis, atelectasis, reduced lung volume and pulmonary fibrosis that leads to breathlessness. The risk of thromboembolism is increased, especially in patients with antiphospholipid antibodies.</ce:para></ce:section><ce:section id="s1370"><ce:section-title id="st1255">Neurological</ce:section-title><ce:para id="p4845">Fatigue, headache and poor concentration are common and often occur in the absence of laboratory evidence of active disease. More specific features of cerebral lupus include visual hallucinations, chorea, organic psychosis, transverse myelitis and lymphocytic meningitis.</ce:para></ce:section><ce:section id="s1375"><ce:section-title id="st1260">Haematological</ce:section-title><ce:para id="p4850">Neutropenia, lymphopenia, thrombocytopenia and haemolytic anaemia may occur, due to antibody-mediated destruction of peripheral blood cells. The degree of lymphopenia is a good guide to disease activity.</ce:para></ce:section><ce:section id="s1380"><ce:section-title id="st1265">Gastrointestinal</ce:section-title><ce:para id="p4855">Mouth ulcers may occur and may or may not be painful. Peritoneal serositis can cause acute pain. Mesenteric vasculitis is a serious complication, which can present with abdominal pain, bowel infarction or perforation. Hepatitis is a recognised, though rare, feature.</ce:para></ce:section><ce:section id="s1385"><ce:section-title id="st1270">Paediatric disease</ce:section-title><ce:para id="p4860">Renal disease and cutaneous manifestations are more frequent in juvenile-onset SLE compared to disease in adults. Similarly, there is subsequently a higher incidence of renal disease, malar rash, Raynaud's phenomenon, cutaneous vasculitis and neuropsychiatric manifestations than in adults.</ce:para></ce:section></ce:section><ce:section id="s1390"><ce:section-title id="st1275">Investigations</ce:section-title><ce:para id="p4865">The diagnosis is based on a combination of clinical features and laboratory abnormalities. To fulfil the classification criteria for SLE, at least 4 of the 11 factors shown in <ce:cross-ref id="crf1095" refid="b0320">Box 24.63</ce:cross-ref><ce:float-anchor refid="b0320"/> must be present or have occurred in the past. Checking of ANAs, antibodies to ENAs and complement, routine haematology, biochemistry and urinalysis are mandatory. Patients with active SLE test positive for ANA. Some authorities believe that ANA-negative SLE occurs (e.g. in the presence of antibodies to Ro) but others regard SLE as necessarily ANA-positive; the issue may be more to do with sensitivity of the ANA assay at any given time in a disease course. Anti-dsDNA antibodies are positive in many, but not all, patients and are tested at the time of diagnosis by most laboratories using ELISA. ELISAs have low specificity, whereas testing for anti-dsDNA antibodies using <ce:italic>Crithidia luciliae</ce:italic> is highly specific. Patients with active disease tend to have low levels of C3 due to complement consumption, but in some people low C3 and C4 may be the result of inherited complement deficiency in C1, C2 or C4 that predisposes to SLE (<ce:intra-ref id="ii9025" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0070">p. 66</ce:intra-ref>). Studies of other family members can help to differentiate inherited deficiency from complement consumption. A raised ESR, leucopenia and lymphopenia are typical of active SLE, along with anaemia, haemolytic anaemia and thrombocytopenia. CRP is often normal in active SLE, except in the presence of serositis; thus an elevated CRP suggests infection.</ce:para></ce:section><ce:section id="s1395"><ce:section-title id="st1280">Management</ce:section-title><ce:para id="p4875">The therapeutic goals are to educate the patient about the nature of the illness, to control symptoms and to prevent organ damage and maintain normal function. Patients should be advised to avoid sun and ultraviolet light exposure and to employ sun blocks (sun protection factor 25–50).</ce:para><ce:section id="s1400"><ce:section-title id="st1285">Mild to moderate disease</ce:section-title><ce:para id="p4880">Patients with mild disease restricted to skin and joints can sometimes be managed with analgesics, NSAIDs and hydroxychloroquine. Frequently, however, glucocorticoids are also necessary (prednisolone 5–20 mg/day), often in combination with immunosuppressants such as methotrexate, azathioprine or mycophenolate mofetil (MMF). Increased doses of glucocorticoids may be required for flares in activity or complications such as pleurisy or pericarditis. The monoclonal antibody belimumab, which targets the β-cell growth factor BLyS, has recently been shown to be effective in patients with active SLE who have responded inadequately to standard therapy.</ce:para></ce:section><ce:section id="s1405"><ce:section-title id="st1290">Severe and life-threatening disease</ce:section-title><ce:para id="p4885">High-dose glucocorticoids and immunosuppressants are required for the treatment of renal, CNS and cardiac involvement. A commonly used regimen is pulsed methylprednisolone (10 mg/kg IV) plus cyclophosphamide (15 mg/kg IV), repeated at 2–3-weekly intervals for six cycles. Cyclophosphamide may cause haemorrhagic cystitis but the risk can be minimised by good hydration and co-prescription of mesna (2-mercaptoethane sulfonate), which binds its urotoxic metabolites. Because of the risk of azoospermia and premature menopause, sperm or oöcyte collection and storage need to be considered prior to treatment with cyclophosphamide.</ce:para><ce:para id="p4890">MMF has been used successfully with high-dose glucocorticoids for renal involvement with results similar to those of pulsed cyclophosphamide but fewer adverse effects. Belimumab in combination with standard therapy significantly decreases disease activity in SLE patients and is safe and well tolerated. Its role in patients with renal and neurological disease is still under investigation.</ce:para><ce:para id="p4895">Rituximab has been reported as being effective in selected cases, though randomised controlled trials have not shown significant overall efficacy.</ce:para></ce:section><ce:section id="s1410"><ce:section-title id="st1295">Maintenance therapy</ce:section-title><ce:para id="p4900">Following control of acute disease, a typical maintenance regimen is oral prednisolone in a dose of 40–60 mg daily, gradually reducing to 10–15 mg/day or less by 3 months. Azathioprine (2–2.5 mg/kg/day), methotrexate (10–25 mg/week) or MMF (2–3 g/day) should also be prescribed. The long-term aim is to continue the lowest dose of glucocorticoid and immunosuppressant to maintain remission. Cardiovascular risk factors, such as hypertension and hyperlipidaemia, should be controlled and patients should be advised to stop smoking.</ce:para><ce:para id="p4905">Patients with SLE and the antiphospholipid antibody syndrome, who have had previous thrombosis, require life-long warfarin therapy. SLE patients are at risk of osteoporosis and hypovitaminosis D, and should be screened with biochemistry and DXA scanning accordingly.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1415"><ce:section-title id="st1300">Systemic sclerosis</ce:section-title><ce:para id="p4910">Systemic sclerosis (SScl) is an autoimmune disorder of connective tissue, which results in fibrosis affecting the skin, internal organs and vasculature. It is characterised typically by Raynaud's phenomenon, digital ischaemia (<ce:cross-ref id="crf1115" refid="f0250">Fig. 24.47</ce:cross-ref><ce:float-anchor refid="f0250"/>), sclerodactyly, and cardiac, lung, gut and renal disease. The peak age of onset is in the fourth and fifth decades and overall prevalence is 10–20 per 100 000, with a 4 : 1 female-to-male ratio. It is subdivided into diffuse cutaneous systemic sclerosis (dcSScl: 30% of cases) and limited cutaneous systemic sclerosis (lcSScl: 70% of cases). Some patients with lcSScl have calcinosis and telangiectasia. The prognosis in dcSScl is poor (5-year survival about 70%). Features that associate with a poor prognosis include older age, diffuse skin disease, proteinuria, high ESR, a low gas transfer factor for carbon monoxide (TLCO) and pulmonary hypertension.</ce:para><ce:section id="s1420"><ce:section-title id="st1305">Pathophysiology</ce:section-title><ce:para id="p4915">The cause of SScl is not completely understood. There is evidence for a genetic component and associations with alleles at the HLA locus have been found. The disease occurs in all ethnic groups and race may influence severity. Isolated cases have been reported in which an SScl-like disease has been triggered by exposure to silica dust, vinyl chloride, epoxy resins and trichloroethylene. There is clear evidence of immunological dysfunction: T lymphocytes, especially those of the Th17 subtype, infiltrate the skin and there is abnormal fibroblast activation, leading to increased production of extracellular matrix in the dermis, primarily type I collagen. This results in symmetrical thickening, tightening and induration of the skin (scleroderma). Arterial and arteriolar narrowing occurs due to intimal proliferation and vessel wall inflammation. Endothelial injury causes release of vasoconstrictors and platelet activation, resulting in further ischaemia, which is thought to exacerbate the fibrotic process.</ce:para></ce:section><ce:section id="s1425"><ce:section-title id="st1310">Clinical features</ce:section-title><ce:section id="s1430"><ce:section-title id="st1315">Skin</ce:section-title><ce:para id="p4920">Initially, there is non-pitting oedema of fingers and flexor tendon sheaths. Subsequently, the skin becomes shiny and taut, and distal skin creases disappear. There can be capillary loss. The face and neck are often involved, with thinning of the lips and radial furrowing. In some patients, skin thickening stops at this stage. Skin involvement restricted to sites distal to the elbow or knee (apart from the face) is thus classified as lcSScl (<ce:cross-ref id="crf1120" refid="f0255">Fig. 24.48</ce:cross-ref><ce:float-anchor refid="f0255"/>). Involvement proximal to the knee and elbow and on the trunk is classified as ‘diffuse disease’ (dcSScl).</ce:para></ce:section><ce:section id="s1435"><ce:section-title id="st1320">Raynaud's phenomenon</ce:section-title><ce:para id="p4925">This is a universal feature and can precede other features by many years. Involvement of small blood vessels in the extremities may cause critical tissue ischaemia, leading to localised distal skin infarction and necrosis.</ce:para></ce:section><ce:section id="s1440"><ce:section-title id="st1325">Musculoskeletal features</ce:section-title><ce:para id="p4930">Arthralgia and flexor tenosynovitis are common. Restricted hand function is due to skin rather than joint disease and erosive arthropathy is uncommon. Muscle weakness and wasting can result from myositis.</ce:para></ce:section><ce:section id="s1445"><ce:section-title id="st1330">Gastrointestinal involvement</ce:section-title><ce:para id="p4935">Smooth muscle atrophy and fibrosis in the lower two-thirds of the oesophagus lead to reflux with erosive oesophagitis. Dysphagia and odynophagia may also occur. Involvement of the stomach causes early satiety and occasionally outlet obstruction. Recurrent occult upper gastrointestinal bleeding may indicate a ‘watermelon’ stomach (antral vascular ectasia; up to 20% of patients). Small intestine involvement may lead to malabsorption due to bacterial overgrowth and intermittent bloating, pain or constipation. Dilatation of bowel due to autonomic neuropathy may cause pseudo-obstruction with nausea, vomiting, abdominal discomfort and distension, often worse after food (symptoms can mimic those of an acute abdomen and can lead to erroneous laparotomy).</ce:para></ce:section><ce:section id="s1450"><ce:section-title id="st1335">Pulmonary involvement</ce:section-title><ce:para id="p4940">Pulmonary hypertension complicates long-standing disease and is six times more prevalent in lcSScl than in dcSScl. It usually presents with insidiously evolving exertional dyspnoea and signs of right heart failure. Interstitial lung disease is common in patients with dcSScl who have topoisomerase 1 antibodies (Scl70). Dyspnoea can evolve slowly over time or rapidly in occasional cases.</ce:para></ce:section><ce:section id="s1455"><ce:section-title id="st1340">Renal involvement</ce:section-title><ce:para id="p4945">One of the main causes of death is hypertensive renal crisis, characterised by rapidly developing accelerated phase hypertension (<ce:intra-ref id="ii9030" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1945">p. 514</ce:intra-ref>) and renal failure. Hypertensive renal crisis is much more likely to occur in dcSScl than in lcSScl, and in patients with topoisomerase 1 and RNP antibodies.</ce:para></ce:section></ce:section><ce:section id="s1460"><ce:section-title id="st1345">Investigations</ce:section-title><ce:para id="p4950">As SScl can affect multiple organs, routine haematology, renal, liver and bone function tests and urinalysis are essential. ANA is positive in about 70%. About 30% of patients with dcSScl have antibodies to topoisomerase 1 (Scl70). About 60% of patients with lcSScl syndrome have anticentromere antibodies (<ce:cross-ref id="crf9285" refid="p0760">p. 991</ce:cross-ref>). Chest X-ray, transthoracic echocardiography and lung function tests are recommended to assess for interstitial lung disease and pulmonary hypertension (low corrected transfer factor may indicate early pulmonary hypertension). High-resolution lung CT is recommended if interstitial lung disease suspected. If pulmonary hypertension is suspected, right heart catheter measurements should be arranged at a specialist cardiac centre. A barium swallow can assess oesophageal involvement. A hydrogen breath test can indicate bacterial overgrowth (<ce:intra-ref id="ii0495" xlink:href="pii:B978-0-7020-7028-0.00021-4#p3960">p. 808</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1465"><ce:section-title id="st1350">Management</ce:section-title><ce:para id="p4955">No treatments are available that halt or reverse the fibrotic changes that underlie the disease. The focus of management, therefore, is to slow the effects of the disease on target organs.<ce:list id="ulist0790"><ce:list-item id="u2850"><ce:label>•</ce:label><ce:para id="p4960"><ce:italic>Raynaud's phenomenon and digital ulcers</ce:italic>. Avoidance of cold exposure, use of thermal insulating gloves/socks and maintenance of a high core temperature all help. If symptoms are persistent, calcium channel blockers, losartan, fluoxetine and sildenafil have efficacy. Courses of intravenous prostacyclin are used for severe disease and critical ischemia (e.g. 6–8 hours daily for 5 days). The endothelin-1 antagonist bosentan is licensed for treating ischaemic digital ulcers, and digital tip tissue health can be maintained with regular use of fucidin–hydrocortisone cream.</ce:para></ce:list-item><ce:list-item id="u2855"><ce:label>•</ce:label><ce:para id="p4965"><ce:italic>Gastrointestinal complications</ce:italic>. Oesophageal reflux should be treated with proton pump inhibitors and anti-reflux agents. Rotating courses of antibiotics may be required for bacterial overgrowth (e.g. rifaximin, a tetracycline and metronidazole), while metoclopramide or domperidone may help patients with symptoms of dysmotility/pseudo-obstruction.</ce:para></ce:list-item><ce:list-item id="u2860"><ce:label>•</ce:label><ce:para id="p4970"><ce:italic>Hypertension</ce:italic>. Aggressive treatment with ACE inhibitors is needed, even if renal impairment is present.</ce:para></ce:list-item><ce:list-item id="u2865"><ce:label>•</ce:label><ce:para id="p4975"><ce:italic>Joint involvement</ce:italic>. This may be treated with analgesics and/or NSAIDs. If synovitis is present and both RA (i.e. an ‘overlap’ condition, which needs treatment on its own merit) and OA have been ruled out, low-dose methotrexate can be of value.</ce:para></ce:list-item><ce:list-item id="u2870"><ce:label>•</ce:label><ce:para id="p4980"><ce:italic>Progressive pulmonary hypertension</ce:italic>. Early treatment with bosentan is required. In severe or progressive disease, heart–lung transplant may be considered.</ce:para></ce:list-item><ce:list-item id="u2875"><ce:label>•</ce:label><ce:para id="p4985"><ce:italic>Interstitial lung disease</ce:italic>. Glucocorticoids and (pulse intravenous) cyclophosphamide are the mainstays of treatment in patients who have progressive interstitial lung disease.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s1470"><ce:section-title id="st1355">Mixed connective tissue disease</ce:section-title><ce:para id="p4990">Mixed connective tissue disease (MCTD) is a condition in which some clinical features of SScl, myositis and SLE all occur in the same patient. It commonly presents with indolent puffiness of the fingers (the appearance is between that of SpA-type dactylitis and sclerodactyly) with Raynaud's phenomenon and myalgias. Most patients have anti-RNP antibodies. Management focuses on treating the components of the disease (see other sections).</ce:para></ce:section><ce:section id="s1475"><ce:section-title id="st1360">Primary Sjögren's syndrome</ce:section-title><ce:para id="p4995">Primary Sjögren's syndrome (PSS) is characterised by lymphocytic infiltration of salivary and lacrimal glands, leading to glandular fibrosis and exocrine failure. The typical age of onset is between 40 and 50, with a 9 : 1 female-to-male ratio. The disease may occur with other autoimmune diseases (secondary Sjögren's syndrome).</ce:para><ce:section id="s1480"><ce:section-title id="st1365">Clinical features</ce:section-title><ce:para id="p5000">The eye symptoms, termed keratoconjunctivitis sicca, are due to a lack of lubricating tears, which reflects inflammatory infiltration of the lacrimal glands. Conjunctivitis and blepharitis are frequent, and may lead to filamentary keratitis due to binding of tenacious mucous filaments to the cornea and conjunctiva. Oral involvement manifests as a dry mouth (xerostomia). There is a high incidence of dental caries and high risk of dental failure. Other sites of extraglandular involvement are listed in <ce:cross-ref id="crf1125" refid="b0325">Box 24.64</ce:cross-ref><ce:float-anchor refid="b0325"/>. Often the most disabling symptom is fatigue. There may be an association with inflammatory small-joint OA (clinical suspicion, though formal studies have not been done). Sialadenitis, osteoarthritis and xerostomia (SOX) syndrome has been described; this may occur independently of PSS or, more likely, constitute a mild form. Both interstitial lung disease and interstitial nephritis (sometimes complicated by renal tubular acidosis) require proactive screening. PSS is associated with a 40-fold increased lifetime risk of lymphoma, though the complication is still very rare.</ce:para></ce:section><ce:section id="s1485"><ce:section-title id="st1370">Investigations</ce:section-title><ce:para id="p5190">The diagnosis can be established by the Schirmer tear test, which measures tear flow over 5 minutes using absorbent paper strips placed on the lower eyelid; a normal result is more than 6 mm of wetting. Staining with rose bengal may show punctate epithelial abnormalities over the area not covered by the open eyelid. If the diagnosis remains in doubt, it can be confirmed by demonstrating focal lymphocytic infiltrate in a minor salivary gland biopsy. Most patients have an elevated ESR and hypergammaglobulinaemia, and one or more autoantibodies, including ANA and RF. ANA-negative disease exists. Anti-Ro and anti-La antibodies are commonly present (see <ce:cross-ref id="crf1130" refid="b0055">Box 24.10</ce:cross-ref>, <ce:cross-ref id="crf9290" refid="s0170">p. 992</ce:cross-ref>). Patients with joint pain, fatigue and RF (with or without ANA) need careful assessment because a number of possibilities exist: PSS and inflammatory OA; RA with incidental ANA; RA/SLE overlap; or RA/PSS overlap. Knowing ACPA status can help (it is positive in RA). Interstitial lung disease complicates PSS in a sizable minority of patients (persistent dry cough, dyspnoea, coarse ‘Velcro’ crackles on lung auscultation). A chest X-ray and lung function tests should be performed.</ce:para></ce:section><ce:section id="s1490"><ce:section-title id="st1375">Management</ce:section-title><ce:para id="p5195">No treatments that have disease-modifying effects have yet been identified and management is symptomatic. Lacrimal substitutes, such as hypromellose, should be used during the day in combination with more viscous lubricating application at night. Soft contact lenses can be useful for corneal protection in patients with filamentary keratitis, and occlusion of the lacrimal ducts is occasionally needed. Artificial saliva sprays, saliva-stimulating tablets, and pastilles and oral gels can be tried for xerostomia but often chewing gum is most effective. Adequate postprandial oral hygiene and prompt treatment of oral candidiasis are essential. Vaginal dryness is treated with lubricants. A trial of systemic pilocarpine (5–30 mg daily in divided doses) is worthwhile in early disease to amplify glandular function. Hydroxychloroquine (200 mg twice daily) is often used to address skin and musculoskeletal features and may help fatigue. Immunosuppression does not improve sicca symptoms but is essential for progressive interstitial lung disease (e.g. glucocorticoids and cyclophosphamide) and for interstitial nephritis (if hydroxychloroquine is ineffective alone). If non-resolving lymphadenopathy or salivary gland enlargement develops, biopsy should be undertaken to exclude malignancy.</ce:para></ce:section></ce:section><ce:section id="s1495"><ce:section-title id="st1380">Polymyositis and dermatomyositis</ce:section-title><ce:para id="p5200">Polymyositis (PM) and dermatomyositis (DM) are characterised by proximal skeletal and (cardiac and gut) smooth muscle inflammation. In DM, characteristic skin changes also occur. Both diseases are rare, with an incidence of 2–10 cases per million/year. They can occur in isolation or in association with other autoimmune diseases, and both are notably connected with (either previously diagnosed or undisclosed) malignancy.</ce:para><ce:section id="s1500"><ce:section-title id="st1385">Clinical features</ce:section-title><ce:para id="p5205">The typical presentation of PM and DM is with symmetrical proximal muscle weakness over a few weeks, usually affecting the lower limbs more than the upper, in adults between 40 and 60 years of age. Patients report difficulty rising from a chair, climbing stairs and lifting, often (though not always) with muscle pain. Systemic features of fever, weight loss and fatigue are common. Respiratory or pharyngeal muscle involvement can lead to ventilatory failure or aspiration that requires urgent treatment. Interstitial lung disease occurs in up to 30% of patients and is strongly associated with the presence of antisynthetase (Jo-1) antibodies.</ce:para><ce:para id="p5210">In DM, the skin lesions include Gottron's papules, which are scaly, erythematous or violaceous, psoriasiform plaques occurring over the extensor surfaces of PIP and DIP joints, and a heliotrope rash that is a violaceous discoloration of the eyelid in combination with periorbital oedema (<ce:cross-ref id="crf1135" refid="f0260">Fig. 24.49</ce:cross-ref><ce:float-anchor refid="f0260"/>). Similar rashes occur on the upper back, chest and shoulders (‘shawl’ distribution). Periungual nail-fold capillaries are often enlarged and tortuous.</ce:para></ce:section><ce:section id="s1505"><ce:section-title id="st1390">Investigations</ce:section-title><ce:para id="p5215">Muscle biopsy is the pivotal investigation and shows the typical features of fibre necrosis, regeneration and inflammatory cell infiltrate (<ce:cross-ref id="crf1140" refid="f0265">Fig. 24.50</ce:cross-ref><ce:float-anchor refid="f0265"/>). Occasionally, however, a biopsy may be normal, particularly if myositis is patchy so, invariably, MRI should be used to identify areas of abnormal muscle for biopsy. Serum levels of creatine kinase are typically raised and are a useful measure of disease activity, although a normal creatine kinase does not exclude the diagnosis, particularly in juvenile myositis. Electromyography is very useful for highlighting non-autoimmune/non-inflammatory myopathies. Screening for underlying malignancy should be undertaken routinely (full examination, chest X-ray, serum urine and protein electrophoresis, CT of chest/abdomen/pelvis; prostate-specific antigen should be included in men, and mammography in women).</ce:para></ce:section><ce:section id="s1510"><ce:section-title id="st1395">Management</ce:section-title><ce:para id="p5220">Oral glucocorticoids (prednisolone 1 mg/kg daily) are the mainstay of initial treatment of PM and DM but high-dose intravenous methylprednisolone (1 g/day for 3 days) may be required in patients with respiratory or pharyngeal weakness. If there is a good response, glucocorticoids should be reduced by approximately 25% per month to a maintenance dose of 5–7.5 mg. Although most patients respond well to glucocorticoids, many need additional immunosuppressive therapy. Methotrexate and MMF are the first choices of many but azathioprine and ciclosporin are also used as alternatives. Rituximab appears to show efficacy in a majority of patients, although the only controlled study (which was criticised for its suboptimal design) was negative. In clinical practice, rituximab is an option for use with glucocorticoids, to maintain an early glucocorticoid-induced remission. Intravenous immunoglobulin (IVIg) may be effective in refractory cases. Mepacrine or hydroxychloroquine has been used for skin-predominant disease to some good effect in certain cases. One risk of treatment is glucocorticoid-induced myopathy. If the initial response to treatment is poor, further biopsy then shows type II fibre atrophy in glucocorticoid myopathy (compared with fibre necrosis and regeneration in active myositis).</ce:para></ce:section></ce:section><ce:section id="s1515"><ce:section-title id="st1400">Juvenile dermatomyositis</ce:section-title><ce:para id="p5225">Juvenile dermatomyositis (JDM) is by far the most common inflammatory myopathy in children and adolescents, and typically does not require a search for malignancy. The incidence is 2–4 per million (USA and UK) with a median age of onset of 7 years (25% are below 4 years at diagnosis). Many clinical features are similar to those in the adult disease. JDM can be monocyclic, lasting up to 3 years (25–40%), or polycyclic, with periods of remission and relapse (60–75%). In some cases, polycyclic JDM can be chronic and life-long. It is ulcerative in 10–20%. As in adults, calcinosis occurs in about 30%.</ce:para><ce:para id="p5230">Intravenous methylprednisolone, then oral glucocorticoids and methotrexate produce a rapid response in many cases. Cyclophosphamide is used for lesional ulceration. IVIg is given in resistant cases.</ce:para></ce:section><ce:section id="s1520"><ce:section-title id="st1405">Undifferentiated autoimmune connective tissue disease</ce:section-title><ce:para id="p5235">In some patients, clinical features of AICTD occur, either simultaneously or sequentially, but at any one time the features and results of investigations do not allow a clear diagnosis to be made on the basis of conventional criteria. However, recognising that autoimmunity is present (‘autoimmune diathesis’) without making a specific diagnosis can help patients move forwards with chronic symptomology. Some of these individuals will progress to having a recognisable AICTD with time; others will continue to have an undifferentiated disease that remains the same for many years, and in others the symptoms will recede. Clinical monitoring and periodic autoimmune serological testing of all patients is sensible.</ce:para></ce:section><ce:section id="s1525"><ce:section-title id="st1410">Adult-onset Still's disease</ce:section-title><ce:para id="p5240">Adult-onset Still's disease is a rare systemic inflammatory disorder of unknown cause, possibly triggered by infection; it is similar to sJIA. It presents with intermittent fever, rash and arthralgia, and has been associated with pregnancy and the postpartum period and with high levels of IL-18. Splenomegaly, hepatomegaly and lymphadenopathy may be present. Investigations typically provide evidence of an acute phase response, with a markedly elevated serum ferritin. Tests for RF and ANA are negative and so adult-onset Still's disease may be better classified as an autoinflammatory rather than an autoimmune disease. Most patients respond to glucocorticoids but immunosuppressants, such as azathioprine or MMF, can be added when response is inadequate. Canakinumab or anakinra can be used for patients with resistant disease.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1530"><ce:section-title id="st1415">Vasculitis</ce:section-title><ce:para id="p5245">Vasculitis is characterised by inflammation and necrosis of blood-vessel walls, with associated damage to skin, kidney, lung, heart, brain and gastrointestinal tract. There is a wide spectrum of involvement and severity, ranging from mild and transient disease affecting only the skin, to life-threatening fulminant disease with multiple organ failure. Principal sites of involvement for the main types of vasculitis are summarised in <ce:cross-ref id="crf1145" refid="f0270">Figure 24.51</ce:cross-ref><ce:float-anchor refid="f0270"/>. The clinical features result from a combination of local tissue ischaemia (due to vessel inflammation and narrowing) and the systemic effects of widespread inflammation. Systemic vasculitis should be considered in any patient with fever, weight loss, fatigue, evidence of multisystem involvement, rashes, raised inflammatory markers and abnormal urinalysis (<ce:cross-ref id="crf1150" refid="b0330">Box 24.65</ce:cross-ref><ce:float-anchor refid="b0330"/>).</ce:para><ce:section id="s1535"><ce:section id="s1540"><ce:section-title id="st1420">Antineutrophil cytoplasmic antibody-associated vasculitis</ce:section-title><ce:para id="p5345">Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a life-threatening disorder characterised by inflammatory infiltration of small blood vessels, fibrinoid necrosis and the presence of circulating antibodies to antineutrophil cytoplasmic antibody (ANCA). The combined incidence is about 10–15/1 000 000. Two main subtypes are recognised. Microscopic polyangiitis is a necrotising small-vessel vasculitis found with rapidly progressive glomerulonephritis, often in association with alveolar haemorrhage. Cutaneous and gastrointestinal involvement is common and other features include neuropathy (15%) and pleural effusions (15%). Patients are usually myeloperoxidase (MPO) antibody-positive. Secondly, granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) is characterised by granuloma formation, mainly affecting the nasal passages, airways and kidney. A minority of patients present with glomerulonephritis. The most common presentation of granulomatosis with polyangiitis is with epistaxis, nasal crusting and sinusitis, but haemoptysis and mucosal ulceration may also occur. Deafness may be a feature due to inner ear involvement, and proptosis may occur because of inflammation of the retro-orbital tissue (<ce:cross-ref id="crf1155" refid="f0275">Fig. 24.52</ce:cross-ref><ce:float-anchor refid="f0275"/>). This causes diplopia due to entrapment of the extra-ocular muscles, or loss of vision due to optic nerve compression. Disturbance of colour vision is an early feature of optic nerve compression. Untreated nasal disease ultimately leads to destruction of bone and cartilage. Migratory pulmonary infiltrates and nodules occur in 50% of patients (as seen on high-resolution CT of lungs). Patients with granulomatosis with polyangiitis are usually proteinase-3 (PR3) antibody-positive (ELISA).</ce:para><ce:para id="p5350">Patients with active disease usually have a leucocytosis with elevated CRP, ESR and PR3. Complement levels are usually normal or slightly elevated. Imaging of the upper airways or chest with MRI can be useful in localising abnormalities but, where possible, the diagnosis should be confirmed by biopsy of the kidney or lesions in the sinuses and upper airways.</ce:para><ce:para id="p5355">Management for organ-threatening or acute–severe disease is with high-dose glucocorticoids (e.g. daily pulse intravenous methylprednisolone 0.5–1 g for 3 days, then oral prednisolone 0.5 mg/kg) and intravenous cyclophosphamide (e.g. 0.5–1 g every 2 weeks for 3 months), followed by maintenance therapy with lower-dose glucocorticoids and azathioprine, methotrexate or MMF. Plasmapheresis should be considered for fulminant lung disease. Rituximab in combination with high-dose glucocorticoids is equally effective as <ce:italic>oral</ce:italic> cyclophosphamide at inducing remission in AAV. Glucocorticoids and methotrexate are an effective combination for treating limited AAV where there is indolent sinus, lung or skin disease. AAV has a tendency to relapse and patients must be followed on a regular and long-term basis, monitoring urinalysis for blood and protein, plasma creatinine, ESR, CRP, lung function and PR3 or MPO antibody titres.</ce:para></ce:section><ce:section id="s1545"><ce:section-title id="st1425">Takayasu arteritis</ce:section-title><ce:para id="p5360">Takayasu arteritis affects the aorta, its major branches and occasionally the pulmonary arteries. The typical age at onset is 25–30 years, with an 8 : 1 female-to-male ratio. It has a worldwide distribution but is most common in Asia. Takayasu arteritis is characterised by granulomatous inflammation of the vessel wall, leading to occlusion or weakening of the vessel wall. It presents with claudication, fever, arthralgia and weight loss. Clinical examination may reveal loss of pulses, bruits, hypertension and aortic incompetence. Investigation will identify an acute phase response and normocytic, normochromic anaemia but the diagnosis is based on angiography, which reveals coarctation, occlusion and aneurysmal dilatation. Treatment is with high-dose glucocorticoids and immunosuppressants, as described for ANCA-associated vasculitis. With successful treatment, the 5-year survival is 83%.</ce:para></ce:section><ce:section id="s1550"><ce:section-title id="st1430">Kawasaki disease</ce:section-title><ce:para id="p5365">Kawasaki disease is a vasculitis that mostly involves the coronary vessels. It presents as an acute systemic disorder, usually affecting children under 5 years. It occurs mainly in Japan and other Asian countries, such as China and Korea, but other ethnic groups may also be affected. Presentation is with fever, generalised rash, including palms and soles, inflamed oral mucosa and conjunctival injection resembling a viral exanthem. The cause is unknown but is thought to be an abnormal immune response to an infectious trigger. Cardiovascular complications include coronary arteritis, leading to myocardial infarction, transient coronary dilatation, myocarditis, pericarditis, peripheral vascular insufficiency and gangrene. Treatment is with aspirin (5 mg/kg daily for 14 days) and IVIg (400 mg/kg daily for 4 days).</ce:para></ce:section><ce:section id="s1555"><ce:section-title id="st1435">Polyarteritis nodosa</ce:section-title><ce:para id="p5370">Polyarteritis nodosa has a peak incidence between the ages of 40 and 50, with a male-to-female ratio of 2 : 1. The annual incidence is about 2/1 000 000. Hepatitis B is an important risk factor and the incidence is 10 times higher in the Inuit of Alaska, in whom hepatitis B infection is endemic. Presentation is with fever, myalgia, arthralgia and weight loss, in combination with manifestations of multisystem disease. The most common skin lesions are palpable purpura (<ce:cross-ref id="crf1160" refid="f0280">Fig. 24.53</ce:cross-ref><ce:float-anchor refid="f0280"/>), ulceration, infarction and livedo reticularis (see <ce:cross-ref id="crf1165" refid="f0245">Fig. 24.46</ce:cross-ref>). Pathological changes comprise necrotising inflammation and vessel occlusion, and in 70% of patients arteritis of the vasa nervorum leads to neuropathy, which is typically symmetrical and affects both sensory and motor function. Severe hypertension and/or renal impairment may occur due to multiple renal infarctions but glomerulonephritis is rare (in contrast to microscopic polyangiitis). The diagnosis is confirmed by conventional or magnetic resonance angiography, which shows multiple aneurysms and smooth narrowing of mesenteric, hepatic or renal systems, or by muscle or sural nerve biopsy, which reveals the histological changes described above. Treatment is with high-dose glucocorticoids and immunosuppressants, as described for ANCA-associated vasculitis.</ce:para></ce:section><ce:section id="s1560"><ce:section-title id="st1440">Giant cell arteritis and polymyalgia rheumatica</ce:section-title><ce:para id="p5375">Giant cell arteritis (GCA) is a granulomatous arteritis that affects any large (including aorta) and medium-sized arteries. It is commonly associated with polymyalgia rheumatica (PMR), which presents with symmetrical, immobility-associated neck and shoulder girdle pain and stiffness. Since many patients with GCA have symptoms of PMR, and many patients with PMR go on to develop GCA if untreated, many rheumatologists consider them to be different manifestations of the same underlying disorder. Both diseases are rare under the age of 60 years. The average age at onset is 70, with a female-to-male ratio of about 3 : 1. The overall prevalence is about 20 per 100 000 in those over the age of 50 years.</ce:para><ce:section id="s1565"><ce:section-title id="st1445">Clinical features</ce:section-title><ce:para id="p5380">The cardinal symptom of GCA is headache, which is often localised to the temporal or occipital region and may be accompanied by scalp tenderness. Jaw pain develops in some patients, brought on by chewing or talking. Visual disturbance can occur (most specifically amaurosis) and a catastrophic presentation is with blindness in one eye due to occlusion of the posterior ciliary artery. On fundoscopy, the optic disc may appear pale and swollen with haemorrhages, but these changes may take 24–36 hours to develop and the fundi may initially appear normal. Rarely, neurological involvement may occur, with transient ischaemic attacks, brainstem infarcts and hemiparesis.</ce:para><ce:para id="p5385">In GCA, constitutional symptoms, such as weight loss, fatigue, malaise and night sweats, are common. With PMR, there may be stiffness and painful restriction of active shoulder movements on waking. Muscles are not otherwise tender, and weakness and muscle-wasting are absent. Other conditions that cause PMR-like symptoms are shown in <ce:cross-ref id="crf1170" refid="b0335">Box 24.66</ce:cross-ref><ce:float-anchor refid="b0335"/>.</ce:para></ce:section><ce:section id="s1570"><ce:section-title id="st1450">Investigations</ce:section-title><ce:para id="p5440">The typical laboratory abnormality is an elevated ESR, often with a normochromic, normocytic anaemia. CRP may also be elevated and abnormal liver function can occur. Rarely, PMR and GCA can present with a normal ESR. More objective evidence for GCA should be obtained whenever possible. There are three investigations to consider: temporal artery biopsy, ultrasound of the temporal arteries and <ce:sup loc="post">19</ce:sup>fluorodeoxyglucose positron emission tomography (<ce:sup loc="post">19</ce:sup>FDG PET scan). Characteristic biopsy findings are fragmentation of the internal elastic lamina with necrosis of the media in combination with a mixed inflammatory cell infiltrate. Diagnostic yield is highest with multiple biopsies and multiple section analysis (to detect ‘skip’ lesions). A negative biopsy does not exclude the diagnosis. On ultrasound examination, affected temporal arteries show a ‘halo’ sign. A strongly positive <ce:sup loc="post">19</ce:sup>FDG PET scan is highly specific but sensitivity is low. Caution is needed in interpreting weakly positive images. Low-grade vascular uptake may occur in atheromatous arterial disease.</ce:para></ce:section><ce:section id="s1575"><ce:section-title id="st1455">Management</ce:section-title><ce:para id="p5445">Prednisolone should be commenced urgently in suspected GCA because of the risk of visual loss (<ce:cross-ref id="crf1175" refid="b0340">Box 24.67</ce:cross-ref><ce:float-anchor refid="b0340"/>). Response is dramatic, such that symptoms will completely resolve within 48–72 hours of starting therapy in virtually all patients. It is customary to use higher doses in GCA (60–80 mg prednisolone) than in PMR (15–20 mg), although the evidence base for this is weak. In both conditions, the glucocorticoid dose should be progressively reduced, guided by symptoms and ESR, with the aim of reaching a dose of 10–15 mg by about 8 weeks. The rate of reduction should then be slowed by 1 mg per month. If symptoms recur, the dose should be increased to that which previously controlled the symptoms, and reduction attempted again in another few weeks. Most patients need glucocorticoids for an average of 12–24 months. For advice on prophylaxis against giant cell-induced osteoporosis, see <ce:cross-ref id="crf9295" refid="s1660">page 1047</ce:cross-ref>.</ce:para></ce:section></ce:section><ce:section id="s1580"><ce:section-title id="st1460">Eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome)</ce:section-title><ce:para id="p5485">Eosinophilic granulomatosis with polyangiitis (formerly known as Churg–Strauss syndrome) is a small-vessel vasculitis with an incidence of about 1–3 per 1 000 000. It is associated with eosinophilia. Some patients have a prodromal period for many years, characterised by allergic rhinitis, nasal polyposis and late-onset asthma that is often difficult to control. The typical acute presentation is with a triad of skin lesions (purpura or nodules), asymmetric mononeuritis multiplex and eosinophilia. Pulmonary infiltrates and pleural or pericardial effusions due to serositis may be present. Up to 50% of patients have abdominal symptoms provoked by mesenteric vasculitis. Patients with active disease have raised levels of ESR and CRP and an eosinophilia. Although antibodies to MPO or PR3 can be detected in up to 60% of cases, eosinophilic granulomatosis with polyangiitis is considered to be a distinct disorder from the other ANCA-associated vasculitides. Biopsy of an affected site reveals a small-vessel vasculitis with eosinophilic infiltration of the vessel wall. Management is with high-dose glucocorticoids and cyclophosphamide, followed by maintenance therapy with low-dose glucocorticoids and azathioprine, methotrexate or MMF.</ce:para></ce:section><ce:section id="s1585"><ce:section-title id="st1465">Henoch–Schönlein purpura</ce:section-title><ce:para id="p5490">Henoch–Schönlein purpura is a small-vessel vasculitis caused by immune complex deposition following an infectious trigger. It is predominantly a disease of children and young adults. The usual presentation is with purpura over the buttocks and lower legs, accompanied by abdominal pain, gastrointestinal bleeding and arthralgia. Nephritis can also occur and may present up to 4 weeks after the onset of other symptoms. Biopsy of affected tissue shows a vasculitis with IgA deposits in the vessel wall. Henoch–Schönlein purpura is usually a self-limiting disorder that settles spontaneously without specific treatment. Glucocorticoids and immunosuppressive therapy may be required in patients with more severe disease, particularly in the presence of nephritis.</ce:para></ce:section><ce:section id="s1590"><ce:section-title id="st1470">Cryoglobulinaemic vasculitis</ce:section-title><ce:para id="p5495">This is a small-vessel vasculitis that occurs when immunoglobulins precipitate out in the cold. Cryoglobulins are classified into three types (see <ce:intra-ref id="ii0520" xlink:href="pii:B978-0-7020-7028-0.00004-4#b0110">Box 4.21</ce:intra-ref>, <ce:intra-ref id="ii0525" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0565">p. 84</ce:intra-ref>). Types II and III are associated with vasculitis. The typical presentation is with a vasculitic rash over the lower limbs, arthralgia, Raynaud's phenomenon and neuropathy. Some cases are secondary to hepatitis C infection and others are associated with other autoimmune diseases. Affected patients should be screened for evidence of hepatitis B and C infection, and if the results are positive, these should be treated appropriately (<ce:intra-ref id="ii0530" xlink:href="pii:B978-0-7020-7028-0.00022-6#p2860">pp. 875</ce:intra-ref> and <ce:intra-ref id="ii0535" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0745">878</ce:intra-ref>). There is no consensus as to how best to treat cryoglobulinaemic vasculitis in the absence of an obvious trigger. Glucocorticoids and immunosuppressive therapy are often used empirically but their efficacy is uncertain. In severe cases, plasmapheresis can be considered.</ce:para></ce:section><ce:section id="s1595"><ce:section-title id="st1475">Behçet's disease</ce:section-title><ce:para id="p5500">This is a vasculitis of unknown aetiology that characteristically targets small arteries and venules. It is rare in Western Europe but more common in ‘Silk Route’ countries, around the Mediterranean and in Japan, where there is a strong association with HLA-B51.</ce:para><ce:para id="p5505">Oral ulcers are universal (<ce:cross-ref id="crf1180" refid="f0285">Fig. 24.54</ce:cross-ref><ce:float-anchor refid="f0285"/>). Unlike aphthous ulcers, they are usually deep and multiple, and last for 10–30 days. Genital ulcers are also a common problem, occurring in 60–80% of cases. The usual skin lesions are erythema nodosum or acneiform lesions but migratory thrombophlebitis and vasculitis also occur. Ocular involvement is common and may include anterior or posterior uveitis or retinal vasculitis. Neurological involvement occurs in 5% and mainly involves the brainstem, although the meninges, hemispheres and cord can also be affected, causing pyramidal signs, cranial nerve lesions, brainstem symptoms or hemiparesis. Recurrent thromboses also occur. Renal involvement is extremely rare.</ce:para><ce:para id="p5510">The diagnosis is primarily made on clinical grounds (<ce:cross-ref id="crf1185" refid="b0345">Box 24.68</ce:cross-ref><ce:float-anchor refid="b0345"/>) but one characteristic feature that can be of diagnostic value is the pathergy test, which involves pricking the skin with a needle and looking for evidence of pustule development within 48 hours.</ce:para><ce:para id="p5540">Oral ulceration can be managed with topical glucocorticoid preparations (soluble prednisolone mouthwashes, glucocorticoid pastes). Colchicine can be effective for erythema nodosum and arthralgia. Thalidomide (100–300 mg per day for 28 days initially) is very effective for resistant oral and genital ulceration but is teratogenic and neurotoxic. Glucocorticoids and immunosuppressants are indicated for uveitis and neurological disease.</ce:para></ce:section><ce:section id="s1600"><ce:section-title id="st1480">Relapsing polychondritis</ce:section-title><ce:para id="p5545">Relapsing polychondritis is a rare inflammatory disease of cartilage that classically presents with acute pain and swelling of one or both ear pinnae, sparing the lower non-cartilaginous portion. Around 30% of patients have coexisting autoimmune or connective tissue disease. Involvement of tracheobronchial cartilage leads to a hoarse voice, cough, stridor or expiratory wheeze. Other manifestations include collapse of the bridge of the nose, scleritis, hearing loss and cardiac valve dysfunction. Cartilage biopsy shows an inflammatory infiltrate in the perichondrium. Both ESR and CRP are raised in active disease. Pulmonary function tests, including flow–volume loops, should be performed to assess the degree of laryngotracheal disease, since this is an important cause of mortality. Mild disease usually responds to low-dose glucocorticoids or NSAIDs, whereas major tracheobronchial involvement requires high-dose glucocorticoids and immunosuppressants, as described for SLE.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1605"><ce:section-title id="st1485">Diseases of bone</ce:section-title><ce:section id="s1610"><ce:section-title id="st1490">Osteoporosis</ce:section-title><ce:para id="p5550">Osteoporosis is the most common bone disease. It has been estimated that more than 8.9 million fractures occur annually worldwide and most of these occur in patients with osteopenia or osteoporosis. About one-third of all women and one-fifth of men aged 50 and above suffer fractures at some point in life. The burden of osteoporosis-related fractures is predicted to increase by two- to threefold by 2050 on a worldwide basis, due to ageing of the population. Osteoporosis is under-diagnosed and under-treated in Asia and the Indian subcontinent, particularly in rural areas, due to low provision of technologies like DXA, which are required to make the diagnosis. Fractures in patients with osteoporosis can affect any bone but common sites are the forearm (Colles’ fracture), spine (vertebral fractures), humerus and hip. All of these fractures become more common with increasing age (<ce:cross-ref id="crf9010" refid="f0290">Fig. 24.55</ce:cross-ref><ce:float-anchor refid="f0290"/>). Since only about one-third of vertebral fractures come to medical attention (clinical vertebral fractures), the true number of patients with vertebral fracture is much greater than that shown in <ce:cross-ref id="crf1190" refid="f0290">Figure 24.55</ce:cross-ref>. Of these, hip fractures are the most serious and have an immediate mortality of about 12% and a continued increase in mortality of about 20% when compared with age-matched controls. Treatment of hip fracture accounts for the majority of the health-care costs associated with osteoporosis.</ce:para><ce:section id="s1615"><ce:section id="s1620"><ce:section-title id="st1495">Pathophysiology</ce:section-title><ce:para id="p5555">The defining feature of osteoporosis is reduced bone density, which causes micro-architectural deterioration of bone tissue and leads to an increased risk of fracture, in response to minor trauma. The risk of fracture increases markedly with age in both genders (<ce:cross-ref id="crf1195" refid="f0290">Fig. 24.55</ce:cross-ref>). This is mostly attributable to an increased risk of falling with age (<ce:intra-ref id="ii0540" xlink:href="pii:B978-0-7020-7028-0.00032-9#s0135">p. 1308</ce:intra-ref>) but is also due in part to an age-related decline in bone mass, especially in women (<ce:cross-ref id="crf1200" refid="f0300">Fig. 24.56</ce:cross-ref><ce:float-anchor refid="f0300"/>). Bone mass increases during growth to reach a peak between the ages of 20 and about 45 years, but falls thereafter in both genders with an accelerated phase of bone loss after the menopause in women due to oestrogen deficiency. The loss of bone with ageing is caused by an imbalance in the bone remodelling cycle, whereby the amount of new bone formed by osteoblasts cannot keep pace with the amount that is removed by osteoclasts (see <ce:cross-ref id="crf1205" refid="f0025">Fig. 24.2</ce:cross-ref>, <ce:cross-ref id="crf9300" refid="u0275">p. 985</ce:cross-ref>). The reduction in bone formation is thought to be partly due to differentiation of bone marrow stem cells to adipocytes, as opposed to osteoblasts. Osteoporosis sometimes occurs because of failure to attain adequate levels of peak bone mass but is more commonly due to age-related bone loss.</ce:para><ce:para id="p5560">Osteoporosis is a complex disease that can occur in association with a wide variety of risk factors, as summarised in <ce:cross-ref id="crf1210" refid="b0350">Box 24.69</ce:cross-ref><ce:float-anchor refid="b0350"/>. Genetic factors account for up to 80% of variation in bone density, and genome-wide association studies have shown that susceptibility is determined in part by a large number of common variants, some of which are involved in the RANK and Wnt signalling pathways (see <ce:cross-ref id="crf1225" refid="f0030">Fig. 24.3</ce:cross-ref>, <ce:cross-ref id="crf9305" refid="s0045">p. 986</ce:cross-ref>). Rarely, osteoporosis may be caused by mutations in single genes. Environmental factors, such as exercise and calcium intake during growth and adolescence, are important in maximising peak bone mass and in regulating rates of post-menopausal bone loss. Smoking has a detrimental effect on BMD and is associated with an increased fracture risk, partly because female smokers have an earlier menopause than non-smokers. Heavy alcohol intake is a recognised cause of osteoporosis and fractures but moderate intake does not substantially alter risk.</ce:para><ce:section id="s1625"><ce:section-title id="st1500">Idiopathic osteoporosis</ce:section-title><ce:para id="p5745">The term idiopathic osteoporosis is frequently used to describe the occurrence of osteoporosis in patients with no specific underlying cause. It is slightly misleading, since most, if not all, patients in this category have age-related osteoporosis or osteoporosis associated with inheritance of genetic variants that regulate bone density.</ce:para></ce:section><ce:section id="s1630"><ce:section-title id="st1505">Secondary osteoporosis</ce:section-title><ce:para id="p5750">Osteoporosis can occur in association with a variety of diseases and drug treatments, and in many cases more than one disease or risk factor is operative. The most important causes are summarised in <ce:cross-ref id="crf1230" refid="b0350">Box 24.69</ce:cross-ref>. Secondary causes of osteoporosis are particularly common in men, occurring in up to 50% of patients. Hypogonadism, glucocorticoid use (see below) and alcohol excess are the most important predisposing factors.</ce:para></ce:section><ce:section id="s1635"><ce:section-title id="st1510">Glucocorticoid-induced osteoporosis</ce:section-title><ce:para id="p5755">Glucocorticoid-induced osteoporosis is a common problem in patients with systemic inflammatory and chronic pulmonary diseases. The risk of osteoporosis is related to dose and duration of glucocorticoid therapy and increases substantially in patients who have taken more than 7.5 mg of prednisolone daily for more than 3 months (or an equivalent dose of another glucocorticoid). Inhaled glucocorticoids can reduce bone density but the risk of osteoporosis is much lower than with systemic therapy. Glucocorticoids mainly cause osteoporosis by inhibiting bone formation and causing apoptosis of osteoblasts and osteocytes. Other contributory mechanisms include inhibition of intestinal calcium absorption, increased renal excretion of calcium and secondary hyperparathyroidism, which stimulates osteoclastic bone resorption.</ce:para></ce:section><ce:section id="s1640"><ce:section-title id="st1515">Pregnancy-associated osteoporosis</ce:section-title><ce:para id="p5760">This is a rare form of osteoporosis that typically presents with back pain and multiple vertebral fractures during the second or third trimester. The cause is unknown but may relate to an exaggeration of the bone loss that normally occurs during pregnancy in patients with pre-existing low bone mass.</ce:para></ce:section></ce:section><ce:section id="s1645"><ce:section-title id="st1520">Clinical features</ce:section-title><ce:para id="p5765">Osteoporosis does not cause symptoms until a fracture occurs. Non-vertebral fractures are almost always caused by a traumatic event, most usually a simple fall. The term ‘fragility fracture’ is used to describe a fracture that occurs as the result of a fall from standing height or less. These are typical of osteoporosis. It is important to remember that the majority of people who suffer a fragility fracture do not have osteoporosis; some have normal bone density but most have osteopenia (<ce:cross-ref id="crf1235" refid="f0305">Fig. 24.57</ce:cross-ref><ce:float-anchor refid="f0305"/> and <ce:cross-ref id="crf9310" refid="s0085">p. 988</ce:cross-ref>). The clinical signs of fracture are pain, local tenderness and deformity. In hip fracture, the patient is (with rare exceptions) unable to weight-bear and has a shortened and externally rotated limb on the affected side. The presentation of vertebral fractures is variable. Some patients present with acute severe back pain. This may radiate to the anterior chest or abdominal wall and be mistaken for a myocardial infarction, aortic dissection or intra-abdominal pathology (<ce:intra-ref id="ii0555" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0030">p. 176</ce:intra-ref>). In others the presentation is with height loss and kyphosis in the absence of pain or with chronic back pain. Sometimes the presentation of osteoporosis is with radiological osteopenia or as a vertebral deformity on an X-ray that has been performed for other reasons.</ce:para></ce:section><ce:section id="s1650"><ce:section-title id="st1525">Investigations</ce:section-title><ce:para id="p5770">The most important investigation is DXA at the lumbar spine and hip (see <ce:cross-ref id="crf1240" refid="f0060">Fig. 24.9</ce:cross-ref>, <ce:cross-ref id="crf9315" refid="s0130">p. 990</ce:cross-ref>). This should be considered in patients age over 50 who have already suffered a fragility fracture, and in those with clinical risk factors (<ce:cross-ref id="crf1245" refid="b0355">Box 24.70</ce:cross-ref><ce:float-anchor refid="b0355"/>) when a fracture risk assessment tool (<ce:cross-ref id="crf9320" refid="s2040">p. 1060</ce:cross-ref>) has returned an elevated value. The risk at which DXA should be performed remains a subject of debate but a 10-year risk of over 10% has been suggested, since there is evidence of benefit from treatment at this level. Other indications for DXA are in patients under 50 years who have very strong risk factors, such as premature menopause or high-dose glucocorticoids. <ce:cross-ref id="crf1250" refid="f0310">Figure 24.58</ce:cross-ref><ce:float-anchor refid="f0310"/> provides a suggested algorithm for the investigation of patients with suspected osteoporosis.</ce:para><ce:para id="p5810">A history should be taken to identify any predisposing causes, such as early menopause, excessive alcohol intake, smoking and glucocorticoid therapy. Signs of endocrine disease, neoplasia and inflammatory disease should be sought on clinical examination. A falls history should be taken and a ‘get up and go’ test performed, especially in older patients (<ce:intra-ref id="ii0575" xlink:href="pii:B978-0-7020-7028-0.00032-9#b0010">p. 1303</ce:intra-ref>). Screening for secondary causes of osteoporosis should be performed, as summarised in <ce:cross-ref id="crf1260" refid="b0360">Box 24.71</ce:cross-ref><ce:float-anchor refid="b0360"/>.</ce:para></ce:section><ce:section id="s1655"><ce:section-title id="st1530">Management</ce:section-title><ce:para id="p5820">The aim of treatment is to reduce the risk of fracture and this can be achieved by a combination of approaches.</ce:para><ce:section id="s1660"><ce:section-title id="st1535">Non-pharmacological interventions</ce:section-title><ce:para id="p5825">Advice on smoking cessation, moderation of alcohol intake, adequate dietary calcium intake and exercise should be given. Those with recurrent falls or unsteadiness on a ‘get up and go’ test should be referred to a multidisciplinary falls prevention team (<ce:intra-ref id="ii0580" xlink:href="pii:B978-0-7020-7028-0.00032-9#s0135">p. 1308</ce:intra-ref>). Hip protectors can reduce the risk of hip fracture in selected patients but adherence is often poor.</ce:para></ce:section><ce:section id="s1665"><ce:section-title id="st1540">Pharmacological interventions</ce:section-title><ce:para id="p5830">Several drug treatments are now available to reduce the risk of fracture in osteoporosis. The dosages, mode of administration and indications are summarised in <ce:cross-ref id="crf1275" refid="b0365">Box 24.72</ce:cross-ref><ce:float-anchor refid="b0365"/>. More detail on the individual drugs is provided below.</ce:para><ce:section id="s1670"><ce:section-title id="st1545">Bisphosphonates</ce:section-title><ce:para id="p5845">Bisphosphonates are the first-line treatment for osteoporosis. These are a class of drugs with a central core of P-C-P atoms, to which various side-chains are attached. Following administration, they target bone surfaces and are ingested by osteoclasts during the process of bone resorption. The bisphosphonate is released within the osteoclasts and impairs bone resorption. This in turn causes an increase in bone density but this is principally due to increased mineralisation of bone, rather than an increase in bone mass (<ce:cross-ref id="crf1280" refid="f0315">Fig. 24.59</ce:cross-ref><ce:float-anchor refid="f0315"/>). Bisphosphonates reduce the risk of fracture in patients with osteoporosis but do not completely prevent fractures occurring.</ce:para><ce:para id="p5850">Oral bisphosphonates are typically given for a period of 5 years, at which point the need for continued therapy should be evaluated, with a repeat DXA if possible. If patients have remained free of fractures after 5 years and if BMD levels have increased and no longer remain in the osteoporotic range, it is usual to instigate a 5-year spell off therapy. Treatment may be continued for up to 10 years in patients whose BMD levels remain in the osteoporotic range after 5 years. A change in treatment should be considered in patients who have lost BMD despite oral bisphosphonates (more than 4%). Most commonly, this will be a switch to parenteral zoledronic acid but teriparatide (TPTD) can also be considered in those with severe spinal osteoporosis. With intravenous zoledronic acid, 3 years of therapy is equivalent to 6 years in terms of fracture risk reduction and many experts recommend periods of 3 years on and 3 years off treatment to reduce the risk of over-suppression of bone turnover.</ce:para><ce:para id="p5855">Oral bisphosphonates are poorly absorbed from the gastrointestinal tract and should be taken on an empty stomach with plain water; no food should be eaten for 30–45 minutes after administration. They are contraindicated in patients with oesophageal stricture or achalasia, since tablets may stick in the oesophagus, causing ulceration and perforation. Upper gastrointestinal upset occurs in about 5% of cases. Oral bisphosphonates can be used in patients with gastro-oesophageal reflux disease but may cause worsening of symptoms. The most common adverse effect with intravenous bisphosphonates is a transient influenza-like illness typified by fever, malaise, anorexia and generalised aches, which occurs 24–48 hours after administration. This is self-limiting but can be treated with paracetamol or NSAIDs if necessary. It predominantly occurs after the first exposure and tolerance develops thereafter. Other adverse effects are shown in <ce:cross-ref id="crf1285" refid="b0370">Box 24.73</ce:cross-ref><ce:float-anchor refid="b0370"/>. Osteonecrosis of the jaw is characterised by the presence of necrotic bone in the mandible or maxilla, typically occurring after tooth extraction when the socket fails to heal. This complication is very rare in osteoporosis but patients receiving bisphosphonates should be advised to pay attention to good oral hygiene. There is no evidence that temporarily stopping bisphosphonates for tooth extraction alters the risk of osteonecrosis of the jaw. Atypical subtrochanteric fractures have been described in patients who have received long-term bisphosphonates and appear to be the result of over-suppression of normal bone remodelling. In the vast majority, the benefits of bisphosphonate therapy far outweigh the risks but it is important for treatment to be targeted to patients with low BMD who are most likely to benefit.</ce:para></ce:section><ce:section id="s1690"><ce:section-title id="st1565">Denosumab</ce:section-title><ce:para id="p5915">Denosumab is a monoclonal antibody that inhibits bone resorption by neutralising the effects of RANKL (see <ce:cross-ref id="crf1290" refid="f0025">Fig. 24.2</ce:cross-ref>, <ce:cross-ref id="crf9325" refid="u0275">p. 985</ce:cross-ref>). It is administered by subcutaneous injection of 60 mg every 6 months in the treatment of osteoporosis and has similar efficacy to zoledronic acid. One potential adverse effect is hypocalcaemia but this can be mitigated by calcium and vitamin D supplements. Denosumab may rarely cause osteonecrosis of the jaw and atypical subtrochanteric fractures. If it is stopped, there is a rebound increase in bone turnover that can be associated with a greater risk of fracture and even hypercalcaemia. Because of this, many experts advise giving a bisphosphonate following cessation of denosumab.</ce:para></ce:section><ce:section id="s1695"><ce:section-title id="st1570">Calcium and vitamin D</ce:section-title><ce:para id="p5920">Combined calcium and vitamin D supplements have limited efficacy in the prevention of osteoporotic fractures when given alone but are widely used as an adjunct to other treatments. A typical daily dosage is 1000 mg calcium and 800 IU vitamin D. Calcium and vitamin D supplements have efficacy in preventing fragility fractures in elderly or institutionalised patients who are at high risk of deficiency (<ce:cross-ref id="crf1295" refid="b0375">Box 24.74</ce:cross-ref><ce:float-anchor refid="b0375"/>). Vitamin D supplements alone do not prevent fractures in osteoporosis but there is evidence that the response to bisphosphonates is blunted in patients with vitamin D deficiency. If the patient's dietary calcium is sufficient, stand-alone vitamin D supplements (800 IU daily) can be prescribed as an adjunct to anti-osteoporosis therapies.</ce:para></ce:section><ce:section id="s1700"><ce:section-title id="st1575">Teriparatide</ce:section-title><ce:para id="p5960">Teriparatide (TPTD) is the 1-34 fragment of human PTH. It is an effective treatment for osteoporosis, which works by stimulating new bone formation. Although TPTD also stimulates bone resorption, the increase in bone formation is greater, resulting in increased bone density, particularly at sites rich in trabecular bone such as the spine. It is given by a self-administered subcutaneous injection in a dose of 20 µg daily for 2 years. At the end of this period, bisphosphonate therapy or another inhibitor of bone resorption should be administered to maintain the increase in BMD. TPTD and oral bisphosphonates should not be given in combination, however, since the bisphosphonate blunts the anabolic effect. The efficacy of TPTD for prevention of non-vertebral fractures is similar to that of bisphosphonates but it is superior to oral bisphosphonates in preventing vertebral fractures. The most common adverse effects are headache, muscle cramps and dizziness. Mild hypercalcaemia may occur but it is usually asymptomatic and does not require discontinuation of treatment. Monitoring of serum calcium is not required during TPTD treatment.</ce:para></ce:section><ce:section id="s9005"><ce:section-title id="st9000">Abaloparatide</ce:section-title><ce:para id="p9010">Abaloparatide is the 1-34 fragment of PTH-related protein. It works in a similar way to TPTD to stimulate bone formation. It is given as a self-administered injection of 80 μg daily for 18 months. At the end of this period an inhibitor of bone resorption should be given to maintain the increase in bone mass. Efficacy has been demonstrated for the prevention of vertebral fractures with effects similar to those of TPTD. Adverse effects are similar to those of TPTD.</ce:para></ce:section><ce:section id="s1705"><ce:section-title id="st1580">Hormone replacement therapy</ce:section-title><ce:para id="p5965">Cyclical HRT with oestrogen and progestogen prevents post-menopausal bone loss and reduces the risk of vertebral and non-vertebral fractures in post-menopausal women. It is primarily indicated for the prevention of osteoporosis in women with an early menopause (<ce:intra-ref id="ii0595" xlink:href="pii:B978-0-7020-7028-0.00018-4#p2280">p. 655</ce:intra-ref>) and for treatment of women with osteoporosis in their early fifties who have troublesome menopausal symptoms. It is not recommended above the age of 60 because the risk of an increased risk of breast cancer, cardiovascular disease and venous thromboembolic disease.</ce:para></ce:section><ce:section id="s1710"><ce:section-title id="st1585">Raloxifene</ce:section-title><ce:para id="p5970">Raloxifene is a selective oestrogen receptor modulator (SERM) that acts as a partial agonist at oestrogen receptors in bone and liver, but as an antagonist in breast and endometrium. It is effective in reducing the risk of vertebral fractures but does not influence the risk of non-vertebral fracture and is seldom used. Adverse effects include muscle cramps, worsening of hot flushes and an increased risk of venous thromboembolic disease. Bazedoxifene is a related SERM that has similar effects to raloxifene.</ce:para></ce:section><ce:section id="s1715"><ce:section-title id="st1590">Tibolone</ce:section-title><ce:para id="p5975">Tibolone has partial agonist activity at oestrogen, progestogen and androgen receptors. It has been shown to prevent vertebral and non-vertebral fractures in post-menopausal osteoporosis. Treatment is associated with a slightly increased risk of stroke but a reduced risk of breast cancer.</ce:para></ce:section><ce:section id="s1720"><ce:section-title id="st1595">Other drugs</ce:section-title><ce:para id="p5980">Romosozumab is antibody directed against sclerostin, which is under development for the treatment of osteoporosis. It increases bone formation, inhibits bone resorption and increases BMD. When given subcutaneously in a dose of 210 mg monthly, it reduces the risk of vertebral fractures in patients with postmenopausal osteoporosis. Calcitriol (1,25(OH)<ce:inf loc="post">2</ce:inf>D<ce:inf loc="post">3</ce:inf>), the active metabolite of vitamin D, is licensed for treatment of osteoporosis but it is seldom used because the data on fracture prevention are less robust than for other agents.</ce:para></ce:section></ce:section><ce:section id="s1725"><ce:section-title id="st1600">Surgery</ce:section-title><ce:para id="p5985">Orthopaedic surgery with internal fixation is frequently required to reduce and stabilise osteoporotic fractures. Patients with intracapsular fracture of the femoral neck generally need hemi-arthroplasty or total hip replacement in view of the high risk of avascular necrosis.</ce:para><ce:para id="p5990">Vertebroplasty is sometimes used in the treatment of painful vertebral compression fractures. It involves injecting methyl methacrylate (MMA) into the affected vertebral body under sedation and local anaesthesia. While randomised trials have shown that vertebroplasty provides no better pain relief than a sham procedure, it is still widely used, particularly in North America. Kyphoplasty is used under similar circumstances, but in this case a needle is introduced into the affected vertebral body and a balloon is inflated, which is then filled with MMA. It has similar efficacy to vertebroplasty but adverse effects are more common. Adverse effects with both procedures include spinal cord compression due to leakage of MMA and fat embolism.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1730"><ce:section-title id="st1605">Osteomalacia, rickets and vitamin D deficiency</ce:section-title><ce:para id="p5995">Osteomalacia and rickets are characterised by defective mineralisation of bone. The most common cause is vitamin D deficiency, but both conditions can also occur as the result of inherited defects in renal phosphate excretion, and inherited defects in the vitamin D receptor and in the pathways responsible for vitamin D activation. Other causes are summarised in <ce:cross-ref id="crf1300" refid="b0380">Box 24.75</ce:cross-ref><ce:float-anchor refid="b0380"/> and are discussed in more detail below. The term osteomalacia refers to the syndrome when it occurs in adults and rickets is the equivalent syndrome in children. The disease remains prevalent in frail older people who have a poor diet and limited sunlight exposure, and in some Muslim women.</ce:para><ce:section id="s1735"><ce:section-title id="st1610">Vitamin D deficiency</ce:section-title><ce:para id="p6005">Vitamin D deficiency is defined to exist when serum 25(OH)D concentrations are below 25 nmol/L (10 ng/mL). People with vitamin D levels in the range 25–50 nmol/L (10–20 ng/mL) are classified as having vitamin D insufficiency, whereas those with 25(OH)D levels above 50 nmol/L (20 ng/mL) are classified as having normal vitamin D status. In the elderly, a more appropriate normal threshold may be 75 nmol/L (30 ng/mL) or more, though there is some debate on the issue and evidence is not conclusive. The likelihood of developing vitamin D deficiency is strongly related to sunlight exposure. It is common in northern latitudes (or southern latitudes in the southern hemisphere) and shows seasonal variation. Vitamin D deficiency is also common in women who, for cultural reasons, cover their skin and face. Vitamin D deficiency is more common in the winter and spring, and less common in summer and autumn (<ce:cross-ref id="crf1305" refid="f0320">Fig. 24.60</ce:cross-ref><ce:float-anchor refid="f0320"/>).</ce:para><ce:section id="s1740"><ce:section-title id="st1615">Pathogenesis</ce:section-title><ce:para id="p6010">The source of vitamin D and pathways involved in regulating its metabolism are shown in <ce:cross-ref id="crf1310" refid="f0325">Figure 24.61</ce:cross-ref><ce:float-anchor refid="f0325"/>. In normal individuals, vitamin D (also known as cholecalciferol) comes from two sources: about 70% is made in the skin, where 7-dehydrocholesterol is converted to cholecalciferol under the influence of ultraviolet light, whereas the remaining 30% is derived from the diet. The main dietary sources are oily fish and meat, although bread and dairy products are fortified with vitamin D in some countries. On entering the circulation, vitamin D is hydroxylated in the liver to form 25(OH) vitamin D and this is further hydroxylated in the kidney to form 1,25(OH)<ce:inf loc="post">2</ce:inf>D, the biologically active metabolite. The 1,25(OH)<ce:inf loc="post">2</ce:inf>D primarily acts on the gut to increase intestinal calcium absorption but also acts on the skeleton to stimulate bone remodelling. Synthesis of 1,25(OH)<ce:inf loc="post">2</ce:inf>D is regulated by a negative feedback loop orchestrated by the parathyroid glands. When vitamin D levels fall – as the result of lower sunlight exposure or dietary lack – production of 1,25(OH)<ce:inf loc="post">2</ce:inf>D is reduced, causing a reduction in calcium absorption from the gut. This causes a transient fall in serum calcium, which is detected by calcium-sensing receptors on the parathyroid chief cells; this increases PTH secretion, which restores calcium levels to normal. Vitamin D deficiency is, therefore, usually characterised by a low level of 25(OH)D and a raised level of PTH. Sometimes, low 25(OH)D levels may be observed in the presence of a normal PTH concentration. This is of uncertain clinical significance but might be due to variations in levels of vitamin D-binding protein. Serum concentrations of vitamin D are under genetic control and are associated with variants close to the <ce:italic>GC</ce:italic> gene, which encodes vitamin D-binding protein; the <ce:italic>DHCR7</ce:italic> gene, which encodes 7-dehydrocholesterol reductase, responsible for catalysing conversion of 7-DHC to 25(OH)D; the <ce:italic>CYP2R1</ce:italic> gene, which encodes vitamin D-25-hydroxylase, responsible for hydroxylation of vitamin D in the liver; and the <ce:italic>CYP24A1</ce:italic> gene, which encodes vitamin D-24-hydroxylase, responsible for converting 25(OH)D to the inactive metabolite 24,25(OH)<ce:inf loc="post">2</ce:inf>D.</ce:para></ce:section><ce:section id="s1745"><ce:section-title id="st1620">Clinical features</ce:section-title><ce:para id="p6015">Vitamin D deficiency does not cause symptoms and the diagnosis is made as the result of biochemical testing. Low circulating concentrations of vitamin D have been associated with a wide range of diseases, including most types of cancer, diabetes, multiple sclerosis and chronic inflammatory diseases. These associations are unlikely to be causal but most probably arise as the result of reduced sunlight exposure and poor diet in people who are ill. If vitamin D deficiency is prolonged and severe, then osteomalacia and rickets may occur, as discussed below. The consequences of biochemical vitamin D deficiency and insufficiency on bone health and general health are unclear.</ce:para></ce:section><ce:section id="s1750"><ce:section-title id="st1625">Investigations</ce:section-title><ce:para id="p6020">The diagnosis can be made by measurement of serum 25(OH)D. In patients with low 25(OH)D, measurements of PTH, serum calcium, phosphate and ALP should also be considered. Low levels of 25(OH)D in the absence of other abnormalities is unlikely to be of any clinical significance and may be due to low levels of vitamin D-binding protein. If low 25(OH)D levels are combined with raised levels of PTH, this is of more significance since it indicates secondary hyperparathyroidism. Serum ALP, calcium and phosphate levels are normal in uncomplicated vitamin D deficiency.</ce:para></ce:section><ce:section id="s1755"><ce:section-title id="st1630">Management</ce:section-title><ce:para id="p6025">The clinical benefit of treating biochemical vitamin D deficiency is uncertain. Vitamin D supplements should be considered in patients who have low 25(OH)D levels and raised levels of PTH. In most patients, cholecalciferol in a dose of 800 IU daily should be sufficient to correct the deficiency. The benefit of treating seasonal vitamin D deficiency or vitamin D insufficiency is uncertain. There is some evidence that response to bisphosphonate treatment of osteoporosis is impaired in patients with vitamin D deficiency and this is another indication for supplements. In patients who are receiving intravenous bisphosphonates and denosumab for osteoporosis, vitamin D deficiency should be corrected by supplementation to reduce the risk of hypocalcaemia. In this case, it is customary to give higher doses of vitamin D, such as 20 000–25 000 IU once a week for 4 weeks or to give lower doses over a more prolonged period.</ce:para></ce:section></ce:section><ce:section id="s1760"><ce:section-title id="st1635">Osteomalacia and rickets</ce:section-title><ce:para id="p6030">Severe and prolonged vitamin D deficiency can result in the occurrence of osteomalacia in adults and rickets in children. Improvements in nutrition mean that these are now relatively uncommon conditions in developed countries but they remain prevalent in elderly housebound individuals, some Muslim women who wear a veil (hijab) that covers a large amount of exposed skin, and people with malabsorption.</ce:para><ce:section id="s1765"><ce:section-title id="st1640">Pathogenesis</ce:section-title><ce:para id="p6035">Osteomalacia and rickets occur as the result of chronic secondary hyperparathyroidism, which invariably accompanies severe and long-standing vitamin D deficiency. The sustained elevation in PTH levels maintains normal levels of serum calcium by increasing bone resorption, which eventually causes progressive demineralisation of the skeleton. Phosphate that is released during the process of bone resorption is lost through increased renal excretion, resulting in hypophosphataemia. The raised levels of PTH stimulate osteoblast activity and cause new bone formation but the matrix is not mineralised properly because of deficiency of calcium and phosphate. The under-mineralised bone is soft, mechanically weak and subject to fractures, particularly stress fractures. Normal levels of serum calcium tend to be maintained until a very advanced stage, when hypocalcaemia may occur.</ce:para></ce:section><ce:section id="s1770"><ce:section-title id="st1645">Clinical features</ce:section-title><ce:para id="p6040">Vitamin D deficiency in children causes delayed development, muscle hypotonia, craniotabes (small unossified areas in membranous bones of the skull that yield to finger pressure with a cracking feeling), bossing of the frontal and parietal bones and delayed anterior fontanelle closure, enlargement of epiphyses at the lower end of the radius, and swelling of the rib costochondral junctions (‘rickety rosary’). Osteomalacia in adults can present with fractures and low BMD, mimicking osteoporosis. Other symptoms include bone pain and general malaise. Proximal muscle weakness is prominent and the patient may walk with a waddling gait and struggle to climb stairs or stand up from a chair. There may be bone and muscle tenderness on pressure, and focal bone pain can be due to fissure fractures of the ribs and pelvis.</ce:para></ce:section><ce:section id="s1775"><ce:section-title id="st1650">Investigations</ce:section-title><ce:para id="p6045">The diagnosis can usually be made by measurement of serum 25(OH)D, PTH, calcium, phosphate and ALP. Typically, serum ALP levels are raised, 25(OH)D levels are undetectable and PTH is markedly elevated. Serum phosphate levels tend to be low but serum calcium is usually normal, unless the disease is advanced. X-rays often show osteopenia or vertebral crush fractures and, with more advanced disease, focal radiolucent areas (pseudofractures or Looser's zones) may be seen in ribs, pelvis and long bones (<ce:cross-ref id="crf1315" refid="f0330">Fig. 24.62A</ce:cross-ref><ce:float-anchor refid="f0330"/>). In children, there is thickening and widening of the epiphyseal plate. A radionuclide bone scan may show multiple hot spots in the ribs and pelvis at the site of fractures and the appearance may be mistaken for metastases. Where there is doubt, the diagnosis can be confirmed by bone biopsy, which shows the pathognomonic features of increased thickness and extent of osteoid seams (<ce:cross-ref id="crf1320" refid="f0330">Fig. 24.62B</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1780"><ce:section-title id="st1655">Management</ce:section-title><ce:para id="p6050">Osteomalacia and rickets respond promptly to treatment with vitamin D. A wide variety of doses can be used. Treatment with between 10 000 and 25 000 IU daily for 2–4 weeks is associated with rapid clinical improvement, an elevation in serum 25(OH)D and a reduction in PTH. Serum ALP levels sometimes rise initially as mineralisation of bone increases but eventually fall to within the reference range as the bone disease heals. Subsequently, the dose of vitamin D can usually be reduced to a maintenance level of 800–1600 IU daily (10–20 µg), except in patients with malabsorption, who may require higher doses.</ce:para></ce:section></ce:section><ce:section id="s1785"><ce:section-title id="st1660">Vitamin D-resistant rickets</ce:section-title><ce:para id="p6055">This is a genetically determined condition that presents in childhood with rickets that is resistant to therapy with vitamin D in standard dosages.</ce:para><ce:section id="s1790"><ce:section-title id="st1665">Pathogenesis</ce:section-title><ce:para id="p6060">Type I vitamin D-resistant rickets (VDRR) is caused by inactivating mutations in the 25-hydroxyvitamin D 1α-hydroxylase (<ce:italic>CYP27B1</ce:italic>) enzyme, which converts 25(OH)D to the active metabolite 1,25(OH)<ce:inf loc="post">2</ce:inf>D<ce:inf loc="post">3</ce:inf>. Type II VDRR is caused by inactivating mutations in the vitamin D receptor, which impair its ability to activate gene transcription. Both are recessive disorders and consanguinity is common.</ce:para></ce:section><ce:section id="s1795"><ce:section-title id="st1670">Clinical features</ce:section-title><ce:para id="p6065">These are as described above for infantile rickets. The diagnosis is usually first suspected when the patient fails to respond to vitamin D supplementation.</ce:para></ce:section><ce:section id="s1800"><ce:section-title id="st1675">Investigations</ce:section-title><ce:para id="p6070">The biochemical features of type I VDRR are similar to those of ordinary vitamin D deficiency, except that levels of 25(OH)D are normal but 1,25(OH)<ce:inf loc="post">2</ce:inf>D is low. In type II VDRR, 25(OH)D is normal but PTH and 1,25(OH)<ce:inf loc="post">2</ce:inf>D<ce:inf loc="post">3</ce:inf> values are raised.</ce:para></ce:section><ce:section id="s1805"><ce:section-title id="st1680">Management</ce:section-title><ce:para id="p6075">Type I VDRR responds fully to treatment with the active vitamin D metabolites 1α-hydroxyvitamin D (1–2 µg daily, orally) or 1,25-dihydroxyvitamin D (0.25–1.5 µg daily, orally). Calcium supplements are not necessary unless there is dietary deficiency. Type II VDRR sometimes responds partially to very high doses of active vitamin D metabolites, which can activate the mutant receptor, although additional calcium and phosphate supplements are also necessary.</ce:para></ce:section></ce:section><ce:section id="s1810"><ce:section-title id="st1685">Hereditary hypophosphataemic rickets</ce:section-title><ce:para id="p6080">This group of disorders are caused by inherited defects in renal tubular phosphate reabsorption. The most common is X-linked hypophosphataemic rickets (XLH), but autosomal dominant and autosomal recessive forms also occur (<ce:cross-ref id="crf1325" refid="b0380">Box 24.75</ce:cross-ref>).</ce:para><ce:section id="s1815"><ce:section-title id="st1690">Pathophysiology</ce:section-title><ce:para id="p6085">All forms of hereditary hypophosphataemic rickets are associated with raised circulating concentrations of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23). This hormone is produced by osteocytes (see <ce:cross-ref id="crf1330" refid="f0030">Fig 24.3</ce:cross-ref>, <ce:cross-ref id="crf9330" refid="s0045">p. 986</ce:cross-ref>) and enters the circulation, where it is normally inactivated by proteolytic cleavage. Production of FGF23 by osteocytes is under tonic inhibition by DMP1 and PHEX. In XLH, the inhibitory effect on FGF23 production is lost due to mutations in <ce:italic>PHEX</ce:italic> and a similar situation occurs in autosomal recessive hypophosphataemic rickets (ARHR1) due to loss-of-function mutations in <ce:italic>DMP1</ce:italic>. Mutations in the <ce:italic>ENPP1</ce:italic> gene, which encodes a phosphatase responsible for degradation of pyrophosphate, can also cause a recessive form of hypophosphataemic rickets (ARHR2). In autosomal dominant hypophosphataemic rickets (ADHR), the FGF23 protein carries mutations that prevent FGF23 being degraded, thereby causing accumulation of intact FGF23 hormone in the circulation. In all three diseases, the elevation in FGF23 results in osteomalacia and rickets by causing phosphaturia by down-regulation of sodium-dependent phosphate transporters in the renal tubules, and also by inhibiting conversion of 25(OH)D to 1,25(OH)<ce:inf loc="post">2</ce:inf>D by the kidney, which in turn causes reduced calcium and phosphate absorption from the gut.</ce:para></ce:section><ce:section id="s1820"><ce:section-title id="st1695">Clinical features</ce:section-title><ce:para id="p6090">The presentation is with symptoms and signs of rickets during childhood that do not respond to vitamin D supplementation. In adults, hypophosphataemic rickets may be accompanied by dental abscesses, and by bone and joint pain due to the development of an enthesopathy.</ce:para></ce:section><ce:section id="s1825"><ce:section-title id="st1700">Investigations</ce:section-title><ce:para id="p6095">The diagnosis can be confirmed by the finding of low serum phosphate levels and a reduction in tubular reabsorption of phosphate. Serum levels of vitamin D are normal and PTH is normal or slightly elevated. Serum concentrations of FGF23 are markedly elevated. The causal mutation can be defined by genetic testing.</ce:para></ce:section><ce:section id="s1830"><ce:section-title id="st1705">Management</ce:section-title><ce:para id="p6100">The aim of treatment is to ameliorate symptoms, restore normal growth and maintain serum phosphate levels within the reference range. Traditionally, treatment has been with phosphate supplements (1–4 g daily) and 1-α-hydroxyvitamin D (1–2 µg daily) or 1,25-dihydroxyvitamin D (0.5–1.5 µg daily) with the aim of promoting intestinal calcium and phosphate absorption. Levels of calcium and phosphate, as well as renal function, should be monitored regularly and the doses of phosphate and vitamin D metabolites carefully titrated to maintain serum phosphate within the normal range but avoid hypercalcaemia. Recently, a neutralising antibody to FGF23 has been developed that can reverse the biochemical abnormalities in hereditary hypophosphataemic rickets and it is likely that this will be a future treatment option.</ce:para></ce:section></ce:section><ce:section id="s1835"><ce:section-title id="st1710">Tumour-induced osteomalacia</ce:section-title><ce:para id="p6105">This is a rare syndrome caused by over-production of FGF23 by mesenchymal tumours. The presentation is with severe osteomalacia and hypophosphataemia in an adult patient with no obvious predisposing risk factor for vitamin D deficiency. Biochemical findings are as described for <ce:cross-ref id="crf1335" refid="s1810">hereditary hypophosphataemic rickets</ce:cross-ref>. The underlying tumour can sometimes be identified by whole-body MRI or CT. Medical management is with phosphate supplements and active vitamin D metabolites but the treatment of choice is surgical resection of the primary tumour, which is curative.</ce:para></ce:section><ce:section id="s1840"><ce:section-title id="st1715">Hypophosphatasia</ce:section-title><ce:para id="p6110">Hypophosphatasia is an autosomal recessive disorder caused by loss-of-function mutations in the <ce:italic>TNALP</ce:italic> gene, which result in accumulation of pyrophosphate and inhibition of bone mineralisation. Chondrocalcinosis may also occur. The typical presentation is with severe intractable rickets during infancy, sometimes in association with seizures. Investigations show low or undetectable levels of serum ALP but normal levels of calcium, phosphate, PTH and vitamin D metabolites. Urinary excretion of pyridoxal 5′ phosphate and phosphoethanolamine (substrates for ALP) is increased. Until recently, this condition was fatal during childhood but remarkable therapeutic responses have been obtained with recombinant ALP therapy (asfotase alfa), which is curative. Heterozygous carriers of mutation in <ce:italic>TNALP</ce:italic> may present in adulthood with osteoporosis, fractures and low ALP values. The best mode of treatment for these patients remains to be determined, except that bisphosphonates should be avoided since they may exacerbate the mineralisation defect.</ce:para></ce:section><ce:section id="s1845"><ce:section-title id="st1720">Other causes of osteomalacia</ce:section-title><ce:para id="p6115">These are summarised in <ce:cross-ref id="crf1340" refid="b0380">Box 24.75</ce:cross-ref>. Osteomalacia may occur as a component of renal osteodystrophy in patients with chronic kidney disease. The mechanism is reduced conversion of 25(OH)D into the active metabolite 1,25(OH)<ce:inf loc="post">2</ce:inf>D by the failing kidney (<ce:intra-ref id="ii0605" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0825">p. 418</ce:intra-ref>). Aluminium intoxication is now rare due to reduced use of aluminium-containing phosphate binders and removal of aluminium from the water supplies used in dialysis. If aluminium intoxication is suspected, the diagnosis can be confirmed by demonstration of aluminium at the calcification front in a bone biopsy. Osteomalacia due to bisphosphonates has mostly been described in patients with Paget's disease who are receiving etidronate and high-dose pamidronate. It is usually asymptomatic and healing occurs when treatment is stopped. Excessive fluoride intake causes osteomalacia due to direct inhibition of mineralisation and is common in parts of the world where there is a high fluoride content in drinking water. The condition reverses when fluoride intake is reduced.</ce:para></ce:section></ce:section><ce:section id="s1850"><ce:section-title id="st1725">Paget's disease of bone</ce:section-title><ce:para id="p6120">Paget's disease of bone (PDB) is characterised by focal areas of increased and disorganised bone remodelling involving one or more skeletal sites. The disease is common in the UK, affecting about 1% of those aged above 55, and in other countries in Europe. It is rare in Scandinavia, the Indian subcontinent and the rest of Asia. The prevalence doubles each decade from the age of 50 onwards and affects up to 8% of the UK population by the age of 85.</ce:para><ce:section id="s1855"><ce:section id="s1860"><ce:section-title id="st1730">Pathophysiology</ce:section-title><ce:para id="p6125">The primary abnormality is increased osteoclastic bone resorption, accompanied by marrow fibrosis, increased vascularity of bone and increased, but disorganised, bone formation. Osteoclasts in PDB are greater in number and unusually large, containing characteristic nuclear inclusion bodies. Genetic factors are important and mutations in the <ce:italic>SQSTM1</ce:italic> gene are a common cause of classical PDB. The presence of nuclear inclusion bodies in osteoclasts has fuelled speculation that PDB might be caused by a slow virus infection but this is unproven. Biomechanical factors may influence which bones are affected, as PDB often starts at sites of muscle insertions into bone and, in some cases, localises to bones or limbs that have been subjected to repetitive trauma or overuse. Involvement of subchondral bone can compromise the joint and predispose to OA. The prevalence of PDB has fallen in many countries over recent decades, suggesting that environmental factors play a role, but the identity of these triggers remains unclear.</ce:para></ce:section><ce:section id="s1865"><ce:section-title id="st1735">Clinical features</ce:section-title><ce:para id="p6130">The axial skeleton is predominantly affected and common sites of involvement are the pelvis, femur, tibia, lumbar spine, skull and scapula. The most common presentation is with bone pain localised to an affected site but bone deformity, deafness and pathological fractures may also be presenting features. Many patients are asymptomatic and the diagnosis is frequently made on the basis of an X-ray or blood test performed for another reason. Clinical signs include bone deformity and expansion, and increased warmth over an affected bone. Neurological problems, such as deafness, cranial nerve defects, nerve root pain, spinal cord compression and spinal stenosis, may occur due to enlargement of affected bones and encroachment on the spinal cord and nerve foramina. Surprisingly, deafness seldom results from compression of the auditory nerve but is conductive, due to osteosclerosis of the temporal bone. The increased vascularity of Pagetic bone can rarely precipitate high-output cardiac failure in elderly patients with limited cardiac reserve. Osteosarcoma is an unusual but serious complication that presents with increasing pain and swelling of an affected site.</ce:para></ce:section><ce:section id="s1870"><ce:section-title id="st1740">Investigations</ce:section-title><ce:para id="p6135">The characteristic features are an isolated elevation in ALP and bone expansion on X-rays, with alternating areas of radiolucency and osteosclerosis (<ce:cross-ref id="crf1345" refid="f0335">Fig. 24.63B</ce:cross-ref><ce:float-anchor refid="f0335"/>). Levels of ALP can be normal if only a single bone is affected. The best way of identifying affected sites is a radionuclide bone scan, which shows increased uptake in affected bones (<ce:cross-ref id="crf1350" refid="f0335">Fig. 24.63A</ce:cross-ref>). If the bone scan is positive, X-rays should be taken to confirm the diagnosis. Bone biopsy is not usually required but may help to exclude osteosclerotic metastases in cases of diagnostic uncertainty.</ce:para></ce:section><ce:section id="s1875"><ce:section-title id="st1745">Management</ce:section-title><ce:para id="p6140">The main indication for treatment with inhibitors of bone resorption is bone pain, which is thought to be due to increased metabolic activity (<ce:cross-ref id="crf1355" refid="b0385">Box 24.76</ce:cross-ref><ce:float-anchor refid="b0385"/>). Patients should be carefully assessed to determine the cause of the pain since it can be difficult to differentiate the pain caused by increased metabolic activity of PDB from that caused by complications such as bone deformity, nerve compression symptoms and OA. The bisphosphonates pamidronate, risedronate and zoledronic acid are highly effective at suppressing the elevations in bone turnover that are characteristic of PDB and also improve bone pain that is caused by increased metabolic activity. If there is doubt about whether the pain is due to PDB, it can be worthwhile giving a therapeutic trial of bisphosphonate to determine whether the symptoms improve. A positive response indicates that the pain was due to increased metabolic activity. There is no evidence as yet to suggest that bisphosphonates prevent the development of complications in PDB. Repeated courses of bisphosphonates can be given if symptoms recur.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1880"><ce:section-title id="st1750">Other bone diseases</ce:section-title><ce:section id="s1885"><ce:section-title id="st1755">Complex regional pain syndrome type 1</ce:section-title><ce:para id="p6150">Complex regional pain syndrome (CRPS) type 1 is characterised by gradual onset of pain, swelling and local tenderness, usually affecting a limb extremity. It may be triggered by fracture but can also occur in association with soft tissue injury, pregnancy and intercurrent illness or can develop spontaneously. The cause is unknown but abnormalities of the sympathetic nervous system are thought to play a pathogenic role. The affected limb is swollen and tender, and there may be evidence of regional autonomic dysfunction, with abnormal sweating and changes in skin colour and temperature. The diagnosis is primarily clinical, based on the features shown in <ce:intra-ref id="ii0610" xlink:href="pii:B978-0-7020-7028-0.00034-2#b0065">Box 34.12</ce:intra-ref> (<ce:intra-ref id="ii0615" xlink:href="pii:B978-0-7020-7028-0.00034-2#s0195">p. 1349</ce:intra-ref>). Support for the diagnosis can be obtained with MRI, which shows bone marrow oedema, or radionuclide bone scan, which shows a local increase in tracer uptake (<ce:cross-ref id="crf1360" refid="f0340">Fig. 24.64</ce:cross-ref><ce:float-anchor refid="f0340"/>). X-rays show localised osteoporosis. Haematology, biochemistry and immunology are normal.</ce:para><ce:para id="p6155">The aims of treatment are to control pain and encourage mobilisation. Analgesics, NSAIDs, antineuropathic agents, calcitonin, glucocorticoids, β-adrenoceptor antagonists (β-blockers), sympathectomy and bisphosphonates have all been tried but none is particularly effective. Although some cases resolve with time, many individuals have persistent symptoms and fail to regain normal function.</ce:para></ce:section><ce:section id="s1890"><ce:section-title id="st1760">Osteonecrosis</ce:section-title><ce:para id="p6160">Osteonecrosis describes death of bone due to impairment of its blood supply. The most commonly affected sites are the femoral head, humeral head and femoral condyles. In some cases, the condition occurs as the result of direct trauma that interrupts the blood supply to the affected bone. This is the reason for osteonecrosis of the femoral head in patients with subtrochanteric fractures of the femoral neck, and in patients with thrombophilia and haemoglobinopathies, such as sickle cell disease. Other important predisposing factors include high-dose glucocorticoid treatment, alcohol excess, SLE, HIV and radiotherapy, but in many of these conditions the pathophysiology is poorly understood. The presentation is with pain localised to the affected site, which is exacerbated by weight-bearing. The diagnosis can be confirmed by MRI, which shows evidence of subchondral necrotic bone and bone marrow oedema. X-rays are normal in the early stages but later may show evidence of osteosclerosis and deformity of the affected bone. There is no specific treatment. Management should focus on controlling pain and encouraging mobilisation (<ce:cross-ref id="crf9335" refid="s0395">p. 1000</ce:cross-ref>). Symptoms often improve spontaneously with time but joint replacement may be required in patients who have persisting pain in association with significant structural damage to the affected joint.</ce:para></ce:section><ce:section id="s1895"><ce:section-title id="st1765">Scheuermann's osteochondritis</ce:section-title><ce:para id="p6165">This disorder predominantly affects adolescent boys, who develop a dorsal kyphosis in association with irregular radiographic ossification of the vertebral end plates. It has a strong genetic component and may be inherited in an autosomal dominant manner. Most patients are asymptomatic but back pain, aggravated by exercise and relieved by rest, may occur. Excessive exercise and heavy manual labour before epiphyseal fusion has occurred may aggravate symptoms. Management consists of advice to avoid excessive activity and provision of protective postural exercises. Rarely, corrective surgery may be required if there is severe deformity. Scheuermann's disease can sometimes present for the first time in adulthood, when it can be confused with osteoporotic vertebral fractures. It can be differentiated from osteoporosis by the characteristic X-ray changes, which show mild wedge deformity of 3–4 adjacent vertebrae, irregularity of the vertebral end plates, and normal BMD on DXA examination.</ce:para></ce:section><ce:section id="s1900"><ce:section-title id="st1770">Polyostotic fibrous dysplasia</ce:section-title><ce:para id="p6170">This is an acquired systemic disorder that mainly affects the skeleton and is caused by somatic mutations in the <ce:italic>GNAS1</ce:italic> gene. The characteristic presentation is with bone pain and pathological fractures. Associated features include endocrine dysfunction, especially precocious puberty, and café-au-lait skin pigmentation (McCune–Albright syndrome). The diagnosis can usually be made by imaging, which shows focal, predominantly osteolytic lesions with bone expansion on X-rays (<ce:cross-ref id="crf1365" refid="f0345">Fig. 24.65</ce:cross-ref><ce:float-anchor refid="f0345"/>), and focal increased uptake on bone scan. The condition can resemble Paget's disease of bone but the earlier age of onset and pattern of involvement are usually distinctive. Very rarely, malignant change can occur and should be suspected if there is a sudden increase in pain and swelling. Management is symptomatic. Intravenous bisphosphonates are often used in an attempt to control pain but the evidence base for their use is weak. Orthopaedic surgery may be required for treatment of fracture and deformity. Endocrine manifestations, such as precocious puberty (<ce:intra-ref id="ii0625" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0560">p. 654</ce:intra-ref>), may require specific treatment.</ce:para></ce:section><ce:section id="s1905"><ce:section-title id="st1775">Osteogenesis imperfecta</ce:section-title><ce:para id="p6175">Osteogenesis imperfecta (OI) is the name given to a group of disorders characterised by severe osteoporosis and multiple fractures in infancy and childhood. Most cases are caused by mutations in the <ce:italic>COL1A1</ce:italic> and <ce:italic>COL1A2</ce:italic> genes, which encode the proteins that make type I collagen. These result in reduced collagen production (in mild OI) or in formation of abnormal collagen chains that are rapidly degraded (in severe OI). Mutations in several other genes have been described that can cause OI, some of which affect post-translational modification of collagen and others that affect bone formation. Many patients have no family history. Some of these have new mutations whereas others may have recessive forms of the disease. The Sillence classification is commonly used to grade severity. This varies from neonatal lethal OI (type II), through very severe OI with multiple fractures in infancy and childhood (types III and IV), to mild (type I), in which affected patients typically have blue sclerae. The diagnosis of OI is usually obvious clinically, based on the presentation with multiple low-trauma fractures during infancy. The disease can be mistaken for non-accidental injury in childhood and for osteoporosis in adulthood; in such cases, genetic testing can be of diagnostic value. Treatment is multidisciplinary, involving surgical reduction and fixation of fractures and correction of limb deformities, and physiotherapy and occupational therapy for rehabilitation of patients with bone deformity. Bisphosphonates are widely used in the treatment of OI, especially intravenous pamidronate in children, but there is limited evidence for efficacy in fracture prevention.</ce:para></ce:section><ce:section id="s1910"><ce:section-title id="st1780">Osteopetrosis</ce:section-title><ce:para id="p6180">Osteopetrosis is a rare group of inherited diseases caused by failure of osteoclast function. Presentation is highly variable, ranging from a lethal disorder that presents with bone marrow failure in infancy to a milder and sometimes asymptomatic form that presents in adulthood. Severe osteopetrosis is inherited in an autosomal recessive manner and presents with failure to thrive, delayed dentition, cranial nerve palsies (due to absent cranial foramina), blindness, anaemia and recurrent infections due to bone marrow failure. The adult-onset type (Albers–Schönberg disease) shows autosomal dominant inheritance and presents with bone pain, cranial nerve palsies, osteomyelitis, OA or fracture, or is sometimes detected as an incidental radiographic finding. The responsible mutations affect either the genes that regulate osteoclast differentiation (<ce:italic>RANK</ce:italic>, <ce:italic>RANKL</ce:italic>), causing ‘osteoclast-poor’ osteopetrosis, or the genes involved in bone resorption, causing ‘osteoclast-rich’ osteopetrosis. These include mutations in the <ce:italic>TCIRG1</ce:italic> gene, which encodes a component of the osteoclast proton pump, and mutations in the <ce:italic>CLCN7</ce:italic> gene, which encodes the osteoclast chloride pump. Management is difficult. IFN-γ treatment can improve blood counts and reduce frequency of infections, but in severe cases haematopoietic stem cell transplantation is required to provide a source of osteoclasts that resorb bone normally.</ce:para></ce:section><ce:section id="s1915"><ce:section-title id="st1785">Sclerosing bone dysplasias</ce:section-title><ce:para id="p6185">These are rare diseases characterised by osteosclerosis and increased bone formation. Van Buchem's disease and sclerosteosis are recessive disorders caused by loss-of-function mutations in the <ce:italic>SOST</ce:italic> gene, which normally suppresses bone formation (see <ce:cross-ref id="crf1370" refid="f0030">Fig. 24.3</ce:cross-ref>, <ce:cross-ref id="crf9340" refid="s0045">p. 986</ce:cross-ref>). The resulting lack of sclerostin causes increased bone formation and bone overgrowth, leading to enlargement of the cranium and jaw, tall stature and cranial nerve palsies. There is no effective treatment. High bone mass syndrome is a benign disorder caused by mutations in the <ce:italic>LRP4</ce:italic> or <ce:italic>LRP5</ce:italic> gene, which is characterised by unusually high bone density. The mutations render the LRP receptors resistant to the inhibitory effects of SOST. Most patients are asymptomatic but bone overgrowth in the palate (torus palatinus) and enlargement of the mandible can occur in later life. Treatment is not usually required. Camurati–Engelmann disease is an autosomal dominant condition caused by gain of function in the <ce:italic>TGFB1</ce:italic> gene. It presents with bone pain, muscle weakness and osteosclerosis mainly affecting the diaphysis of long bones. Glucocorticoids can help the bone pain, although usually analgesics are also required.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1920"><ce:section-title id="st1790">Bone and joint tumours</ce:section-title><ce:para id="p6190">Primary tumours of bones and joints are rare, have a peak incidence in childhood and adolescence, and can be benign or malignant (<ce:cross-ref id="crf1375" refid="b0390">Box 24.77</ce:cross-ref><ce:float-anchor refid="b0390"/>). Paget's disease of bone (<ce:cross-ref id="crf9345" refid="s1835">p. 1053</ce:cross-ref>) accounts for most cases of osteosarcoma occurring above the age of 40.</ce:para><ce:section id="s1925"><ce:section id="s1930"><ce:section-title id="st1795">Osteosarcoma</ce:section-title><ce:para id="p6200">This is a rare tumour with an incidence of 0.6–0.85 per 100 000 population. It is the most common primary bone tumour. Most patients present under the age of 30 but osteosarcoma also occurs in the elderly in association with Paget's disease. The presentation is with local pain and swelling. X-rays show expansion of the bone with a surrounding soft tissue mass, often containing islands of calcification. If the diagnosis is being considered, MRI or CT should be performed to determine the extent of tumour. Patients suspected of having osteosarcoma should be referred to a specialist team for biopsy. Treatment depends on histological type but generally involves surgical removal of the tumour, followed by chemotherapy and radiotherapy. The prognosis is normally good in cases that present in childhood and adolescence, but poor in elderly patients with osteosarcoma related to Paget's disease of bone.</ce:para></ce:section><ce:section id="s1935"><ce:section-title id="st1800">Chondrosarcoma</ce:section-title><ce:para id="p6205">This is the second most common primary bone tumour. Presentation is as described for <ce:cross-ref id="crf1380" refid="s1930">osteosarcoma</ce:cross-ref>. The treatment of choice is surgical resection since chondrosarcomas are relatively resistant to chemotherapy and radiotherapy. The prognosis is good for low-grade tumours but poor for anaplastic tumours.</ce:para></ce:section><ce:section id="s1940"><ce:section-title id="st1805">Ewing's sarcoma</ce:section-title><ce:para id="p6210">This is the third most common sarcoma, which presents almost exclusively under the age of 40. Presentation is as described for <ce:cross-ref id="crf1385" refid="s1930">osteosarcoma</ce:cross-ref>. Treatment is by local excision and surgical resection. The prognosis is excellent for patients who present before metastasis has occurred.</ce:para></ce:section><ce:section id="s1945"><ce:section-title id="st1810">Metastatic bone disease</ce:section-title><ce:para id="p6215">Metastatic bone disease may present in a variety of ways: with localised or generalised progressive bone pain, generalised regional pain, symptoms of spinal cord compression, or acute pain due to pathological fracture. Systemic features, such as weight loss and anorexia, and symptoms referable to the primary tumour are often present. The tumours that most commonly metastasise to bone are myeloma and those of bronchus, breast, prostate, kidney and thyroid. Management is discussed in <ce:intra-ref id="ii0640" xlink:href="pii:B978-0-7020-7028-0.00033-0#c00033">Chapter 33</ce:intra-ref>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1950"><ce:section-title id="st1815">Rheumatological involvement in other diseases</ce:section-title><ce:para id="p6220">Many systemic diseases can affect the locomotor system, and many drugs may cause adverse locomotor effects (<ce:cross-ref id="crf1390" refid="b0395">Box 24.78</ce:cross-ref><ce:float-anchor refid="b0395"/>). The most common examples are described here. Bone disease in sarcoidosis is described on <ce:intra-ref id="ii0645" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1590">page 608</ce:intra-ref>, haemophilia on <ce:intra-ref id="ii0650" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1665">page 972</ce:intra-ref> and sickle-cell anaemia on <ce:intra-ref id="ii0655" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1010">page 952</ce:intra-ref>.</ce:para><ce:section id="s1955"><ce:section id="s1960"><ce:section-title id="st1820">Malignant disease</ce:section-title><ce:para id="p6230">Malignant disease can cause a variety of non-metastatic musculoskeletal problems (<ce:cross-ref id="crf1395" refid="b0400">Box 24.79</ce:cross-ref><ce:float-anchor refid="b0400"/>). One of the most striking is hypertrophic pulmonary osteoarthropathy (HPOA), characterised by clubbing and painful swelling of the limbs, periosteal new bone formation and arthralgia/arthritis. The most common causes are bronchial carcinoma and mesothelioma (<ce:intra-ref id="ii0660" xlink:href="pii:B978-0-7020-7028-0.00017-2#p5130">pp. 598</ce:intra-ref> and <ce:intra-ref id="ii0665" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1850">618</ce:intra-ref>). Bone scans show increased periosteal uptake before new bone is apparent on X-ray. The course follows that of the underlying malignancy and HPOA resolves if this is cured.</ce:para></ce:section><ce:section id="s1965"><ce:section-title id="st1825">Endocrine disease</ce:section-title><ce:para id="p6275">Hypothyroidism (<ce:intra-ref id="ii0670" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0135">p. 639</ce:intra-ref>) may present with carpal tunnel syndrome or, rarely, with painful, symmetrical proximal myopathy and muscle hypertrophy. Both resolve with levothyroxine replacement. Primary hyperparathyroidism (<ce:intra-ref id="ii0675" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0835">p. 663</ce:intra-ref>) is associated with osteoporosis and also predisposes to calcium pyrophosphate dihydrate deposition disease and to calcific periarthritis, especially in patients with renal disease.</ce:para><ce:para id="p6280">Diabetes mellitus (<ce:intra-ref id="ii0680" xlink:href="pii:B978-0-7020-7028-0.00020-2#c00020">Ch. 20</ce:intra-ref>) commonly causes diabetic cheiroarthropathy, characterised by tightening of skin and periarticular structures, causing flexion deformities of the fingers that may be painful. Diabetic osteopathy presents as forefoot pain with radiographic progression from osteopenia to complete osteolysis of the phalanges and metatarsals. Diabetes also predisposes to osteoporosis, fragility fractures, adhesive capsulitis, Dupuytren's contracture, septic arthritis and Charcot's joints.</ce:para><ce:para id="p6285">Acromegaly (<ce:intra-ref id="ii0685" xlink:href="pii:B978-0-7020-7028-0.00018-4#p5050">p. 685</ce:intra-ref>) can be associated with mechanical back pain, with normal or excessive movement; carpal tunnel syndrome; and Raynaud's syndrome and an arthropathy (50%). The arthropathy mainly affects the large joints and has clinical similarities to OA but with a normal or increased range of movement. X-rays may show widening of joint spaces, squaring of bone ends, generalised osteopenia and tufting of terminal phalanges. It does not improve with treatment of the acromegaly.</ce:para></ce:section><ce:section id="s1970"><ce:section-title id="st1830">Haematological disease</ce:section-title><ce:para id="p6290">Haemochromatosis (<ce:intra-ref id="ii0690" xlink:href="pii:B978-0-7020-7028-0.00022-6#s1265">p. 895</ce:intra-ref>) is complicated by an arthropathy in about 50% of cases. It typically presents between the ages of 40 and 50, and may predate other features of the disease. The small joints of the hands and wrists are typically affected but the hips, shoulders and knees may also be involved. The X-ray changes resemble OA but cysts are often multiple and prominent, with little osteophyte formation. Involvement of the radiocarpal and MCP joints may occur, which is unusual in primary OA, and about 30% have calcium pyrophosphate dihydrate deposition disease and/or pseudogout. Treatment of the haemochromatosis does not influence the arthropathy, and management is as described for OA. Haemophilia (<ce:intra-ref id="ii0695" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1665">p. 972</ce:intra-ref>) can be complicated by haemarthrosis, which, if recurrent, can result in the development of secondary OA. Sickle-cell disease (<ce:intra-ref id="ii0700" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1010">p. 952</ce:intra-ref>) may be associated with bone pain, osteonecrosis and osteomyelitis. Thalassaemia (<ce:intra-ref id="ii0705" xlink:href="pii:B978-0-7020-7028-0.00023-8#u2565">p. 953</ce:intra-ref>) may be complicated by bone deformity, especially affecting the craniofacial bones, and by osteoporosis.</ce:para></ce:section><ce:section id="s1975"><ce:section-title id="st1835">Neurological disease</ce:section-title><ce:para id="p6295">Neurological disease may result in rapidly destructive arthritis of joints, first described by Charcot in association with syphilis. The cause is incompletely understood but may involve repetitive trauma as the result of sensory loss and altered blood flow secondary to impaired sympathetic nervous system control. The main predisposing diseases and sites of involvement are:<ce:list id="ulist1025"><ce:list-item id="u3545"><ce:label>•</ce:label><ce:para id="p6300">diabetic neuropathy (hindfoot)</ce:para></ce:list-item><ce:list-item id="u3550"><ce:label>•</ce:label><ce:para id="p6305">syringomyelia (shoulder, elbow, wrist)</ce:para></ce:list-item><ce:list-item id="u3555"><ce:label>•</ce:label><ce:para id="p6310">leprosy (hands, feet)</ce:para></ce:list-item><ce:list-item id="u3560"><ce:label>•</ce:label><ce:para id="p6315">tabes dorsalis (knees, spine).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p6320">The presentation is with subacute or chronic monoarthritis. Pain can occur, especially at the onset, but once the joint is severely deranged, pain is often minimal and signs become disproportionately greater than symptoms. The joint is often grossly swollen, with effusion, crepitus, marked instability and deformity, but usually no increased warmth. X-rays show disorganisation of normal joint architecture and often multiple loose bodies (<ce:cross-ref id="crf1400" refid="f0350">Fig. 24.66</ce:cross-ref><ce:float-anchor refid="f0350"/>), and either no (atrophic) or gross (hypertrophic) new bone formation. Management principally involves orthoses and occasionally arthrodesis.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1980"><ce:section-title id="st1840">Miscellaneous conditions</ce:section-title><ce:section id="s1985"><ce:section id="s1990"><ce:section-title id="st1845">Anterior tibial compartment syndrome</ce:section-title><ce:para id="p6325">This is characterised by severe pain in the front of the lower leg, aggravated by exercise and relieved by rest. Symptoms result from fascial compression of the muscles in the anterior tibial compartment and may be associated with foot drop. Treatment is by surgical decompression.</ce:para></ce:section><ce:section id="s1995"><ce:section-title id="st1850">Carpal tunnel syndrome</ce:section-title><ce:para id="p6330">This is a common nerve entrapment syndrome caused by compression of the median nerve at the wrist. It presents with numbness, tingling and pain in a median nerve distribution (<ce:intra-ref id="ii0710" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2065">p. 1139</ce:intra-ref>). The most common causes are hypothyroidism, diabetes mellitus, RA, obesity and pregnancy, especially in the third trimester. In some patients, no underlying cause may be identified. Carpal tunnel syndrome often responds to treatment of the underlying condition but other options include local glucocorticoid injections and surgical decompression.</ce:para></ce:section><ce:section id="s2000"><ce:section-title id="st1855">Diffuse idiopathic skeletal hyperostosis</ce:section-title><ce:para id="p6335">Diffuse idiopathic skeletal hyperostosis (DISH) is a common disorder, affecting 10% of men and 8% of women over the age of 65, and is associated with obesity, hypertension and type 2 diabetes mellitus. It is characterised by florid new bone formation along the anterolateral aspect of at least four contiguous vertebral bodies (<ce:cross-ref id="crf1405" refid="f0355">Fig. 24.67</ce:cross-ref><ce:float-anchor refid="f0355"/>). DISH is distinguished from lumbar spondylosis by the absence of disc space narrowing and marginal vertebral body sclerosis, and from ankylosing spondylitis by the absence of sacroiliitis or apophyseal joint fusion. It is usually an asymptomatic radiographic finding but can cause back pain or pain at peripheral sites, such as the heel, in association with calcaneal spur formation.</ce:para></ce:section><ce:section id="s2005"><ce:section-title id="st1860">Dupuytren's contracture</ce:section-title><ce:para id="p6340">Dupuytren's contracture results from fibrosis and contracture of the superficial palmar fascia of the hands. The patient is unable to extend the fingers fully and there is puckering of the skin with palpable nodules. The ring and little fingers are usually the first and worst affected. Dupuytren's contracture is usually painless but causes problems due to limitation of hand function and snagging of the curled fingers in pockets. It is age-related, usually bilateral and more common in men. There is a strong genetic component and sometimes may be familial, with dominant inheritance. The condition can be associated with plantar fibromatosis, Peyronie's disease, alcohol misuse and chronic vibration injury. It is very slowly progressive. Often no treatment is required but it can be treated medically by local injections of collagenase or surgically by fasciotomy if symptoms are troublesome.</ce:para></ce:section><ce:section id="s2010"><ce:section-title id="st1865">Hypermobility syndromes</ce:section-title><ce:para id="p6345">Hypermobility is characterised by increased joint laxity and joint pain. Causes include Marfan's syndrome, resulting from mutations in the <ce:italic>FBN1</ce:italic> gene (<ce:intra-ref id="ii0715" xlink:href="pii:B978-0-7020-7028-0.00016-0#p4835">p. 508</ce:intra-ref>); osteogenesis imperfecta (<ce:cross-ref id="crf9350" refid="s1885">p. 1055</ce:cross-ref>); and Ehlers–Danlos syndrome types I, II and IV, caused by mutations in the <ce:italic>COL3A1</ce:italic>, <ce:italic>COL5A1</ce:italic> and <ce:italic>COL5A2</ce:italic> genes (<ce:intra-ref id="ii0725" xlink:href="pii:B978-0-7020-7028-0.00023-8#p5845">p. 970</ce:intra-ref>).</ce:para><ce:para id="p6350">The term hypermobile Ehlers–Danlos syndrome (hEDS), which is also known as EDS type III, is used to describe a polygenic form of hypermobility. Many patients with this condition have hypermobile joints but do not have symptoms, whereas in others a range of symptoms can occur, including chronic joint and ligamentous pain, fibromyalgia-like symptoms, recurrent dislocations, easy bruising, abdominal symptoms, mitral valve prolapse (<ce:intra-ref id="ii0730" xlink:href="pii:B978-0-7020-7028-0.00016-0#s2120">p. 520</ce:intra-ref>) and postural tachycardia syndrome, in which there is dizziness, hypotension and an increased heart rate on standing. The diagnosis of EDS type III is clinical and can be made when the modified Beighton score is 4 or above in the presence of arthralgia in four or more joints (<ce:cross-ref id="crf1410" refid="b0405">Box 24.80</ce:cross-ref><ce:float-anchor refid="b0405"/>). There is no specific treatment, apart from the general principles listed on <ce:cross-ref id="crf9355" refid="s0395">page 1000</ce:cross-ref>, but some patients become very disabled as the result of their symptoms and are difficult to manage.</ce:para></ce:section><ce:section id="s2015"><ce:section-title id="st1870">Inclusion body myositis</ce:section-title><ce:para id="p6360">Inclusion body myositis is the most frequent primary myopathy in middle age and after. It is characterised by slowly progressive muscle weakness and atrophy, with pathological changes of inflammation, degeneration and mitochondrial abnormality in affected muscle fibres. Inclusion body myositis typically presents with distal muscle weakness. In time, muscles atrophy. Investigation is the same as for polymyositis (<ce:cross-ref id="crf9360" refid="p5195">p. 1039</ce:cross-ref>). There is typically a slightly elevated creatine kinase and myopathic changes on EMG. Muscle biopsy shows abnormal fibres containing rimmed vacuoles and filamentous inclusions in the nucleus and cytoplasm. Therapeutic response to glucocorticoids and immunosuppressants is notably poor. There is anecdotal report of efficacy with IVIg but trial evidence is lacking.</ce:para></ce:section><ce:section id="s2020"><ce:section-title id="st1875">Periodic fever syndromes</ce:section-title><ce:para id="p6365">These are a group of rare inherited disorders that present with intermittent attacks of fever, rash, arthralgia and myalgia. They are discussed in more detail on <ce:intra-ref id="ii0745" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0470">page 81</ce:intra-ref>.</ce:para></ce:section><ce:section id="s2025"><ce:section-title id="st1880">Pigmented villonodular synovitis</ce:section-title><ce:para id="p6370">Pigmented villonodular synovitis is an uncommon proliferative disorder of synovium, which typically affects young adults. It is caused by a somatic chromosomal translocation in synovial cells that places the <ce:italic>CSF1</ce:italic> gene downstream of the <ce:italic>COL6A3</ce:italic> gene promoter. The result is local over-production of M-CSF, which causes accumulation of macrophages in the joint. The presentation is with joint swelling, limitation of movement and local discomfort. The diagnosis can be confirmed by MRI or synovial biopsy. Treatment is by surgical or radiation synovectomy.</ce:para></ce:section><ce:section id="s2030"><ce:section-title id="st1885">Scoliosis</ce:section-title><ce:para id="p6375">Scoliosis is characterised by an abnormal lateral curvature of the spine of greater than 10°. It typically presents during childhood or adolescence but usually persists into adulthood, when it can be associated with back pain, deformity and secondary OA. In about 20% of cases, scoliosis is secondary to a neuromuscular disorder, such as muscular dystrophy, cerebral palsy or neurofibromatosis. It may also occur in association with connective tissue disorders, such as Marfan's syndrome. The term idiopathic scoliosis is used to described the remaining cases where there is no obvious cause. In fact, there is strong evidence from twin studies that idiopathic scoliosis is genetically mediated. The diagnosis can usually be made clinically by physical examination, which shows the characteristic spinal deformity. Spinal X-rays can be used to confirm the diagnosis and assess severity. External bracing and/or surgical intervention are often performed in adolescents with severe deformities to correct deformity or prevent progression but the evidence base is poor. In adulthood, treatment is symptomatic in nature with analgesics, NSAID or antineuropathic medications.</ce:para></ce:section><ce:section id="s2035"><ce:section-title id="st1890">Spondylolysis</ce:section-title><ce:para id="p6380">Spondylolysis describes a break in the integrity of the neural arch. The principal cause is an acquired defect in the pars interarticularis due to a fracture, mainly seen in gymnasts, dancers and runners, in whom it is an important cause of back pain. Spondylolisthesis describes the condition in which a defect causes slippage of a vertebra on the one below. This may be congenital, post-traumatic or degenerative. Rarely, it can result from metastatic destruction of the posterior elements. Uncomplicated spondylolysis does not cause symptoms but spondylolisthesis can lead to low back pain aggravated by standing and walking. Occasionally, symptoms of nerve root or spinal compression may occur. The diagnosis can be made on lateral X-rays of the lumbar spine but MRI may be required if there is neurological involvement. Advice on posture and muscle-strengthening exercises is required in mild cases. Surgical fusion is indicated for severe and recurrent low back pain. Surgical decompression is mandatory prior to fusion in patients with significant lumbar stenosis or symptoms of cauda equina compression.</ce:para></ce:section><ce:section id="s2040"><ce:section-title id="st1895">Synovitis–acne–pustulosis–hyperostosis–osteitis syndrome</ce:section-title><ce:para id="p6385">The synovitis–acne–pustulosis–hyperostosis–osteitis (SAPHO) syndrome is a disorder characterised by bone pain and swelling due to a sterile osteomyelitis and hyperostosis predominantly targeting the clavicles and bones of the anterior chest wall. SAPHO syndrome is thought to be part of a spectrum of autoinflammatory bone diseases that includes chronic recurrent (sterile) multifocal osteomyelitis in children and adolescents. Other features include a pustulotic rash affecting the palms and soles of the feet, sacroiliitis and synovitis of peripheral joints. It most commonly presents in children and young or middle-aged adults. Various treatments have been used, including glucocorticoids, DMARDs, bisphosphonates, anakinra and TNF blockers, with most success arising from biologic use. The cause is unknown but has been suggested to be an autoimmune process triggered by a bacterial or viral pathogen.</ce:para></ce:section><ce:section id="s2045"><ce:section-title id="st1900">Trigger finger</ce:section-title><ce:para id="p6390">This occurs as the result of stenosing tenosynovitis in the flexor tendon sheath, with intermittent locking of the finger in flexion. It can arise spontaneously or in association with inflammatory diseases such as RA. Symptoms usually respond to local glucocorticoid injections but surgical decompression is occasionally required.</ce:para></ce:section></ce:section></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st1905">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st1910">Journal articles</ce:section-title><ce:bib-reference id="bib2"><ce:label>Campion, 2016</ce:label><sb:reference id="sr0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>EW</ce:given-name><ce:surname>Campion</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Calcium pyrophosphate deposition disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>374</sb:volume-nr></sb:series><sb:date>2016</sb:date></sb:issue><sb:pages><sb:first-page>2575</sb:first-page><sb:last-page>2578</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>Compston, 2016</ce:label><sb:reference id="sr0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J</ce:given-name><ce:surname>Compston</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Osteoporosis: advances in risk assessment and management</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin Med (Lond)</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:issue-nr>Suppl 6</sb:issue-nr><sb:date>2016</sb:date></sb:issue><sb:pages><sb:first-page>s121</sb:first-page><sb:last-page>s124</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>Gossec et al, 2016</ce:label><sb:reference id="sr0025"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L</ce:given-name><ce:surname>Gossec</ce:surname></sb:author><sb:author><ce:given-name>JS</ce:given-name><ce:surname>Smolen</ce:surname></sb:author><sb:author><ce:given-name>S</ce:given-name><ce:surname>Ramiro</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Rheum Dis</sb:maintitle></sb:title><sb:volume-nr>75</sb:volume-nr></sb:series><sb:date>2016</sb:date></sb:issue><sb:pages><sb:first-page>499</sb:first-page><sb:last-page>510</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>Mukhtyar et al, 2008</ce:label><sb:reference id="sr0030"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C</ce:given-name><ce:surname>Mukhtyar</ce:surname></sb:author><sb:author><ce:given-name>O</ce:given-name><ce:surname>Flossman</ce:surname></sb:author><sb:author><ce:given-name>B</ce:given-name><ce:surname>Hellmich</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Rheum Dis</sb:maintitle></sb:title><sb:volume-nr>67</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>1004</sb:first-page><sb:last-page>1010</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>Ralston, 2013</ce:label><sb:reference id="sr0035"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>SH</ce:given-name><ce:surname>Ralston</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Paget's disease of bone</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>368</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>644</sb:first-page><sb:last-page>650</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>Scott, Woolf, Huizinga, 2010</ce:label><sb:reference id="sr0040"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>DL</ce:given-name><ce:surname>Scott</ce:surname></sb:author><sb:author><ce:given-name>F</ce:given-name><ce:surname>Woolf</ce:surname></sb:author><sb:author><ce:given-name>TW</ce:given-name><ce:surname>Huizinga</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Rheumatoid arthritis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lancet</sb:maintitle></sb:title><sb:volume-nr>376</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>1094</sb:first-page><sb:last-page>1108</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>Taurog, Avneesh, Colbert, 2016</ce:label><sb:reference id="sr0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>JD</ce:given-name><ce:surname>Taurog</ce:surname></sb:author><sb:author><ce:given-name>C</ce:given-name><ce:surname>Avneesh</ce:surname></sb:author><sb:author><ce:given-name>RA</ce:given-name><ce:surname>Colbert</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Ankylosing spondylitis and axial spondyloarthritis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>374</sb:volume-nr></sb:series><sb:date>2016</sb:date></sb:issue><sb:pages><sb:first-page>2563</sb:first-page><sb:last-page>2567</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>Teng et al, 2015</ce:label><sb:reference id="sr0050"><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Teng</ce:surname><ce:given-name>MWL</ce:given-name></sb:author><sb:author><ce:given-name>EP</ce:given-name><ce:surname>Bowman</ce:surname></sb:author><sb:author><ce:given-name>JJ</ce:given-name><ce:surname>McElwee</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat Med</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:date>2015</sb:date></sb:issue><sb:pages><sb:first-page>719</sb:first-page><sb:last-page>729</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>Zhang et al, 2006</ce:label><sb:reference id="sr0055"><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Zhang</ce:surname><ce:given-name>W</ce:given-name></sb:author><sb:author><ce:given-name>M</ce:given-name><ce:surname>Doherty</ce:surname></sb:author><sb:author><ce:given-name>T</ce:given-name><ce:surname>Bardin</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>EULAR recommendations for gout. Part II: Management</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Rheum Dis</sb:maintitle></sb:title><sb:volume-nr>65</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>1312</sb:first-page><sb:last-page>1324</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:further-reading-sec><ce:further-reading-sec id="fs0015"><ce:section-title id="st1915">Websites</ce:section-title><ce:bib-reference id="bib11"><ce:label>,</ce:label><sb:reference id="sr0060"><sb:host><sb:e-host><ce:inter-ref id="iw0010" xlink:href="http://4s-dawn.com/DAS28">4s-dawn.com/DAS28</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0685"><ce:italic>Calculator for this measure of activity in rheumatoid arthritis.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>,</ce:label><sb:reference id="sr0065"><sb:host><sb:e-host><ce:inter-ref id="iw0015" xlink:href="http://asas-group.org">asas-group.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0690"><ce:italic>Repository of resources to aid assessment of spondyloarthritis.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>,</ce:label><sb:reference id="sr0070"><sb:host><sb:e-host><ce:inter-ref id="iw0020" xlink:href="http://basdai.com/BASDAI.php">basdai.com/BASDAI.php</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0695"><ce:italic>BASDAI calculator for assessing ankylosing spondylitis.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>,</ce:label><sb:reference id="sr0080"><sb:host><sb:e-host><ce:inter-ref id="iw0030" xlink:href="http://omim.org">omim.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0705"><ce:italic>Online Mendelian Inheritance in Man (OMIM): genetic diseases.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>,</ce:label><sb:reference id="sr0085"><sb:host><sb:e-host><ce:inter-ref id="iw0035" xlink:href="http://shef.ac.uk/FRAX/">shef.ac.uk/FRAX/</ce:inter-ref></sb:e-host></sb:host><sb:comment>and</sb:comment><sb:host><sb:e-host><ce:inter-ref id="iw0040" xlink:href="http://qfracture.org/">qfracture.org/</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0710"><ce:italic>Fracture risk assessment tools.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>,</ce:label><sb:reference id="sr0090"><sb:host><sb:e-host><ce:inter-ref id="iw0045" xlink:href="http://www.sign.ac.uk">sign.ac.uk</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0715"><ce:italic>Scottish Intercollegiate Guidelines Network 142 – Management of osteoporosis and the prevention of fragility fractures.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>,</ce:label><sb:reference id="sr0095"><sb:host><sb:e-host><ce:inter-ref id="iw0050" xlink:href="http://thefreelibrary.com">thefreelibrary.com</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0720"><ce:italic>Information on drug-induced myopathies.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>,</ce:label><sb:reference id="sr0100"><sb:host><sb:e-host><ce:inter-ref id="iw0055" xlink:href="http://vasculitis.org/">vasculitis.org/</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0725"><ce:italic>Vasculitis resources from the European Vasculitis Society.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>